Hepatitis C virus inhibitors

ABSTRACT

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. non-provisional application Ser. No. 11/835,524, filed Aug. 8, 2007, and claims the benefit of U.S. provisional application No. 60/837,247, filed Aug. 11, 2006.

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

HCV is a major human pathogen, infecting an estimated 170 million persons worldwide—roughly five times the number infected by human immunodeficiency virus type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma.

Presently, the most effective HCV therapy employs a combination of alpha-interferon and ribavirin, leading to sustained efficacy in 40% of patients. Recent clinical results demonstrate that pegylated alpha-interferon is superior to unmodified alpha-interferon as monotherapy. However, even with experimental therapeutic regimens involving combinations of pegylated alpha-interferon and ribavirin, a substantial fraction of patients do not have a sustained reduction in viral load. Thus, there is a clear and long-felt need to develop effective therapeutics for treatment of HCV infection.

HCV is a positive-stranded RNA virus. Based on a comparison of the deduced amino acid sequence and the extensive similarity in the 5′ untranslated region, HCV has been classified as a separate genus in the Flaviviridae family. All members of the Flaviviridae family have enveloped virions that contain a positive stranded RNA genome encoding all known virus-specific proteins via translation of a single, uninterrupted, open reading frame.

Considerable heterogeneity is found within the nucleotide and encoded amino acid sequence throughout the HCV genome. At least six major genotypes have been characterized, and more than 50 subtypes have been described. The major genotypes of HCV differ in their distribution worldwide, and the clinical significance of the genetic heterogeneity of HCV remains elusive despite numerous studies of the possible effect of genotypes on pathogenesis and therapy.

The single strand HCV RNA genome is approximately 9500 nucleotides in length and has a single open reading frame (ORF) encoding a single large polyprotein of about 3000 amino acids. In infected cells, this polyprotein is cleaved at multiple sites by cellular and viral proteases to produce the structural and non-structural (NS) proteins. In the case of HCV, the generation of mature non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) is effected by two viral proteases. The first one is believed to be a metalloprotease and cleaves at the NS2-NS3 junction; the second one is a serine protease contained within the N-terminal region of NS3 (also referred to herein as NS3 protease) and mediates all the subsequent cleavages downstream of NS3, both in cis, at the NS3-NS4A cleavage site, and in trans, for the remaining NS4A-NS4B, NS4B-NS5A, NS5A-NS5B sites. The NS4A protein appears to serve multiple functions, acting as a cofactor for the NS3 protease and possibly assisting in the membrane localization of NS3 and other viral replicase components. The complex formation of the NS3 protein with NS4A seems necessary to the processing events, enhancing the proteolytic efficiency at all of the sites. The NS3 protein also exhibits nucleoside triphosphatase and RNA helicase activities. NS5B (also referred to herein as HCV polymerase) is a RNA-dependent RNA polymerase that is involved in the replication of HCV.

Compounds useful for treating HCV-infected patients are desired which selectively inhibit HCV viral replication. In particular, compounds which are effective to inhibit the function of the NS5A protein are desired. The HCV NS5A protein is described, for example, in Tan, S.-L., Katzel, M. G. Virology 2001, 284, 1-12; and in Park, K.-J.; Choi, S.-H, J. Biological Chemistry 2003.

In its first aspect the present disclosure provides a compound of Formula (I)

or a pharmaceutically acceptable salt thereof, wherein

u and v are independently 0, 1, 2, or 3;

A and B are independently selected from phenyl and a six-membered heteroaromatic ring containing one, two, or three nitrogen atoms;

each R¹ and R² is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, formyl, halo, haloalkyl, hydroxy, hydroxyalkyl, —NR^(a)R^(b), (NR^(a)R^(b))alkyl, and (NR^(a)R^(b))carbonyl;

R³ and R⁴ are each independently selected from hydrogen, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, haloalkyl, (NR^(a)R^(b))carbonyl, and trialkylsilylalkoxyalkyl;

R⁵ and R⁶ are each independently selected from hydrogen, alkenyl, alkoxyalkyl, alkyl, haloalkyl, and (NR^(a)R^(b))alkyl; or,

R⁵ and R⁶, together with the carbon atom to which they are attached, form a five or six membered saturated ring optionally containing one or two heteroatoms selected from NR^(z), O, and S; wherein R^(z) is selected from hydrogen and alkyl;

R⁷ is selected from hydrogen, R⁹—C(O)—, and R⁹—C(S)—;

R⁸ is selected from hydrogen and alkyl;

R⁹ is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonylalkyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, aryloxyalkyl, cycloalkyl, (cycloalkyl)alkenyl, (cycloalkyl)alkyl, cycloalkyloxyalkyl, haloalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, hydroxyalkyl, —NR^(c)R^(d), (NR^(c)R^(d))alkenyl, (NR^(c)R^(d))alkyl, and (NR^(c)R^(d))carbonyl;

R¹⁰ is selected from

R¹¹ and R¹² are each independently selected from hydrogen, alkenyl, alkoxyalkyl, alkyl, haloalkyl, and (NR^(a)R^(b))alkyl; or,

R¹¹ and R¹², together with the carbon atom to which they are attached, form a five or six membered saturated ring optionally containing one or two heteroatoms selected from NR^(z), O, and S; wherein R^(z) is selected from hydrogen and alkyl;

R¹³ is selected from hydrogen and alkyl;

R¹⁴ is selected from hydrogen, R¹⁵—C(O)—, and R¹⁵—C(S)—;

R¹⁵ is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonylalkyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, aryloxyalkyl, cycloalkyl, (cycloalkyl)alkenyl, (cycloalkyl)alkyl, cycloalkyloxyalkyl, haloalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, hydroxyalkyl, —NR^(c)R^(d), (NR^(c)R^(d))alkenyl, (NR^(c)R^(d))alkyl, and (NR^(c)R^(d))carbonyl;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

X is selected from O, S, S(O), SO₂, CH₂, CHR¹⁶, and C(R¹⁶)₂; provided that when m is 0, X is selected from CH₂, CHR¹⁶, and C(R¹⁶)₂;

each R¹⁶ is independently selected from alkoxy, alkyl, aryl, halo, haloalkyl, hydroxy, and —NR^(a)R^(b), wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups.

In a first embodiment of the first aspect m is 0.

In a second embodiment of the first aspect u and v are each independently 0 or 1; and each R¹ and R² is independently selected from alkyl and halo.

In a third embodiment of the first aspect u and v are each 0.

In a fourth embodiment of the first aspect X is selected from CH₂ and CHR¹⁶. In a fifth embodiment of the first aspect X is CH₂.

In a sixth embodiment of the first aspect R³ and R⁴ are each independently selected from hydrogen, haloalkyl, and trialkylsilylalkoxyalkyl. In a seventh embodiment R³ and R⁴ are each independently selected from hydrogen and haloalkyl.

In an eighth embodiment of the first aspect n is 0, 1, or 2; and, when present, each R¹⁶ is halo. In a ninth embodiment n is 0.

In a tenth embodiment of the first aspect R⁵ and R⁶ are independently selected from hydrogen and alkyl.

In an eleventh embodiment of the first aspect R¹¹ and R¹² are independently selected from hydrogen and alkyl.

In a twelfth embodiment of the first aspect at least one of R⁷ and R¹⁴ is hydrogen.

In a thirteenth embodiment of the first aspect R⁷ is R⁹—C(O)—; and R¹⁴ is R¹⁵—C(O)—. In a fourteenth embodiment R⁹ and R¹⁵ are each independently selected from alkoxy, alkoxyalkyl, alkyl, alkylcarbonylalkyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, aryloxyalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkyloxyalkyl, heterocyclyl, heterocyclylalkyl, hydroxyalkyl, —NR^(c)R^(d), (NR^(c)R^(d))alkenyl, (NR^(c)R^(d))alkyl, and (NR^(c)R^(d))carbonyl. In a fifteenth embodiment R⁹ and R¹⁵ are each independently selected from alkoxy, arylalkoxy, arylalkyl, and (NR^(c)R^(d))alkyl.

In a second aspect the present disclosure provides a compound of Formula (II)

or a pharmaceutically acceptable salt thereof, wherein

A and B are independently selected from phenyl and a six-membered heteroaromatic ring containing one, two, or three nitrogen atoms;

R³ and R⁴ are each independently selected from hydrogen, haloalkyl, and trialkylsilylalkoxyalkyl;

R⁵ and R⁶ are each independently selected from hydrogen, and alkyl;

R⁷ is selected from hydrogen and R⁹—C(O)—;

R⁸ is selected from hydrogen and alkyl;

R⁹ is independently selected from alkoxy, arylalkoxy, arylalkyl, and (NR^(c)R^(d))alkyl;

R¹⁰ is selected from

R¹¹ and R¹² are each independently selected from hydrogen and alkyl;

R¹³ is selected from hydrogen and alkyl;

R¹⁴ is selected from hydrogen and R¹⁵—C(O)—; and

R¹⁵ is independently selected from alkoxy, arylalkoxy, arylalkyl, and (NR^(c)R^(d))alkyl.

In a third aspect the present disclosure provides a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In a first embodiment of the third aspect, the composition comprises one or two additional compounds having anti-HCV activity. In a second embodiment of the third aspect at least one of the additional compounds is an interferon or a ribavirin. In a third embodiment of the third aspect the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.

In a fourth embodiment of the third aspect the present disclosure provides a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and one or two additional compounds having anti-HCV activity, wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.

In a fifth embodiment of the third aspect the present disclosure provides a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and one or two additional compounds having anti-HCV activity, wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.

In a fourth aspect the present disclosure provides a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In a first embodiment of the fourth aspect the method further comprises administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of Formula (I), or a pharmaceutically acceptable salt thereof. In a second embodiment of the fourth aspect at least one of the additional compounds is an interferon or a ribavirin. In a third embodiment of the fourth aspect the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.

In a fourth embodiment of the fourth aspect the present disclosure provides a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof and administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.

In a fifth embodiment of the fourth aspect the present disclosure provides a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof and administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.

Other embodiments of the present disclosure may comprise suitable combinations of two or more of embodiments and/or aspects disclosed herein.

Yet other embodiments and aspects of the disclosure will be apparent according to the description provided below.

The compounds of the present disclosure also exist as tautomers; therefore the present disclosure also encompasses all tautomeric forms.

The description of the present disclosure herein should be construed in congruity with the laws and principals of chemical bonding. In some instances it may be necessary to remove a hydrogen atom in order accommodate a substitutent at any given location. For example, in the structure shown below

R⁸ may be attached to either the carbon atom in the imidazole ring or, alternatively, R⁸ may take the place of the hydrogen atom on the nitrogen ring to form an N-substituted imidazole.

It should be understood that the compounds encompassed by the present disclosure are those that are suitably stable for use as pharmaceutical agent.

It is intended that the definition of any substituent or variable (e.g., R¹, R², R⁵, R⁶, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule. For example, when u is 2, each of the two R¹ groups may be the same or different.

All patents, patent applications, and literature references cited in the specification are herein incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure, including definitions, will prevail.

As used in the present specification, the following terms have the meanings indicated:

As used herein, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise.

Unless stated otherwise, all aryl, cycloalkyl, and heterocyclyl groups of the present disclosure may be substituted as described in each of their respective definitions. For example, the aryl part of an arylalkyl group may be substituted as described in the definition of the term ‘aryl’.

The term “alkenyl,” as used herein, refers to a straight or branched chain group of two to six carbon atoms containing at least one carbon-carbon double bond.

The term “alkenyloxy,” as used herein, refers to an alkenyl group attached to the parent molecular moiety through an oxygen atom.

The term “alkenyloxycarbonyl,” as used herein, refers to an alkenyloxy group attached to the parent molecular moiety through a carbonyl group.

The term “alkoxy,” as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom.

The term “alkoxyalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three alkoxy groups.

The term “alkoxyalkylcarbonyl,” as used herein, refers to an alkoxyalkyl group attached to the parent molecular moiety through a carbonyl group.

The term “alkoxycarbonyl,” as used herein, refers to an alkoxy group attached to the parent molecular moiety through a carbonyl group.

The term “alkoxycarbonylalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three alkoxycarbonyl groups.

The term “alkyl,” as used herein, refers to a group derived from a straight or branched chain saturated hydrocarbon containing from one to six carbon atoms. In the compounds of the present disclosure, when m and/or n is 1 or 2; X and/or Y is CHR⁵ and/or CHR⁶, respectively, and R⁵ and/or R⁶ is alkyl, each alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom to provide one of the structures shown below:

where z is 1, 2, 3, or 4, w is 0, 1, or 2, and R⁵⁰ is alkyl. When w is 2, the two R⁵⁰ alkyl groups may be the same or different.

The term “alkylcarbonyl,” as used herein, refers to an alkyl group attached to the parent molecular moiety through a carbonyl group.

The term “alkylcarbonylalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three alkylcarbonyl groups.

The term “alkylcarbonyloxy,” as used herein, refers to an alkylcarbonyl group attached to the parent molecular moiety through an oxygen atom.

The term “alkylsulfanyl,” as used herein, refers to an alkyl group attached to the parent molecular moiety through a sulfur atom.

The term “alkylsulfonyl,” as used herein, refers to an alkyl group attached to the parent molecular moiety through a sulfonyl group.

The term “aryl,” as used herein, refers to a phenyl group, or a bicyclic fused ring system wherein one or both of the rings is a phenyl group. Bicyclic fused ring systems consist of a phenyl group fused to a four- to six-membered aromatic or non-aromatic carbocyclic ring. The aryl groups of the present disclosure can be attached to the parent molecular moiety through any substitutable carbon atom in the group. Representative examples of aryl groups include, but are not limited to, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl. The aryl groups of the present disclosure are optionally substituted with one, two, three, four, or five substituents independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, a second aryl group, arylalkoxy, arylalkyl, arylcarbonyl, cyano, halo, haloalkoxy, haloalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, hydroxy, hydroxyalkyl, nitro, —NR^(x)R^(y), (NR^(x)R^(y))alkyl, oxo, and —P(O)OR₂, wherein each R is independently selected from hydrogen and alkyl; and wherein the alkyl part of the arylalkyl and the heterocyclylalkyl are unsubstituted and wherein the second aryl group, the aryl part of the arylalkyl, the aryl part of the arylcarbonyl, the heterocyclyl, and the heterocyclyl part of the heterocyclylalkyl and the heterocyclylcarbonyl are further optionally substituted with one, two, or three substituents independently selected from alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, and nitro.

The term “arylalkenyl,” as used herein, refers to an alkenyl group substituted with one, two, or three aryl groups.

The term “arylalkoxy,” as used herein, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.

The term “arylalkoxyalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three arylalkoxy groups.

The term “arylalkoxyalkylcarbonyl,” as used herein, refers to an arylalkoxyalkyl group attached to the parent molecular moiety through a carbonyl group.

The term “arylalkoxycarbonyl,” as used herein, refers to an arylalkoxy group attached to the parent molecular moiety through a carbonyl group.

The term “arylalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three aryl groups. The alkyl part of the arylalkyl is further optionally substituted with one or two additional groups independently selected from alkoxy, alkylcarbonyloxy, halo, haloalkoxy, haloalkyl, heterocyclyl, hydroxy, and —NR^(c)R^(d), wherein the heterocyclyl is further optionally substituted with one or two substituents independently selected from alkoxy, alkyl, unsubstituted aryl, unsubstituted arylalkoxy, unsubstituted arylalkoxycarbonyl, halo, haloalkoxy, haloalkyl, hydroxy, and —NR^(x)R^(y).

The term “arylalkylcarbonyl,” as used herein, refers to an arylalkyl group attached to the parent molecular moiety through a carbonyl group.

The term “arylcarbonyl,” as used herein, refers to an aryl group attached to the parent molecular moiety through a carbonyl group.

The term “aryloxy,” as used herein, refers to an aryl group attached to the parent molecular moiety through an oxygen atom.

The term “aryloxyalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three aryloxy groups.

The term “aryloxycarbonyl,” as used herein, refers to an aryloxy group attached to the parent molecular moiety through a carbonyl group.

The term “arylsulfonyl,” as used herein, refers to an aryl group attached to the parent molecular moiety through a sulfonyl group.

The terms “Cap” and “cap” as used herein, refer to the group which is placed on the nitrogen atom of the terminal nitrogen-containing ring, i.e., the pyrrolidine rings of compound 1e. It should be understood that “Cap” or “cap” can refer to the reagent used to append the group to the terminal nitrogen-containing ring or to the fragment in the final product, i.e., “Cap-51” or “The Cap-51 fragment found in LS-19”.

The term “carbonyl,” as used herein, refers to —C(O)—.

The term “carboxy,” as used herein, refers to —CO₂H.

The term “cyano,” as used herein, refers to —CN.

The term “cycloalkyl,” as used herein, refers to a saturated monocyclic, hydrocarbon ring system having three to seven carbon atoms and zero heteroatoms. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. The cycloalkyl groups of the present disclosure are optionally substituted with one, two, three, four, or five substituents independently selected from alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, heterocyclyl, hydroxy, hydroxyalkyl, nitro, and —NR^(x)R^(y), wherein the aryl and the heterocyclyl are further optionally substituted with one, two, or three substituents independently selected from alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and nitro.

The term “(cycloalkyl)alkenyl,” as used herein, refers to an alkenyl group substituted with one, two, or three cycloalkyl groups.

The term “(cycloalkyl)alkyl,” as used herein, refers to an alkyl group substituted with one, two, or three cycloalkyl groups. The alkyl part of the (cycloalkyl)alkyl is further optionally substituted with one or two groups independently selected from hydroxy and —NR^(c)R^(d).

The term “cycloalkyloxy,” as used herein, refers to a cycloalkyl group attached to the parent molecular moiety through an oxygen atom.

The term “cycloalkyloxyalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three cycloalkyloxy groups.

The term “cycloalkylsulfonyl,” as used herein, refers to a cycloalkyl group attached to the parent molecular moiety through a sulfonyl group.

The term “formyl,” as used herein, refers to —CHO.

The terms “halo” and “halogen,” as used herein, refer to F, Cl, Br, or I.

The term “haloalkoxy,” as used herein, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.

The term “haloalkoxycarbonyl,” as used herein, refers to a haloalkoxy group attached to the parent molecular moiety through a carbonyl group.

The term “haloalkyl,” as used herein, refers to an alkyl group substituted by one, two, three, or four halogen atoms.

The term “heterocyclyl,” as used herein, refers to a four-, five-, six-, or seven-membered ring containing one, two, three, or four heteroatoms independently selected from nitrogen, oxygen, and sulfur. The four-membered ring has zero double bonds, the five-membered ring has zero to two double bonds, and the six- and seven-membered rings have zero to three double bonds. The term “heterocyclyl” also includes bicyclic groups in which the heterocyclyl ring is fused to another monocyclic heterocyclyl group, or a four- to six-membered aromatic or non-aromatic carbocyclic ring; as well as bridged bicyclic groups such as 7-azabicyclo[2.2.1]hept-7-yl, 2-azabicyclo[2.2.2]oc-2-tyl, and 2-azabicyclo[2.2.2]oc-3-tyl. The heterocyclyl groups of the present disclosure can be attached to the parent molecular moiety through any carbon atom or nitrogen atom in the group. Examples of heterocyclyl groups include, but are not limited to, benzothienyl, furyl, imidazolyl, indolinyl, indolyl, isothiazolyl, isoxazolyl, morpholinyl, oxazolyl, piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrrolopyridinyl, pyrrolyl, thiazolyl, thienyl, thiomorpholinyl, 7-azabicyclo[2.2.1]hept-7-yl, 2-azabicyclo[2.2.2]oc-2-tyl, and 2-azabicyclo[2.2.2]oc-3-tyl. The heterocyclyl groups of the present disclosure are optionally substituted with one, two, three, four, or five substituents independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, arylalkyl, arylcarbonyl, cyano, halo, haloalkoxy, haloalkyl, a second heterocyclyl group, heterocyclylalkyl, heterocyclylcarbonyl, hydroxy, hydroxyalkyl, nitro, —NR^(x)R^(y), (NR^(x)R^(y))alkyl, and oxo, wherein the alkyl part of the arylalkyl and the heterocyclylalkyl are unsubstituted and wherein the aryl, the aryl part of the arylalkyl, the aryl part of the arylcarbonyl, the second heterocyclyl group, and the heterocyclyl part of the heterocyclylalkyl and the heterocyclylcarbonyl are further optionally substituted with one, two, or three substituents independently selected from alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, and nitro.

The term “heterocyclylalkenyl,” as used herein, refers to an alkenyl group substituted with one, two, or three heterocyclyl groups.

The term “heterocyclylalkoxy,” as used herein, refers to a heterocyclyl group attached to the parent molecular moiety through an alkoxy group.

The term “heterocyclylalkoxycarbonyl,” as used herein, refers to a heterocyclylalkoxy group attached to the parent molecular moiety through a carbonyl group.

The term “heterocyclylalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three heterocyclyl groups. The alkyl part of the heterocyclylalkyl is further optionally substituted with one or two additional groups independently selected from alkoxy, alkylcarbonyloxy, aryl, halo, haloalkoxy, haloalkyl, hydroxy, and —NR^(c)R^(d), wherein the aryl is further optionally substituted with one or two substituents independently selected from alkoxy, alkyl, unsubstituted aryl, unsubstituted arylalkoxy, unsubstituted arylalkoxycarbonyl, halo, haloalkoxy, haloalkyl, hydroxy, and —NR^(x)R^(y).

The term “heterocyclylalkylcarbonyl,” as used herein, refers to a heterocyclylalkyl group attached to the parent molecular moiety through a carbonyl group.

The term “heterocyclylcarbonyl,” as used herein, refers to a heterocyclyl group attached to the parent molecular moiety through a carbonyl group.

The term “heterocyclyloxy,” as used herein, refers to a heterocyclyl group attached to the parent molecular moiety through an oxygen atom.

The term “heterocyclyloxyalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three heterocyclyloxy groups.

The term “heterocyclyloxycarbonyl,” as used herein, refers to a heterocyclyloxy group attached to the parent molecular moiety through a carbonyl group.

The term “hydroxy,” as used herein, refers to —OH.

The term “hydroxyalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three hydroxy groups.

The term “hydroxyalkylcarbonyl,” as used herein, refers to a hydroxyalkyl group attached to the parent molecular moiety through a carbonyl group.

The term “nitro,” as used herein, refers to —NO₂.

The term “—NR^(a)R^(b),” as used herein, refers to two groups, R^(a) and R^(b), which are attached to the parent molecular moiety through a nitrogen atom. R^(a) and R^(b) are independently selected from hydrogen, alkenyl, and alkyl.

The term “(NR^(a)R^(b))alkyl,” as used herein, refers to an alkyl group substituted with one, two, or three —NR^(a)R^(b) groups.

The term “(NR^(a)R^(b))carbonyl,” as used herein, refers to an —NR^(a)R^(b) group attached to the parent molecular moiety through a carbonyl group.

The term “NR^(c)R^(d),” as used herein, refers to two groups, R^(c) and R^(d), which are attached to the parent molecular moiety through a nitrogen atom. R^(c) and R^(d) are independently selected from hydrogen, alkenyloxycarbonyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkoxycarbonyl, arylalkyl, arylalkylcarbonyl, arylcarbonyl, aryloxycarbonyl, arylsulfonyl, cycloalkyl, cycloalkylsulfonyl, formyl, haloalkoxycarbonyl, heterocyclyl, heterocyclylalkoxycarbonyl, heterocyclylalkyl, heterocyclylalkylcarbonyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, hydroxyalkylcarbonyl, (NR^(e)R^(f))alkyl, (NR^(e)R^(f))alkylcarbonyl, (NR^(e)R^(f))carbonyl, (NR^(e)R^(f))sulfonyl, —C(NCN)OR′, and —C(NCN)NR^(x)R^(y), wherein R′ is selected from alkyl and unsubstituted phenyl, and wherein the alkyl part of the arylalkyl, the arylalkylcarbonyl, the heterocyclylalkyl, and the heterocyclylalkylcarbonyl are further optionally substituted with one —NR^(e)R^(f) group; and wherein the aryl, the aryl part of the arylalkoxycarbonyl, the arylalkyl, the arylalkylcarbonyl, the arylcarbonyl, the aryloxycarbonyl, and the arylsulfonyl, the heterocyclyl, and the heterocyclyl part of the heterocyclylalkoxycarbonyl, the heterocyclylalkyl, the heterocyclylalkylcarbonyl, the heterocyclylcarbonyl, and the heterocyclyloxycarbonyl are further optionally substituted with one, two, or three substituents independently selected from alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, and nitro.

The term “(NR^(c)R^(d))alkenyl,” as used herein, refers to an alkenyl group substituted with one, two, or three —NR^(c)R^(d) groups.

The term “(NR^(c)R^(d))alkyl,” as used herein, refers to an alkyl group substituted with one, two, or three —NR^(c)R^(d) groups. The alkyl part of the (NR^(c)R^(d))alkyl is further optionally substituted with one or two additional groups selected from alkoxy, alkoxyalkylcarbonyl, alkoxycarbonyl, alkylsulfanyl, arylalkoxyalkylcarbonyl, carboxy, heterocyclyl, heterocyclylcarbonyl, hydroxy, and (NR^(e)R^(f))carbonyl; wherein the heterocyclyl is further optionally substituted with one, two, three, four, or five substituents independently selected from alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, and nitro.

The term “(NR^(c)R^(d))carbonyl,” as used herein, refers to an —NR^(c)R^(d) group attached to the parent molecular moiety through a carbonyl group.

The term “—NR^(e)R^(f),” as used herein, refers to two groups, R^(e) and R^(f) which are attached to the parent molecular moiety through a nitrogen atom. R^(e) and R^(f) are independently selected from hydrogen, alkyl, unsubstituted aryl, unsubstituted arylalkyl, unsubstituted cycloalkyl, unsubstituted (cycloalkyl)alkyl, unsubstituted heterocyclyl, unsubstituted heterocyclylalkyl, (NR^(x)R^(y))alkyl, and (NR^(x)R^(y))carbonyl.

The term “(NR^(e)R^(f))alkyl,” as used herein, refers to an alkyl group substituted with one, two, or three —NR^(e)R^(f) groups.

The term “(NR^(e)R^(f))alkylcarbonyl,” as used herein, refers to an (NR^(e)R^(f))alkyl group attached to the parent molecular moiety through a carbonyl group.

The term “(NR^(e)R^(f))carbonyl,” as used herein, refers to an —NR^(e)R^(f) group attached to the parent molecular moiety through a carbonyl group.

The term “(NR^(e)R^(f))sulfonyl,” as used herein, refers to an —NR^(e)R^(f) group attached to the parent molecular moiety through a sulfonyl group.

The term “—NR^(x)R^(y),” as used herein, refers to two groups, R^(x) and R^(y), which are attached to the parent molecular moiety through a nitrogen atom. R^(x) and R^(y) are independently selected from hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, unsubstituted aryl, unsubstituted arylalkoxycarbonyl, unsubstituted arylalkyl, unsubstituted cycloalkyl, unsubstituted heterocyclyl, and (NR^(x′)R^(y′))carbonyl, wherein R^(x′) and R^(y′) are independently selected from hydrogen and alkyl.

The term “(NR^(x)R^(y))alkyl,” as used herein, refers to an alkyl group substituted with one, two, or three —NR^(x)R^(y) groups.

The term “oxo,” as used herein, refers to ═O.

The term “sulfonyl,” as used herein, refers to —SO₂—.

The term “trialkylsilyl,” as used herein, refers to —SiR₃, wherein R is alkyl. The R groups may be the same or different.

The term “trialkylsilylalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three trialkylsilyl groups.

The term “trialkylsilylalkoxy,” as used herein, refers to a trialkylsilylalkyl group attached to the parent molecular moiety through an oxygen atom.

The term “trialkylsilylalkoxyalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three trialkylsilylalkoxy groups.

Asymmetric centers exist in the compounds of the present disclosure. These centers are designated by the symbols “R” or “S”, depending on the configuration of substituents around the chiral carbon atom. It should be understood that the disclosure encompasses all stereochemical isomeric forms, or mixtures thereof, which possess the ability to inhibit NS5A. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art.

Certain compounds of the present disclosure may also exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. The present disclosure includes each conformational isomer of these compounds and mixtures thereof.

The term “compounds of the present disclosure”, and equivalent expressions, are meant to embrace compounds of Formula (I), and pharmaceutically acceptable enantiomers, diastereomers, and salts thereof. Similarly, references to intermediates are meant to embrace their salts where the context so permits.

The compounds of the present disclosure can exist as pharmaceutically acceptable salts. The term “pharmaceutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds of the present disclosure which are water or oil-soluble or dispersible, which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use The salts can be prepared during the final isolation and purification of the compounds or separately by reacting a suitable nitrogen atom with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate; digluconate, dihydrobromide, dihydrochloride, dihydroiodide, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate, and undecanoate. Examples of acids which can be employed to form pharmaceutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.

Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of pharmaceutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, and N,N′-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

When it is possible that, for use in therapy, therapeutically effective amounts of a compound of formula (I), as well as pharmaceutically acceptable salts thereof, may be administered as the raw chemical, it is possible to present the active ingredient as a pharmaceutical composition. Accordingly, the disclosure further provides pharmaceutical compositions, which include therapeutically effective amounts of compounds of formula (I) or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. The term “therapeutically effective amount,” as used herein, refers to the total amount of each active component that is sufficient to show a meaningful patient benefit, e.g., a reduction in viral load. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially, or simultaneously. The compounds of formula (I) and pharmaceutically acceptable salts thereof, are as described above. The carrier(s), diluent(s), or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another aspect of the present disclosure there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of formula (J), or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, diluents, or excipients. The term “pharmaceutically acceptable,” as used herein, refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.

Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Dosage levels of between about 0.01 and about 250 milligram per kilogram (“mg/kg”) body weight per day, preferably between about 0.05 and about 100 mg/kg body weight per day of the compounds of the present disclosure are typical in a monotherapy for the prevention and treatment of HCV mediated disease. Typically, the pharmaceutical compositions of this disclosure will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending on the condition being treated, the severity of the condition, the time of administration, the route of administration, the rate of excretion of the compound employed, the duration of treatment, and the age, gender, weight, and condition of the patient. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. Treatment may be initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general, the compound is most desirably administered at a concentration level that will generally afford antivirally effective results without causing any harmful or deleterious side effects.

When the compositions of this disclosure comprise a combination of a compound of the present disclosure and one or more additional therapeutic or prophylactic agent, both the compound and the additional agent are usually present at dosage levels of between about 10 to 150%, and more preferably between about 10 and 80% of the dosage normally administered in a monotherapy regimen.

Pharmaceutical formulations may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parenteral (including subcutaneous, intracutaneous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional, intravenous, or intradermal injections or infusions) route. Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s). Oral administration or administration by injection are preferred.

Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil emulsions.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing, and coloring agent can also be present.

Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate, or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate, or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, and the like. Lubricants used in these dosage forms include sodium oleate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, betonite, xanthan gum, and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant, and pressing into tablets. A powder mixture is prepared by mixing the compound, suitable comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelating, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or and absorption agent such as betonite, kaolin, or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage, or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc, or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present disclosure can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material, and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

Oral fluids such as solution, syrups, and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners, or saccharin or other artificial sweeteners, and the like can also be added.

Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax, or the like.

The compounds of formula (I), and pharmaceutically acceptable salts thereof, can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

The compounds of formula (I) and pharmaceutically acceptable salts thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research 1986, 3(6), 318.

Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils.

Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas.

Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a course powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or nasal drops, include aqueous or oil solutions of the active ingredient.

Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurized aerosols, nebulizers, or insufflators.

Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations.

Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

The term “patient” includes both human and other mammals.

The term “treating” refers to: (i) preventing a disease, disorder or condition from occurring in a patient that may be predisposed to the disease, disorder, and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease, disorder, or condition, i.e., arresting its development; and (iii) relieving the disease, disorder, or condition, i.e., causing regression of the disease, disorder, and/or condition.

The compounds of the present disclosure can also be administered with a cyclosporin, for example, cyclosporin A. Cyclosporin A has been shown to be active against HCV in clinical trials (Hematology 2003, 38, 1282; Biochem. Biophys. Res. Commun. 2004, 313, 42; J. Gastroenterol. 2003, 38, 567).

Table 1 below lists some illustrative examples of compounds that can be administered with the compounds of this disclosure. The compounds of the disclosure can be administered with other anti-HCV activity compounds in combination therapy, either jointly or separately, or by combining the compounds into a composition.

TABLE 1 Physiological Type of Inhibitor or Source Brand Name Class Target Company NIM811 Cyclophilin Novartis Inhibitor Zadaxin Immunomodulator Sciclone Suvus Methylene blue Bioenvision Actilon (CPG10101) TLR9 agonist Coley Batabulin (T67) Anticancer β-tubulin inhibitor Tularik Inc., South San Francisco, CA ISIS 14803 Antiviral antisense ISIS Pharmaceuticals Inc, Carlsbad, CA/Elan Phamaceuticals Inc., New York, NY Summetrel Antiviral antiviral Endo Pharmaceuticals Holdings Inc., Chadds Ford, PA GS-9132 (ACH-806) Antiviral HCV Inhibitor Achillion/ Gilead Pyrazolopyrimidine Antiviral HCV Inhibitors Arrow compounds and salts Therapeutics From WO- Ltd. 2005047288 26 May 2005 Levovirin Antiviral IMPDH inhibitor Ribapharm Inc., Costa Mesa, CA Merimepodib Antiviral IMPDH inhibitor Vertex (VX-497) Pharmaceuticals Inc., Cambridge, MA XTL-6865 (XTL-002) Antiviral monoclonal XTL antibody Biopharmaceuticals Ltd., Rehovot, Isreal Telaprevir Antiviral NS3 serine protease Vertex (VX-950, LY-570310) inhibitor Pharmaceuticals Inc., Cambridge, MA/Eli Lilly and Co. Inc., Indianapolis, IN HCV-796 Antiviral NS5B Replicase Wyeth/ Inhibitor Viropharma NM-283 Antiviral NS5B Replicase Idenix/ Inhibitor Novartis GL-59728 Antiviral NS5B Replicase Gene Labs/ Inhibitor Novartis GL-60667 Antiviral NS5B Replicase Gene Labs/ Inhibitor Novartis 2′C MeA Antiviral NS5B Replicase Gilead Inhibitor PSI 6130 Antiviral NS5B Replicase Roche Inhibitor R1626 Antiviral NS5B Replicase Roche Inhibitor 2′C Methyl adenosine Antiviral NS5B Replicase Merck Inhibitor JTK-003 Antiviral RdRp inhibitor Japan Tobacco Inc., Tokyo, Japan Levovirin Antiviral ribavirin ICN Pharmaceuticals, Costa Mesa, CA Ribavirin Antiviral ribavirin Schering- Plough Corporation, Kenilworth, NJ Viramidine Antiviral Ribavirin Prodrug Ribapharm Inc., Costa Mesa, CA Heptazyme Antiviral ribozyme Ribozyme Pharmaceuticals Inc., Boulder, CO BILN-2061 Antiviral serine protease Boehringer inhibitor Ingelheim Pharma KG, Ingelheim, Germany SCH 503034 Antiviral serine protease Schering inhibitor Plough Zadazim Immune Immune modulator SciClone modulator Pharmaceuticals Inc., San Mateo, CA Ceplene Immunomodulator immune modulator Maxim Pharmaceuticals Inc., San Diego, CA CellCept Immunosuppressant HCV IgG F. Hoffmann- immunosuppressant La Roche LTD, Basel, Switzerland Civacir Immunosuppressant HCV IgG Nabi immunosuppressant Biopharmaceuticals Inc., Boca Raton, FL Albuferon-α Interferon albumin IFN-α2b Human Genome Sciences Inc., Rockville, MD Infergen A Interferon IFN alfacon-1 InterMune Pharmaceuticals Inc., Brisbane, CA Omega IFN Interferon IFN-ω Intarcia Therapeutics IFN-β and EMZ701 Interferon IFN-β and EMZ701 Transition Therapeutics Inc., Ontario, Canada Rebif Interferon IFN-β1a Serono, Geneva, Switzerland Roferon A Interferon IFN-α2a F. Hoffmann- La Roche LTD, Basel, Switzerland Intron A Interferon IFN-α2b Schering- Plough Corporation, Kenilworth, NJ Intron A and Zadaxin Interferon IFN-α2b/α1- RegeneRx thymosin Biopharmiceuticals Inc., Bethesda, MD/ SciClone Pharmaceuticals Inc, San Mateo, CA Rebetron Interferon IFN-α2b/ribavirin Schering- Plough Corporation, Kenilworth, NJ Actimmune Interferon INF-γ InterMune Inc., Brisbane, CA Interferon-β Interferon Interferon-β-1a Serono Multiferon Interferon Long lasting IFN Viragen/Valentis Wellferon Interferon lymphoblastoid GlaxoSmithKline IFN-αn1 plc, Uxbridge, UK Omniferon Interferon natural IFN-α Viragen Inc., Plantation, FL Pegasys Interferon PEGylated IFN-α2a F. Hoffmann- La Roche LTD, Basel, Switzerland Pegasys and Ceplene Interferon PEGylated IFN- Maxim α2a/ Pharmaceuticals immune modulator Inc., San Diego, CA Pegasys and Ribavirin Interferon PEGylated IFN- F. Hoffmann- α2a/ribavirin La Roche LTD, Basel, Switzerland PEG-Intron Interferon PEGylated IFN-α2b Schering- Plough Corporation, Kenilworth, NJ PEG-Intron/ Interferon PEGylated IFN- Schering- Ribavirin α2b/ribavirin Plough Corporation, Kenilworth, NJ IP-501 Liver protection antifibrotic Indevus Pharmaceuticals Inc., Lexington, MA IDN-6556 Liver protection caspase inhibitor Idun Pharmaceuticals Inc., San Diego, CA ITMN-191 (R-7227) Antiviral serine protease InterMune inhibitor Pharmaceuticals Inc., Brisbane, CA GL-59728 Antiviral NS5B Replicase Genelabs Inhibitor ANA-971 Antiviral TLR-7 agonist Anadys

The compounds of the present disclosure may also be used as laboratory reagents. Compounds may be instrumental in providing research tools for designing of viral replication assays, validation of animal assay systems and structural biology studies to further enhance knowledge of the HCV disease mechanisms. Further, the compounds of the present disclosure are useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition.

The compounds of this disclosure may also be used to treat or prevent viral contamination of materials and therefore reduce the risk of viral infection of laboratory or medical personnel or patients who come in contact with such materials, e.g., blood, tissue, surgical instruments and garments, laboratory instruments and garments, and blood collection or transfusion apparatuses and materials.

This disclosure is intended to encompass compounds having formula (I) when prepared by synthetic processes or by metabolic processes including those occurring in the human or animal body (in vivo) or processes occurring in vitro.

The abbreviations used in the present application, including particularly in the illustrative schemes and examples which follow, are well-known to those skilled in the art. Some of the abbreviations used are as follows: HATU for O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; Boc or BOC for tert-butoxycarbonyl; NBS for N-bromosuccinimide; tBu or t-Bu for tert-butyl; SEM for -(trimethylsilyl)ethoxymethyl; DMSO for dimethylsulfoxide; MeOH for methanol; TFA for trifluoroacetic acid; RT for room temperature or retention time (context will dictate); t_(R) for retention time; EDCl for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DMAP for 4-dimethylaminopyridine; THF for tetrahydrofuran; DBU for 1,8-diazabicyclo[5.4.0]undec-7-ene; t-Bu; DEA for diethylamine; HMDS for hexamethyldisilazide; DMF for N,N-dimethylformamide; Bzl for benzyl; EtOH for ethanol; iPrOH or i-PrOH for isopropanol; Me₂S for dimethylsulfide; Et₃N or TEA for triethylamine; Ph for phenyl; OAc for acetate; EtOAc for ethyl acetate; dppf for 1,1′-bis(diphenylphosphino)ferrocene; iPr₂EtN or DIPEA for diisopropylethylamine; Cbz for carbobenzyloxy; n-BuLi for n-butyllithium; ACN for acetonitrile; h or hr for hours; m or min for minutes; s for seconds; LiHMDS for lithium hexamethyldisilazide; DIBAL for diisobutyl aluminum hydride; TBDMSCl for tert-butyldimethylsilyl chloride; Me for methyl; ca. for about; OAc for acetate; iPr for isopropyl; Et for ethyl; Bn for benzyl; and HOAT for 1-hydroxy-7-azabenzotriazole.

The compounds and processes of the present disclosure will be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds of the present disclosure may be prepared. Starting materials can be obtained from commercial sources or prepared by well-established literature methods known to those of ordinary skill in the art. It will be readily apparent to one of ordinary skill in the art that the compounds defined above can be synthesized by substitution of the appropriate reactants and agents in the syntheses shown below. It will also be readily apparent to one skilled in the art that the selective protection and deprotection steps, as well as the order of the steps themselves, can be carried out in varying order, depending on the nature of the variables to successfully complete the syntheses below. The variables are as defined above unless otherwise noted below.

Scheme 1 Symmetric or Asymmetric Biphenyls

Aryl halide 1 and boronic ester 2 can be coupled to produce biaryl 3 using standard Suzuki-Miayura coupling conditions (Angew Chem. Int. Ed. Engl 2001, 40, 4544). It should be noted that the boronic acid analog of 2 may be used in place of the ester. Mono-deprotection of the pyrrolidine moiety may be accomplished when R¹² and R¹³ are different. When R¹²=benzyl, and R¹³=t-butyl treatment to hydrogenolytic conditions produces 4. For example, Pd/C catalyst in the presence of a base such as potassium carbonate can be used. Acylation of 4 can be accomplished under standard acylation conditions. A coupling reagent such as HATU in combination with an amine base such as Hunig's base can be used in this regard. Alternatively, 4 may be reacted with an isocyanate or carbamoyl chloride to provide compounds of formula 5 where R⁹ is an amine. Further deprotection of 5 can be accomplished by treatment with strong acid such as HCl or trifluoroacetic acid. Standard conditions analogous to those used to convert 4 to 5 can be used to prepare 7 from 6. In another embodiment where R¹²═R¹³=t-Bu, direct conversion to 8 can be accomplished by treatment of 3 with strong acid such as HCl or trifluoroacetic acid. Conversion of 8 to 7 is accomplished in analogous fashion to the methods used to prepare 5 from 4 or 7 from 6. In this instance however, the caps in 7 will be identical.

Conversion of 6 (from Scheme 1) to 10 can be done using standard amide coupling conditions such as HATU with an amine base, such as Hunig's base. Deprotection can be accomplished with strong acid such as HCl or trifluoroacetic acid affording 11. Compound 11 can then be converted to 12, 13, or 14 using an acid chloride, an isocyanate or carbamoyl chloride, or a chloroformate respectively.

Compound 15 (15=7 (Scheme 1) wherein each R⁹ is —CH(NHBoc)R¹⁸) can be converted to 16 via treatment with strong acid such as HCl or trifluoroacetic acid. Compounds 17, 18, and 19 can be prepared from 16 by treating 16 with an appropriate chloroformate, isocyanate or carbamoyl chloride, or an acid chloride respectively.

Symmetrical biphenyl analogs (compounds of formula 7 where both halves of the molecule are equivalent) can be synthesized starting from bromoketone 20. Amination by displacement with a nucleophile such as azide, phthalimide or preferably sodium diformylamide (Yinglin and Hongwen, Synthesis 1990, 122) followed by deprotection affords 21. Condensation under standard amination conditions such as HATU and Hunig's base with an appropriately protected amino acid provides 22. Heating with ammonium acetate under thermal or microwave conditions results in the formation of 3 which can be deprotected with strong acid such as HCl or trifluoroacetic acid (R¹²═R¹³=t-Bu) or by hydrogenolysis with hydrogen gas and a transition metal catalyst such as Pd/C (R¹²═R¹³=benzyl). Acylation can be affected with a carboxylic acid (R⁹CO₂H) in a manner similar to the conversion of 21 to 22. Urea formation can be accomplished by treatment with an appropriate isocyanate (R⁹═R²⁴R²⁵N; R²⁵═H) or carbamoyl chloride (R⁹═R²⁴R²⁵N; R²⁵ is other than hydrogen).

Scheme 5 describes the preparation of some of the starting materials required for the synthetic sequences depicted in Schemes 1-4. Key intermediate 25 (analogous to 1 in Scheme 1) is prepared from keto-amide 24 or keto-ester 27 via heating with ammonium acetate under thermal or microwave conditions. Keto-amide 24 can be prepared from 23 via condensation with an appropriate cyclic or acyclic amino acid under standard amide formation conditions. Bromide 26 can give rise to 23 by treatment with a nucleophile such as azide, phthalimide or sodium diformylamide (Synthesis 1990, 122) followed by deprotection. Bromide 26 can also be converted to 27 by reacting with an appropriate cyclic or acyclic N-protected amino acid in the presence of base such as potassium carbonate or sodium bicarbonate. Bromination of 28 with a source of bromonium ion such as bromine, NBS, or CBr₄ results in the formation of 26. Bromide 25 can be converted to boronic ester 2 via treatment with bis-pinacalotodiboron under palladium catalysis according to the method described in Journal of Organic Chemistry 1995, 60, 7508, or variations thereof.

In another embodiment, starting materials such as 31a (analogous to 25 in Scheme 5 and 1 in Scheme 1) may be prepared by reacting bromoimidazole derivatives 31 under Suzuki-type coupling conditions with a variety of chloro-substituted aryl boronic acids which can either be prepared by standard methodologies (see, for example, Organic Letters 2006, 8, 305 and references cited therein) or purchased from commercial suppliers. Bromoimidazole 31 can be obtained by brominating imidazole 30 with a source of bromonium ion such as bromine, CBr₄, or N-bromosuccinimide. Imidazole 30 can be prepared from N-protected amino acids which are appropriately substituted by reacting with glyoxal in a methanolic solution of ammonium hydroxide.

In yet another embodiment of the current disclosure, aryl halide 32 can be coupled under Suzuki-Miyaura palladium catalyzed conditions to form the heteroaryl derivative 34. Compound 34 can be elaborated to 35 by treatment to hydrogenolytic conditions with hydrogen and a transition metal catalyst such as palladium on carbon (R¹³=benzyl). Acylation of 35 can be accomplished with an appropriate acid chloride (R⁹COCl) in the presence of a base such as triethylamine, with an appropriately substituted carboxylic acid (R⁹CO₂H) in the presence of a standard coupling reagent such as HATU, or with an isocyanate (R²⁷NCO wherein R⁹═R²⁷R²⁸N—; R²⁸═H) or carbamoyl chloride (R²⁷R²⁸NCOCl wherein R⁹═R²⁷R²⁸N—). Compound 37 can be prepared from 36 (R¹²=t-Bu) via treatment with strong acid such as HCl or trifluoroacetic acid. Acylation of the resulting amine in 37 to give 38 can be accomplished as in the transformation of 35 to 36. In cases where R¹²═R¹³, 34 can be directly transformed into 39 by treatment with strong acid such as HCl or trifluoroacetic acid (R¹²═R¹³=t-Bu) or by employing hydrogenolytic conditions with hydrogen and a transition metal catalyst such as palladium on carbon (R¹²═R¹³=benzyl). Acylation of 39 can be accomplished in analogous fashion to that described for the transformation of 35 to 36.

Heteroaryl chloride 29 can be converted to symmetrical analog 40 via treatment with a source of palladium such as dichlorobis(benzonitrile) palladium in the presence of tetrakis(dimethylamino)ethylene at elevated temperature. Removal of the SEM ether and Boc carbamates found in 40 can be accomplished in one step by treatment with a strong acid such as HCl or trifluoroacetic acid providing 41. Conversion to 42 can be accomplished in similar fashion to the conditions used to convert 38 to 39 in Scheme 7.

Compound 43 (analogous to 42 wherein R₂₃=—CH(NHBoc)R₂₄) may be elaborated to 45, 46, and 47 via similar methodologies to those described in Scheme 3. In cases where R₂₀=alkoxymethyl (ie; SEM), removal can be accomplished simultaneously with removal of the Boc carbamate (cf, 43 to 44) using strong acid such as HCl or trifluoroacetic acid.

Heteroaryl bromides 54 may be reacted with a vinyl stannane such as tributyl(1-ethoxyvinyl)tin in the presence of a source of palladium such as dichlorobis(triphenylphosphine)palladium (II) to provide 55 which can be subsequently transformed into bromoketone 51 via treatment with a source of bromonium ion such as N-bromosuccinimide, CBr₄, or bromine. Alternatively, keto-substituted heteroaryl bromides 53 may be directly converted to 51 via treatment with a source of bromonium ion such as bromine, CBr₄, or N-bromosuccinimide. Bromide 51 can be converted to aminoketone 48 via addition of sodium azide, potassium phthalimide or sodium diformylamide (Synthesis 1990 122) followed by deprotection. Aminoketone 48 can then be coupled with an appropriately substituted amino acid under standard amide formation conditions (i.e.; a coupling reagent such as HATU in the presence of a mild base such as Hunig's base) to provide 49. Compound 49 can then be further transformed into imidazole 50 via reacting with ammonium acetate under thermal or microwave conditions. Alternatively, 51 can be directly reacted with an appropriately substituted amino acid in the presence of a base such as sodium bicarbonate or potassium carbonate providing 52 which can in turn be reacted with ammonium acetate under thermal or microwave conditions to provide 50. Imidazole 50 can be protected with an alkoxymethyl group by treatment with the appropriate alkoxymethyl halide such as 2-(trimethylsilyl)ethoxymethyl chloride after first being deprotonated with a strong base such as sodium hydride.

Substituted phenylglycine derivatives can be prepared by a number of methods shown below. Phenylglycine t-butyl ester can be reductively alkylated (pathway A) with an appropriate aldehyde and a reductant such as sodium cyanoborohydride in acidic medium. Hydrolysis of the t-butyl ester can be accomplished with strong acid such as HCl or trifluoroacetic acid. Alternatively, phenylglycine can be alkylated with an alkyl halide such as ethyl iodide and a base such as sodium bicarbonate or potassium carbonate (pathway B). Pathway C illustrates reductive alkylation of phenylglycine as in pathway A followed by a second reductive alkylation with an alternate aldehyde such as formaldehyde in the presence of a reducing agent and acid. Pathway D illustrates the synthesis of substituted phenylglycines via the corresponding mandelic acid analogs. Conversion of the secondary alcohol to a competent leaving group can be accomplished with p-toluenesulfonyl chloride. Displacement of the tosylate group with an appropriate amine followed by reductive removal of the benzyl ester can provide substituted phenylglycine derivatives. In pathway E a racemic substituted phenylglycine derivative is resolved by esterification with an enantiomerically pure chiral auxiliary such as but not limited to (+)-1-phenylethanol, (−)-1-phenylethanol, an Evan's oxazolidinone, or enantiomerically pure pantolactone. Separation of the diastereomers is accomplished via chromatography (silica gel, HPLC, crystallization, etc) followed by removal of the chiral auxiliary providing enantiomerically pure phenylglycine derivatives. Pathway H illustrates a synthetic sequence which intersects with pathway E wherein the aforementioned chiral auxiliary is installed prior to amine addition. Alternatively, an ester of an arylacetic acid can be brominated with a source of bromonium ion such as bromine, N-bromosuccinimide, or CBr₄. The resultant benzylic bromide can be displaced with a variety of mono- or disubstituted amines in the presence of a tertiary amine base such as triethylamine or Hunig's base. Hydrolysis of the methyl ester via treatment with lithium hydroxide at low temperature or 6N HCl at elevated temperature provides the substituted phenylglycine derivatives. Another method is shown in pathway G. Glycine analogs can be derivatized with a variety of aryl halides in the presence of a source of palladium (0) such as palladium bis(tributylphosphine) and base such as potassium phosphate. The resultant ester can then be hydrolyzed by treatment with base or acid. It should be understood that other well known methods to prepare phenylglycine derivatives exist in the art and can be amended to provide the desired compounds in this description. It should also be understood that the final phenylglycine derivatives can be purified to enantiomeric purity greater than 98% ee via preparative HPLC.

In another embodiment of the present disclosure, acylated phenylglycine derivatives may be prepared as illustrated below. Phenylglycine derivatives wherein the carboxylic acid is protected as an easily removed ester, may be acylated with an acid chloride in the presence of a base such as triethylamine to provide the corresponding amides (pathway A). Pathway B illustrates the acylation of the starting phenylglycine derivative with an appropriate chloroformate while pathway C shows reaction with an appropriate isocyanate or carbamoyl chloride. Each of the three intermediates shown in pathways A-C may be deprotected by methods known by those skilled in the art (ie; treatment of the t-butyl ester with strong base such as HCl or trifluoroacetic acid).

Amino-substituted phenylacetic acids may be prepared by treatment of a chloromethylphenylacetic acid with an excess of an amine.

Compound Analysis Conditions

Purity assessment and low resolution mass analysis were conducted on a Shimadzu LC system coupled with Waters Micromass ZQ MS system. It should be noted that retention times may vary slightly between machines. The LC conditions employed in determining the retention time (RT) were:

Condition 1 Column = Phenomenex-Luna 3.0 × 50 mm S10 Start % B = 0 Final % B = 100 Gradient time = 2 min Stop time = 3 min Flow Rate = 4 mL/min Wavelength = 220 nm Slovent A = 0.1% TFA in 10% methanol/90% H₂O Solvent B = 0.1% TFA in 90% methanol/10% H₂O Condition 2 Column = Phenomenex-Luna 4.6 × 50 mm S10 Start % B = 0 Final % B = 100 Gradient time = 2 min Stop time = 3 min Flow Rate = 5 mL/min Wavelength = 220 nm Slovent A = 0.1% TFA in 10% methanol/90% H₂O Solvent B = 0.1% TFA in 90% methanol/10% H₂O Condition 3 Column = HPLC XTERRA C18 3.0 × 50 mm S7 Start % B = 0 Final % B = 100 Gradient time = 3 min Stop time = 4 min Flow Rate = 4 mL/min Wavelength = 220 nm Slovent A = 0.1% TFA in 10% methanol/90% H₂O Solvent B = 0.1% TFA in 90% methanol/10% H₂O Condition M1 Column: Luna 4.6 × 50 mm S10 Start % B = 0 Final % B = 100 Gradient time = 3 min Stop time = 4 min Flow rate = 4 mL/min Solvent A: = 95% H₂0: 5% CH₃CN, 10 mm Ammonium acetate Solvent B: = 5% H₂O: 95% CH₃CN; 10 mm Ammonium acetate

Synthesis of Common Caps

A suspension of 10% Pd/C (2.0 g) in methanol (10 mL) was added to a mixture of (R)-2-phenylglycine (10 g, 66.2 mmol), formaldehyde (33 mL of 37% wt. in water), 1N HCl (30 mL) and methanol (30 mL), and exposed to H₂ (60 psi) for 3 hours. The reaction mixture was filtered through diatomaceous earth (Celite®), and the filtrate was concentrated in vacuo. The resulting crude material was recrystallized from isopropanol to provide the HCl salt of Cap-1 as a white needle (4.0 g). Optical rotation: −117.1° [c=9.95 mg/mL in H₂O; λ=589 nm]. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 500 MHz): δ 7.43-7.34 (m, 5H), 4.14 (s, 1H), 2.43 (s, 6H); LC (Cond. 1): RT=0.25; LC/MS: Anal. Calcd. for [M+H]⁻ C₁₀H₁₄NO₂ 180.10; found 180.17; HRMS: Anal. Calcd. for [M+H]⁻ C₁₀H₁₄NO₂ 180.1025; found 180.1017.

NaBH₃CN (6.22 g, 94 mmol) was added in portions over a few minutes to a cooled (ice/water) mixture of (R)-2-Phenylglycine (6.02 g, 39.8 mmol) and MeOH (100 mL), and stirred for 5 min. Acetaldehyde (10 mL) was added drop-wise over 10 min and stirring was continued at the same cooled temperature for 45 min and at ambient temperature for ˜6.5 hr. The reaction mixture was cooled back with ice-water bath, treated with water (3 mL) and then quenched with a drop-wise addition of concentrated HCl over ˜45 min until the pH of the mixture is ˜1.5-2.0. The cooling bath was removed and the stirring was continued while adding concentrated HCl in order to maintain the pH of the mixture around 1.5-2.0. The reaction mixture was stirred over night, filtered to remove the white suspension, and the filtrate was concentrated in vacuo. The crude material was recrystallized from ethanol to afford the HCl salt of Cap-2 as a shining white solid in two crops (crop-1: 4.16 g; crop-2: 2.19 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): 10.44 (1.00, br s, 1H), 7.66 (m, 2H), 7.51 (m, 3H), 5.30 (s, 1H), 3.15 (br m, 2H), 2.98 (br m, 2H), 1.20 (app br s, 6H). Crop-1: [α]²⁵ −102.21° (c=0.357, H₂O); crop-2: [α]²⁵ −99.7° (c=0.357, H₂O). LC (Cond. 1): RT=0.43 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₂H₁₈NO₂: 208.13; found 208.26

Acetaldehyde (5.0 mL, 89.1 mmol) and a suspension of 10% Pd/C (720 mg) in methanol/H₂O (4 mL/1 mL) was sequentially added to a cooled (˜15° C.) mixture of (R)-2-phenylglycine (3.096 g, 20.48 mmol), 1N HCl (30 mL) and methanol (40 mL). The cooling bath was removed and the reaction mixture was stirred under a balloon of H₂ for 17 hours. An additional acetaldehyde (10 mL, 178.2 mmol) was added and stirring continued under H₂ atmosphere for 24 hours [Note: the supply of H₂ was replenished as needed throughout the reaction]. The reaction mixture was filtered through diatomaceous earth (Celite®), and the filtrate was concentrated in vacuo. The resulting crude material was recrystallized from isopropanol to provide the HCl salt of (R)-2-(ethylamino)-2-phenylacetic acid as a shining white solid (2.846 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 14.15 (br s, 1H), 9.55 (br s, 2H), 7.55-7.48 (m, 5H), 2.88 (br m, 1H), 2.73 (br m, 1H), 1.20 (app t, J=7.2, 3H). LC (Cond. 1): RT=0.39 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₀H₁₄NO₂: 180.10; found 180.18.

A suspension of 10% Pd/C (536 mg) in methanol/H₂O (3 mL/1 mL) was added to a mixture of (R)-2-(ethylamino)-2-phenylacetic acid/HCl (1.492 g, 6.918 mmol), formaldehyde (20 mL of 37% wt. in water), 1N HCl (20 mL) and methanol (23 mL). The reaction mixture was stirred under a balloon of H₂ for ˜72 hours, where the H₂ supply was replenished as needed. The reaction mixture was filtered through diatomaceous earth (Celite®) and the filtrate was concentrated in vacuo. The resulting crude material was recrystallized from isopropanol (50 mL) to provide the HCl salt of Cap-3 as a white solid (985 mg). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 10.48 (br s, 1H), 7.59-7.51 (m, 5H), 5.26 (s, 1H), 3.08 (app br s, 2H), 2.65 (br s, 3H), 1.24 (br m, 3H). LC (Cond. 1): RT=0.39 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₁H₁₆NO₂: 194.12; found 194.18; HRMS: Anal. Calcd. for [M+H]⁺ C₁₁H₁₆NO₂: 194.1180; found 194.1181.

ClCO₂Me (3.2 mL, 41.4 mmol) was added dropwise to a cooled (ice/water) THF (410 mL) semi-solution of (R)-tert-butyl 2-amino-2-phenylacetate/HCl (9.877 g, 40.52 mmol) and diisopropylethylamine (14.2 mL, 81.52 mmol) over 6 min, and stirred at similar temperature for 5.5 hours. The volatile component was removed in vacuo, and the residue was partitioned between water (100 mL) and ethyl acetate (200 mL). The organic layer was washed with 1N HCl (25 mL) and saturated NaHCO₃ solution (30 mL), dried (MgSO₄), filtered, and concentrated in vacuo. The resultant colorless oil was triturated from hexanes, filtered and washed with hexanes (100 mL) to provide (R)-tert-butyl 2-(methoxycarbonylamino)-2-phenylacetate as a white solid (7.7 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): 7.98 (d, J=8.0, 1H), 7.37-7.29 (m, 5H), 5.09 (d, J=8, 1H), 3.56 (s, 3H), 1.33 (s, 9H). LC (Cond. 1): RT=1.53 min; ˜90% homogeneity index; LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₄H₁₉NNaO₄:288.12; found 288.15.

TFA (16 mL) was added dropwise to a cooled (ice/water) CH₂Cl₂ (160 mL) solution of the above product over 7 minutes, and the cooling bath was removed and the reaction mixture was stirred for 20 hours. Since the deprotection was still not complete, an additional TFA (1.0 mL) was added and stirring continued for an additional 2 hours. The volatile component was removed in vacuo, and the resulting oil residue was treated with diethyl ether (15 mL) and hexanes (12 mL) to provide a precipitate. The precipitate was filtered and washed with diethyl ether/hexanes (˜1:3 ratio; 30 mL) and dried in vacuo to provide Cap-4 as a fluffy white solid (5.57 g). Optical rotation: −176.9° [c=3.7 mg/mL in H₂O; λ=589 nm]. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.84 (br s, 1H), 7.96 (d, J=8.3, 1H), 7.41-7.29 (m, 5H), 5.14 (d, J=8.3, 1H), 3.55 (s, 3H). LC (Cond. 1): RT=1.01 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₀H₁₂NO₄ 210.08; found 210.17; HRMS: Anal. Calcd. for [M+H]⁺ C₁₀H₁₂NO₄ 210.0766; found 210.0756.

A mixture of (R)-2-phenylglycine (1.0 g, 6.62 mmol), 1,4-dibromobutane (1.57 g, 7.27 mmol) and Na₂CO₃ (2.10 g, 19.8 mmol) in ethanol (40 mL) was heated at 100° C. for 21 hours. The reaction mixture was cooled to ambient temperature and filtered, and the filtrate was concentrated in vacuo. The residue was dissolved in ethanol and acidified with 1N HCl to pH 3-4, and the volatile component was removed in vacuo. The resulting crude material was purified by a reverse phase HPLC (water/methanol/TFA) to provide the TFA salt of Cap-5 as a semi-viscous white foam (1.0 g). ¹H NMR (DMSO-d₆, δ=2.5, 500 MHz) δ 10.68 (br s, 1H), 7.51 (m, 5H), 5.23 (s, 1H), 3.34 (app br s, 2H), 3.05 (app br s, 2H), 1.95 (app br s, 4H); RT=0.30 min (Cond. 1); >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₂H₁₆NO₂: 206.12; found 206.25.

The TFA salt of Cap-6 was synthesized from (R)-2-phenylglycine and 1-bromo-2-(2-bromoethoxy)ethane by using the method of preparation of Cap-5. ¹H NMR (DMSO-d₆, δ=2.5, 500 MHz) δ 12.20 (br s, 1H), 7.50 (m, 5H), 4.92 (s, 1H), 3.78 (app br s, 4H), 3.08 (app br s, 2H), 2.81 (app br s, 2H); RT=0.32 min (Cond. 1); >98%; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₂H₁₆NO₃: 222.11; found 222.20; HRMS: Anal. Calcd. for [M+H]⁺ C₁₂H₁₆NO₃: 222.1130; found 222.1121.

A CH₂Cl₂ (200 mL) solution of p-toluenesulfonyl chloride (8.65 g, 45.4 mmol) was added dropwise to a cooled (−5° C.) CH₂Cl₂ (200 mL) solution of (S)-benzyl 2-hydroxy-2-phenylacetate (10.0 g, 41.3 mmol), triethylamine (5.75 mL, 41.3 mmol) and 4-dimethylaminopyridine (0.504 g, 4.13 mmol), while maintaining the temperature between −5° C. and 0° C. The reaction was stirred at 0° C. for 9 hours, and then stored in a freezer (−25° C.) for 14 hours. It was allowed to thaw to ambient temperature and washed with water (200 mL), 1N HCl (100 mL) and brine (100 mL), dried (MgSO₄), filtered, and concentrated in vacuo to provide benzyl 2-phenyl-2-(tosyloxy)acetate as a viscous oil which solidified upon standing (16.5 g). The chiral integrity of the product was not checked and that product was used for the next step without further purification. ¹H NMR (DMSO-d₆, δ=2.5, 500 MHz) δ 7.78 (d, J=8.6, 2H), 7.43-7.29 (m, 10H), 7.20 (m, 2H), 6.12 (s, 1H), 5.16 (d, J=12.5, 1H), 5.10 (d, J=12.5, 1H), 2.39 (s, 3H). RT=3.00 (Cond. 3); >90% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₂H₂₀NaO₅S: 419.09. found 419.04.

A THF (75 mL) solution of benzyl 2-phenyl-2-(tosyloxy)acetate (6.0 g, 15.1 mmol), 1-methylpiperazine (3.36 mL, 30.3 mmol) and N,N-diisopropylethylamine (13.2 mL, 75.8 mmol) was heated at 65° C. for 7 hours. The reaction was allowed to cool to ambient temperature and the volatile component was removed in vacuo. The residue was partitioned between ethylacetate and water, and the organic layer was washed with water and brine, dried (MgSO₄), filtered, and concentrated in vacuo. The resulting crude material was purified by flash chromatography (silica gel, ethyl acetate) to provide benzyl 2-(4-methylpiperazin-1-yl)-2-phenylacetate as an orangish-brown viscous oil (4.56 g). Chiral HPLC analysis (Chiralcel OD-H) indicated that the sample is a mixture of enantiomers in a 38.2 to 58.7 ratio. The separation of the enantiomers were effected as follow: the product was dissolved in 120 mL of ethanol/heptane (1:1) and injected (5 mL/injection) on chiral HPLC column (Chiracel OJ, 5 cm ID×50 cm L, 20 μm) eluting with 85:15 Heptane/ethanol at 75 mL/min, and monitored at 220 nm. Enantiomer-1 (1.474 g) and enantiomer-2 (2.2149 g) were retrieved as viscous oil. ¹H NMR (CDCl₃, δ=7.26, 500 MHz) 7.44-7.40 (m, 2H), 7.33-7.24 (m, 6H), 7.21-7.16 (m, 2H), 5.13 (d, J=12.5, 1H), 5.08 (d, J=12.5, 1H), 4.02 (s, 1H), 2.65-2.38 (app br s, 8H), 2.25 (s, 3H). RT=2.10 (Cond. 3); >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₀H₂₅N₂O₂: 325.19; found 325.20.

A methanol (10 mL) solution of either enantiomer of benzyl 2-(4-methylpiperazin-1-yl)-2-phenylacetate (1.0 g, 3.1 mmol) was added to a suspension of 10% Pd/C (120 mg) in methanol (5.0 mL). The reaction mixture was exposed to a balloon of hydrogen, under a careful monitoring, for <50 min. Immediately after the completion of the reaction, the catalyst was filtered through diatomaceous earth (Celite®) and the filtrate was concentrated in vacuo to provide Cap-7, contaminated with phenylacetic acid as a tan foam (867.6 mg; mass is above the theoretical yield). The product was used for the next step without further purification. ¹H NMR (DMSO-d₆, δ=2.5, 500 MHz) δ 7.44-7.37 (m, 2H), 7.37-7.24 (m, 3H), 3.92 (s, 1H), 2.63-2.48 (app. bs, 2H), 2.48-2.32 (m, 6H), 2.19 (s, 3H); RT=0.31 (Cond. 2); >90% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₃H₁₉N₂O₂: 235.14; found 235.15; HRMS: Anal. Calcd. for [M+H]⁺ C₁₃H₁₉N₂O₂: 235.1447; found 235.1440.

The synthesis of Cap-8 and Cap-9 was conducted according to the synthesis of Cap-7 by using appropriate amines for the SN₂ displacement step (i.e., 4-hydroxypiperidine for Cap-8 and (S)-3-fluoropyrrolidine for Cap-9) and modified conditions for the separation of the respective stereoisomeric intermediates, as described below.

The enantiomeric separation of the intermediate benzyl 2-(4-hydroxypiperidin-1-yl)-2-phenyl acetate was effected by employing the following conditions: the compound (500 mg) was dissolved in ethanol/heptane (5 mL/45 mL). The resulting solution was injected (5 mL/injection) on a chiral HPLC column (Chiracel OJ, 2 cm ID×25 cm L, 10 μm) eluting with 80:20 heptane/ethanol at 10 mL/min, monitored at 220 nm, to provide 186.3 mg of enantiomer-1 and 209.1 mg of enantiomer-2 as light-yellow viscous oils. These benzyl ester was hydrogenolysed according to the preparation of Cap-7 to provide Cap-8: ¹H NMR (DMSO-d₆, δ=2.5, 500 MHz) 7.40 (d, J=7, 2H), 7.28-7.20 (m, 3H), 3.78 (s 1H), 3.46 (m, 1H), 2.93 (m, 1H), 2.62 (m, 1H), 2.20 (m, 2H), 1.70 (m, 2H), 1.42 (m, 2H). RT=0.28 (Cond. 2); >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₃H₁₈NO₃: 236.13; found 236.07; HRMS: Calcd. for [M+H]⁺ C₁₃H₁₈NO₃: 236.1287; found 236.1283.

The diastereomeric separation of the intermediate benzyl 2-((S)-3-fluoropyrrolidin-1-yl)-2-phenylacetate was effected by employing the following conditions: the ester (220 mg) was separated on a chiral HPLC column (Chiracel OJ-H, 0.46 cm ID×25 cm L, 5 μm) eluting with 95% CO₂/5% methanol with 0.1% TFA, at 10 bar pressure, 70 mL/min flow rate, and a temperature of 35° C. The HPLC elute for the respective stereoisomers was concentrated, and the residue was dissolved in CH₂Cl₂ (20 mL) and washed with an aqueous medium (10 mL water+1 mL saturated NaHCO₃ solution). The organic phase was dried (MgSO₄), filtered, and concentrated in vacuo to provide 92.5 mg of fraction-1 and 59.6 mg of fraction-2. These benzyl esters were hydrogenolysed according to the preparation of Cap-7 to prepare Caps 9a and 9b. Cap-9a (diastereomer-1; the sample is a TFA salt as a result of purification on a reverse phase HPLC using H₂O/methanol/TFA solvent): ¹H NMR (DMSO-d₆, δ=2.5, 400 MHz) 7.55-7.48 (m, 5H), 5.38 (d of m, J=53.7, 1H), 5.09 (br s, 1H), 3.84-2.82 (br m, 4H), 2.31-2.09 (m, 2H). RT=0.42 (Cond. 1); >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₂H₁₅FNO₂: 224.11; found 224.14; Cap-9b (diastereomer-2): ¹H NMR (DMSO-d₆, δ=2.5, 400 MHz) 7.43-7.21 (m, 5H), 5.19 (d of m, J=55.9, 1H), 3.97 (s, 1H), 2.95-2.43 (m, 4H), 2.19-1.78 (m, 2H). RT=0.44 (Cond. 1); LC/MS: Anal. Calcd. for [M+H]⁺ C₁₂H₁₅FNO₂: 224.11; found 224.14.

To a solution of D-proline (2.0 g, 17 mmol) and formaldehyde (2.0 mL of 37% wt. in H₂O) in methanol (15 mL) was added a suspension of 10% Pd/C (500 mg) in methanol (5 mL). The mixture was stirred under a balloon of hydrogen for 23 hours. The reaction mixture was filtered through diatomaceous earth (Celite®) and concentrated in vacuo to provide Cap-10 as an off-white solid (2.15 g). ¹H NMR (DMSO-d₆, δ=2.5, 500 MHz) 3.42 (m, 1H), 3.37 (dd, J=9.4, 6.1, 1H), 2.85-2.78 (m, 1H), 2.66 (s, 3H), 2.21-2.13 (m, 1H), 1.93-1.84 (m, 2H), 1.75-1.66 (m, 1H). RT=0.28 (Cond. 2); >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₆H₁₂NO₂: 130.09; found 129.96.

A mixture of (2S,4R)-4-fluoropyrrolidine-2-carboxylic acid (0.50 g, 3.8 mmol), formaldehyde (0.5 mL of 37% wt. in H₂O), 12 N HCl (0.25 mL) and 10% Pd/C (50 mg) in methanol (20 mL) was stirred under a balloon of hydrogen for 19 hours. The reaction mixture was filtered through diatomaceous earth (Celite®) and the filtrate was concentrated in vacuo. The residue was recrystallized from isopropanol to provide the HCl salt of Cap-11 as a white solid (337.7 mg). ¹H NMR (DMSO-d₆, δ=2.5, 500 MHz) 5.39 (d m, J=53.7, 1H), 4.30 (m, 1H), 3.90 (ddd, J=31.5, 13.5, 4.5, 1H), 3.33 (dd, J=25.6, 13.4, 1H), 2.85 (s, 3H), 2.60-2.51 (m, 1H), 2.39-2.26 (m, 1H). RT=0.28 (Cond. 2); >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₆H₁₁FNO₂: 148.08; found 148.06.

L-Alanine (2.0 g, 22.5 mmol) was dissolved in 10% aqueous sodium carbonate solution (50 mL), and a THF (50 mL) solution of methyl chloroformate (4.0 mL) was added to it. The reaction mixture was stirred under ambient conditions for 4.5 hours and concentrated in vacuo. The resulting white solid was dissolved in water and acidified with 1N HCl to a pH ˜2-3. The resulting solutions was extracted with ethyl acetate (3×100 mL), and the combined organic phase was dried (Na₂SO₄), filtered, and concentrated in vacuo to provide a colorless oil (2.58 g). 500 mg of this material was purified by a reverse phase HPLC (H₂O/methanol/TFA) to provide 150 mg of Cap-12 as a colorless oil. ¹H NMR (DMSO-d₆, δ=2.5, 500 MHz) 7.44 (d, J=7.3, 0.8H), 7.10 (br s, 0.2H), 3.97 (m, 1H), 3.53 (s, 3H), 1.25 (d, J=7.3, 3H).

A mixture of L-alanine (2.5 g, 28 mmol), formaldehyde (8.4 g, 37 wt. %), 1N HCl (30 mL) and 10% Pd/C (500 mg) in methanol (30 mL) was stirred under a hydrogen atmosphere (50 psi) for 5 hours. The reaction mixture was filtered through diatomaceous earth (Celite®) and the filtrate was concentrated in vacuo to provide the HCl salt of Cap-13 as an oil which solidified upon standing under vacuum (4.4 g; the mass is above theoretical yield). The product was used without further purification. ¹H NMR (DMSO-d₆, δ=2.5, 500 MHz) δ 12.1 (br s, 1H), 4.06 (q, J=7.4, 1H), 2.76 (s, 6H), 1.46 (d, J=7.3, 3H).

Step 1: A mixture of (R)-(−)-D-phenylglycine tert-butyl ester (3.00 g, 12.3 mmol), NaBH₃CN (0.773 g, 12.3 mmol), KOH (0.690 g, 12.3 mmol) and acetic acid (0.352 mL, 6.15 mmol) were stirred in methanol at 0° C. To this mixture was added glutaric dialdehyde (2.23 mL, 12.3 mmol) dropwise over 5 minutes. The reaction mixture was stirred as it was allowed to warm to ambient temperature and stirring was continued at the same temperature for 16 hours. The solvent was subsequently removed and the residue was partitioned with 10% aqueous NaOH and ethyl acetate. The organic phase was separated, dried (MgSO₄), filtered and concentrated to dryness to provide a clear oil. This material was purified by reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH₃CN—H₂O-0.1% TFA) to give the intermediate ester (2.70 g, 56%) as a clear oil. ¹HNMR (400 MHz, CDCl₃) δ 7.53-7.44 (m, 3H), 7.40-7.37 (m, 2H), 3.87 (d, J=10.9 Hz, 1H), 3.59 (d, J=10.9 Hz, 1H), 2.99 (t, J=11.2 Hz, 1H), 2.59 (t, J=11.4 Hz, 1H), 2.07-2.02 (m, 2H), 1.82 (d, J=1.82 Hz, 3H), 1.40 (s, 9H). LC/MS: Anal. Calcd. for C₁₇H₂₅NO₂: 275; found: 276 (M+H)⁺.

Step 2: To a stirred solution of the intermediate ester (1.12 g, 2.88 mmol) in dichloromethane (10 mL) was added TFA (3 mL). The reaction mixture was stirred at ambient temperature for 4 hours and then it was concentrated to dryness to give a light yellow oil. The oil was purified using reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH₃CN—H₂O-0.1% TFA). The appropriate fractions were combined and concentrated to dryness in vacuo. The residue was then dissolved in a minimum amount of methanol and applied to applied to MCX LP extraction cartridges (2×6 g). The cartridges were rinsed with methanol (40 mL) and then the desired compound was eluted using 2M ammonia in methanol (50 mL). Product-containing fractions were combined and concentrated and the residue was taken up in water. Lyophilization of this solution provided the title compound (0.492 g, 78%) as a light yellow solid. ¹HNMR (DMSO-d₆) δ 7.50 (s, 5H), 5.13 (s, 1H), 3.09 (br s, 2H), 2.92-2.89 (m, 2H), 1.74 (m, 4H), 1.48 (br s, 2H). LC/MS: Anal. Calcd. for C₁₃H₁₇NO₂: 219; found: 220 (M+H)⁺.

Step 1; (S)-1-Phenylethyl 2-bromo-2-phenylacetate: To a mixture of α-bromophenylacetic acid (10.75 g, 0.050 mol), (S)-(−)-1-phenylethanol (7.94 g, 0.065 mol) and DMAP (0.61 g, 5.0 mmol) in dry dichloromethane (100 mL) was added solid EDCI (12.46 g, 0.065 mol) all at once. The resulting solution was stirred at room temperature under Ar for 18 hours and then it was diluted with ethyl acetate, washed (H₂O×2, brine), dried (Na₂SO₄), filtered, and concentrated to give a pale yellow oil. Flash chromatography (SiO₂/hexane-ethyl acetate, 4:1) of this oil provided the title compound (11.64 g, 73%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.53-7.17 (m, 10H), 5.95 (q, J=6.6 Hz, 0.5H), 5.94 (q, J=6.6 Hz, 0.5H), 5.41 (s, 0.5H), 5.39 (s, 0.5H), 1.58 (d, J=6.6 Hz, 1.5H), 1.51 (d, J=6.6 Hz, 1.5H).

Step 2; (S)-1-Phenylethyl (R)-2-(4-hydroxy-4-methylpiperidin-1-yl)-2-phenylacetate: To a solution of (S)-1-phenylethyl 2-bromo-2-phenylacetate (0.464 g, 1.45 mmol) in THF (8 mL) was added triethylamine (0.61 mL, 4.35 mmol), followed by tetrabutylammonium iodide (0.215 g, 0.58 mmol). The reaction mixture was stirred at room temperature for 5 minutes and then a solution of 4-methyl-4-hydroxypiperidine (0.251 g, 2.18 mmol) in THF (2 mL) was added. The mixture was stirred for 1 hour at room temperature and then it was heated at 55-60° C. (oil bath temperature) for 4 hours. The cooled reaction mixture was then diluted with ethyl acetate (30 mL), washed (H₂O×2, brine), dried (MgSO₄), filtered and concentrated. The residue was purified by silica gel chromatography (0-60% ethyl acetate-hexane) to provide first the (S,R)-isomer of the title compound (0.306 g, 60%) as a white solid and then the corresponding (S,S)-isomer (0.120 g, 23%), also as a white solid. (S,R)-isomer: ¹HNMR (CD₃OD) δ 7.51-7.45 (m, 2H), 7.41-7.25 (m, 8H), 5.85 (q, J=6.6 Hz, 1H), 4.05 (s, 1H), 2.56-2.45 (m, 2H), 2.41-2.29 (m, 2H), 1.71-1.49 (m, 4H), 1.38 (d, J=6.6 Hz, 3H), 1.18 (s, 3H). LCMS: Anal. Calcd. for C₂₂H₂₇NO₃: 353; found: 354 (M+H)⁺. (S,S)-isomer: ¹HNMR (CD₃OD) δ 7.41-7.30 (m, 5H), 7.20-7.14 (m, 3H), 7.06-7.00 (m, 2H), 5.85 (q, J=6.6 Hz, 1H), 4.06 (s, 1H), 2.70-2.60 (m, 1H), 2.51 (dt, J=6.6, 3.3 Hz, 1H), 2.44-2.31 (m, 2H), 1.75-1.65 (m, 1H), 1.65-1.54 (m, 3H), 1.50 (d, J=6.8 Hz, 3H), 1.20 (s, 3H). LCMS: Anal. Calcd. for C₂₂H₂₇NO₃: 353; found: 354 (M+H)⁺.

Step 3; (R)-2-(4-Hydroxy-4-methylpiperidin-1-yl)-2-phenylacetic acid: To a solution of (S)-1-phenylethyl (R)-2-(4-hydroxy-4-methylpiperidin-1-yl)-2-phenylacetate (0.185 g, 0.52 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (1 mL) and the mixture was stirred at room temperature for 2 hours. The volatiles were subsequently removed in vacuo and the residue was purified by reverse-phase preparative HPLC (Primesphere C-18, 20×100 mm; CH₃CN—H₂O-0.1% TFA) to give the title compound (as TFA salt) as a pale bluish solid (0,128 g, 98%). LCMS: Anal. Calcd. for C₁₄H₁₉NO₃: 249; found: 250 (M+H)⁺.

Step 1; (S)-1-Phenylethyl 2-(2-fluorophenyl)acetate: A mixture of 2-fluorophenylacetic acid (5.45 g, 35.4 mmol), (S)-1-phenylethanol (5.62 g, 46.0 mmol), EDCI (8.82 g, 46.0 mmol) and DMAP (0.561 g, 4.60 mmol) in CH₂Cl₂ (100 mL) was stirred at room temperature for 12 hours. The solvent was then concentrated and the residue partitioned with H₂O-ethyl acetate. The phases were separated and the aqueous layer back-extracted with ethyl acetate (2×). The combined organic phases were washed (H₂O, brine), dried (Na₂SO₄), filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (Biotage/0-20% ethyl acetate-hexane) to provide the title compound as a colorless oil (8.38 g, 92%). ¹HNMR (400 MHz, CD₃OD) δ 7.32-7.23 (m, 7H), 7.10-7.04 (m, 2), 5.85 (q, J=6.5 Hz, 1H), 3.71 (s, 2H), 1.48 (d, J=6.5 Hz, 3H).

Step 2; (R)-((S)-1-Phenylethyl) 2-(2-fluorophenyl)-2-(piperidin-1-yl)acetate: To a solution of (S)-1-phenylethyl 2-(2-fluorophenyl)acetate (5.00 g, 19.4 mmol) in THF (1200 mL) at 0° C. was added DBU (6.19 g, 40.7 mmol) and the solution was allowed to warm to room temperature while stirring for 30 minutes. The solution was then cooled to −78° C. and a solution of CBr₄ (13.5 g, 40.7 mmol) in THF (100 mL) was added and the mixture was allowed to warm to −10° C. and stirred at this temperature for 2 hours. The reaction mixture was quenched with saturated aq. NH₄Cl and the layers were separated. The aqueous layer was back-extracted with ethyl acetate (2×) and the combined organic phases were washed (H₂O, brine), dried (Na₂SO₄), filtered, and concentrated in vacuo. To the residue was added piperidine (5.73 mL, 58.1 mmol) and the solution was stirred at room temperature for 24 hours. The volatiles were then concentrated in vacuo and the residue was purified by silica gel chromatography (Biotage/0-30% diethyl ether-hexane) to provide a pure mixture of diastereomers (2:1 ratio by ¹HNMR) as a yellow oil (2.07 g, 31%), along with unreacted starting material (2.53 g, 51%). Further chromatography of the diastereomeric mixture (Biotage/0-10% diethyl ether-toluene) provided the title compound as a colorless oil (0.737 g, 11%). ¹HNMR (400 MHz, CD₃OD) δ 7.52 (ddd, J=9.4, 7.6, 1.8 Hz, 1H), 7.33-7.40 (m, 1), 7.23-7.23 (m, 4H), 7.02-7.23 (m, 4H), 5.86 (q, J=6.6 Hz, 1H), 4.45 (s, 1H), 2.39-2.45 (m, 4H), 1.52-1.58 (m, 4H), 1.40-1.42 (m, 1H), 1.38 (d, J=6.6 Hz, 3H). LCMS: Anal. Calcd. for C₂₁H₂₄FNO₂: 341; found: 342 (M+H)⁺.

Step 3; (R)-2-(2-fluorophenyl)-2-(piperidin-1-yl)acetic acid: A mixture of (R)—((S)-1-phenylethyl) 2-(2-fluorophenyl)-2-(piperidin-1-yl)acetate (0.737 g, 2.16 mmol) and 20% Pd(OH)₂/C (0.070 g) in ethanol (30 mL) was hydrogenated at room temperature and atmospheric pressure (H₂ balloon) for 2 hours. The solution was then purged with Ar, filtered through diatomaceous earth (Celite®), and concentrated in vacuo. This provided the title compound as a colorless solid (0.503 g, 98%). ¹HNMR (400 MHz, CD₃OD) δ 7.65 (ddd, J=9.1, 7.6, 1.5 Hz, 1H), 7.47-7.53 (m, 1H), 7.21-7.30 (m, 2H), 3.07-3.13 (m, 4H), 1.84 (br s, 4H), 1.62 (br s, 2H). LCMS: Anal. Calcd. for C₁₃H₁₆FNO₂: 237; found: 238 (M+H)⁺.

Step 1; (S)-1-Phenylethyl (R)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-2-phenylacetate: To a solution of (S)-1-phenylethyl 2-bromo-2-phenylacetate (1.50 g, 4.70 mmol) in THF (25 mL) was added triethylamine (1.31 mL, 9.42 mmol), followed by tetrabutylammonium iodide (0.347 g, 0.94 mmol). The reaction mixture was stirred at room temperature for 5 minutes and then a solution of 4-phenyl-4-hydroxypiperidine (1.00 g, 5.64 mmol) in THF (5 mL) was added. The mixture was stirred for 16 hours and then it was diluted with ethyl acetate (100 mL), washed (H₂O×2, brine), dried (MgSO₄), filtered and concentrated. The residue was purified on a silica gel column (0-60% ethyl acetate-hexane) to provide an approximately 2:1 mixture of diastereomers, as judged by ¹HNMR. Separation of these isomers was performed using supercritical fluid chromatography (Chiralcel OJ-H, 30×250 mm; 20% ethanol in CO₂ at 35° C.), to give first the (R)-isomer of the title compound (0.534 g, 27%) as a yellow oil and then the corresponding (S)-isomer (0.271 g, 14%), also as a yellow oil. (S,R)-isomer: ¹HNMR (400 MHz, CD₃OD) δ 7.55-7.47 (m, 4H), 7.44-7.25 (m, 10H), 7.25-7.17 (m, 1H), 5.88 (q, J=6.6 Hz, 1H), 4.12 (s, 1H), 2.82-2.72 (m, 1H), 2.64 (dt, J=11.1, 2.5 Hz, 1H), 2.58-2.52 (m, 1H), 2.40 (dt, J=11.1, 2.5 Hz, 1H), 2.20 (dt, J=12.1, 4.6 Hz, 1H), 2.10 (dt, J=12.1, 4.6 Hz, 1H), 1.72-1.57 (m, 2H), 1.53 (d, J=6.5 Hz, 3H). LCMS: Anal. Calcd. for C₂₇H₂₉NO₃: 415; found: 416 (M+H)⁺; (S,S)-isomer: ¹HNMR (400 MHz, CD₃OD) δ 7.55-7.48 (m, 2H), 7.45-7.39 (m, 2H), 7.38-7.30 (m, 5H), 7.25-7.13 (m, 4H), 7.08-7.00 (m, 2H), 5.88 (q, J=6.6 Hz, 1H), 4.12 (s, 1H), 2.95-2.85 (m, 1H), 2.68 (dt, J=11.1, 2.5 Hz, 1H), 2.57-2.52 (m, 1H), 2.42 (dt, J=11.1, 2.5 Hz, 1H), 2.25 (dt, J=12.1, 4.6 Hz, 1H), 2.12 (dt, J=12.1, 4.6 Hz, 1H), 1.73 (dd, J=13.6, 3.0 Hz, 1H), 1.64 (dd, J=13.6, 3.0 Hz, 1H), 1.40 (d, J=6.6 Hz, 3H). LCMS: Anal. Calcd. for C₂₇H₂₉NO₃: 415; found: 416 (M+H)⁺.

The following esters were prepared in similar fashion employing step 1 in the synthesis of Cap-17.

Intermediate- 17a

Diastereomer 1: ¹H NMR (500 MHz, DSMO-d₆) δ ppm 1.36 (d, J = 6.41 Hz, 3 H) 2.23-2.51 (m, 4 H) 3.35 (s, 4 H) 4.25 (s, 1 H) 5.05 (s, 2 H) 5.82 (d, J = 6.71 Hz, 1 H) 7.15-7.52 (m, 15 H). LCMS: Anal. Calcd. for: C₂₈H₃₀N₂O₄ 458.55; Found: 459.44 (M + H)⁺. Diastereomer 2: ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.45 (d, J = 6.71 Hz, 3 H) 2.27-2.44 (m, 4 H) 3.39 (s, 4 H) 4.23 (s, 1 H) 5.06 (s, 2 H) 5.83 (d, J = 6.71 Hz, 1 H) 7.12 (dd, J = 6.41, 3.05 Hz, 2 H) 7.19-7.27 (m, 3 H) 7.27-7.44 (m, 10 H). LCMS: Anal. Calcd. for: C₂₈H₃₀N₂O₄ 458.55; Found: 459.44 (M + H)⁺. * * * * * * Intermediate- 17b

Diastereomer 1: RT = 11.76 min (Cond'n II); LCMS: Anal. Calcd. for: C₂₀H₂₂N₂O₃ 338.4 Found: 339.39 (M + H)⁺; Diastereomer 2: RT = 10.05 min (Cond'n II); LCMS: Anal. Calcd. for: C₂₀H₂₂N₂O₃ 338.4; Found: 339.39 (M + H)⁺. * * * * * Intermediate- 17c

Diastereomer 1: T_(R) = 4.55 min (Cond'n I); LCMS: Anal. Calcd. for: C₂₁H₂₆N₂O₂ 338.44 Found: 339.45 (M + H)⁺; Diastereomer 2: T_(R) 6.00 min (Cond'n I); LCMS: Anal. Calcd. for: C₂₁H₂₆N₂O₂ 338.44 Found: 339.45 (M + H)⁺. * * * * * Intermediate- 17d

Diastereomer 1: RT = 7.19 min (Cond'n I); LCMS: Anal. Calcd. for: C₂₇H₂₉NO₂ 399.52 Found: 400.48 (M + H)⁺; Diastereomer 2: RT = 9.76 min (Cond'n I); LCMS: Anal. Calcd. for: C₂₇H₂₉NO₂ 399.52 Found: 400.48 (M + H)⁺. Chiral SFC Conditions for Determining Retention Time for Intermediates 17b-17d Condition 1 Column: Chiralpak AD-H Column, 4.6×250 mm, 5 μm Solvents: 90% CO₂-10% methanol with 0.1% DEA Temp: 35° C. Pressure: 150 bar Flow rate: 2.0 mL/min. UV monitored@220 nm Injection: 1.0 mg/3 mL methanol Condition 2 Column: Chiralcel OD-H Column, 4.6×250 mm, 5 μm Solvents: 90% CO₂-10% methanol with 0.1% DEA Temp: 35° C. Pressure: 150 bar Flow rate: 2.0 mL/min. UV monitored@220 nm Injection: 1.0 mg/mL methanol

Cap-17, Step 2; (R)-2-(4-Hydroxy-4-phenylpiperidin-1-yl)-2-phenylacetic acid: To a solution of (S)-1-phenylethyl (R)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-2-phenylacetate (0.350 g, 0.84 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1 mL) and the mixture was stirred at room temperature for 2 hours. The volatiles were subsequently removed in vacuo and the residue was purified by reverse-phase preparative HPLC (Primesphere C-18, 20×100 mm; CH₃CN—H₂O-0.1% TFA) to give the title compound (as TFA salt) as a white solid (0.230 g, 88%). LCMS: Anal. Calcd. for C₁₉H₂₁NO₃: 311; found: 312 (M+H)⁺.

The following carboxylic acids were prepared in a similar fashion:

Cap- 17a

RT = 2.21 (Con'n II); ¹H NMR (500 MHz, DMSO- d₆) δ ppm 2.20-2.35 (m, 2 H) 2.34-2.47 (m, 2 H) 3.37 (s, 4 H) 3.71 (s, 1 H) 5.06 (s, 2 H) 7.06-7.53 (m, 10 H). LCMS: Anal. Calcd. for: C₂₀H₂₂N₂O₄ 354.40; Found: 355.38 (M + H)⁺. Cap- 17b

RT = 0.27 (Cond'n III); LCMS: Anal. Calcd. for: C₁₂H₁₄N₂O₃ 234.25; Found: 235.22 (M + H)⁺. Cap- 17c

RT = 0.48 (Cond'n II); LCMS: Anal. Calcd. for: C₁₃H₁₈N₂O₂ 234.29; Found: 235.31 (M + H)⁺. Cap- 17d

RT = 2.21 (Cond'n I); LCMS: Anal. Calcd. for: C₁₉H₂₁NO₂ 295.38; Found: 296.33 (M + H)⁺. LCMS Conditions for Determining Retention Time for Caps 17a-17d Condition 1 Column: Phenomenex-Luna 4.6×50 mm S10 Start % B=0 Final % B=100 Gradient Time=4 min Flow Rate=4 mL/min Wavelength=220 Solvent A=10% methanol−90% H₂O−0.1% TFA Solvent B=90% methanol−10% H₂O−0.1% TFA Condition 2 Column: Waters-Sunfire 4.6×50 mm S5 Start % B=0 Final % B=100 Gradient Time=2 min Flow Rate=4 mL/min Wavelength=220 Solvent A=10% methanol−90% H₂O−0.1% TFA Solvent B=90% methanol−10% H₂O−0.1% TFA Condition 3 Column: Phenomenex 10μ 3.0×50 mm Start % B=0 Final % B=100 Gradient Time=2 min Flow Rate=4 mL/min Wavelength=220 Solvent A=10% methanol−90% H₂O−0.1% TFA Solvent B=90% methanol−10% H₂O−0.1% TFA

Step 1; (R,S)-Ethyl 2-(4-pyridyl)-2-bromoacetate: To a solution of ethyl 4-pyridylacetate (1.00 g, 6.05 mmol) in dry THF (150 mL) at 0° C. under argon was added DBU (0.99 mL, 6.66 mmol). The reaction mixture was allowed to warm to room temperature over 30 minutes and then it was cooled to −78° C. To this mixture was added CBr₄ (2.21 g, 6.66 mmol) and stirring was continued at −78° C. for 2 hours. The reaction mixture was then quenched with sat. aq. NH₄Cl and the phases were separated. The organic phase was washed (brine), dried (Na₂SO₄), filtered, and concentrated in vacuo. The resulting yellow oil was immediately purified by flash chromatography (SiO₂/hexane-ethyl acetate, 1:1) to provide the title compound (1.40 g, 95%) as a somewhat unstable yellow oil. ¹HNMR (400 MHz, CDCl₃) δ 8.62 (dd, J=4.6, 1.8 Hz, 2H), 7.45 (dd, J=4.6, 1.8 Hz, 2H), 5.24 (s, 1H), 4.21-4.29 (m, 2H), 1.28 (t, J=7.1 Hz, 3H). LCMS: Anal. Calcd. for C₉H₁₀BrNO₂: 242, 244; found: 243, 245 (M+H)⁺.

Step 2; (R,S)-Ethyl 2-(4-pyridyl)-2-(N,N-dimethylamino)acetate: To a solution of (R,S)-ethyl 2-(4-pyridyl)-2-bromoacetate (1.40 g, 8.48 mmol) in DMF (10 mL) at room temperature was added dimethylamine (2M in THF, 8.5 mL, 17.0 mmol). After completion of the reaction (as judged by tlc) the volatiles were removed in vacuo and the residue was purified by flash chromatography (Biotage, 40+M SiO₂ column; 50%-100% ethyl acetate-hexane) to provide the title compound (0.539 g, 31%) as a light yellow oil. ¹HNMR (400 MHz, CDCl₃) δ 8.58 (d, J=6.0 Hz, 2H), 7.36 (d, J=6.0 Hz, 2H), 4.17 (m, 2H), 3.92 (s, 1H), 2.27 (s, 6H), 1.22 (t, J=7.0 Hz). LCMS: Anal. Calcd. for C₁₁H₁₆N₂O₂: 208; found: 209 (M+H)⁺.

Step 3; (R,S)-2-(4-Pyridyl)-2-(N,N-dimethylamino)acetic acid: To a solution of (R,S)-ethyl 2-(4-pyridyl)-2-(N,N-dimethylamino)acetate (0.200 g, 0.960 mmol) in a mixture of THF-methanol-H₂O (1:1:1, 6 mL) was added powdered LiOH (0.120 g, 4.99 mmol) at room temperature. The solution was stirred for 3 hours and then it was acidified to pH 6 using 1N HCl. The aqueous phase was washed with ethyl acetate and then it was lyophilized to give the dihydrochloride of the title compound as a yellow solid (containing LiCl). The product was used as such in subsequent steps. ¹HNMR (400 MHz, DMSO-d₆) δ 8.49 (d, J=5.7 Hz, 2H), 7.34 (d, J=5.7 Hz, 2H), 3.56 (s, 1H), 2.21 (s, 6H).

The following examples were prepared in similar fashion using the method described above.

Cap-19

LCMS: Anal. Calcd. for C₉H₁₂N₂O₂: 180; found: 181 (M + H)⁺. Cap-20

LCMS: no ionization. ¹HNMR (400 MHz, CD₃OD) δ 8.55 (d, J = 4.3 Hz, 1 H), 7.84 (app t, J = 5.3 Hz, 1 H), 7.61 (d, J = 7.8 Hz, 1 H), 7.37 (app t, J = 5.3 Hz, 1 H), 4.35 (s, 1 H), 2.60 (s, 6 H). Cap-21

LCMS: Anal. Calcd. for C₉H_(11Cl)N₂O₂: 214, 216; found: 215, 217 (M + H)⁺. Cap-22

LCMS: Anal. Calcd. for C₁₀H₁₂N₂O₄: 224; found: 225 (M + H)⁺. Cap-23

LCMS: Anal. Calcd. for C₁₄H₁₅NO₂: 247; found: 248 (M + H)⁺. Cap-24

LCMS: Anal. Calcd. for C₁₁H₁₂F₃NO₂: 247; found: 248 (M + H)⁺. Cap-25

LCMS: Anal. Calcd. for C₁₁H₁₂F₃NO₂: 247; found: 248 (M + H)⁺. Cap-26

LCMS: Anal. Calcd. for C₁₀H₁₂FNO₂: 247; found: 248 (M + H)⁺. Cap-27

LCMS: Anal. Calcd. for C₁₀H₁₂FNO₂: 247; found: 248 (M + H)⁺. Cap-28

LCMS: Anal. Calcd. for C₁₀H₁₂ClNO₂: 213, 215; found: 214, 217 (M + H)⁺. Cap-29

LCMS: Anal. Calcd. for C₁₀H₁₂ClNO₂: 213, 215; found: 214, 217 (M + H)⁺. Cap-30

LCMS: Anal. Calcd. for C₁₀H₁₂ClNO₂: 213, 215; found: 214, 217 (M + H)⁺. Cap-31

LCMS: Anal. Calcd. for C₈H₁₁N₂O₂S: 200; found: 201 (M + H)⁺. Cap-32

LCMS: Anal. Calcd. for C₈H₁₁NO₂S: 185; found: 186 (M + H)⁺. Cap-33

LCMS: Anal. Calcd. for C₈H₁₁NO₂S: 185; found: 186 (M + H)⁺. Cap-34

LCMS: Anal. Calcd. for C₁₁H₁₂N₂O₃: 220; found: 221 (M + H)⁺. Cap-35

LCMS: Anal. Calcd. for C₁₂H₁₃NO₂S: 235; found: 236 (M + H)⁺. Cap-36

LCMS: Anal. Calcd. for C₁₂H₁₄N₂O₂S: 250; found: 251 (M + H)⁺.

Step 1; (R,S)-Ethyl 2-(quinolin-3-yl)-2-(N,N-dimethylamino)-acetate: A mixture of ethyl N,N-dimethylaminoacetate (0.462 g, 3.54 mmol), K₃PO₄ (1.90 g, 8.95 mmol), Pd(t-Bu₃P)₂ (0.090 g, 0.176 mmol) and toluene (10 mL) was degassed with a stream of Ar bubbles for 15 minutes. The reaction mixture was then heated at 100° C. for 12 hours, after which it was cooled to room temperature and poured into H₂O. The mixture was extracted with ethyl acetate (2×) and the combined organic phases were washed (H₂O, brine), dried (Na₂SO₄), filtered, and concentrated in vacuo. The residue was purified first by reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH₃CN—H₂O-5 mM NH₄OAc) and then by flash chromatography (SiO₂/hexane-ethyl acetate, 1:1) to provide the title compound (0.128 g, 17%) as an orange oil. ¹HNMR (400 MHz, CDCl₃) δ 8.90 (d, J=2.0 Hz, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.03-8.01 (m, 2H), 7.77 (ddd, J=8.3, 6.8, 1.5 Hz, 1H), 7.62 (ddd, J=8.3, 6.8, 1.5 Hz, 1H), 4.35 (s, 1H), 4.13 (m, 2H), 2.22 (s, 6H), 1.15 (t, J=7.0 Hz, 3H). LCMS: Anal. Calcd. for C₁₅H₁₈N₂O₂: 258; found: 259 (M+H)⁺.

Step 2; (R,S) 2-(Quinolin-3-yl)-2-(N,N-dimethylamino)acetic acid: A mixture of (R,S)-ethyl 2-(quinolin-3-yl)-2-(N,N-dimethylamino)acetate (0.122 g, 0.472 mmol) and 6M HCl (3 mL) was heated at 100° C. for 12 hours. The solvent was removed in vacuo to provide the dihydrochloride of the title compound (0.169 g, >100%) as a light yellow foam. The unpurified material was used in subsequent steps without further purification. LCMS: Anal. Calcd. for C₁₃H₁₄N₂O₂: 230; found: 231 (M+H)⁺.

Step 1; (R)—((S)-1-phenylethyl) 2-(dimethylamino)-2-(2-fluorophenyl)acetate and (S)—((S)-1-phenylethyl) 2-(dimethylamino)-2-(2-fluorophenyl)acetate: To a mixture of (RS)-2-(dimethylamino)-2-(2-fluorophenyl)acetic acid (2.60 g, 13.19 mmol), DMAP (0.209 g, 1.71 mmol) and (S)-1-phenylethanol (2.09 g, 17.15 mmol) in CH₂Cl₂ (40 mL) was added EDCI (3.29 g, 17.15 mmol) and the mixture was allowed to stir at room temperature for 12 hours. The solvent was then removed in vacuo and the residue partitioned with ethyl acetate-H₂O. The layers were separated, the aqueous layer was back-extracted with ethyl acetate (2×) and the combined organic phases were washed (H₂O, brine), dried (Na₂SO₄), filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (Biotage/0-50% diethyl ether-hexane). The resulting pure diastereomeric mixture was then separated by reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH₃CN—H₂O-0.1% TFA) to give first (S)-1-phenethyl (R)-2-(dimethylamino)-2-(2-fluorophenyl)acetate (0.501 g, 13%) and then (S)-1-phenethyl (S)-2-(dimethylamino)-2-(2-fluorophenyl)-acetate (0.727 g. 18%), both as their TFA salts. (S,R)-isomer: ¹HNMR (400 MHz, CD₃OD) δ 7.65-7.70 (m, 1H), 7.55-7.60 (ddd, J=9.4, 8.1, 1.5 Hz, 1H), 7.36-7.41 (m, 2H), 7.28-7.34 (m, 5H), 6.04 (q, J=6.5 Hz, 1H), 5.60 (s, 1H), 2.84 (s, 6H), 1.43 (d, J=6.5 Hz, 3H). LCMS: Anal. Calcd. for C₁₈H₂₀FNO₂: 301; found: 302 (M+H)⁺; (S,S)-isomer: ¹HNMR (400 MHz, CD₃OD) δ 7.58-7.63 (m, 1H), 7.18-7.31 (m, 6H), 7.00 (dd, J=8.5, 1.5 Hz, 2H), 6.02 (q, J=6.5 Hz, 1H), 5.60 (s, 1H), 2.88 (s, 6H), 1.54 (d, J=6.5 Hz, 3H). LCMS: Anal. Calcd. for C₁₈H₂₀FNO₂: 301; found: 302 (M+H)⁺.

Step 2; (R)-2-(dimethylamino)-2-(2-fluorophenyl)acetic acid: A mixture of (R)—((S)-1-phenylethyl) 2-(dimethylamino)-2-(2-fluorophenyl)acetate TFA salt (1.25 g, 3.01 mmol) and 20% Pd(OH)₂/C (0.125 g) in ethanol (30 mL) was hydrogenated at room temperature and atmospheric pressure (H₂ balloon) for 4 hours. The solution was then purged with Ar, filtered through diatomaceous earth (Celite®), and concentrated in vacuo. This gave the title compound as a colorless solid (0.503 g, 98%). ¹HNMR (400 MHz, CD₃OD) δ 7.53-7.63 (m, 2H), 7.33-7.38 (m, 2H), 5.36 (s, 1H), 2.86 (s, 6H). LCMS: Anal. Calcd. for C₁₀H₁₂FNO₂: 197; found: 198 (M+H)⁺.

The S-isomer could be obtained from (S)—((S)-1-phenylethyl) 2-(dimethylamino)-2-(2-fluorophenyl)acetate TFA salt in similar fashion.

A mixture of (R)-(2-chlorophenyl)glycine (0.300 g, 1.62 mmol), formaldehyde (35% aqueous solution, 0.80 mL, 3.23 mmol) and 20% Pd(OH)₂/C (0.050 g) was hydrogenated at room temperature and atmospheric pressure (H₂ balloon) for 4 hours. The solution was then purged with Ar, filtered through diatomaceous earth (Celite®) and concentrated in vacuo. The residue was purified by reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH₃CN—H₂O-0.1% TFA) to give the TFA salt of the title compound (R)-2-(dimethylamino)-2-(2-chlorophenyl)acetic acid as a colorless oil (0.290 g, 55%). ¹H NMR (400 MHz, CD₃OD) δ 7.59-7.65 (m, 2H), 7.45-7.53 (m, 2H), 5.40 (s, 1H), 2.87 (s, 6H). LCMS: Anal. Calcd. for C₁₀H₁₂ClNO₂: 213, 215; found: 214, 216 (M+H)⁺.

To an ice-cold solution of (R)-(2-chlorophenyl)glycine (1.00 g, 5.38 mmol) and NaOH (0.862 g, 21.6 mmol) in H₂O (5.5 mL) was added methyl chloroformate (1.00 mL, 13.5 mmol) dropwise. The mixture was allowed to stir at 0° C. for 1 hour and then it was acidified by the addition of conc. HCl (2.5 mL). The mixture was extracted with ethyl acetate (2×) and the combined organic phase was washed (H₂O, brine), dried (Na₂SO₄), filtered, and concentrated in vacuo to give the title compound (R)-2-(methoxycarbonylamino)-2-(2-chlorophenyl)acetic acid as a yellow-orange foam (1.31 g, 96%). ¹H NMR (400 MHz, CD₃OD) δ 7.39-7.43 (m, 2H), 7.29-7.31 (m, 2H), 5.69 (s, 1H), 3.65 (s, 3H). LCMS: Anal. Calcd. for C₁₀H₁₀ClNO₄: 243, 245; found: 244, 246 (M+H)⁺.

To a suspension of 2-(2-(chloromethyl)phenyl)acetic acid (2.00 g, 10.8 mmol) in THF (20 mL) was added morpholine (1.89 g, 21.7 mmol) and the solution was stirred at room temperature for 3 hours. The reaction mixture was then diluted with ethyl acetate and extracted with H₂O (2×). The aqueous phase was lyophilized and the residue was purified by silica gel chromatography (Biotage/0-10% methanol-CH₂Cl₂) to give the title compound 2-(2-(Morpholinomethyl)phenyl)acetic acid as a colorless solid (2.22 g, 87%). ¹HNMR (400 MHz, CD₃OD) δ 7.37-7.44 (m, 3H), 7.29-7.33 (m, 1H), 4.24 (s, 2H), 3.83 (br s, 4H), 3.68 (s, 2H), 3.14 (br s, 4H). LCMS Anal. Calcd. for C₁₃H₁₇NO₃: 235; found: 236 (M+H)⁺.

The following caps were similarly prepared using the method described for Cap-41:

Cap-42

LCMS: Anal. Calcd. for C₁₄H₁₉NO₂: 233; found: 234 (M + H)⁺. Cap-43

LCMS: Anal. Calcd. for C₁₃H₁₇NO₂: 219; found: 220 (M + H)⁺. Cap-44

LCMS: Anal. Calcd. for C₁₁H₁₅NO₂: 193; found: 194 (M + H)⁺. Cap-45

LCMS: Anal. Calcd. for C₁₄H₂₀N₂O₂: 248; found: 249 (M + H)⁺.

HMDS (1.85 mL, 8.77 mmol) was added to a suspension of (R)-2-amino-2-phenylacetic acid p-toluenesulfonate (2.83 g, 8.77 mmol) in CH₂Cl₂ (10 mL) and the mixture was stirred at room temperature for 30 minutes. Methyl isocyanate (0.5 g, 8.77 mmol) was added in one portion stirring continued for 30 minutes. The reaction was quenched by addition of H₂O (5 mL) and the resulting precipitate was filtered, washed with H₂O and n-hexanes, and dried under vacuum. (R)-2-(3-methylureido)-2-phenylacetic acid (1.5 g; 82%). was recovered as a white solid and it was used without further purification. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.54 (d, J=4.88 Hz, 3H) 5.17 (d, J=7.93 Hz, 1H) 5.95 (q, J=4.48 Hz, 1H) 6.66 (d, J=7.93 Hz, 1H) 7.26-7.38 (m, 5H) 12.67 (s, 1H). LCMS: Anal. Calcd. for C₁₀H₁₂N₂O₃ 208.08 found 209.121 (M+H)⁺; HPLC Phenomenex C-18 3.0×46 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=1.38 min, 90% homogeneity index.

The desired product was prepared according to the method described for Cap-45. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.96 (t, J=7.17 Hz, 3H) 2.94-3.05 (m, 2H) 5.17 (d, J=7.93 Hz, 1H) 6.05 (t, J=5.19 Hz, 1H) 6.60 (d, J=7.63 Hz, 1H) 7.26-7.38 (m, 5H) 12.68 (s, 1H). LCMS: Anal. Calcd. for C₁₁H₁₄N₂O₃ 222.10 found 209.121 (M+H)⁺.

HPLC XTERRA C-18 3.0×506 mm, 0 to 100% B over 2 minutes, 1 minutes hold time, A=90% water, 10% methanol, 0.2% H₃PO₄, B=10% water, 90% methanol, 0.2% H₃PO₄, RT=0.87 min, 90% homogeneity index.

Step 1; (R)-tert-butyl 2-(3,3-dimethylureido)-2-phenylacetate: To a stirred solution of (R)-tert-butyl-2-amino-2-phenylacetate (1.0 g, 4.10 mmol) and Hunig's base (1.79 mL, 10.25 mmol) in DMF (40 mL) was added dimethylcarbamoyl chloride (0.38 mL, 4.18 mmol) dropwise over 10 minutes. After stirring at room temperature for 3 hours, the reaction was concentrated under reduced pressure and the resulting residue was dissolved in ethyl acetate. The organic layer was washed with H₂O, 1N aq. HCl and brine, dried (MgSO₄), filtered and concentrated under reduced pressure. (R)-tert-butyl 2-(3,3-dimethylureido)-2-phenylacetate was obtained as a white solid (0.86 g; 75%) and used without further purification. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.33 (s, 9H) 2.82 (s, 6H) 5.17 (d, J=7.63 Hz, 1H) 6.55 (d, J=7.32 Hz, 1H) 7.24-7.41 (m, 5H). LCMS: Anal. Calcd. for C₁₅H₂₂N₂O₃ 278.16 found 279.23 (M+H)⁺; HPLC Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 4 minutes, 1 minutes hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=2.26 min, 97% homogeneity index.

Step 2; (R)-2-(3,3-dimethylureido)-2-phenylacetic acid: To a stirred solution of ((R)-tert-butyl 2-(3,3-dimethylureido)-2-phenylacetate (0.86 g, 3.10 mmol) in CH₂Cl₂ (250 mL) was added TFA (15 mL) dropwise and the resulting solution was stirred at rt for 3 h. The desired compound was then precipitated out of solution with a mixture of EtOAC:Hexanes (5:20), filtered off and dried under reduced pressure. (R)-2-(3,3-dimethylureido)-2-phenylacetic acid was isolated as a white solid (0.59 g, 86%) and used without further purification. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.82 (s, 6H) 5.22 (d, J=7.32 Hz, 1H) 6.58 (d, J=7.32 Hz, 1H) 7.28 (t, J=7.17 Hz, 1H) 7.33 (t, J=7.32 Hz, 2H) 7.38-7.43 (m, 2H) 12.65 (s, 1H). LCMS: Anal. Calcd. for C₁₁H₁₄N₂O₃: 222.24; found: 223.21 (M+H)⁺. HPLC XTERRA C-18 3.0×50 mm, 0 to 100% B over 2 minutes, 1 minutes hold time, A=90% water, 10% methanol, 0.2% H₃PO₄, B=10% water, 90% methanol, 0.2% H₃PO₄, RT=0.75 min, 93% homogeneity index.

Step 1; (R)-tert-butyl 2-(3-cyclopentylureido)-2-phenylacetate: To a stirred solution of (R)-2-amino-2-phenylacetic acid hydrochloride (1.0 g, 4.10 mmol) and Hunig's base (1.0 mL, 6.15 mmol) in DMF (15 mL) was added cyclopentyl isocyanate (0.46 mL, 4.10 mmol) dropwise and over 10 minutes. After stirring at room temperature for 3 hours, the reaction was concentrated under reduced pressure and the resulting residue was taken up in ethyl acetate. The organic layer was washed with H₂O and brine, dried (MgSO₄), filtered, and concentrated under reduced pressure. (R)-tert-butyl 2-(3-cyclopentylureido)-2-phenylacetate was obtained as an opaque oil (1.32 g; 100%) and used without further purification. ¹H NMR (500 MHz, CD₃Cl-D) δ ppm 1.50-1.57 (m, 2H) 1.58-1.66 (m, 2H) 1.87-1.97 (m, 2H) 3.89-3.98 (m, 1H) 5.37 (s, 1H) 7.26-7.38 (m, 5H). LCMS: Anal. Calcd. for C₁₈H₂₆N₂O₃ 318.19 found 319.21 (M+H)⁺; HPLC XTERRA C-18 3.0×50 mm, 0 to 100% B over 4 minutes, 1 minutes hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=2.82 min, 96% homogeneity index.

Step 2; (R)-2-(3-cyclopentylureido)-2-phenylacetic acid: To a stirred solution of (R)-tert-butyl 2-(3-cyclopentylureido)-2-phenylacetate (1.31 g, 4.10 mmol) in CH₂Cl₂ (25 mL) was added TFA (4 mL) and triethylsilane (1.64 mL; 10.3 mmol) dropwise, and the resulting solution was stirred at room temperature for 6 hours. The volatile components were removed under reduced pressure and the crude product was recrystallized in ethyl acetate/pentanes to yield (R)-2-(3-cyclopentylureido)-2-phenylacetic acid as a white solid (0.69 g, 64%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.17-1.35 (m, 2H) 1.42-1.52 (m, 2H) 1.53-1.64 (m, 2H) 1.67-1.80 (m, 2H) 3.75-3.89 (m, 1H) 5.17 (d, J=7.93 Hz, 1H) 6.12 (d, J=7.32 Hz, 1H) 6.48 (d, J=7.93 Hz, 1H) 7.24-7.40 (m, 5H) 12.73 (s, 1H). LCMS: Anal. Calcd. for C₁₄H₁₈N₂O₃: 262.31; found: 263.15 (M+H)⁺. HPLC XTERRA C-18 3.0×50 mm, 0 to 100% B over 2 minutes, 1 minutes hold time, A=90% water, 10% methanol, 0.2% H₃PO₄, B=10% water, 90% methanol, 0.2% H₃PO₄, RT=1.24 min, 100% homogeneity index.

To a stirred solution of 2-(benzylamino)acetic acid (2.0 g, 12.1 mmol) in formic acid (91 mL) was added formaldehyde (6.94 mL, 93.2 mmol). After five hours at 70° C., the reaction mixture was concentrated under reduced pressure to 20 mL and a white solid precipitated. Following filtration, the mother liquors were collected and further concentrated under reduced pressure providing the crude product. Purification by reverse-phase preparative HPLC (Xterra 30×100 mm, detection at 220 nm, flow rate 35 mL/min, 0 to 35% B over 8 min; A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA) provided the title compound 2-(benzyl(methyl)-amino)acetic acid as its TFA salt (723 mg, 33%) as a colorless wax. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 2.75 (s, 3H) 4.04 (s, 2H) 4.34 (s, 2H) 7.29-7.68 (m, 5H). LCMS: Anal. Calcd. for: C₁₀H₁₃NO₂ 179.22;

Found: 180.20 (M+H)⁺.

To a stirred solution of 3-methyl-2-(methylamino)butanoic acid (0.50 g, 3.81 mmol) in water (30 mL) was added K₂CO₃ (2.63 g, 19.1 mmol) and benzyl chloride (1.32 g, 11.4 mmol). The reaction mixture was stirred at ambient temperature for 18 hours. The reaction mixture was extracted with ethyl acetate (30 mL×2) and the aqueous layer was concentrated under reduced pressure providing the crude product which was purified by reverse-phase preparative HPLC (Xterra 30×100 mm, detection at 220 nm, flow rate 40 mL/min, 20 to 80% B over 6 min; A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA) to provide 2-(benzyl(methyl)amino)-3-methylbutanoic acid, TFA salt (126 mg, 19%) as a colorless wax. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.98 (d, 3H) 1.07 (d, 3H) 2.33-2.48 (m, 1H) 2.54-2.78 (m, 3H) 3.69 (s, 1H) 4.24 (s, 2H) 7.29-7.65 (m, 5H). LCMS: Anal. Calcd. for: C₁₃H₁₉NO₂ 221.30; Found: 222.28 (M+H)⁺.

Na₂CO₃ (1.83 g, 17.2 mmol) was added to NaOH (33 mL of 1M/H₂O, 33 mmol) solution of L-valine (3.9 g, 33.29 mmol) and the resulting solution was cooled with ice-water bath. Methyl chloroformate (2.8 mL, 36.1 mmol) was added drop-wise over 15 min, the cooling bath was removed and the reaction mixture was stirred at ambient temperature for 3.25 hr. The reaction mixture was washed with ether (50 mL, 3×), and the aqueous phase was cooled with ice-water bath and acidified with concentrated HCl to a pH region of 1-2, and extracted with CH₂Cl₂ (50 mL, 3×). The organic phase was dried (MgSO₄), filtered, and concentrated in vacuo to afford Cap-51 as a white solid (6 g). ¹H NMR for the dominant rotamer (DMSO-d₆, δ=2.5 ppm, 500 MHz): 12.54 (s, 1H), 7.33 (d, J=8.6, 1H), 3.84 (dd, J=8.4, 6.0, 1H), 3.54 (s, 3H), 2.03 (m, 1H), 0.87 (m, 6H). HRMS: Anal. Calcd. for [M+H]⁺ C₇H₁₄NO₄: 176.0923; found 176.0922

Cap-52 was synthesized from L-alanine according to the procedure described for the synthesis of Cap-51. For characterization purposes, a portion of the crude material was purified by a reverse phase HPLC (H₂O/MeOH/TFA) to afford Cap-52 as a colorless viscous oil. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 500 MHz): 12.49 (br s, 1H), 7.43 (d, J=7.3, 0.88H), 7.09 (app br s, 0.12H), 3.97 (m, 1H), 3.53 (s, 3H), 1.25 (d, J=7.3, 3H).

Cap-53 to -64 were prepared from appropriate starting materials according to the procedure described for the synthesis of Cap-51, with noted modifications if any.

Cap Structure Data Cap-53a: (R) Cap-53b: (S)

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 500 MHz): δ 12.51 (br s, 1 H), 7.4 (d, J = 7.9, 0.9 H), 7.06 (app s, 0.1 H), 3.86-3.82 (m, 1 H), 3.53 (s, 3 H), 1.75-1.67 (m, 1 H), 1.62-1.54 (m, 1 H), 0.88 (d, J = 7.3, 3 H). RT = 0.77 minutes (Cond. 2); LC/MS: Anal. Calcd. for [M + Na]⁺ C₆H₁₁NNaO₄: 184.06; found 184.07. HRMS Calcd. for [M + Na]⁺ C₆H₁₁NNaO₄: 184.0586; found 184.0592. Cap-54a: (R) Cap-54b: (S)

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 500 MHz): δ 12.48 (s, 1 H), 7.58 (d, J = 7.6, 0.9 H), 7.25 (app s, 0.1 H), 3.52 (s, 3 H), 3.36-3.33 (m, 1 H), 1.10-1.01 (m, 1 H), 0.54-0.49 (m, 1 H), 0.46- 0.40 (m, 1 H), 0.39-0.35 (m, 1 H), 0.31-0.21 (m, 1 H). HRMS Calcd. for [M + H]⁺ C₇H₁₂NO₄: 174.0766; found 174.0771 Cap-55

¹H NMR (DMSO-d₆, δ 2.5 ppm, 500 MHz): δ 12.62 (s, 1 H), 7.42 (d, J = 8.2, 0.9 H), 7.07 (app s, 0.1 H), 5.80-5.72 (m, 1 H), 5.10 (d, J = 17.1, 1 H), 5.04 (d, J = 10.4, 1 H), 4.01-3.96 (m, 1 H), 3.53 (s, 3 H), 2.47-2.42 (m, 1 H), 2.35- 2.29 (m, 1 H). Cap-56

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 500 MHz): δ 12.75 (s, 1 H), 7.38 (d, J = 8.3, 0.9 H), 6.96 (app s, 0.1 H), 4.20-4.16 (m, 1 H), 3.60-3.55 (m, 2 H), 3.54 (s, 3 H), 3.24 (s, 3 H). Cap-57

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 500 MHz): δ 12.50 (s, 1 H), 8.02 (d, J = 7.7, 0.08 H), 7.40 (d, J = 7.9, 0.76 H), 7.19 (d, J = 8.2, 0.07 H), 7.07 (d, J = 6.7, 0.09 H), 4.21-4.12 (m, 0.08 H), 4.06-3.97 (m, 0.07 H), 3.96-3.80 (m, 0.85 H), 3.53 (s, 3 H), 1.69-1.51 (m, 2 H), 1.39-1.26 (m, 2 H), 0.85 (t, J = 7.4, 3 H). LC (Cond. 2): RT = 1.39 LC/MS: Anal. Calcd. for [M + H]⁺ C₇H₁₄NO₄: 176.09; found 176.06. Cap-58

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 500 MHz): δ 12.63 (bs, 1 H), 7.35 (s, 1 H), 7.31 (d, J = 8.2, 1 H), 6.92 (s, 1 H), 4.33-4.29 (m, 1 H), 3.54 (s, 3 H), 2.54 (dd, J = 15.5, 5.4, 1 H), 2.43 (dd, J = 15.6, 8.0, 1 H). RT = 0.16 min (Cond. 2); LC/MS: Anal. Calcd. for [M + H]⁺ C₆H₁₁N₂O₅: 191.07; found 191.14. Cap-59a: (R) Cap-59b: (S)

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 400 MHz): δ 12.49 (br s, 1 H), 7.40 (d, J = 7.3, 0.89 H), 7.04 (br s, 0.11 H), 4.00-3.95 (m, 3 H), 1.24 (d, J = 7.3, 3 H), 1.15 (t, J = 7.2, 3 H). HRMS: Anal. Calcd. for [M + H]⁺ C₆H₁₂NO₄: 162.0766; found 162.0771. Cap-60

The crude material was purified with a reverse phase HPLC (H₂O/MeOH/TFA) to afford a colorless viscous oil that crystallized to a white solid upon exposure to high vacuum. ¹H NMR (DMSO-d₆, δ = 2.5 ppm, 400 MHz): δ 12.38 (br s, 1 H), 7.74 (s, 0.82 H), 7.48 (s, 0.18 H), 3.54/3.51 (two s, 3 H), 1.30 (m, 2 H), 0.98 (m, 2 H).HRMS: Anal. Calcd. for [M + H]⁺ C₆H₁₀NO₄: 160.0610; found 160.0604. Cap-61

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 400 MHz): δ 12.27 (br s, 1 H), 7.40 (br s, 1 H), 3.50 (s, 3 H), 1.32 (s, 6 H). HRMS: Anal. Calcd. for [M + H]⁺ C₆H₁₂NO₄: 162.0766; found 16.0765. Cap-62

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 400 MHz); δ 12.74 (br s, 1 H), 4.21 (d, J = 10.3, 0.6 H), 4.05 (d, J = 10.0, 0.4 H), 3.62/3.60 (two singlets, 3 H), 3.0 (s, 3 H), 2.14-2.05 (m, 1 H), 0.95 (d, J = 6.3, 3 H), 0.81 (d, J = 6.6, 3 H). LC/MS: Anal. Calcd. for [M − H]⁻ C₈H₁₄NO₄: 188.09; found 188.05. Cap-63

[Note: the reaction was allowed to run for longer than what was noted for the general procedure.] ¹H NMR (DMSO-d₆, δ = 2.5 ppm, 400 MHz): 12.21 (br s, 1 H), 7.42 (br s, 1 H), 3.50 (s, 3 H), 2.02-1.85 (m, 4 H), 1.66-1.58 (m, 4 H). LC/MS: Anal. Calcd. for [M + H]⁺ C₈H₁₄NO₄: 188.09; found 188.19. Cap-64

[Note: the reaction was allowed to run for longer than what was noted for the general procedure.] ¹H NMR (DMSO-d₆, δ = 2.5 ppm, 400 MHz): 12.35 (br s, 1 H), 7.77 (s, 0.82 H), 7.56/7.52 (overlapping br s, 0.18 H), 3.50 (s, 3 H), 2.47-2.40 (m, 2 H), 2.14-2.07 (m, 2 H), 1.93-1.82 (m, 2 H).

Methyl chloroformate (0.65 mL, 8.39 mmol) was added dropwise over 5 min to a cooled (ice-water) mixture of Na₂CO₃ (0.449 g, 4.23 mmol), NaOH (8.2 mL of 1M/H₂O, 8.2 mmol) and (S)-3-hydroxy-2-(methoxycarbonylamino)-3-methylbutanoic acid (1.04 g, 7.81 mmol). The reaction mixture was stirred for 45 min, and then the cooling bath was removed and stirring was continued for an additional 3.75 hr. The reaction mixture was washed with CH₂Cl₂, and the aqueous phase was cooled with ice-water bath and acidified with concentrated HCl to a pH region of 1-2. The volatile component was removed in vacuo and the residue was taken up in a 2:1 mixture of MeOH/CH₂Cl₂ (15 mL) and filtered, and the filterate was rotervaped to afford Cap-65 as a white semi-viscous foam (1.236 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 6.94 (d, J=8.5, 0.9H), 6.53 (br s, 0.1H), 3.89 (d, J=8.8, 1H), 2.94 (s, 3H), 1.15 (s, 3H), 1.13 (s, 3H).

Cap-66 and -67 were prepared from appropriate commercially available starting materials by employing the procedure described for the synthesis of Cap-65.

¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.58 (br s, 1H), 7.07 (d, J=8.3, 0.13H), 6.81 (d, J=8.8, 0.67H), 4.10-4.02 (m, 1.15H), 3.91 (dd, J=9.1, 3.5, 0.85H), 3.56 (s, 3H), 1.09 (d, J=6.2, 3H). [Note: only the dominant signals of NH were noted]

¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): 12.51 (br s, 1H), 7.25 (d, J=8.4, 0.75H), 7.12 (br d, J=0.4, 0.05H), 6.86 (br s, 0.08H), 3.95-3.85 (m, 2H), 3.54 (s, 3H), 1.08 (d, J=6.3, 3H). [Note: only the dominant signals of NH were noted]

Methyl chloroformate (0.38 ml, 4.9 mmol) was added drop-wise to a mixture of 1N NaOH (aq) (9.0 ml, 9.0 mmol), 1M NaHCO₃ (aq) (9.0 ml, 9.0 mol), L-aspartic acid β-benzyl ester (1.0 g, 4.5 mmol) and Dioxane (9 ml). The reaction mixture was stirred at ambient conditions for 3 hr, and then washed with Ethyl acetate (50 ml, 3×). The aqueous layer was acidified with 12N HCl to a pH ˜1-2, and extracted with ethyl acetate (3×50 ml). The combined organic layers were washed with brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to afford Cap-68 as a light yellow oil (1.37 g; mass is above theoretical yield, and the product was used without further purification). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 500 MHz): δ 12.88 (br s, 1H), 7.55 (d, J=8.5, 1H), 7.40-7.32 (m, 5H), 5.13 (d, J=12.8, 1H), 5.10 (d, J=12.9, 1H), 4.42-4.38 (m, 1H), 3.55 (s, 3H), 2.87 (dd, J=16.2, 5.5, 1H), 2.71 (dd, J=16.2, 8.3, 1H). LC (Cond. 2): RT=1.90 min; LC/MS: Anal. Calcd. For [M+H]⁺ C₁₃H₁₆NO₆: 282.10; found 282.12.

NaCNBH₃ (2.416 g, 36.5 mmol) was added in batches to a chilled (˜15° C.) water (17 mL)/MeOH (10 mL) solution of alanine (1.338 g, 15.0 mmol). A few minutes later acetaldehyde (4.0 mL, 71.3 mmol) was added drop-wise over 4 min, the cooling bath was removed, and the reaction mixture was stirred at ambient condition for 6 hr. An additional acetaldehyde (4.0 mL) was added and the reaction was stirred for 2 hr. Concentrated HCl was added slowly to the reaction mixture until the pH reached ˜1.5, and the resulting mixture was heated for 1 hr at 40° C. Most of the volatile component was removed in vacuo and the residue was purified with a Dowex® 50WX8-100 ion-exchange resin (column was washed with water, and the compound was eluted with dilute NH₄OH, prepared by mixing 18 ml of NH₄OH and 282 ml of water) to afford Cap-69 (2.0 g) as an off-white soft hygroscopic solid. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 3.44 (q, J=7.1, 1H), 2.99-2.90 (m, 2H), 2.89-2.80 (m, 2H), 1.23 (d, J=7.1, 3H), 1.13 (t, J=7.3, 6H).

Cap-70 to -74x were prepared according to the procedure described for the synthesis of Cap-69 by employing appropriate starting materials.

Cap-70a: (R) Cap-70b: (S)

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 400 MHz): δ 3.42 (q, J = 7.1, 1 H), 2.68-2.60 (m, 4 H), 1.53-1.44 (m, 4 H), 1.19 (d, J = 7.3, 3 H), 0.85 (t, J = 7.5, 6 H). LC/MS: Anal. Calcd. for [M + H]⁺ C₉H₂₀NO₂: 174.15; found 174.13. Cap-71a: (R) Cap-71b: (S)

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 500 MHz): δ 3.18-3.14 (m, 1 H), 2.84-2.77 (m, 2 H), 2.76- 2.68 (m, 2 H), 1.69-1.54 (m, 2 H), 1.05 (t, J = 7.2, 6 H), 0.91 (t, J = 7.3, 3 H). LC/MS: Anal. Calcd. for [M + H]⁺ C₈H₁₈NO₂: 160.13; found 160.06. Cap-72

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 400 MHz): δ 2.77-2.66 (m, 3 H), 2.39-2.31 (m, 2 H), 1.94- 1.85 (m, 1 H), 0.98 (t, J = 7.1, 6 H), 0.91 (d, J = 6.5, 3 H), 0.85 (d, J = 6.5, 3 H). LC/MS: Anal. Calcd. for [M + H]⁺ C₉H₂₀NO₂: 174.15; found 174.15. Cap-73

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 500 MHz): δ 9.5 (br s, 1 H), 3.77 (dd, J = 10.8, 4.1, 1 H), 3.69-3.61 (m, 2 H), 3.26 (s, 3 H), 2.99-2.88 (m, 4 H), 1.13 (t, J = 7.2, 6 H). Cap-74

¹H NMR (DMSO-d₆, δ = 2.5 ppm, 500 MHz): δ 7.54 (s, 1 H), 6.89 (s, 1 H), 3.81 (t, J = 6.6, k, 1 H), 2.82-2.71 (m, 4 H), 2.63 (dd, J = 15.6, 7.0, 1 H), 2.36 (dd, J = 15.4, 6.3, 1 H), 1.09 (t, J = 7.2, 6 H). RT = 0.125 minutes (Cond. 2); LC/MS: Anal. Calcd. for [M + H]⁺ C₈H₁₇N₂O₃: 189.12; found 189.13. Cap-74x

LC/MS: Anal. Calcd. for [M + H]⁺ C₁₀H₂₂NO₂: 188.17; found 188.21

NaBH₃CN (1.6 g, 25.5 mmol) was added to a cooled (ice/water bath) water (25 ml)/methanol (15 ml) solution of H-D-Ser-OBzl HCl (2.0 g, 8.6 mmol). Acetaldehyde (1.5 ml, 12.5 mmol) was added drop-wise over 5 min, the cooling bath was removed, and the reaction mixture was stirred at ambient condition for 2 hr. The reaction was carefully quenched with 12N HCl and concentrated in vacuo. The residue was dissolved in water and purified with a reverse phase HPLC (MeOH/H₂O/TFA) to afford the TFA salt of (R)-benzyl 2-(diethylamino)-3-hydroxypropanoate as a colorless viscous oil (1.9 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 500 MHz): δ 9.73 (br s, 1H), 7.52-7.36 (m, 5H), 5.32 (d, J=12.2, 1H), 5.27 (d, J=12.5, 1H), 4.54-4.32 (m, 1H), 4.05-3.97 (m, 2H), 3.43-3.21 (m, 4H), 1.23 (t, J=7.2, 6H). LC/MS (Cond. 2): RT=1.38 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₄H₂₂NO₃: 252.16; found 252.19.

Cap-75

NaH (0.0727 g, 1.82 mmol, 60%) was added to a cooled (ice-water) THF (3.0 mL) solution of the TFA salt (R)-benzyl 2-(diethylamino)-3-hydroxypropanoate (0.3019 g, 0.8264 mmol) prepared above, and the mixture was stirred for 15 min. Methyl iodide (56 μL, 0.90 mmol) was added and stirring was continued for 18 hr while allowing the bath to thaw to ambient condition. The reaction was quenched with water and loaded onto a MeOH pre-conditioned MCX (6 g) cartridge, and washed with methanol followed by compound elution with 2N NH₃/Methanol. Removal of the volatile component in vacuo afforded Cap-75, contaminated with (R)-2-(diethylamino)-3-hydroxypropanoic acid, as a yellow semi-solid (100 mg). The product was used as is without further purification.

NaCNBH₃ (1.60 g, 24.2 mmol) was added in batches to a chilled (˜15° C.) water/MeOH (12 mL each) solution of (S)-4-amino-2-(tert-butoxycarbonylamino)butanoic acid (2.17 g, 9.94 mmol). A few minutes later acetaldehyde (2.7 mL, 48.1 mmol) was added drop-wise over 2 min, the cooling bath was removed, and the reaction mixture was stirred at ambient condition for 3.5 hr. An additional acetaldehyde (2.7 mL, 48.1 mmol) was added and the reaction was stirred for 20.5 hr. Most of the MeOH component was removed in vacuo, and the remaining mixture was treated with concentrated HCl until its pH reached ˜1.0 and then heated for 2 hr at 40° C. The volatile component was removed in vacuo, and the residue was treated with 4 M HCl/dioxane (20 mL) and stirred at ambient condition for 7.5 hr. The volatile component was removed in vacuo and the residue was purified with Dowex® 50WX8-100 ion-exchange resin (column was washed with water and the compound was eluted with dilute NH₄OH, prepared from 18 ml of NH₄OH and 282 ml of water) to afford intermediate (S)-2-amino-4-(diethylamino)butanoic acid as an off-white solid (1.73 g).

Methyl chloroformate (0.36 mL, 4.65 mmol) was added drop-wise over 11 min to a cooled (ice-water) mixture of Na₂CO₃ (0.243 g, 2.29 mmol), NaOH (4.6 mL of 1M/H₂O, 4.6 mmol) and the above product (802.4 mg). The reaction mixture was stirred for 55 min, and then the cooling bath was removed and stirring was continued for an additional 5.25 hr. The reaction mixture was diluted with equal volume of water and washed with CH₂Cl₂ (30 mL, 2×), and the aqueous phase was cooled with ice-water bath and acidified with concentrated HCl to a pH region of 2. The volatile component was then removed in vacuo and the crude material was free-based with MCX resin (6.0 g; column was washed with water, and sample was eluted with 2.0 M NH₃/MeOH) to afford impure Cap-76 as an off-white solid (704 mg). ¹H NMR (MeOH-d₄, δ=3.29 ppm, 400 MHz): δ 3.99 (dd, J=7.5, 4.7, 1H), 3.62 (s, 3H), 3.25-3.06 (m, 6H), 2.18-2.09 (m, 1H), 2.04-1.96 (m, 1H), 1.28 (t, J=7.3, 6H). LC/MS: Anal. Calcd. for [M+H]⁺ C₁₀H₂₁N₂O₄: 233.15; found 233.24.

The synthesis of Cap-77 was conducted according to the procedure described for Cap-7 by using 7-azabicyclo[2.2.1]heptane for the SN₂ displacement step, and by effecting the enantiomeric separation of the intermediate benzyl 2-(7-azabicyclo[2.2.1]heptan-7-yl)-2-phenylacetate using the following condition: the intermediate (303.7 mg) was dissolved in ethanol, and the resulting solution was injected on a chiral HPLC column (Chiracel AD-H column, 30×250 mm, 5 um) eluting with 90% CO₂-10% EtOH at 70 mL/min, and a temperature of 35° C. to provide 124.5 mg of enantiomer-1 and 133.8 mg of enantiomer-2. These benzyl esters were hydrogenolysed according to the preparation of Cap-7 to provide Cap-77: ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 7.55 (m, 2H), 7.38-7.30 (m, 3H), 4.16 (s, 1H), 3.54 (app br s, 2H), 2.08-1.88 (m, 4H), 1.57-1.46 (m, 4H). LC (Cond. 1): RT=0.67 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₄H₁₈BrNO₂: 232.13; found 232.18. HRMS: Anal. Calcd. for [M+H]⁺ C₁₄H₁₈BrNO₂: 232.1338; found 232.1340.

NaCNBH₃ (0.5828 g, 9.27 mmol) was added to a mixture of the HCl salt of (R)-2-(ethylamino)-2-phenylacetic acid (an intermediate in the synthesis of Cap-3; 0.9923 mg, 4.60 mmol) and (1-ethoxycyclopropoxy)trimethylsilane (1.640 g, 9.40 mmol) in MeOH (10 mL), and the semi-heterogeneous mixture was heated at 50° C. with an oil bath for 20 hr. More (1-ethoxycyclopropoxy)trimethylsilane (150 mg, 0.86 mmol) and NaCNBH₃ (52 mg, 0.827 mmol) were added and the reaction mixture was heated for an additional 3.5 hr. It was then allowed to cool to ambient temperature and acidified to a ˜pH region of 2 with concentrated HCl, and the mixture was filtered and the filtrate was rotervaped. The resulting crude material was taken up in i-PrOH (6 mL) and heated to effect dissolution, and the non-dissolved part was filtered off and the filtrate concentrated in vacuo. About ⅓ of the resultant crude material was purified with a reverse phase HPLC (H₂O/MeOH/TFA) to afford the TFA salt of Cap-78 as a colorless viscous oil (353 mg). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz; after D₂O exchange): δ 7.56-7.49 (m, 5H), 5.35 (S, 1H), 3.35 (m, 1H), 3.06 (app br s, 1H), 2.66 (m, 1H), 1.26 (t, J=7.3, 3H), 0.92 (m, 1H), 0.83-0.44 (m, 3H). LC (Cond. 1): RT=0.64 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₃H₁₈NO₂: 220.13; found 220.21. HRMS: Anal. Calcd. for [M+H]⁺ C₁₃H₁₈NO₂: 220.1338; found 220.1343.

Ozone was bubbled through a cooled (−78° C.) CH₂Cl₂ (5.0 mL) solution Cap-55 (369 mg, 2.13 mmol) for about 50 min until the reaction mixture attained a tint of blue color. Me₂S (10 pipet drops) was added, and the reaction mixture was stirred for 35 min. The −78° C. bath was replaced with a −10° C. bath and stirring continued for an additional 30 min, and then the volatile component was removed in vacuo to afford a colorless viscous oil.

NaBH₃CN (149 mg, 2.25 mmol) was added to a MeOH (5.0 mL) solution of the above crude material and morpholine (500 μL, 5.72 mmol) and the mixture was stirred at ambient condition for 4 hr. It was cooled to ice-water temperature and treated with concentrated HCl to bring its pH to ˜2.0, and then stirred for 2.5 hr. The volatile component was removed in vacuo, and the residue was purified with a combination of MCX resin (MeOH wash; 2.0 N NH₃/MeOH elution) and a reverse phase HPLC (H₂O/MeOH/TFA) to afford Cap-79 containing unknown amount of morpholine.

In order to consume the morpholine contaminant, the above material was dissolved in CH₂Cl₂ (1.5 mL) and treated with Et₃N (0.27 mL, 1.94 mmol) followed by acetic anhydride (0.10 mL, 1.06 mmol) and stirred at ambient condition for 18 hr. THF (1.0 mL) and H₂O (0.5 mL) were added and stirring continued for 1.5 hr. The volatile component was removed in vacuo, and the resultant residue was passed through MCX resin (MeOH wash; 2.0 N NH₃/MeOH elution) to afford impure Cap-79 as a brown viscous oil, which was used for the next step without further purification.

SOCl₂ (6.60 mL, 90.5 mmol) was added drop-wise over 15 min to a cooled (ice-water) mixture of (S)-3-amino-4-(benzyloxy)-4-oxobutanoic acid (10.04 g, 44.98 mmol) and MeOH (300 mL), the cooling bath was removed and the reaction mixture was stirred at ambient condition for 29 hr. Most of the volatile component was removed in vacuo and the residue was carefully partitioned between EtOAc (150 mL) and saturated NaHCO₃ solution. The aqueous phase was extracted with EtOAc (150 mL, 2×), and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo to afford (S)-1-benzyl 4-methyl 2-aminosuccinate as a colorless oil (9.706 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 7.40-7.32 (m, 5H), 5.11 (s, 2H), 3.72 (app t, J=6.6, 1H), 3.55 (s, 3H), 2.68 (dd, J=15.9, 6.3, 1H), 2.58 (dd, J=15.9, 6.8, 1H), 1.96 (s, 2H). LC (Cond. 1): RT=0.90 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₂H₁₆NO₄: 238.11; found 238.22.

Pb(NO₃)₂ (6.06 g, 18.3 mmol) was added over 1 min to a CH₂Cl₂ (80 mL) solution of (S)-1-benzyl 4-methyl 2-aminosuccinate (4.50 g, 19.0 mmol), 9-bromo-9-phenyl-9H-fluorene (6.44 g, 20.0 mmol) and Et₃N (3.0 mL, 21.5 mmol), and the heterogeneous mixture was stirred at ambient condition for 48 hr. The mixture was filtered and the filtrate was treated with MgSO₄ and filtered again, and the final filtrate was concentrated. The resulting crude material was submitted to a Biotage purification (350 g silica gel, CH₂Cl₂ elution) to afford (S)-1-benzyl 4-methyl 2-(9-phenyl-9H-fluoren-9-ylamino)succinate as highly viscous colorless oil (7.93 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 7.82 (m, 2H), 7.39-7.13 (m, 16H), 4.71 (d, J=12.4, 1H), 4.51 (d, J=12.6, 1H), 3.78 (d, J=9.1, NH), 3.50 (s, 3H), 2.99 (m, 1H), 2.50-2.41 (m, 2H, partially overlapped with solvent). LC (Cond. 1): RT=2.16 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₁H₂₈NO₄: 478.20; found 478.19.

LiHMDS (9.2 mL of 1.0 M/THF, 9.2 mmol) was added drop-wise over 10 min to a cooled (−78° C.) THF (50 mL) solution of (S)-1-benzyl 4-methyl 2-(9-phenyl-9H-fluoren-9-ylamino)succinate (3.907 g, 8.18 mmol) and stirred for ˜1 hr. MeI (0.57 mL, 9.2 mmol) was added drop-wise over 8 min to the mixture, and stirring was continued for 16.5 hr while allowing the cooling bath to thaw to room temperature. After quenching with saturated NH₄Cl solution (5 mL), most of the organic component was removed in vacuo and the residue was partitioned between CH₂Cl₂ (100 mL) and water (40 mL). The organic layer was dried (MgSO₄), filtered, and concentrated in vacuo, and the resulting crude material was purified with a Biotage (350 g silica gel; 25% EtOAc/hexanes) to afford 3.65 g of a 2S/3S and 2S/3R diastereomeric mixtures of 1-benzyl 4-methyl 3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)succinate in ˜1.0:0.65 ratio (¹H NMR). The stereochemistry of the dominant isomer was not determined at this juncture, and the mixture was submitted to the next step without separation. Partial ¹H NMR data (DMSO-d₆, δ=2.5 ppm, 400 MHz): major diastereomer, δ 4.39 (d, J=12.3, 1H of CH₂), 3.33 (s, 3H, overlapped with H₂O signal), 3.50 (d, J=10.9, NH), 1.13 (d, J=7.1, 3H); minor diastereomer, δ 4.27 (d, J=12.3, 1H of CH₂), 3.76 (d, J=10.9, NH), 3.64 (s, 3H), 0.77 (d, J=7.0, 3H). LC (Cond. 1): RT=2.19 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₂H₃₀NO₄: 492.22; found 492.15.

Diisobutylaluminum hydride (20.57 ml of 1.0 M in hexanes, 20.57 mmol) was added drop-wise over 10 min to a cooled (−78° C.) THF (120 mL) solution of (2S)-1-benzyl 4-methyl 3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)succinate (3.37 g, 6.86 mmol) prepared above, and stirred at −78° C. for 20 hr. The reaction mixture was removed from the cooling bath and rapidly poured into ˜1M H₃PO₄/H₂O (250 mL) with stirring, and the mixture was extracted with ether (100 mL, 2×). The combined organic phase was washed with brine, dried (MgSO₄), filtered and concentrated in vacuo. A silica gel mesh of the crude material was prepared and submitted to chromatography (25% EtOAc/hexanes; gravity elution) to afford 1.1 g of (2S,3S)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate, contaminated with benzyl alcohol, as a colorless viscous oil and (2S,3R)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate containing the (2S,3R) stereoisomer as an impurity. The later sample was resubmitted to the same column chromatography purification conditions to afford 750 mg of purified material as a white foam. [Note: the (2S,3S) isomer elutes before the (2S,3R) isomer under the above condition]. (2S,3S) isomer: ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): 7.81 (m, 2H), 7.39-7.08 (m, 16H), 4.67 (d, J=12.3, 1H), 4.43 (d, J=12.4, 1H), 4.21 (app t, J=5.2, OH), 3.22 (d, J=10.1, NH), 3.17 (m, 1H), 3.08 (m, 1H), ˜2.5 (m, 1H, overlapped with the solvent signal), 1.58 (m, 1H), 0.88 (d, J=6.8, 3H). LC (Cond. 1): RT=2.00 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₁H₃₀NO₃: 464.45; found 464.22. (2S,3R) isomer: ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): 7.81 (d, J=7.5, 2H), 7.39-7.10 (m, 16H), 4.63 (d, J=12.1, 1H), 4.50 (app t, J=4.9, 1H) 4.32 (d, J=12.1, 1H), 3.59-3.53 (m, 2H), 3.23 (m, 1H), 2.44 (dd, J=9.0, 8.3, 1H), 1.70 (m, 1H), 0.57 (d, J=6.8, 3H). LC (Cond. 1): RT=1.92 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₁H₃₀NO₃: 464.45; found 464.52.

The relative stereochemical assignments of the DIBAL-reduction products were made based on NOE studies conducted on lactone derivatives prepared from each isomer by employing the following protocol: LiHMDS (50 μL of 1.0 M/THF, 0.05 mmol) was added to a cooled (ice-water) THF (2.0 mL) solution of (2S,3S)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate (62.7 mg, 0.135 mmol), and the reaction mixture was stirred at similar temperature for ˜2 hr. The volatile component was removed in vacuo and the residue was partitioned between CH₂Cl₂ (30 mL), water (20 mL) and saturated aqueous NH₄Cl solution (1 mL). The organic layer was dried (MgSO₄), filtered, and concentrated in vacuo, and the resulting crude material was submitted to a Biotage purification (40 g silica gel; 10-15% EtOAc/hexanes) to afford (3S,4S)-4-methyl-3-(9-phenyl-9H-fluoren-9-ylamino)dihydrofuran-2(3H)-one as a colorless film of solid (28.1 mg). (2S,3R)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate was elaborated similarly to (3S,4R)-4-methyl-3-(9-phenyl-9H-fluoren-9-ylamino)dihydrofuran-2(3H)-one. (3S,4S)-lactone isomer: ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz), 7.83 (d, J=7.5, 2H), 7.46-7.17 (m, 11H), 4.14 (app t, J=8.3, 1H), 3.60 (d, J=5.8, NH), 3.45 (app t, J=9.2, 1H), ˜2.47 (m, 1H, partially overlapped with solvent signal), 2.16 (m, 1H), 0.27 (d, J=6.6, 3H). LC (Cond. 1): RT=1.98 min; LC/MS: Anal. Calcd. for [M+Na]⁺ C₂₄H₂₁NNaO₂: 378.15; found 378.42. (3S,4R)-lactone isomer: ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz), 7.89 (d, J=7.6, 1H), 7.85 (d, J=7.3, 1H), 7.46-7.20 (m, 11H), 3.95 (dd, J=9.1, 4.8, 1H), 3.76 (d, J=8.8, 1H), 2.96 (d, J=3.0, NH), 2.92 (dd, J=6.8, 3, NCH), 1.55 (m, 1H), 0.97 (d, J=7.0, 3H). LC (Cond. 1): RT=2.03 min; LC/MS: Anal. Calcd. for [M+Na]⁺ C₂₄H₂₁NNaO₂: 378.15; found 378.49.

TBDMS-Cl (48 mg, 0.312 mmol) followed by imidazole (28.8 mg, 0.423 mmol) were added to a CH₂Cl₂ (3 ml) solution of (2S,3S)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate (119.5 mg, 0.258 mmol), and the mixture was stirred at ambient condition for 14.25 hr. The reaction mixture was then diluted with CH₂Cl₂ (30 mL) and washed with water (15 mL), and the organic layer was dried (MgSO₄), filtered, and concentrated in vacuo. The resultant crude material was purified with a Biotage (40 g silica gel; 5% EtOAc/hexanes) to afford (2S,3S)-benzyl 4-(tert-butyldimethylsilyloxy)-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate, contaminated with TBDMS based impurities, as a colorless viscous oil (124.4 mg). (2S,3R)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate was elaborated similarly to (2S,3R)-benzyl 4-(tert-butyldimethylsilyloxy)-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate. (2S,3S)-silyl ether isomer: ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz), 7.82 (d, J=4.1, 1H), 7.80 (d, J=4.0, 1H), 7.38-7.07 (m, 16H), 4.70 (d, J=12.4, 1H), 4.42 (d, J=12.3, 1H), 3.28-3.19 (m, 3H), 2.56 (dd, J=10.1, 5.5, 1H), 1.61 (m, 1H), 0.90 (d, J=6.8, 3H), 0.70 (s, 9H), −0.13 (s, 3H), −0.16 (s, 3H). LC (Cond. 1, where the run time was extended to 4 min): RT=3.26 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₇H₄₄NO₃Si: 578.31. found 578.40. (2S,3R)-silyl ether isomer: ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz), 7.82 (d, J=3.0, 1H), 7.80 (d, J=3.1, 1H), 7.39-7.10 (m, 16H), 4.66 (d, J=12.4, 1H), 4.39 (d, J=12.4, 1H), 3.61 (dd, J=9.9, 5.6, 1H), 3.45 (d, J=9.5, 1H), 3.41 (dd, J=10, 6.2, 1H), 2.55 (dd, J=9.5, 7.3, 1H), 1.74 (m, 1H), 0.77 (s, 9H), 0.61 (d, J=7.1, 3H), −0.06 (s, 3H), −0.08 (s, 3H).

A balloon of hydrogen was attached to a mixture of (2S,3S)-benzyl 4-(tert-butyldimethylsilyloxy)-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate (836 mg, 1.447 mmol) and 10% Pd/C (213 mg) in EtOAc (16 mL) and the mixture was stirred at room temperature for ˜21 hr, where the balloon was recharged with H₂ as necessary. The reaction mixture was diluted with CH₂Cl₂ and filtered through a pad of diatomaceous earth (Celite-545®), and the pad was washed with EtOAc (200 mL), EtOAc/MeOH (1:1 mixture, 200 mL) and MeOH (750 mL). The combined organic phase was concentrated, and a silica gel mesh was prepared from the resulting crude material and submitted to a flash chromatography (8:2:1 mixture of EtOAc/i-PrOH/H₂O) to afford (2S,3S)-2-amino-4-(tert-butyldimethylsilyloxy)-3-methylbutanoic acid as a white fluffy solid (325 mg). (2S,3R)-benzyl 4-(tert-butyldimethylsilyloxy)-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate was similarly elaborated to (2S,3R)-2-amino-4-(tert-butyldimethylsilyloxy)-3-methylbutanoic acid. (2S,3S)-amino acid isomer: ¹H NMR (Methanol-d₄, δ=3.29 ppm, 400 MHz), 3.76 (dd, J=10.5, 5.2, 1H), 3.73 (d, J=3.0, 1H), 3.67 (dd, J=10.5, 7.0, H), 2.37 (m, 1H), 0.97 (d, J=7.0, 3H), 0.92 (s, 9H), 0.10 (s, 6H). LC/MS: Anal. Calcd. for [M+H]⁺C₁₁H₂₆NO₃Si: 248.17. found 248.44. (2S,3R)-amino acid isomer: ¹H NMR (Methanol-d₄, δ=3.29 ppm, 400 MHz), 3.76-3.75 (m, 2H), 3.60 (d, J=4.1, 1H), 2.16 (m, 1H), 1.06 (d, J=7.3, 3H), 0.91 (s, 9H), 0.09 (s, 6H). Anal. Calcd. for [M+H]⁺C₁₁H₂₆NO₃Si: 248.17; found 248.44.

Water (1 mL) and NaOH (0.18 mL of 1.0 M/H₂O, 0.18 mmol) were added to a mixture of (2S,3S)-2-amino-4-(tert-butyldimethylsilyloxy)-3-methylbutanoic acid (41.9 mg, 0.169 mmol) and Na₂CO₃ (11.9 mg, 0.112 mmol), and sonicated for about 1 min to effect dissolution of reactants. The mixture was then cooled with an ice-water bath, methyl chloroformate (0.02 mL, 0.259 mmol) was added over 30 s, and vigorous stirring was continued at similar temperature for 40 min and then at ambient temperature for 2.7 hr. The reaction mixture was diluted with water (5 mL), cooled with ice-water bath and treated drop-wise with 1.0 N HCl aqueous solution (˜0.23 mL). The mixture was further diluted with water (10 mL) and extracted with CH₂Cl₂ (15 mL, 2×). The combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo to afford Cap-80a as an off-white solid. (2S,3R)-2-amino-4-(tert-butyldimethylsilyloxy)-3-methylbutanoic acid was similarly elaborated to Cap-80b. Cap-80a: ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz), 12.57 (br s, 1H), 7.64 (d, J=8.3, 0.3H), 7.19 (d, J=8.8, 0.7H), 4.44 (dd, J=8.1, 4.6, 0.3H), 4.23 (dd, J=8.7, 4.4, 0.7H), 3.56/3.53 (two singlets, 3H), 3.48-3.40 (m, 2H), 2.22-2.10 (m, 1H), 0.85 (s, 9H), ˜0.84 (d, 0.9H, overlapped with t-Bu signal), 0.79 (d, J=7, 2.1H), 0.02/0.01/0.00 (three overlapping singlets, 6H). LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₃H₂₇NNaO₅Si: 328.16; found 328.46. Cap-80b: ¹H NMR (CDCl₃, δ=7.24 ppm, 400 MHz), 6.00 (br d, J=6.8, 1H), 4.36 (dd, J=7.1, 3.1, 1H), 3.87 (dd, J=10.5, 3.0, 1H), 3.67 (s, 3H), 3.58 (dd, J=10.6, 4.8, 1H), 2.35 (m, 1H), 1.03 (d, J=7.1, 3H), 0.90 (s, 9H), 0.08 (s, 6H). LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₃H₂₇NNaO₅Si: 328.16; found 328.53. The crude products were utilized without further purification.

Prepared according to the protocol described by Falb et al. Synthetic Communications 1993, 23, 2839.

Cap-82 to Cap-85

Cap-82 to Cap-85 were synthesized from appropriate starting materials according to the procedure described for Cap-51. The samples exhibited similar spectral profiles as that of their enantiomers (i.e., Cap-4, Cap-13, Cap-51 and Cap-52, respectively)

To a mixture of O-methyl-L-threonine (3.0 g, 22.55 mmol), NaOH (0.902 g, 22.55 mmol) in H₂O (15 mL) was added ClCO₂Me (1.74 mL, 22.55 mmol) dropwise at 0° C. The mixture was allowed to stir for 12 h and acidified to pH 1 using 1N HCl. The aqueous phase was extracted with EtOAc and (2×250 mL) and 10% MeOH in CH₂Cl₂ (250 mL) and the combined organic phases were concentrated under in vacuo to afford a colorless oil (4.18 g, 97%) which was of sufficient purity for use in subsequent steps. ¹HNMR (400 MHz, CDCl₃) δ 4.19 (s, 1H), 3.92-3.97 (m, 1H), 3.66 (s, 3H), 1.17 (d, J=7.7 Hz, 3H). LCMS: Anal. Calcd. for C₇H₁₃NO₅: 191; found: 190 (M−H)⁻.

To a mixture of L-homoserine (2.0 g, 9.79 mmol), Na₂CO₃ (2.08 g, 19.59 mmol) in H₂O (15 mL) was added ClCO₂Me (0.76 mL, 9.79 mmol) dropwise at 0° C. The mixture was allowed to stir for 48 h and acidified to pH 1 using 1N HCl. The aqueous phase was extracted with EtOAc and (2×250 mL) and the combined organic phases were concentrated under in vacuo to afford a colorless solid (0.719 g, 28%) which was of sufficient purity for use in subsequent steps. ¹HNMR (400 MHz, CDCl₃) δ 4.23 (dd, J=4.5, 9.1 Hz, 1H), 3.66 (s, 3H), 3.43-3.49 (m, 2H), 2.08-2.14 (m, 1H), 1.82-1.89 (m, 1H). LCMS: Anal. Calcd. for C₇H₁₃NO₅: 191; found: 192 (M+H)⁺.

A mixture of L-valine (1.0 g, 8.54 mmol), 3-bromopyridine (1.8 mL, 18.7 mmol), K₂CO₃ (2.45 g, 17.7 mmol) and CuI (169 mg, 0.887 mmol) in DMSO (10 mL) was heated at 100° C. for 12 h. The reaction mixture was cooled to rt, poured into H₂O (ca. 150 mL) and washed with EtOAc (×2). The organic layers were extracted with a small amount of H₂O and the combined aq phases were acidified to ca. pH 2 with 6N HCl. The volume was reduced to about one-third and 20 g of cation exchange resin (Strata) was added. The slurry was allowed to stand for 20 min and loaded onto a pad of cation exchange resin (Strata) (ca. 25 g). The pad was washed with H₂O (200 mL), MeOH (200 mL), and then NH₃ (3M in MeOH, 2×200 mL). The appropriate fractions was concentrated in vacuo and the residue (ca. 1.1 g) was dissolved in H₂O, frozen and lyophilized. The title compound was obtained as a foam (1.02 g, 62%). ¹HNMR (400 MHz, DMSO-d₆) δ 8.00 (s, br, 1H), 7.68-7.71 (m, 1H), 7.01 (s, br, 1H), 6.88 (d, J=7.5 Hz, 1H), 5.75 (s, br, 1H), 3.54 (s, 1H), 2.04-2.06 (m, 1H), 0.95 (d, J=6.0 Hz, 3H), 0.91 (d, J=6.6 Hz, 3H). LCMS: Anal. Calcd. for C₁₀H₁₄N₂O₂: 194; found: 195 (M+H)⁺.

A mixture of L-valine (1.0 g, 8.54 mmol), 5-bromopyrimidine (4.03 g, 17.0 mmol), K₂CO₃ (2.40 g, 17.4 mmol) and CuI (179 mg, 0.94 mmol) in DMSO (10 mL) was heated at 100° C. for 12 h. The reaction mixture was cooled to RT, poured into H₂O (ca. 150 mL) and washed with EtOAc (×2). The organic layers were extracted with a small amount of H₂O and the combined aq phases were acidified to ca. pH 2 with 6N HCl. The volume was reduced to about one-third and 20 g of cation exchange resin (Strata) was added. The slurry was allowed to stand for 20 min and loaded onto a pad of cation exchange resin (Strata) (ca. 25 g). The pad was washed with H₂O (200 mL), MeOH (200 mL), and then NH₃ (3M in MeOH, 2×200 mL). The appropriate fractions was concentrated in vacuo and the residue (ca. 1.1 g) was dissolved in H₂O, frozen and lyophilized. The title compound was obtained as a foam (1.02 g, 62%). ¹HNMR (400 MHz, CD₃OD) showed the mixture to contain valine and the purity could not be estimated. The material was used as is in subsequent reactions. LCMS: Anal. Calcd. for C₉H₁₃N₃O₂: 195; found: 196 (M+H)⁺.

Cap-90 was prepared according to the method described for the preparation of Cap-1. The crude material was used as is in subsequent steps. LCMS: Anal. Calcd. for C₁₁H₁₅NO₂: 193; found: 192 (M−H)⁻.

The following caps were prepared according to the method of Cap-51:

Cap Structure LCMS Cap-91

LCMS: Anal. Calcd. for C₁₁H₁₃NO₄: 223; found 222 (M − H)⁻. Cap-92

LCMS: Anal. Calcd. for C₁₁H₁₃NO₄: 223; found 222 (M − H)⁻. Cap-93

LCMS: Anal. Calcd. for C₁₀H₁₂N₂O₄: 224; found 225 (M + H)⁺. Cap-94

LCMS: Anal. Calcd. for C₈H₁₁N₃O₄: 213; found 214 (M + H)⁺. Cap-95

LCMS: Anal. Calcd. for C₁₃H₁₇NO₄: 251; found 250 (M − H)⁻. Cap-96

LCMS: Anal. Calcd. for C₁₂H₅₀NO₄: 237; found 236 (M − H)⁻. Cap-97

LCMS: Anal. Calcd. for C₉H₁₅NO₄: 201; found 200 (M − H)⁻. Cap-98

LCMS: Anal. Calcd. for C₉H₁₅NO₄: 201; found 202 (M + H)⁺. Cap-99

¹HNMR (400 MHz, CD₃OD) δ 3.88-3.94 (m, 1 H), 3.60, 3.61 (s, 3 H), 2.80 (m, 1 H), 2.20 (m 1 H), 1.82-1.94 (m, 3 H), 1.45-1.71 (m, 2 H). Cap-99a

¹HNMR (400 MHz, CD₃OD) δ 3.88-3.94 (m, 1 H), 3.60, 3.61 (s, 3 H), 2.80 (m, 1 H), 2.20 (m 1 H), 1.82-1.94 (m, 3 H), 1.45-1.71 (m, 2 H). Cap-100

LCMS: Anal. Calcd. for C₁₂H₁₄NO₄F: 255; found 256 (M + H)⁺. Cap-101

LCMS: Anal. Calcd. for C₁₁H₁₃NO₄: 223; found 222 (M − H)⁻. Cap-102

LCMS: Anal. Calcd. for C₁₁H₁₃NO₄: 223; found 222 (M − H)⁻. Cap-103

LCMS: Anal. Calcd. for C₁₀H₁₂NO₄: 224; found 225 (M + H)⁺. Cap-104

¹HNMR (400 MHz, CD₃OD) δ 3.60 (s, 3 H), 3.50-3.53 (m, 1 H), 2.66-2.69 and 2.44- 2.49 (m, 1 H), 1.91-2.01 (m, 2 H), 1.62-1.74 (m, 4 H), 1.51-1.62 (m, 2 H). Cap-105

¹HNMR (400 MHz, CD₃OD) δ 3.60 (s, 3 H), 3.33-3.35 (m, 1 H, partially obscured by solvent), 2.37-2.41 and 2.16-2.23 (m, 1 H), 1.94- 2.01 (m, 4 H), 1.43-1.53 (m, 2 H), 1.17-1.29 (m, 2 H). Cap-106 (prepared following the procedure described for Cap- 2))

¹HNMR (400 MHz, CD₃OD) δ 3.16 (q, J = 7.3 Hz, 4 H), 2.38-2.41 (m, 1 H), 2.28- 2.31 (m, 2 H), 1.79-1.89 (m, 2 H), 1.74 (app, ddd J = 3.5, 12.5, 15.9 Hz, 2 H), 1.46 (app dt J = 4.0, 12.9 Hz, 2 H), 1.26 (t, J = 7.3 Hz, 6 H). Cap-107

LCMS: Anal. Calcd. for C₈H₁₀N₂O₄S: 230; found: 231 (M + H)⁺. Cap-108

LCMS: Anal. Calcd. for C₁₅H₁₇N₃O₄: 303; found: 304 (M + H)⁺. Cap-109

LCMS: Anal. Calcd. for C₁₀H₁₂N₂O₄: 224; found: 225 (M + H)⁺. Cap-110

LCMS: Anal. Calcd. for C₁₀H₁₂N₂O₄: 224; found: 225 (M + H)⁺. Cap-111

LCMS: Anal. Calcd. for C₁₂H₁₆NO₈P: 333; found: 334 (M + H)⁺. Cap-112

LCMS: Anal. Calcd. for C₁₃H₁₄N₂O₄: 262; found: 263 (M + H)⁺. Cap-113

LCMS: Anal. Calcd. for C₁₈H₁₉NO₅: 329; found: 330 (M + H)⁺. Cap-114

¹HNMR (400 MHz, CDCl₃) δ 4.82-4.84 (m, 1 H), 4.00- 4.05 (m, 2 H), 3.77 (s, 3 H), 2.56 (s, br, 2 H) Cap-115

¹HNMR (400 MHz, CDCl₃) δ 5.13 (s, br, 1 H), 4.13 (s, br, 1 H), 3.69 (s, 3 H), 2.61 (d, J = 5.0 Hz, 2 H), 1.28 (d, J = 9.1 Hz, 3 H). Cap-116

¹HNMR (400 MHz, CDCl₃) δ 5.10 (d, J = 8.6 Hz, 1 H), 3.74-3.83 (m, 1 H), 3.69 (s, 3 H), 2.54-2.61 (m, 2 H), 1.88 (sept, J = 7.0 Hz, 1 H), 0.95 (d, J = 7.0 Hz, 6 H).

Cap-117 to Cap-123

For the preparation of caps Cap-117 to Cap-123 the Boc amino acids were commercially available and were deprotected by treatment with 25% TFA in CH₂Cl₂. After complete reaction as judged by LCMS the solvents were removed in vacuo and the corresponding TFA salt of the amino acid was carbamoylated with methyl chloroformate according to the procedure for Cap-51.

Cap Structure LCMS Cap-117

LCMS: Anal. Calcd. for C₁₂H₁₅NO₄S: 237; found: 238 (M + H)⁺. Cap-118

LCMS: Anal. Calcd. for C₁₀H₁₃NO₄S: 243; found: 244 (M + H)⁺. Cap-119

LCMS: Anal. Calcd. for C₁₀H₁₃NO₄S: 243; found: 244 (M + H)⁺. Cap-120

LCMS: Anal. Calcd. for C₁₀H₁₃NO₄S: 243; found: 244 (M + H)⁺. Cap-121

¹HNMR (400 MHz, CDCl₃) δ 4.06-4.16 (m, 1 H), 3.63 (s, 3 H), 3.43 (s, 1 H), 2.82 and 2.66 (s, br, 1 H), 1.86-2.10 (m, 3 H), 1.64-1.76 (m, 2 H), 1.44-1.53 (m, 1 H). Cap-122

¹HNMR (400 MHz, CDCl₃) δ 5.28 and 5.12 (s, br, 1 H), 3.66 (s, 3 H), 2.64-2.74 (m, 1 H), 1.86- 2.12 (m, 3 H), 1.67- 1.74 (m, 2 H), 1.39-1.54 (m, 1 H). Cap-123

LCMS: Anal. Calcd. for C₂₇H₂₆N₂O₆: 474; found: 475 (M + H)⁺.

Preparation of Cap-124. (4S,5R)-5-methyl-2-oxooxazolidine-4-carboxylic acid

The hydrochloride salt of L-threonine tert-butyl ester was carbamoylated according to the procedure for Cap-51. The crude reaction mixture was acidified with 1N HCl to pH ˜1 and the mixture was extracted with EtOAc (2×50 mL). The combined organic phases were concentrated in vacuo to give a colorless which solidified on standing. The aqueous layer was concentrated in vacuo and the resulting mixture of product and inorganic salts was triturated with EtOAc-CH₂Cl₂-MeOH (1:1:0.1) and then the organic phase concentrated in vacuo to give a colorless oil which was shown by LCMS to be the desired product. Both crops were combined to give 0.52 g of a solid. ¹HNMR (400 MHz, CD₃OD) δ 4.60 (m, 1H), 4.04 (d, J=5.0 Hz, 1H), 1.49 (d, J=6.3 Hz, 3H). LCMS: Anal. Calcd. for C₅H₇NO₄: 145; found: 146 (M+H)⁺.

Preparation of Cap-125. (S)-2-(tert-butoxycarbonylamino)-4-(dimethylamino)butanoic acid

Cap-125 was prepared according to the procedure for the preparation of Cap-1. The crude product was used as is in subsequent reactions. LCMS: Anal. Calcd. for C₁₁H₂₂N₂O₄: 246; found: 247 (M+H)⁺.

Preparation of (S)-2-(methoxycarbonylamino)-3-(1-methyl-1H-imidazol-2-yl)propanoic acid (Cap-126)

This procedure is a modification of that used to prepare Cap-51. To a suspension of (S)-2-amino-3-(1-methyl-1H-imidazol-2-yl)propanoic acid (0.80 g, 4.70 mmol) in THF (10 mL) and H₂O (10 mL) at 0° C. was added NaHCO₃ (0.88 g, 10.5 mmol). The resulting mixture was treated with ClCO₂Me (0.40 mL, 5.20 mmol) and the mixture allowed to stir at 0° C. After stirring for ca. 2 h LCMS showed no starting material remaining. The reaction was acidified to pH 2 with 6 N HCl.

The solvents were removed in vacuo and the residue was suspended in 20 mL of 20% MeOH in CH₂Cl₂. The mixture was filtered and concentrated to give a light yellow foam (1.21 g). LCMS and ¹H NMR showed the material to be a 9:1 mixture of the methyl ester and the desired product. This material was taken up in THF (10 mL) and H₂O (10 mL), cooled to 0° C. and LiOH (249.1 mg, 10.4 mmol) was added. After stirring ca. 1 h LCMS showed no ester remaining. Therefore the mixture was acidified with 6N HCl and the solvents removed in vacuo. LCMS and ¹H NMR confirm the absence of the ester. The title compound was obtained as its HCl salt contaminated with inorganic salts (1.91 g, >100%). The compound was used as is in subsequent steps without further purification.

¹HNMR (400 MHz, CD₃OD) δ 8.84, (s, 1H), 7.35 (s, 1H), 4.52 (dd, J=5.0, 9.1 Hz, 1H), 3.89 (s, 3H), 3.62 (s, 3H), 3.35 (dd, J=4.5, 15.6 Hz, 1H, partially obscured by solvent), 3.12 (dd, J=9.0, 15.6 Hz, 1H).

LCMS: Anal. Calcd. for C₁₇H₁₅NO₂: 392; found: 393 (M+H)⁺.

Preparation of (S)-2-(methoxycarbonylamino)-3-(1-methyl-1H-imidazol-4-yl)propanoic acid (Cap-127)

Cap-127 was prepared according to the method for Cap-126 above starting from (S)-2-amino-3-(1-methyl-1H-imidazol-4-yl)propanoic acid (1.11 g, 6.56 mmol), NaHCO₃ (1.21 g, 14.4 mmol) and ClCO₂Me (0.56 mL, 7.28 mmol). The title compound was obtained as its HCl salt (1.79 g, >100%) contaminated with inorganic salts. LCMS and ¹H NMR showed the presence of ca. 5% of the methyl ester. The crude mixture was used as is without further purification.

¹HNMR (400 MHz, CD₃OD) δ 8.90 (s, 1H), 7.35 (s, 1H), 4.48 (dd, J=5.0, 8.6 Hz, 1H), 3.89 (s, 3H), 3.62 (s, 3H), 3.35 (m, 1H), 3.08 (m, 1H).

LCMS: Anal. Calcd. for C₁₇H₁₅NO₂: 392; found: 393 (M+H)⁺.

Preparation of (S)-2-(methoxycarbonylamino)-3-(1H-1,2,3-triazol-4-yl)propanoic acid (Cap-128)

Step 1. Preparation of (S)-benzyl 2-(tert-butoxycarbonylamino)pent-4-ynoate (cj-27b)

To a solution of cj-27a (1.01 g, 4.74 mmol), DMAP (58 mg, 0.475 mmol) and iPr₂NEt (1.7 mL, 9.8 mmol) in CH₂Cl₂ (100 mL) at 0° C. was added Cbz-Cl (0.68 mL, 4.83 mmol). The solution was allowed to stir for 4 h at 0° C., washed (1N KHSO₄, brine), dried (Na₂SO₄), filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (TLC 6:1 hex:EtOAc) to give the title compound (1.30 g, 91%) as a colorless oil. ¹HNMR (400 MHz, CDCl₃) δ 7.35 (s, 5H), 5.35 (d, br, J=8.1 Hz, 1H), 5.23 (d, J=12.2 Hz, 1H), 5.17 (d, J=12.2 Hz, 1H), 4.48-4.53 (m, 1H), 2.68-2.81 (m, 2H), 2.00 (t, J=2.5 Hz, 1H), 1.44 (s, 9H). LCMS: Anal. Calcd. for C₁₇H₂₁NO₄: 303; found: 304 (M+H)⁺.

Step 2. Preparation of (S)-benzyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(tert-butoxycarbonylamino)propanoate (cj-28)

To a mixture of (S)-benzyl 2-(tert-butoxycarbonylamino)pent-4-ynoate (0.50 g, 1.65 mmol), sodium ascorbate (0.036 g, 0.18 mmol), CuSO₄-5H₂O (0.022 g, 0.09 mmol) and NaN₃ (0.13 g, 2.1 mmol) in DMF-H₂O (5 mL, 4:1) at rt was added BnBr (0.24 mL, 2.02 mmol) and the mixture was warmed to 65° C. After 5 h LCMS indicated low conversion. A further portion of NaN₃ (100 mg) was added and heating was continued for 12 h. The reaction was poured into EtOAc and H₂O and shaken. The layers were separated and the aqueous layer extracted 3× with EtOAc and the combined organic phases washed (H₂O×3, brine), dried (Na₂SO₄), filtered, and concentrated. The residue was purified by flash (Biotage, 40+M 0-5% MeOH in CH₂Cl₂; TLC 3% MeOH in CH₂Cl₂) to afford a light yellow oil which solidified on standing (748.3 mg, 104%). The NMR was consistent with the desired product but suggests the presence of DMF. The material was used as is without further purification. ¹HNMR (400 MHz, DMSO-d₆) δ 7.84 (s, 1H), 7.27-7.32 (m, 10H), 5.54 (s, 2H), 5.07 (s, 2H), 4.25 (m, 1H), 3.16 (dd, J=1.0, 5.3 Hz, 1H), 3.06 (dd, J=5.3, 14.7 Hz), 2.96 (dd, J=9.1, 14.7 Hz, 1H), 1.31 (s, 9H).

LCMS: Anal. Calcd. for C₂₄H₂₈N₄O₄: 436; found: 437 (M+H)⁺.

Step 2. Preparation of (S)-benzyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(methoxycarbonylamino)propanoate (cj-29)

A solution of (S)-benzyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(tert-butoxycarbonylamino)propanoate (0.52 g, 1.15 mmol) in CH₂Cl₂ was added TFA (4 mL). The mixture was allowed to stir at room temperature for 2 h. The mixture was concentrated in vacuo to give a colorless oil which solidified on standing. This material was dissolved in THF-H₂O and cooled to 0° C. Solid NaHCO₃ (0.25 g, 3.00 mmol) was added followed by ClCO₂Me (0.25 mL, 3.25 mmol). After stirring for 1.5 h the mixture was acidified to pH ˜2 with 6N HCl and then poured into H₂O-EtOAc. The layers were separated and the aq phase extracted 2× with EtOAc. The combined org layers were washed (H₂O, brine), dried (Na₂SO₄), filtered, and concentrated in vacuo to give a colorless oil (505.8 mg, 111%, NMR suggested the presence of an unidentified impurity) which solidified while standing on the pump. The material was used as is without further purification. ¹HNMR (400 MHz, DMSO-d₆) δ 7.87 (s, 1H), 7.70 (d, J=8.1 Hz, 1H), 7.27-7.32 (m, 10H), 5.54 (s, 2H), 5.10 (d, J=12.7 Hz, 1H), 5.06 (d, J=12.7 Hz, 1H), 4.32-4.37 (m, 1H), 3.49 (s, 3H), 3.09 (dd, J=5.6, 14.7 Hz, 1H), 2.98 (dd, J=9.6, 14.7 Hz, 1H). LCMS: Anal. Calcd. for C₂₁H₂₂N₄O₄: 394; found: 395 (M+H)⁺.

Step 3. Preparation of (S)-2-(methoxycarbonylamino)-3-(1H-1,2,3-triazol-4-yl)propanoic acid (Cap-128)

(S)-benzyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(methoxycarbonylamino)propanoate (502 mg, 1.11 mmol) was hydrogenated in the presence of Pd—C (82 mg) in MeOH (5 mL) at atmospheric pressure for 12 h. The mixture was filtered through diatomaceous earth (Celite®) and concentrated in vacuo. (S)-2-(methoxycarbonylamino)-3-(1H-1,2,3-triazol-4-yl)propanoic acid was obtained as a colorless gum (266 mg, 111%) which was contaminated with ca. 10% of the methyl ester. The material was used as is without further purification.

¹HNMR (400 MHz, DMSO-d₆) δ 12.78 (s, br, 1H), 7.59 9 s, 1H), 7.50 (d, J=8.0 Hz, 1H), 4.19-4.24 (m, 1H), 3.49 (s, 3H), 3.12 (dd, J=4.8 Hz, 14.9 Hz, 1H), 2.96 (dd, J=9.9, 15.0 Hz, 1H). LCMS: Anal. Calcd. for C₇H₁₀N₄O₄: 214; found: 215 (M+H)⁺.

Preparation of (S)-2-(methoxycarbonylamino)-3-(1H-pyrazol-1-yl)propanoic acid (Cap-129)

Step 1. Preparation of (S)-2-(benzyloxycarbonylamino)-3-(1H-pyrazol-1-yl)propanoic acid (cj-31)

A suspension of (S)-benzyl 2-oxooxetan-3-ylcarbamate (0.67 g, 3.03 mmol), and pyrazole (0.22 g, 3.29 mmol) in CH₃CN (12 mL) was heated at 50° C. for 24 h. The mixture was cooled to rt overnight and the solid filtered to afford (S)-2-(benzyloxycarbonylamino)-3-(1H-pyrazol-1-yl)propanoic acid (330.1 mg). The filtrate was concentrated in vacuo and then triturated with a small amount of CH₃CN (ca. 4 mL) to afford a second crop (43.5 mg). Total yield 370.4 mg (44%).

m.p. 165.5-168° C. lit m.p. 168.5-169.5 Vederas et al. J. Am. Chem. Soc. 1985, 107, 7105.

¹HNMR (400 MHz, CD₃OD) δ 7.51 (d, J=2.0, 1H), 7.48 (s, J=1.5 Hz, 1H), 7.24-7.34 (m, 5H), 6.23 m, 1H), 5.05 (d, 12.7H, 1H), 5.03 (d, J=12.7 Hz, 1H), 4.59-4.66 (m, 2H), 4.42-4.49 (m, 1H). LCMS: Anal. Calcd. for C₁₄H₁₅N₃O₄: 289; found: 290 (M+H)⁺.

Step 2. Preparation of (S)-2-(methoxycarbonylamino)-3-(1H-pyrazol-1-yl)propanoic acid (Cap-129)

(S)-2-(benzyloxycarbonylamino)-3-(1H-pyrazol-1-yl)propanoic acid (0.20 g, 0.70 mmol) was hydrogenated in the presence of Pd—C (45 mg) in MeOH (5 mL) at atmospheric pressure for 2 h. The product appeared to be insoluble in MeOH, therefore the r×n mixture was diluted with 5 mL H₂O and a few drops of 6N HCl. The homogeneous solution was filtered through diatomaceous earth (Celite®), and the MeOH removed in vacuo. The remaining solution was frozen and lyophilized to give a yellow foam (188.9 mg). This material was suspended in THF-H₂O (1:1, 10 mL) and then cooled to 0° C. To the cold mixture was added NaHCO₃ (146.0 mg, 1.74 mmol) carefully (evolution of CO₂). After gas evolution had ceased (ca. 15 min) ClCO₂Me (0.06 mL, 0.78 mmol) was added dropwise. The mixture was allowed to stir for 2 h and was acidified to pH ˜2 with 6N HCl and poured into EtOAc. The layers were separated and the aqueous phase extract with EtOAC (×5). The combined organic layers were washed (brine), dried (Na₂SO₄), filtered, and concentrated to give the title compound as a colorless solid (117.8 mg, 79%).

¹HNMR (400 MHz, DMSO-d₆) δ 13.04 (s, 1H), 7.63 (d, J=2.6 Hz, 1H), 7.48 (d, J=8.1 Hz, 1H), 7.44 (d, J=1.5 Hz, 1H), 6.19 (app t, J=2.0 Hz, 1H), 4.47 (dd, J=3.0, 12.9 Hz, 1H), 4.29-4.41 (m, 2H), 3.48 (s, 3H). LCMS: Anal. Calcd. for C₈H₁₁N₃O₄: 213; found: 214 (M+H)⁺.

Cap-130 was prepared by acylation of commercially available (R)-phenylglycine analogous to the procedure given in: Calmes, M.; Daunis, J.; Jacquier, R.; Verducci, J. Tetrahedron, 1987, 43(10), 2285.

EXAMPLES

The present disclosure will now be described in connection with certain embodiments which are not intended to limit its scope. On the contrary, the present disclosure covers all alternatives, modifications, and equivalents as can be included within the scope of the claims. Thus, the following examples, which include specific embodiments, will illustrate one practice of the present disclosure, it being understood that the examples are for the purposes of illustration of certain embodiments and are presented to provide what is believed to be the most useful and readily understood description of its procedures and conceptual aspects.

Solution percentages express a weight to volume relationship, and solution ratios express a volume to volume relationship, unless stated otherwise. Nuclear magnetic resonance (NMR) spectra were recorded either on a Bruker 300, 400, or 500 MHz spectrometer; the chemical shifts (δ) are reported in parts per million. Flash chromatography was carried out on silica gel (SiO₂) according to Still's flash chromatography technique (J. Org. Chem. 1978, 43, 2923).

Purity assessment and low resolution mass analysis were conducted on a Shimadzu LC system coupled with Waters Micromass ZQ MS system. It should be noted that retention times may vary slightly between machines. The LC conditions employed in determining the retention time (RT) were:

Condition 1 Column = Phenomenex-Luna 3.0 × 50 mm S10 Start % B = 0 Final % B = 100 Gradient time = 2 min Stop time = 3 min Flow Rate = 4 mL/min Wavelength = 220 nm Solvent A = 0.1% TFA in 10% methanol/90% H₂O Solvent B = 0.1% TFA in 90% methanol/10% H₂O Condition 2 Column = Phenomenex-Luna 4.6 × 50 mm S10 Start % B = 0 Final % B = 100 Gradient time = 2 min Stop time = 3 min Flow Rate = 5 mL/min Wavelength = 220 nm Solvent A = 0.1% TFA in 10% methanol/90% H₂O Solvent B = 0.1% TFA in 90% methanol/10% H₂O Condition 3 Column = HPLC XTERRA C18 3.0 × 50 mm S7 Start % B = 0 Final % B = 100 Gradient time = 3 min Stop time = 4 min Flow Rate = 4 mL/min Wavelength = 220 nm Solvent A = 0.1% TFA in 10% methanol/90% H₂O Solvent B = 0.1% TFA in 90% methanol/10% H₂O Method A: LCMS—Xterra MS C-18 3.0×50 mm, 0 to 100% B over 30.0 minute gradient, 1 minute hold time, A=5% acetonitrile, 95% water, 10 mm ammonium acetate, B=95% acetonitrile, 5% water, 10 mm ammonium acetate. Method B: HPLC—X-Terra C-18 4.6×50 mm, 0 to 100% B over 10.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.1% TFA, B=90% methanol 10% water 0.1% TFA Method C: HPLC—YMC C-18 4.6×50 mm, 0 to 100% B over 10.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.2% H₃PO₄, B=90% methanol 10% water 0.2% H₃PO₄. Method D: HPLC—Phenomenex C-18 4.6×150 mm, 0 to 100% B over 10.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.2% H₃PO₄, B=90% methanol 10% water 0.2% H₃PO₄. Method E: LCMS—Gemini C-18 4.6×50 mm, 0 to 100% B over 10.0 minute gradient, 1 minute hold time, A=5% acetonitrile, 95% water, 10 mm ammonium acetate, B=95% acetonitrile, 5% water, 10 mm ammonium acetate. Method F: LCMS—Luna C-18 3.0×50 mm, 0 to 100% B over 7.0 minute gradient, 1 minute hold time, A=5% acetonitrile, 95% water, 10 mm ammonium acetate, B=95% acetonitrile, 5% water, 10 mm ammonium acetate.

Example 1 (1R,1′R)-2,2′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

Example 1 Step a

N,N-Diisopropylethylamine (18 mL, 103.3 mmol) was added dropwise, over 15 minutes, to a heterogeneous mixture of N-Boc-L-proline (7.139 g, 33.17 mmol), HATU (13.324 g, 35.04 mmol), the HCl salt of 2-amino-1-(4-bromophenyl)ethanone (8.127 g, 32.44 mmol), and DMF (105 mL), and stirred at ambient condition for 55 minutes. Most of the volatile component was removed in vacuo, and the resulting residue was partitioned between ethyl acetate (300 mL) and water (200 mL). The organic layer was washed with water (200 mL) and brine, dried (MgSO₄), filtered, and concentrated in vacuo. A silica gel mesh was prepared from the residue and submitted to flash chromatography (silica gel; 50-60% ethyl acetate/hexanes) to provide ketoamide 1a as a white solid (12.8 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 8.25-8.14 (m, 1H), 7.92 (br d, J=8.0, 2H), 7.75 (br d, J=8.6, 2H), 4.61 (dd, J=18.3, 5.7, 1H), 4.53 (dd, J=18.1, 5.6, 1H), 4.22-4.12 (m, 1H), 3.43-3.35 (m, 1H), 3.30-3.23 (m, 1H), 2.18-2.20 (m, 1H), 1.90-1.70 (m, 3H), 1.40/1.34 (two app br s, 9H). LC (Cond. 1): RT=1.70 min; LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₈H₂₃BrN₂NaO₄: 433.07; found 433.09.

Analogous compounds such as intermediate 1-1a to 1-5a can be prepared by incorporating the appropriately substituted amino acid and aryl bromide isomer.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.35/1.40 (two br s, 9H), 2.27-2.42 (m, 1H), 2.73-2.95 (m, 1H), 3.62-3.89 (m, 2H), 4.36-4.50 (m, 1H), 4.51-4.60 (m, 1H), 4.62-4.73 (m, 1H), 7.75 (d, J=8.24 Hz, 2H), 7.92 (d, J=7.63 Hz, 2H), 8.31-8.49 (m, 1H). HPLC XTERRA C-18 4.6×30 mm, 0 to 100% B over 4 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.2% H₃PO₄, B=10% water, 90% methanol, 0.2% H₃PO₄, RT=1.59 minutes, 99% homogeneity index. LCMS: Anal. Calcd. for C₁₈H₂₁BrF₂N₂O₄: 446.06; found: 445.43 (M−H)⁻.

¹H NMR (500 MHz, DMSO-d₆) δ ppm (8.25 1H, s), 7.91 (2H, d, J=8.24 Hz), 7.75 (2H, d, J=8.24 Hz), 4.98 (1H, s), 4.59-4.63 (1H, m), 4.46-4.52 (1H, m), 4.23 (1H, m), 3.37 (1H, s), 3.23-3.28 (1H, m), 2.06 (1H, m), 1.88 (1H, s), 1.38 (3H, s), 1.33 (6H, s). LCMS—Phenomenex C-18 3.0×50 mm, 0 to 100% B over 4.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.1% TFA, B=90% methanol 10% water 0.1% TFA mobile phase, RT=3.34 minutes, Anal Calcd. for C₁₈H₂₃BrN₂O₅ 427.30; found 428.08 (M+H)⁻.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.30 (1H, s) 7.93-7.96 (2H, m) 7.76 (2H d, J=8.24 Hz) 5.13 (1H, s) 4.66-4.71 (1H, m) 4.52-4.55 (1H, m) 4.17 (1H, m) 3.51 (1H, s) 3.16-3.19 (1H, m) 2.36 (1H, m) 1.78 (1H, s) 1.40 (s, 3H), 1.34 (s, 6H). LCMS—Phenomenex C-18 3.0×50 mm, 0 to 100% B over 4.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.1% TFA, B=90% methanol 10% water 0.1% TFA, RT=3.69 minutes, Anal Calcd. for C₁₈H₂₃BrN₂O₅ 427.30; found 428.16 (M+H)⁺.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.29-1.47 (m, 9H), 1.67-1.90 (m, 3H), 2.00-2.20 (m, 1H), 3.23-3.30 (m, 1H), 3.34-3.44 (m, 1H), 4.16 (dd, 1H), 4.57 (q, 2H), 7.51 (t, J=7.78 Hz, 1H), 7.86 (dd, J=7.93, 1.22 Hz, 1H), 7.98 (d, J=7.63 Hz, 1H), 8.11 (s, 1H), 8.15-8.29 (m, 1H). LC/MS (M+Na)⁺=433.12/435.12.

LCMS conditions: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume. RT=1.93 min; LRMS: Anal. Calcd. for C₁₉H₁₈BrN₂O₄ 418.05; found: 419.07 (M+H)⁺.

Example 1 Step b

A mixture of ketoamide 1a (12.8 g, 31.12 mmol) and NH₄OAc (12.0 g, 155.7 mmol) in xylenes (155 mL) was heated in a sealed tube at 140° C. for 2 hours. The volatile component was removed in vacuo, and the residue was partitioned carefully between ethyl acetate and water, whereby enough saturated NaHCO₃ solution was added so as to make the pH of the aqueous phase slightly basic after the shaking of the biphasic system. The layers were separated, and the aqueous layer was extracted with an additional ethyl acetate. The combined organic phase was washed with brine, dried (MgSO₄), filtered, and concentrated in vacuo. The resulting material was recrystallized from ethyl acetate/hexanes to provide two crops of imidazole 1b as a light-yellow dense solid, weighing 5.85 g. The mother liquor was concentrated in vacuo and submitted to a flash chromatography (silica gel; 30% ethyl acetate/hexanes) to provide an additional 2.23 g of imidazole 1b. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.17/11.92/11.86 (m, 1H), 7.72-7.46/7.28 (m, 5H), 4.86-4.70 (m, 1H), 3.52 (app br s, 1H), 3.36 (m, 1H), 2.30-1.75 (m, 4H), 1.40/1.15 (app br s, 9H). LC (Cond. 1): RT=1.71 min; >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₈H₂₃BrN₃O₂: 392.10; found 391.96; HRMS: Anal. Calcd. for [M+H]⁺ C₁₈H₂₃BrN₃O₂: 392.0974; found 392.0959

The optical purity of the two samples of 1b were assessed using the chiral HPLC conditions noted below (ee>99% for the combined crops; ee=96.7% for the sample from flash chromatography):

Column: Chiralpak AD, 10 um, 4.6×50 mm

Solvent: 2% ethanol/heptane (isocratic)

Flow rate: 1 mL/min

Wavelength: either 220 or 254 nm

Relative retention time: 2.83 minutes (R), 5.34 minutes (S)

Analogous compounds such as intermediates 1-1b to 1-4b can be prepared by incorporating the appropriate ketoamide.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.17/1.40 (two br s, 9H), 2.50-2.74 (m, J=25.64 Hz, 1H), 2.84-3.07 (m, 1H), 3.88 (d, J=10.07 Hz, 2H), 5.03 (s, 1H), 7.50 (d, J=8.55 Hz, 2H), 7.60 (s, 1H), 7.70 (d, J=8.55 Hz, 2H), 12.10 (s, 1H). HPLC XTERRA C-18 4.6×30 mm, 0 to 100% B over 4 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.2% H₃PO₄, B=10% water, 90% methanol, 0.2% H₃PO₄, RT=1.59 minutes, 99% homogeneity index; LCMS: Anal. Calcd. for C₁₈H₂₀BrF₂N₃O₂: 428.27; found: 428.02 (M)⁺.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 11.89-11.99 (1H, m), 7.68 (2H, d, J=8.54 Hz), 7.52-7.59 (1H, m), 7.48 (2H, d, J=8.54 Hz), 4.80 (1H, m), 4.33 (1H, s), 3.51-3.60 (1H, m), 3.34 (1H, d, J=10.99 Hz), 2.14 (1H, s), 1.97-2.05 (1H, m), 1.37 (3H, s), 1.10 (6H, s); LCMS—Phenomenex C-18 3.0×50 mm, 0 to 100% B over 4.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.1% TFA, B=90% methanol 10% water 0.1% TFA, (RT=3.23 min) Anal Calcd. for C₁₈H₂₂BrN₃O₃ 408.30; found 409.12 (M+H)⁺.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 12.06-12.24 (1H, m), 7.58-7.69 (5H, m), 4.84-4.95 (1H, m), 4.34 (1H, s), 3.61 (1H, s), 3.34-3.40 (1H, m), 2.52 (1H, s), 1.92-2.20 (1H, m), 1.43 (3H, s), 1.22 (6H, s); LCMS—Phenomenex C-18 3.0×50 mm, 0 to 100% B over 4.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.1% TFA, B=90% methanol 10% water 0.1% TFA, (RT=3.41 min) Anal Calcd. for C₁₈H₂₂BrN₃O₃ 408.30; found 409.15 (M+H)⁺.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.98-1.51 (m, 9H), 1.82-2.12 (m, 3H), 2.31-2.48 (m, 1H), 3.30-3.51 (m, 1H), 3.52-3.66 (m, 1H), 4.88-5.16 (m, 1H), 7.47 (t, J=7.93 Hz, 1H), 7.61 (d, J=7.93 Hz, 1H), 7.81 (d, J=7.93 Hz, 1H), 8.04 (s, 1H), 8.12 (d, J=28.38 Hz, 1H), 14.65 (s, 1H). LC/MS (M+H)⁺=391.96/393.96.

Additional imidazole analogs made following procedures similar to those described above.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example Structure Data 1-5b

RT = 1.70 minutes (condition 2, 98%); LRMS: Anal. Calcd. for C₁₉H₁₈BrN₃O₂ 399.05; found: 400.08 (M + H)⁺. 1-6b

RT = 1.64 minutes (condition 2, 98%); LRMS: Anal. Calcd. for C₁₇H₂₂N₃O₂ 379.09; found: 380.06 (M + H)⁺. 1-7b

RT = 2.28 minutes (95%); LRMS: Anal. Calcd. for C₂₀H₂₁BrN₃O₂ 414.08; found: 414.08 (M + H)⁺; HRMS: Anal. Calcd. for C₂₀H₂₁BrN₃O₂ 414.0817; found: 414.0798 (M + H)⁺.

Example 1 Step c

Pd(Ph₃P)₄ (469 mg, 0.406 mmol) was added to a pressure tube containing a mixture of bromide 1b (4.008 g, 10.22 mmol), bis(pinacolato)diboron (5.422 g, 21.35 mmol), potassium acetate (2.573 g, 26.21 mmol) and 1,4-dioxane (80 mL). The reaction flask was purged with nitrogen, capped and heated with an oil bath at 80° C. for 16.5 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The crude material was partitioned carefully between CH₂Cl₂ (150 mL) and an aqueous medium (50 mL water+10 mL saturated NaHCO₃ solution). The aqueous layer was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting material was purified with flash chromatography (sample was loaded with eluting solvent; 20-35% ethyl acetate/CH₂Cl₂) to provide boronate 1c, contaminated with pinacol, as an off-white dense solid; the relative mole ratio of 1c to pinacol was about 10:1 (¹H NMR). The sample weighed 3.925 g after ˜2.5 days exposure to high vacuum. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): 12.22/11.94/11.87 (m, 1H), 7.79-7.50/7.34-7.27 (m, 5H), 4.86-4.70 (m, 1H), 3.52 (app br s, 1H), 3.36 (m, 1H), 2.27-1.77 (m, 4H), 1.45-1.10 (m, 21H). LC (Cond. 1): RT=1.64 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₄H₃₅BN₃O₄: 440.27; found 440.23.

Analogous compounds such as intermediates 1-1c to 1-4c can be prepared by incorporating the appropriate aryl bromide.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.16 (s, 8H), 1.29 (s, 13H), 2.51-2.72 (m, 1H), 2.84-3.03 (m, 1H), 3.79-4.00 (m, 2H), 4.88-5.21 (m, 1H), 7.62 (d, J=7.93 Hz, 2H), 7.67 (s, 1H), 7.76 (d, J=7.93 Hz, 2H), 12.11/12.40 (two br s, 1H). HPLC GEMINI C-18 4.6×50 mm, 0 to 100% B over 4 minutes, 1 minute hold time, A=95% water, 5% acetonitrile, 0.1% NH₄OAc, B=5% water, 95% acetonitrile, 0.1% NH₄OAc, RT=1.62 minutes, 99% homogeneity index. LCMS: Anal. Calcd. for C₃₄H₃₂BF₂N₃O₄: 475.34; found: 474.78 (M−H)⁻.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 11.97 (1H, m), 7.62-7.75 (5H, m), 5.05 (1H d, J=3.36 Hz), 4.82 (m, 1H), 4.35 (m, 1H), 3.58 (1H, m), 2.389 (1H, s), 2.17 (1 H, m), 1.38 (3H, s), 1.30 (12H, s), 1.1 (6H, s); LCMS—Phenomenex C-18 3.0×50 mm, 0 to 100% B over 4.0 minute gradient, 1 minute hold time, A=5% acetonitrile, 95% water, 10 mm ammonium acetate, B=95% acetonitrile, 5% water, 10 mm ammonium acetate, RT=3.63 minutes, Anal. Calcd. for C₂₄H₃₄BN₃O₅ 455.30; found 456.31 (M+H)⁺.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 12.05-12.24 (1H, m), 7.61-7.73 (5H, m), 4.83-5.01 (1H, m), 4.33 (1H, s), 3.54-3.63 (1H, m), 3.39-3.80 (1H, m), 2.38-2.49 (1H, m), 1.98-2.01 (1H, m), 1.42 (3H, s), 1.34 (12H, s), 1.21 (6H, s); LCMS—Phenomenex C-18 3.0×50 mm, 0 to 100% B over 4.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.1% TFA, B=90% methanol 10% water 0.1% TFA, RT=3.64 minutes, Anal. Calcd. for C₂₄H₃₄BN₃O₅ 455.30; found 456.30 (M+H)⁺.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.02-1.54 (m, 21H), 1.75-2.07 (m, 3H), 2.09-2.33 (m, 1H), 3.32-3.44 (m, 1H), 3.55 (s, 1H), 4.69-4.94 (m, 1H), 7.33 (t, J=7.32 Hz, 1H), 7.41-7.57 (m, 2H), 7.84 (d, J=7.32 Hz, 1H), 8.08 (s, 1H), 11.62-12.07 (m, 1H). LC/MS (M+H)⁺=440.32.

Additional boronic esters: Conditions for 1-5c through 1-10c

LCMS conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

1-5c

RT = 1.84 minutes (condition 2); LCMS: Anal. Calcd. for C₂₇H₃₂BN₃O₄ 473; found: 474 (M + H)⁺. 1-6c

RT = 1.84 minutes (condition 2); LCMS: Anal. Calcd. for C₂₂H₃₂BN₃O₄ 413; found: 414 (M + H)⁺. 1-7c

RT = 1.85 minutes (condition 2); LRMS: Anal. Calcd. for C₂₅H₃₁BN₃O₄ 448; found: 448 (M + H)⁺. 1-8c

RT = 2.49 (76%, boronic ester) and 1.81 (21.4%, boronic acid); LCMS: Anal. Calcd. for C₂₃H₃₅N₃O₄B 428.27; found: 428.27 (M + H)⁺; HRMS: Anal. Calcd. for C₂₃H₃₅N₃O₄B 428.2721; found: 428.2716 (M + H)⁺. 1-9c

RT = 2.54 (74.2%, boronic ester) and 1.93 (25.8%, boronic acid); LRMS: Anal. Calcd. for C₂₆H₃₃N₃O₄B 462.26; found: 462.25 (M + H)⁺; HRMS: Anal. Calcd. for C₂₆H₃₃N₃O₄B 462.2564; found: 462.2570 (M + H)⁺. 1-10c

RT = 1.91 (64.5%, boronic ester) and 1.02 (33.8%, boronic acid); LRMS: Anal. Calcd. for C₂₆H₃₂N₄O₃ ¹⁰B 458.26; found: 458.28 (M + H)⁺; HRMS: Anal. Calcd. for C₂₆H₃₂N₄O₃ ¹⁰B 458.2604; found 458.2617 (M + H)⁺.

Example 1 Step d di-tert-butyl (2S,2′S)-2,2′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate)

Pd(Ph₃P)₄ (59.9 mg, 0.0518 mmol) was added to a mixture of bromide 1b (576.1 mg, 1.469 mmol), boronate 1c (621.8 mg, 1.415 mmol), NaHCO₃ (400.4 mg, 4.766 mmol) in 1,2-dimethoxyethane (12 mL) and water (4 mL). The reaction mixture was flushed with nitrogen, heated with an oil bath at 80° C. for 5.75 hours, and then the volatile component was removed in vacuo. The residue was partitioned between 20% methanol/CHCl₃ (60 mL) and water (30 mL), and the aqueous phase was extracted with 20% methanol/CHCl₃ (30 mL). The combined organic phase was washed with brine, dried (MgSO₄), filtered, and concentrated in vacuo. A silica gel mesh was prepared from the resulting crude material and submitted to flash chromatography (ethyl acetate) to provide dimer 1d, contaminated with Ph₃PO, as an off-white solid (563 mg). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.21-12-16/11.95-11.78 (m, 2H), 7.85-7.48/7.32-7.25 (m, 10H), 4.90-4.71 (m, 2H), 3.60-3.32 (m, 4H), 2.30-1.79 (m, 8H), 1.46-1.10 (m, 18H). LC (Cond. 1b): RT=1.77 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₆H₄₅BN₆O₄: 625.35; found 625.48.

Additional biphenyl analogs were prepared similarly.

LC conditions for Examples 1-5d through 1-7d: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Characterization Example Compound Name Structure Data 1-5d di-tert-butyl (4,4′- biphenyldiylbis(1H- imidazol-5,2- diyl(1S)-1,1- ethanediyl))bis (methylcarbamate)

RT = 1.64 minutes (>95%); Condition 2; LCMS: Anal. Calcd C₃₄H₄₅N₆O₄ 601.35; found: 601.48 (M + H)⁺; LRMS: Anal. Calcd. for C₃₄H₄₄N₆O₄ 600.34; found: 601.32 (M + H)⁺. 1-6d tert-butyl (2S)-2-(5- (4′-(2-((1S)-1-((tert- butoxycarbonyl) (methyl)amino) ethyl)- 1H-imidazol-5-yl)- 4-biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinecarboxylate

RT = 1.63 minutes (>95%); Condition 2; LCMS: Anal. Calcd C₃₅H₄₅N₆O₄ 613.34; found: 613.56 (M + H)⁺; LRMS: Anal. Calcd. for C₃₅H₄₄N₆O₄ 612.34; found 613.33 (M + H)⁺. 1-7d benzyl (2S)-2-(5-(4′- (2-((1S)-1-((tert- butoxycarbonyl) (methyl)amino) ethyl)- 1H-imidazol-5-yl)- 4-biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinecarboxylate

RT = 1.65 minutes (>95%); Condition 2; LCMS: Anal. Calcd C₃₈H₄₃N₆O₄ 647.33; found: 647.44 (M + H)⁺; LRMS: Anal. Calcd. for C₃₈H₄₂N₆O₄ 646.33; found 647.34 (M + H)⁺.

Example 1 Step e 5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-2-pyrrolidinyl)-1H-imidazole)

A mixture of carbamate 1d (560 mg) and 25% TFA/CH₂Cl₂ (9.0 mL) was stirred at ambient condition for 3.2 hours. The volatile component was removed in vacuo, and the resulting material was free based using an MCX column (methanol wash; 2.0 M NH₃/methanol elution) to provide pyrrolidine 1e as a dull yellow solid (340 mg). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 11.83 (br s, 2H), 7.80 (d, J=8.1, 4H), 7.66 (d, J=8.3, 4H), 7.46 (br s, 2H), 4.16 (app t, J=7.2, 2H), 2.99-2.69 (m, 6H), 2.09-2.00 (m, 2H), 1.94-1.66 (m, 6H). LC (Cond. 1): RT=1.27 min; >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁻ C₂₆H₂₉N₆: 425.25; found 425.25; HRMS: Anal. Calcd. for [M+H]⁻ C₂₆H₂₉N₆: 425.2454; found 425.2448

Additional analogs were prepared similarly:

Example Compound Name Structure Data 1-5e

RT = 1.37 min; LCMS: Anal. Calcd. for C₂₅H₂₈N₆ 412; found: 413 (M + H)⁺. 1-6e

RT = 1.43 min; LCMS: Anal. Calcd. for C₃₃H₃₅N₆O₂ 547; found: 547 (M + H)⁺. 1-7e

RT = 1.12 min; LRMS: Anal. Calcd. for C₂₄H₂₈N₆ 400.24; found 401.22 (M + H)⁺.

LC Conditions for 1-5e through 1-7e: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example 1 (1R,1′R)-2,2′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

HATU (44.6 mg, 0.117 mmol) was added to a mixture of pyrrolidine 1e (22.9 mg, 0.054 mmol), diisopropylethylamine (45 μL, 0.259 mmol) and Cap-1 (28.1 mg, 0.13 mmol) in DMF (1.5 mL), and the resulting mixture was stirred at ambient for 90 minutes. The volatile component was removed in vacuo, and the residue was purified first by MCX (methanol wash; 2.0 M NH₃/methanol elution) and then by a reverse phase HPLC system (H₂O/methanol/TFA) to provide the TFA salt of Example 1 as an off-white foam (44.1 mg). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 10.25 (br s, 2H), 8.20-7.10 (m, 20H), 5.79-5.12 (m, 4H), 4.05-2.98 (m, 4H), 2.98-2.62 (m, 6H), 2.50-1.70 (m, 14H), [Note: the signal of the imidazole NH was too broad to assign a chemical shift]; LC (Cond. 1): RT=1.40 min; >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₄₆H₅₁N₈O₂: 747.41; found 747.58

Characterization Example Compound Name Structure Data 24-18-1 dimethyl (4,4′- biphenyldiylbis (1H-imidazole-5,2- diyl(1S)-1,1- ethanediyl(methyl- imino)((1R)-2-oxo- 1-phenyl-2,1- ethanediyl))) biscarbamate

RT = 1.55 min¹; LRMS: Anal. Calcd. for C₄₄H₄₆N₈O₆ 782.35; found: 783.37 (M + H)⁺ ; HRMS: Anal. Calcd. for C₄₄H₄₇N₈O₆ 783.3619 found: 783.3630 (M + H)⁺. 24-18-2 (2R,2′R)-N,N′- (4,4′- biphenyldiylbis (1H-imidazole-5,2- diyl(1S)-1,1- ethanediyl))bis(2- (dimethylamino)- N-methyl-2- phenylacetamide)

RT = 1.16 min¹; LRMS: Anal. Calcd. for C₄₄H₅₀N₈O₂ 722.41; found: 723.41 (M + H)⁺; HRMS: Anal. Calcd. for C₄₄H₅₁N₈O₂ 723.4135 found: 723.4152 (M + H)⁺. 24-18-3 (2R,2′R)-N,N′- (4,4′- biphenyldiylbis (1H-imidazol-5,2- diyl(1S)-1,1- ethanediyl))bis(N- methyl-2-phenyl- 2-(1- piperidinyl) acetamide)

RT = 1.28 min¹; LRMS: Anal. Calcd. for C₅₀H₅₈N₈O₂ 802.47; found: 803.50 (M + H)⁺; HRMS: Anal. Calcd. for C₅₀H₅₉N₈O₂ 803.4761 found: 803.4778 (M + H)⁺. 24-18-4 methyl ((1R)-2- ((2S)-2-(5-(4′-(2- ((1S)-1-(((2R)-2- ((methoxycarbonyl) amino)-2- phenylacetyl) (methyl)amino) ethyl)-1H- imidazol-5-yl)-4- biphenylyl)-1H- imidazol-2-yl)- 1-pyrrolidinyl)- 2-oxo-1- phenylethyl) carbamate

RT = 1.53 min¹; LRMS: Anal. Calcd. for C₄₅H₄₆N₈O₆ 794.35; found: 795.39 (M + H)⁺; HRMS: Anal. Calcd. for C₄₅H₄₇N₈O₆ 795.3619 found: 795.3616 (M + H)⁺. 24-18-5 (2R)-2- (dimethylamino)- N-((1S)-1-(5-(4′- (2-((2S)-1-((2R)- 2- (dimethylamino)- 2-phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-4- biphenylyl)-1H- imidazol-2- yl)ethyl)-N- methyl-2- phenylacetamide

RT = 1.21¹; LRMS: Anal. Calcd. for C₄₅H₅₀N₈O₂ 734.41; found: 735.46 (M + H)⁺; HRMS: Anal. Calcd. for C₄₅H₅₁N₈O₂ 735.4135 found: 735.4136 (M + H)⁺. ¹LC Conditions for 24-18-1 through 24-18-5: Phenomenex LUNA C-18 4.6 × 50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A = 90% water, 10% methanol, 0.1% TFA, B = 10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example 28 methyl((1R)-2-oxo-1-phenyl-2-((2S)-2-(5-(4′-(2-((2S)-1-(phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)ethyl)carbamate

Example 28 Step a

HATU (19.868 g, 52.25 mmol) was added to a heterogeneous mixture of N-Cbz-L-proline (12.436 g, 49.89 mmol) and the HCl salt of 2-amino-1-(4-bromophenyl)ethanone (12.157 g, 48.53 mmol) in DMF (156 mL). The mixture was lowered in an ice-water bath, and immediately afterward N,N-diisopropylethylamine (27 mL, 155 mmol) was added dropwise to it over 13 minutes. After the addition of the base was completed, the cooling bath was removed and the reaction mixture was stirred for an additional 50 minutes. The volatile component was removed in vacuo; water (125 mL) was added to the resulting crude solid and stirred for about 1 hour. The off-white solid was filtered and washed with copious water, and dried in vacuo to provide ketoamide 28a as a white solid (20.68 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 8.30 (m, 1H), 7.91 (m, 2H), 7.75 (d, J=8.5, 2H), 7.38-7.25 (m, 5H), 5.11-5.03 (m, 2H), 4.57-4.48 (m, 2H), 4.33-4.26 (m, 1H), 3.53-3.36 (m, 2H), 2.23-2.05 (m, 1H), 1.94-1.78 (m, 3H); LC (Cond. 1): RT=1.65 min; 98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺C₂₁H₂₂BrN₂O₄: 445.08; found 445.31.

Example 28 Step b

Ketoamide 28a (10.723 g, 24.08 mmol) was converted to 28b according to the procedure described for the synthesis of carbamate 1b, with the exception that the crude material was purified by flash chromatography (sample was loaded with eluting solvent; 50% ethyl acetate/hexanes). Bromide 28b was retrieved as an off-white foam (7.622 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.23/12.04/11.97 (m, 1H), 7.73-6.96 (m, 10H), 5.11-4.85 (m, 3H), 3.61 (m, 1H), 3.45 (m, 1H), 2.33-184 (m, 4H). LC (Cond. 1): RT=1.42 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₁H₂₁BrN₃O₂: 426.08; found 426.31; HRMS: Anal. Calcd. for [M+H]⁺ C₂₁H₂₁BrN₃O₂: 426.0817; found: 426.0829. The optical purity of 28b was assessed using the following chiral HPLC methods, and an ee of 99% was observed.

Column: Chiralpak AD, 10 um, 4.6×50 mm

Solvent: 20% ethanol/heptane (isocratic)

Flow rate: 1 mL/min

Wavelength: 254 nm

Relative retention time: 1.82 minutes (R), 5.23 minutes (S)

Example 28 Step c benzyl tert-butyl(2S,2′S)-2,2′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate)

Pd(Ph₃P)₄ (711.4 mg, 0.616 mmol) was added to a mixture of boronate ester 1c (7.582 g, ˜17 mmol), bromide 28b (7.62 g, 17.87 mmol), NaHCO₃ (4.779 g, 56.89 mmol) in 1,2-dimethoxyethane (144 mL) and water (48 mL). The reaction mixture was purged with N₂ and heated with an oil bath at 80° C. for 15.5 hours, and then the volatile component was removed in vacuo. The residue was partitioned between CH₂Cl₂ and water, and the aqueous layer was extracted with CH₂Cl₂. The combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting material was submitted to flash chromatography (sample was loaded as a silica gel mesh; ethyl acetate used as eluent) to provide biphenyl 28c as an off-white foam containing Ph₃PO impurity (7.5 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.24-12.19 (m, 0.36H), 12.00-11.82 (m, 1.64H), 7.85-6.98 (15H), 5.12-4.74 (4H), 3.68-3.34 (4H), 2.34-1.79 (8H), 1.41/1.17 (two br S, 9H); LC (Cond. 1): RT=1.41 minutes; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₉H₄₃N₆O₄: 659.34; found 659.52; HRMS: Anal. Calcd. for [M+H]⁺ C₃₉H₄₃N₆O₄: 659.3346; found 659.3374.

Example 28 Step d tert-butyl(2S)-2-(5-(4′-(2-((2S)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinecarboxylate

K₂CO₃ (187.8 mg, 1.36 mmol) was added to a mixture of catalyst (10% Pd/C; 205.3 mg), carbamate 28c (1.018 g, ˜1.5 mmol), methanol (20 mL) and 3 pipet-drops of water. A balloon of H₂ was attached and the mixture was stirred for 6 hours. Then, additional catalyst (10% Pd/C, 100.8 mg) and K₂CO₃ (101.8 mg, 0.738 mmol) were added and stirring continued for 3.5 hours. During the hydrogenation process, the balloon of H₂ was changed at intervals three times. The reaction mixture was filtered through a pad of diatomaceous earth (Celite® 521), and the filterate was removed in vacuo. The resulting crude material was submitted to flash chromatography using a short column (sample was loaded as a silica gel mesh; 0-20% methanol/CH₂Cl₂ used as eluent) to provide 28d as a light-yellow foam (605.6 mg). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.18/11.89/11.82 (three br s, 2H), 7.83-7.29 (m, 10H), 4.89-4.73 (m, 1H), 4.19 (app t, J=7.2, 1H), 3.55 (app br s 1H), 3.40-3.35 (m, 1H), 3.02-2.96 (m, 1H), 2.91-2.84 (m, 1H), 2.30-1.69 (m, 8H), 1.41/1.16 (two br s, 9H). Note: the signal of pyrrolidine NH appears to have overlapped with signals in the 3.6-3.2 ppm region; LC (Cond. 1): RT=1.21 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺C₃₁H₃₇N₆O₂: 525.30; found 525.40.

Example 28 Step e-f Example 28 Step e tert-butyl(2S)-2-(5-(4′-(2-((2S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinecarboxylate Example 28 Step f methyl((1R)-2-oxo-1-phenyl-2-((2S)-2-(5-(4′-(2-((2S)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)ethyl)carbamate

Step e: HATU (316.6 mg, 0.833 mmol) was added to a DMF (7.0 mL) solution of pyrrolidine 28d (427 mg, 0.813 mmol), Cap-4 (177.6 mg, 0.849 mmol) and diisopropylethylamine (0.32 mL, 1.84 mmol), and the reaction mixture was stirred for 45 minutes. The volatile component was removed in vacuo, and the residue was partitioned between CH₂Cl₂ (50 mL) and an aqueous medium (20 mL H₂O+1 mL saturated NaHCO₃ solution). The aqueous phase was re-extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting yellow oil was purified by flash chromatography (silica gel; ethyl acetate) to provide 28e as a yellow foam (336 mg). LC (Cond. 1): RT=1.68 min; 91% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₄₁H₄₆N₇O₅: 716.35; found 716.53.

Step f: Carbamate 28e was elaborated to amine 28f by employing the procedure described in the conversion of 1d to 1e. LC (Cond. 1): RT=1.49 min; >98% homogeneity index. LC/MS: Anal. Calcd. for [M+H]⁺ C₃₆H₃₈N₇O₃: 616.30; found 616.37; HRMS: Anal. Calcd. for [M+H]⁺ C₃₆H₃₈N₇O₃: 616.3036; found 616.3046.

Example 28 methyl((1R)-2-oxo-1-phenyl-2-((2S)-2-(5-(4′-(2-((2S)-1-(phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)ethyl)carbamate

Amine 28f was converted to the TFA salt of Example 28 by employing the last step of the synthesis of Example 1. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 8.21-7.03 (m, 21H), 5.78-5.14 (3H), 3.98-3.13 (m, 9H; includes the signal for OCH₃ at 3.54 & 3.53), 2.45-1.72 (m, 8H). LC (Cond. 1): RT=1.66 minutes, >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₄₄H₄₄N₇O₄: 734.35; found 734.48; HRMS: Anal. Calcd. for [M+H]⁺ C₄₄H₄₄N₇O₄: 734.3455; 734.3455.

Example 121 (1R,1′R)-2,2′-((2,2′-dimethyl-4,4′-biphenyldiyl)bis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

Example 121 Step a-b

PdCl₂(Ph₃P)₂ (257 mg, 0.367 mmol) was added to a dioxane (45 mL) solution of 1-bromo-4-iodo-2-methylbenzene (3.01 g, 10.13 mmol) and tri-n-butyl(1-ethoxyvinyl)stannane (3.826 g, 10.59 mmol) and heated at 80° C. for ˜17 hours. The reaction mixture was treated with water (15 mL), cooled to ˜0° C. (ice/water), and then NBS (1.839 g, 10.3 mmol) was added in batches over 7 minutes. After about 25 minutes of stirring, the volatile component was removed in vacuo, and the residue was partitioned between CH₂Cl₂ and water. The aqueous layer was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting crude material was purified by a gravity chromatography (silica gel; 4% ethyl acetate/hexanes) to provide bromide 121a as a brownish-yellow solid (2.699 g); the sample is impure and contains stannane-derived impurities, among others. ¹H NMR (CDCl₃, δ=7.24, 400 MHz): 7.83 (s, 1H), 7.63 (s, 2H), 4.30 (s, 2H), 2.46 (s, 3H).

A CH₃CN (15 mL) solution of 121a (2.69 g, <9.21 mmol) was added dropwise over 3 minutes to a CH₃CN (30 mL) solution of (S)-Boc-proline (2.215 g, 10.3 mmol) and triethylamine (1.40 mL, 10.04 mmol), and stirred for 90 minutes. The volatile component was removed in vacuo, and the residue was partitioned between water and CH₂Cl₂, and the organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting crude material was purified by a flash chromatography (silica gel; 15-20% ethyl acetate/hexanes) to provide 121b as a colorless viscous oil (2.74 g). ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): δ 7.98 (m, 1H), 7.78 (d, J=8.3, 1H), 7.72-7.69 (m, 1H), 5.61-5.41 (m, 2H), 4.35-4.30 (m, 1H), 3.41-3.30 (m, 2H), 2.43 (s, 3H), 2.33-2.08 (m, 2H), 1.93-1.83 (m, 2H), 1.40/1.36 (s, 9H); LC (Cond. 1): RT=1.91 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₉H₂₄BrNNaO₅ 448.07; found 448.10.

Additional keto-esters can be prepared in analogous fashion.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example Structure Data 121b-1

RT = 2.15 minutes (condition 2, 98%); LRMS: Anal. Calcd. for C₁₇H₂₂NO₅ 399.07; found: 400.10 (M + H)⁺. 121b-2

RT = 2.78 minutes (condition 1, >90%); LRMS: Anal. Calcd. for C₂₀H₂₀ ³⁷BrNO₅ 435.05.; found: 458.02 (M + Na)⁺.

Example 121 Step c

A mixture of ketoester 121b (1.445 g, 3.39 mmol) and NH₄OAc (2.93 g, 38.0 mmol) in xylenes (18 mL) was heated with a microwave at 140° C. for 80 minutes. The volatile component was removed in vacuo, and the residue was carefully partitioned between CH₂Cl₂ and water, where enough saturated NaHCO₃ solution was added to neutralize the aqueous medium. The aqueous phase was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The crude product was purified by a flash chromatography (silica gel, 40% ethyl acetate/hexanes) to provide imidazole 121c as an off-white solid (1.087 g). ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 12.15/11.91/11.84 (br s, 1H), 7.72-7.24 (m, 4H), 4.78 (m, 1H), 3.52 (m, 1H), 3.38-3.32 (m, 1H), 2.35 (s, 3H), 2.28-1.77 (m, 4H), 1.40/1.14 (s, 9H); LC (Cond. 1): RT=1.91 min; >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₉H₂₅BrN₃O₂ 405.96; found 406.11.

Example 121 Step d

PdCl₂dppf.CH₂Cl₂ (50.1 mg, 0.061 mmol) was added to a pressure tube containing a mixture of bromide 121c (538.3 mg, 1.325 mmol), bis(pinacolato)diboron (666.6 mg, 2.625 mmol), potassium acetate (365.8 mg, 3.727 mmol) and DMF (10 mL). The reaction mixture was flushed with N₂ and heated at 80° C. for 24.5 hours. The volatile component was removed in vacuo and the residue was partitioned between CH₂Cl₂ and water, where enough saturated NaHCO₃ solution was added to make the pH of the aqueous medium neutral. The aqueous phase was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting material was purified by a Biotage system (silica gel, 40-50% ethyl acetate/hexanes) to provide boronate 121d as a white foam (580 mg). According to ¹H NMR the sample contains residual pinacol in a product/pinacol ratio of ˜3. ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): δ 12.16/11.91/11.83 (br s, 1H), 7.63-7.25 (m, 4H), 4.78 (m, 1H), 3.53 (m, 1H), 3.39-3.32 (m, 1H), 2.48/2.47 (s, 3H), 2.28-1.78 (m, 4H), 1.40/1.14/1.12 (br s, 9H), 1.30 (s, 12H); LC (Cond. 1): RT=1.62 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₅H₃₇BN₃O₄ 454.29; found 454.15

Example 121 Step e and Example 121 Step f

Carbamate 121e was prepared from bromide 121c and boronate 121d according to the preparation of dimer 1d; LC (Cond. 1): RT=1.43 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₈H₄₉N₆O₄ 653.38; found 653.65.

The deprotection of carbamate 121e, according to the preparation of pyrrolidine 1e, provided 121f as an off-white foam. ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 11.79 (br s, 2H), 7.66 (s, 2H), 7.57 (d, J=7.8, 2H), 7.41 (br s, 2H), 7.02 (d, J=7.8, 2H), 4.15 (app t, J=7.2, 2H), 3.00-2.94 (m, 2H), 2.88-2.82 (m, 2H), 2.09-2.01 (m, 2H), 2.04 (s, 6H), 1.93-1.85 (m, 2H), 1.82-1.66 (m, 4H). Note: although broad signals corresponding to the pyrrolidine NH appear in the 2.8-3.2 ppm region, the actual range for their chemical shift could not be determined. LC (Cond. 1): RT=1.03 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₈H₃₃N₆ 453.28; found 453.53

Example 121 (1R,1′R)-2,2′-((2,2′-dimethyl-4,4′-biphenyldiyl)bis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

Example 121 (TFA salt) was synthesized from 121f according to the preparation of Example 1 from 1e; LC (Cond. 1): RT=1.14 min; >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₄₈H₅₅N₈O₂ 775.45; 775.75; HRMS: Anal. Calcd. for [M+H]⁺ C₄₈H₅₅N₈O₂ 775.4448; found 775.4473

Examples 126-128

Example 126-128 were prepared starting from bromide 28b and boronate 121d by using the methods described in Example 28 starting with step c.

    Example     Compound Name

RT (LC-Cond.); % homogeneity index; MS data 126 methyl ((1R)-2-((2S)- 2-(5-(4′-(2-((2S)-1- ((2R)-2- (dimethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2′- methyl-4-biphenylyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)-2-oxo-1- phenylethyl)carbamate

1.22 min (Cond. 1); >98%; LC/MS: Anal. Calcd. for [M + H]⁺ C₄₇H₅₁N₈O₄: 791.40; found 791.70; HRMS: Anal. Calcd. for [M + H]⁺ C₄₇H₅₁N₈O₄: 791.4033; found 791.4061 127 methyl ((1R)-2-((2S)- 2-(5-(2′-methyl-4′-(2- ((2S)-1-(3- pyridinylacetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-4- biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2- oxo-1- phenylethyl)carbamate

1.19 minutes (Cond. 1); >98%; LC/MS: Anal. Calcd. for [M + H]⁺ C₄₄H₄₅N₈O₄: 749.36; found 749.62; HRMS: Anal. Calcd. for [M + H]⁺ C₄₄H₄₅N₈O₄: 749.3564; found 749.3592 128 methyl ((1R)-2-((2S)- 2-(5-(2′-methyl-4′-(2- ((2S)-1-((2S)- tetrahydro-2- furanylcarbonyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-4- biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo-1- phenylethyl)carbamate

1.27 minutes (Cond. 1); >98%; LC/MS: Anal. Calcd. for [M + H]⁺ C₄₂H₄₆N₇O₅: 728.36; found 728.59; HRMS: Anal. Calcd. for [M + H]⁺ C₄₂H₄₆N₇O₅: 728.3560; found 728.3593

Example 130 (1R,1′R)-2,2′-((2-(trifluoromethyl)-4,4′-biphenyldiyl)bis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

Example 130 Step a

Glyoxal (2.0 mL of 40% in water) was added dropwise over 11 minutes to a methanol solution of NH₄OH (32 mL) and (S)-Boc-prolinal (8.564 g, 42.98 mmol) and stirred at ambient temperature for 19 hours. The volatile component was removed in vacuo and the residue was purified by a flash chromatography (silica gel, ethyl acetate) followed by a recrystallization (ethyl acetate, room temperature) to provide imidazole 130a as a white fluffy solid (4.43 g). ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 11.68/11.59 (br s, 1H), 6.94 (s, 1H), 6.76 (s, 1H), 4.76 (m, 1H), 3.48 (m, 1H), 3.35-3.29 (m, 1H), 2.23-1.73 (m, 4H), 1.39/1.15 (s, 9H). LC (Cond. 1): RT=0.87 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₂H₂₀N₃O₂ 238.16; found 238.22. Imidazole 130a had an ee of 98.9% when analyzed under chiral HPLC condition noted below.

Column: Chiralpak AD, 10 um, 4.6×50 mm

Solvent: 1.7% ethanol/heptane (isocratic)

Flow rate: 1 mL/min

Wavelength: either 220 or 256 nm

Relative retention time: 3.25 min (R), 5.78 minutes (S)

Example 130 Step b

N-Bromosuccinimide (838.4 mg, 4.71 mmol) was added in batches, over 15 minutes, to a cooled (ice/water) CH₂Cl₂ (20 mL) solution of imidazole 130a (1.0689 g, 4.504 mmol), and stirred at similar temperature for 75 minutes. The volatile component was removed in vacuo. The crude material was purified by a reverse phase HPLC system (H₂O/methanol/TFA) to separate bromide 130b from its dibromo-analog and the non-consumed starting material. The HPLC elute was neutralized with excess NH₃/methanol and the volatile component was removed in vacuo. The residue was partitioned between CH₂Cl₂ and water, and the aqueous layer was extracted with water. The combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo to provide 130b as a white solid (374 mg). ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 12.12 (br s, 1H), 7.10 (m, 1H), 4.70 (m, 1H), 3.31 (m, 1H; overlapped with water signal), 2.25-1.73 (m, 4H), 1.39/1.17 (s, 3.8H+5.2H). LC (Cond. 1): RT=1.10 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₂H₁₉BrN₃O₂ 316.07; found 316.10.

Example 130 Step c

Pd(Ph₃P)₄ (78.5 mg, 0.0679 mmol) was added to a mixture of bromide 130b (545 mg, 1.724 mmol), 2-(4-chloro-3-(trifluoromethyl)phenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (542.8 mg, 1.771 mmol) (commercially available), NaHCO₃ (477 mg, 5.678 mmol) in 1,2-dimethoxyethane (12.5 mL) and water (4.2 mL). The reaction mixture was purged with nitrogen, heated with an oil bath at 80° C. for 27 hours, and then the volatile component was removed in vacuo. The residue was partitioned between CH₂Cl₂ and water, and the organic layer was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting crude material was purified by a Biotage system (silica gel, 40-50% ethyl acetate/hexanes) followed by a reverse phase HPLC (water/methanol/TFA). The HPLC elute was treated with excess NH₃/methanol and concentrated. The residue was partitioned between water and CH₂Cl₂, and the organic layer was dried (MgSO₄), filtered, and concentrated in vacuo to provide 130c as a white foam (317.4 mg). ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 12.36/12.09/12.03 (br s, 1H), 8.15 (d, J=1.8, 0.93H), 8.09 (br s, 0.07H), 8.01 (dd, J=8.3/1.3, 0.93H), 7.93 (m, 0.07H), 7.74 (m, 1H), 7.66 (d, J=8.3, 0.93H), 7.46 (m, 0.07H), 4.80 (m, 1H), 3.53 (m, 1H), 3.36 (m, 1H), 2.30-1.77 (m, 4 h), 1.40/1.15 (s, 3.8H+5.2H). LC (Cond. 1): RT=1.52 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₁₉H₂₂ClF₃N₃O₂ 416.14; found 416.17.

Example 130 Step d-e

Pd[P(t-Bu)₃]₂ (48 mg, 0.094 mmol) was added to a mixture of chloride 130c (245 mg, 0.589 mmol), boronate 1c (277.1 mg, 0.631 mmol), KF (106.7 mg, 1.836 mmol) in DMF (6 mL), and heated at 110° C. for ˜30 hours. The volatile component was removed in vacuo, and the residue was partitioned between CH₂Cl₂ (50 mL), water (20 mL) and saturated NaHCO₃ (1 mL). The aqueous layer was extracted with CH₂Cl₂ (2×), and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting material was purified by a Biotage system (silica gel, ethyl acetate) to provide carbamate 130d as an off-white foam (297 mg). LC (Cond. 1): RT=1.44 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₇H₄₄F₃N₆O₄ 693.34; found 693.34.

The deprotection of 130d, which was conducted according to the preparation of pyrrolidine 1e, provided 130e as a light yellow foam. ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 11.88 (br s, 2H), 8.16 (d, J=1.5, 1H), 8.02 (d, J=7.8, 1H), 7.78 (d, J=8.1, 2H), 7.66 (br s, 1H), 7.48 (br s, 1H), 7.37 (d, J=8.1, 1H), 7.28 (d, J=8.3, 2H), 4.18 (m, 2H), 2.99-2.93 (m, 2H), 2.89-2.83 (m, 2H), 2.11-2.01 (m, 2H), 1.94-1.85 (m, 2H), 1.82-1.67 (m, 4H). Note: although broad signals corresponding to the pyrrolidine NH appear in the 2.8-3.2 ppm region, the actual range for their chemical shift could not be determined. LC (Cond. 1): RT=1.12 min; >95% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₇H₂₈F₃N₆ 493.23; found 493.14.

Example 130 (1R,1′R)-2,2′-((2-(trifluoromethyl)-4,4′-biphenyldiyl)bis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

Example 130 (TFA salt) was prepared from 130e and Cap-1 according to the preparation of Example 1 from pyrrolidine 1e. LC (Cond. 1): RT=1.17 min; >98% homogeneity index; LC/MS: Anal. Calcd. for [M+H]⁺ C₄₇H₅₀F₃N₈O₂ 815.40; found 815.44; HRMS: Anal. Calcd. for [M+H]⁺ C₄₇H₅₀F₃N₈O₂ 815.4009; found 815.4013

Example 131.1-1 to 131.1-2

Examples 131.1-1 through 131.1-2 were prepared in similar fashion to example 28 via the intermediacy of intermediate 1-6e after appending Cap-4.

Example 131.1-1 methyl((1R)-2-(((1S)-1-(5-(4′-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)ethyl) (methyl)amino)-2-oxo-1-phenylethyl)carbamate

Cap-1 was appended after the CBz carbamate was removed from 1-6e with Pd/C/H₂.

LCMS conditions: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume. t_(R)=1.42 min

LRMS: Anal. Calcd. for C₄₅H₄₉N₈O₄ 765.39; found: 765.38 (M+H)⁺.

HRMS: Anal. Calcd. for C₄₅H₄₉N₈O₄ Calcd 765.3877 found: 765.3905 (M+H)⁺.

Example 131.1-1.2 methyl((1R)-2-(methyl((1S)-1-(5-(4′-(2-((2S)-1-((2R)-2-phenyl-2-(1-piperidinyl)acetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)ethyl)amino)-2-oxo-1-phenylethyl)carbamate

Cap-14 was appended after the CBz carbamate was removed from 1-6e with Pd/C/H₂.

LCMS conditions: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume. t_(R)=1.45 min (>95%)

LRMS: Anal. Calcd. for C₄₈H₅₂N₈O₄ 805.42; found: 805.41 (M+H)⁺.

HRMS: Anal. Calcd. C₄₈H₅₂N₈O₄ Calcd 805.4190 found: 805.4214 (M+H)⁺.

Example 131.2 (2R)-2-(dimethylamino)-N-methyl-2-phenyl-N-((1S)-1-(5-(4′-(2-((2S)-1-((2R)-2-phenyl-2-(1-piperidinyl)acetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)ethyl)acetamide

Example 131.2 was prepared in similar fashion to example 131.1-1 and example 131.1-2 via the intermediacy of intermediate 1-6e after appending Cap-1. Cap-14 was appended after the CBz carbamate was removed with Pd/C/H₂. LCMS conditions: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume. t_(R)=1.28 min

LRMS: Anal. Calcd. for C₄₈H₅₄N₈O₂ 775.44; found: 775.45 (M+H)⁺.

HRMS: Anal. Calcd. C₄₈H₅₄N₈O₂ Calcd 775.4448 found: 775.4460 (M+H)⁺.

Example 132 (1R)-2-((2S)-2-(5-(6-(4-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)phenyl)-3-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-N,N-dimethyl-2-oxo-1-phenylethanamine

Example 132 Step a-b

A CH₂Cl₂ (10 mL) solution of Br₂ (7.63 g, 47.74 mmol) was added-drop wise over 5 min to a cooled (ice/water) CH₂Cl₂ (105 mL) solution of 1-(6-bromopyridine-3-yl)ethanone (9.496 g, 47.47 mmol) and 48% HBr (0.4 mL). The cooling bath was removed 40 min later, and stirring was continued at ambient temperature for about 66 hr. The cake of solid that formed was filtered, washed with CH₂Cl₂ and dried in vacuo to afford impure 132a as an off-white solid (15.94 g).

Boc-L-proline (9.70 g, 45.06 mmol) was added in one batch to a heterogeneous mixture of crude 132a (15.4 g) and CH₃CN (150 mL), and immediately afterward Et₃N (13.0 mL, 93.2 mmol) was added drop-wise over 6 min. The reaction mixture was stirred for 50 min, the volatile component was removed in vacuo and the residue was partitioned between CH₂Cl₂ and water. The CH₂Cl₂ layer was dried (MgSO₄), filtered and concentrated in vacuo, and the resultant material was purified by flash chromatography (silica gel; sample was loaded with eluting solvent; 25% EtOAc/hexanes) to afford 132b as a highly viscous yellow oil (11.44 g). ¹H NMR (DMSO, δ=2.5 ppm; 400 MHz): 8.95 (m, 1H), 8.25-8.21 (m, 1H), 7.88 (d, J=8.3, 1H), 5.65-5.46 (m, 2H), 4.36-4.31 (m, 1H), 3.41-3.29 (m, 2H), 2.36-2.22 (m, 1H), 2.14-2.07 (m, 1H), 1.93-1.83 (m, 2H), 1.40 & 1.36 (two s, 9H).

LC (Cond. 1): RT=2.01 min; >90% homogeneity index

LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₇H₂₁NaBrN₂O₅: 435.05; found 435.15

HRMS: Anal. Calcd. for [M+H]⁺ C₁₇H₂₂BrN₂O₅: 413.0712; found 413.0717

Example 132 Step c

A mixture of ketoester 132b (1.318 g, 3.19 mmol) and NH₄OAc (2.729 g, 35.4 mmol) in xylenes (18 mL) was heated with a microwave at 140° C. for 90 min. The volatile component was removed in vacuo and the residue was partitioned between CH₂Cl₂ and water, where enough saturated NaHCO₃ solution was added to neutralize the aqueous medium. The aqueous phase was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting crude material was purified by a Biotage system (silica gel; 50% EtOAc/hexanes) to afford imidazole 132c as an off-white foam (1.025 g). ¹H NMR (DMSO, δ=2.5 ppm, 400 MHz): 12.33/12.09/12.02 (br m, 1H), 8.74 (d, J=2.3, 0.93H), 8.70 (app br s, 0.07H), 8.03/7.98 (dd for the first peak, J=8.3, 1H), 7.69/7.67 (br m, 1H), 7.58/7.43 (d for the first peak, J=8.3, 1H), 4.80 (m, 1H), 3.53 (m, 1H), 3.36 (m, 1H), 2.33-2.11 (m, 1H), 2.04-1.79 (m, 3H), 1.39/1.15 (app br s, 3.9H+5.1H).

LC (Cond. 1): RT=1.52 min; >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₁₇H₂₂BrN₄O₂: 393.09; found 393.19

HRMS: Anal. Calcd. for [M+H]⁺ C₁₇H₂₂BrN₄O₂: 393.0926; found 393.0909

Example 132 Step d-e

Pd(Ph₃P)₄ (115.1 mg, 0.10 mmol) was added to a mixture of bromide 132c (992 mg, 2.52 mmol), boronate 1c (1.207 g, 2.747 mmol), NaHCO₃ (698.8 mg, 8.318 mmol) in 1,2-dimethoxyethane (18 mL) and water (4 mL). The reaction mixture was flushed with nitrogen, heated with an oil bath at 90° C. for 37 hr and allowed to cool to ambient temperature. The suspension that formed was filtered and washed with water followed by 1,2-dimethoxyethane, and dried in vacuo. A silica gel mesh was prepared from the crude solid and submitted to flash chromatography (silica gel; EtOAc) to afford carbamate 132d as a white solid, which yellowed slightly upon standing at ambient conditions (1.124 g). ¹H NMR indicated that the sample contains residual MeOH in a product/MeOH mole ratio of 1.3.

LC (Cond. 1): RT=1.71 min; >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₃₅H44N₇O₄: 626.35; found 626.64

HRMS: Anal. Calcd. for [M+H]⁺ C₃₅H₄₄N₇O₄: 626.3455; 626.3479

Carbamate 132d (217 mg) was treated with 25% TFA/CH₂Cl₂ (3.6 mL) and stirred at ambient condition for 6 hr. The volatile component was removed in vacuo, and the resultant material was free based by MCX column (MeOH wash; 2.0 M NH₃/MeOH elution) to afford 132e as a dull yellow foam that solidified gradually upon standing (150.5 mg; mass is above theoretical yield). ¹H NMR (DMSO, δ=2.5 ppm; 400 MHz): 11.89 (very broad, 2H), 9.01 (d, J=1.8, 1H), 8.13 (dd, J=8.3, 2.2, 1H), 8.07 (d, J=8.6, 2H), 7.92 (d, J=8.3, 1H), 7.83 (d, J=8.5, 2H), 7.61 (br s, 1H), 7.50 (br s, 1H), 4.18 (m, 2H), 3.00-2.93 (m, 2H), 2.90-2.82 (m, 2H), 2.11-2.02 (m, 2H), 1.94-1.85 (m, 2H), 1.83-1.67 (m, 4H). [Note: the exchangeable pyrrolidine hydrogens were not observed]

LC (Cond. 1): RT=1.21 min; >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₂₅H₂₈N₇: 426.24; found 426.40

HRMS: Anal. Calcd. for [M+H]⁺ C₂₅H₂₈N₇: 426.2406; found 426.2425

Example 132 (1R)-2-((2S)-2-(5-(6-(4-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)phenyl)-3-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-N,N-dimethyl-2-oxo-1-phenylethanamine

HATU (41.4 mg, 0.109 mmol) was added to a mixture of pyrrolidine 132e (23.1 mg, 0.054 mmol), (i-Pr)₂EtN (40 μL, 0.23 mmol) and Cap-1 (25.3 mg, 0.117 mmol) in DMF (1.5 mL), and the mixture was stirred at ambient for 1 hr. The volatile component was removed in vacuo, and the residue was purified first by MCX (MeOH wash; 2.0 M NH₃/MeOH elution) and then by a reverse phase HPLC (H₂O/MeOH/TFA) to afford the TFA salt of Example 132 as a yellow foam (39.2 mg).

LC (Cond. 1): RT=1.37 min; >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₅H₅₀N₉O₂: 748.41; found 748.53

HRMS: Anal. Calcd. for [M+H]⁺ C₄₅H₅₀N₉O₂: 748.4087; found 748.4090

Example 133-135 were prepared as TFA salts from 132e by using the same method of preparations as Example 132 and appropriate reagents.

Example 133-135

Example Compound Name

RT(LC-Cond.); % homogeneity index; MS data 133 (1R)-2-((2S)-2-(5-(6-(4-(2- ((2S)-1-((2R)-2-hydroxy-2- phenylacetyl)-2-pyrrolidinyl)- 1H-imidazol-5-yl)phenyl)-3- pyridinyl)-1H-imidazol-2-yl)- 1-pyrrolidinyl)-2-oxo-1- phenylethanol

1.49 min (Cond. 1); >98% LC/MS: Anal. Calcd. for [M + H]⁺ C₄₁H₄₀N₇O₄: 694.31; found 694.42 HRMS: Anal. Calcd. for [M + H]⁺ C₄₁H₄₀N₇O₄: 694.3142, found: 694.3164 134 methyl ((1R)-2-((2S)-2-(5-(6- (4-(2-((2S)-1-((2R)-2- ((methoxycarbonyl)amino)-2- phenylacetyl)-2-pyrrolidinyl)- 1H-imidazol-5-yl)phenyl)-3- pyridinyl)-1H-imidazol-2-yl)- 1-pyrrolidinyl)-2-oxo-1- phenylethyl)carbamate

1.60 min (Cond. 1); >98% LC/MS: Anal. Calcd. for [M + H]⁺ C₄₅H₄₆N₉O₆: 808.36; found 808.51 HRMS: Anal. Calcd. for [M + H]⁺ C₄₅H₄₆N₉O₆: 808.3571; found 808.3576 135 5-(2-((2S)-1-((2R)-2- methoxy-2-phenylacetyl)-2- pyrrolidinyl)-1H-imidazol-5- yl)-2-(4-(2-((2S)-1-((2R)-2- methoxy-2-phenylacetyl)-2- pyrrolidinyl)-1H-imidazol-5- yl)phenyl)pyridine

1.60 min (Cond. 1); >98% LC/MS: Anal. Calcd. for [M + H]⁺ C₄₃H₄₄N₇O₄: 722.35; found 722.40 HRMS: Anal. Calcd. for [M + H]⁺ C₄₃H₄₄N₇O₄: 722.3455; found 722.3464

Example 136 (1R)-2-((2S)-2-(5-(6-(4-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-2-methylphenyl)-3-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-N,N-dimethyl-2-oxo-1-phenylethanamine

Example 136 Steps a and b

PdCl₂(Ph₃P)₂ (257 mg, 0.367 mmol) was added to a dioxane (45 mL) solution of 1-bromo-4-iodo-2-methylbenzene (3.01 g, 10.13 mmol) and tri-n-butyl(1-ethoxyvinyl)stannane (3.826 g, 10.59 mmol) and heated at 80° C. for ˜17 hr. The reaction mixture was treated with water (15 mL), cooled to ˜0° C. (ice/water), and then NBS (1.839 g, 10.3 mmol) was added in batches over 7 min. About 25 min of stirring, the volatile component was removed in vacuo, and the residue was partitioned between CH₂Cl₂ and water. The aqueous layer was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting crude material was purified by a gravity chromatography (silica gel; 4% EtOAc/hexanes) to afford bromide 136a as a brownish-yellow solid (2.699 g); the sample is impure and contains stannane-derived impurities, among others. ¹H NMR (CDCl₃, δ=7.24, 400 MHz): 7.83 (s, 1H), 7.63 (s, 2H), 4.30 (s, 2H), 2.46 (s, 3H).

An CH₃CN (15 mL) solution of 136a (2.69 g, <9.21 mmol) was added drop wise over 3 min to a CH₃CN (30 mL) solution of (S)-Boc-proline (2.215 g, 10.3 mmol) and Et₃N (1.40 mL, 10.04 mmol), and stirred for 90 min. The volatile component was removed in vacuo, and the residue was partitioned between water and CH₂Cl₂, and the organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resultant crude material was purified by a flash chromatography (silica gel; 15-20% EtOAc/hexanes) to afford 136b as a colorless viscous oil (2.74 g). ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 7.98 (m, 1H), 7.78 (d, J=8.3, 1H), 7.72-7.69 (m, 1H), 5.61-5.41 (m, 2H), 4.35-4.30 (m, 1H), 3.41-3.30 (m, 2H), 2.43 (s, 3H), 2.33-2.08 (m, 2H), 1.93-1.83 (m, 2H), 1.40/1.36 (s, 9H).

LC (Cond. 1): RT=1.91 min; >95% homogeneity index

LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₉H₂₄BrNNaO₅ 448.07; found 448.10

Example 136 Step c

A mixture of ketoester 136b (1.445 g, 3.39 mmol) and NH₄OAc (2.93 g, 38.0 mmol) in xylenes (18 mL) was heated with a microwave at 140° C. for 80 min. The volatile component was removed in vacuo, and the residue was carefully partitioned between CH₂Cl₂ and water, where enough saturated NaHCO₃ solution was added to neutralize the aqueous medium. The aqueous phase was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The crude was purified by a flash chromatography (silica gel, 40% EtOAc/hexanes) to afford imidazole 136c as an off-white solid (1.087 g). ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 12.15/11.91/11.84 (br s, 1H), 7.72-7.24 (m, 4H), 4.78 (m, 1H), 3.52 (m, 1H), 3.38-3.32 (m, 1H), 2.35 (s, 3H), 2.28-1.77 (m, 4H), 1.40/1.14 (s, 9H).

LC (Cond. 1): RT=1.91 min; >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₁₉H₂₅BrN₃O₂ 405.96; found 406.11

Example 136 Step d

PdCl₂dppf.CH₂Cl₂ (50.1 mg, 0.061 mmol) was added to a pressure tube containing a mixture of bromide 136c (538.3 mg, 1.325 mmol), bis(pinacolato)diboron (666.6 mg, 2.625 mmol), KOAc (365.8 mg, 3.727 mmol) and DMF (10 mL). The reaction mixture was flushed with N₂ and heated at 80° C. for 24.5 hr. The volatile component was removed in vacuo and the residue was partitioned between CH₂Cl₂ and water, where enough saturated NaHCO₃ solution was added to make the pH of the aqueous medium neutral. The aqueous phase was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting material was purified by a Biotage system (silica gel, 40-50% EtOAc/hexanes) to afford boronate 136d as a white foam (580 mg). According to ¹H NMR the sample contains residual pinacol in a product/pinacol ratio of ˜3. ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 12.16/11.91/11.83 (br s, 1H), 7.63-7.25 (m, 4H), 4.78 (m, 1H), 3.53 (m, 1H), 3.39-3.32 (m, 1H), 2.48/2.47 (s, 3H), 2.28-1.78 (m, 4H), 1.40/1.14/1.12 (br s, 9H), 1.30 (s, 12H).

LC (Cond. 1): RT=1.62 min

LC/MS: Anal. Calcd. for [M+H]⁺ C₂₅H₃₇BN₃O₄ 454.29; found 454.15

Example 136 Step e-f

Biaryl 136e was prepared from bromide 132c and boronate 136d according to the coupling condition described for the preparation of biaryl 132d.

LC (Cond. 1a): RT=1.32 min; >90% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₃₆H₄₅N₇O₄ 640.36; found 640.66

The deprotection of biaryl 136e was done according to the preparation of pyrrolidine 132e to afford 136f as a light yellow foam. ¹H NMR (DMSO-d₆, δ=2.50, 400 MHz): 11.88 (br s, 2H), 9.02 (d, J=2, 1H), 8.12 (dd, J=8.4, 2.3, 1H), 7.67 (s, 1H), 7.64-7.62 (m, 2H), 7.50 (d, J=8.3, 1H), 7.46 (br s, 1H), 7.40 (d, J=7.8, 1H), 4.21-4.14 (m, 2H), 3.00-2.93 (m, 2H), 2.90-2.82 (m, 2H), 2.40 (s, 3H), 2.11-2.01 (m, 2H), 1.94-1.85 (m, 2H), 1.82-1.66 (m, 4H). [Note: the signal for the pyrrolidine NH appears in the region 3.22-2.80 and is too broad to make a chemical shift assignment.]

LC (Cond. 1): RT=0.84 min

LC/MS: Anal. Calcd. for [M+H]⁺ C₂₆H₃₀N₇ 440.26; found 440.50

Example 136 (1R)-2-((2S)-2-(5-(6-(4-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-2-methylphenyl)-3-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-N,N-dimethyl-2-oxo-1-phenylethanamine

Example 136 (TFA salt) was synthesized from 136f according to the preparation of Example 132 from 132e.

1.05 min (Cond. 1); >98%

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₆H₅₂N₉O₂: 762.42, found: 762.77

HRMS: Anal. Calcd. for [M+H]⁺ C₄₆H₅₂N₉O₂: 762.4244; found 762.4243

Example 138 methyl((1R)-2-((2S)-2-(5-(6-(4-(2-((2S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-2-methylphenyl)-3-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-2-oxo-1-phenylethyl)carbamate

Example 138 was prepared similarly from pyrrolidine 136f and Cap-4. 1.60 min (Cond. 1); >98%

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₆H₄₈N₉O₆: 822.37; found 822.74

HRMS: Anal. Calcd. for [M+H]⁺ C₄₆H₄₈N₉O₆: 822.3728; found 822.3760

Example 139 N-((1R)-2-((2S)-2-(5-(6-(4-(2-((2S)-1-((2R)-2-acetamido-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)phenyl)-3-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-2-oxo-1-phenylethyl)acetamide

Example 139 Step a

HATU (99.8 mg, 0.262 mmol) was added to a mixture of 132e (54.1 mg, 0.127 mmol), (R)-2-(t-butoxycarbonylamino)-2-phenylacetic acid (98.5 mg, 0.392 mmol) and i-Pr₂EtN (100 μL, 0.574 mol), and the reaction mixture was stirred for 70 min. The volatile component was removed in vacuo, and the residue was purified by a reverse phase HPLC (H₂O/MeOH/TFA), where the HPLC elute was treated with excess 2.0 N NH₃/MeOH before the removal of the volatile component in vacuo. The resulting material was partitioned between CH₂Cl₂ and water, and the aqueous phase was extracted with CH₂Cl₂ (2×). The combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. Carbamate 139a was obtained as a white film of foam (82.3 mg).

LC (Cond. 1): RT=1.97 min; >95% homogeneity index.

LC/MS: Anal. Calcd. for [M+H]⁺ C₅₁H₅₈N₉O₆: 892.45; found 892.72

Example 139b Step b

Carbamate 139a was deprotected to amine 139b by using the procedure described for the preparation of pyrrolidine 132e from 132d.

LC (Cond. 1): RT=1.37 min; >95% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₁H₄₂N₉O₂: 692.35; found 692.32

Example 139 N-((1R)-2-((2S)-2-(5-(6-(4-(2-((2S)-1-((2R)-2-acetamido-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)phenyl)-3-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-2-oxo-1-phenylethyl)acetamide

Acetic anhydride (20 μL, 0.212 mmol) was added to a DMF (1.5 mL) solution of 139b (31.2 mg, 0.045 mmol), and the reaction mixture was stirred for 1 hr. NH₃/MeOH (1.0 mL of 2N) was added to the reaction mixture and stirring continued for 100 min. The volatile component was removed in vacuo and the resulting crude material was purified by a reverse phase HPLC (H₂O/MeOH/TFA) to afford the TFA salt of Example 139 as a light yellow solid (24.1 mg).

LC (Cond. 1): RT=1.53 min; >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₅H₄₆N₉O₄: 776.37; found 776.38

HRMS: Anal. Calcd. for [M+H]⁺ C₄₅H₄₆N₉O₄: 776.3673; found 776.3680

Example 140 methyl((1R)-2-((2S)-2-(5-(4-(5-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-2-pyridinyl)phenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-2-oxo-1-phenylethyl)carbamate

Example 140 Step a

HATU (19.868 g, 52.25 mmol) was added to a heterogeneous mixture of N-Cbz-L-proline (12.436 g, 49.89 mmol) and the HCl salt of 2-amino-1-(4-bromophenyl)ethanone (12.157 g, 48.53 mmol) in DMF (156 mL). The mixture was lowered in an ice-water bath, and immediately afterward N,N-diisopropylethylamine (27 mL, 155 mmol) was added drop wise to it over 13 min. After the addition of the base was completed, the cooling bath was removed and the reaction mixture was stirred for an additional 50 min. The volatile component was removed in vacuo; water (125 mL) was added to the resultant crude solid and stirred for about 1 hr. The off-white solid was filtered and washed with copious water, and dried in vacuo to afford ketoamide 140a as a white solid (20.68 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): 8.30 (m, 1H), 7.91 (m, 2H), 7.75 (d, J=8.5, 2H), 7.38-7.25 (m, 5H), 5.11-5.03 (m, 2H), 4.57-4.48 (m, 2H), 4.33-4.26 (m, 1H), 3.53-3.36 (m, 2H), 2.23-2.05 (m, 1H), 1.94-1.78 (m, 3H).

LC (Cond. 1): RT=1.65 min; 98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₂₁H₂₂BrN₂O₄: 445.08; found 445.31

Example 140 Step b

Ketoamide 140a (10.723 g, 24.08 mmol) was converted to 140b according to the procedure described for the synthesis of carbamate 132c, with the exception that the crude material was purified by flash chromatography (silica gel; 50% EtOAc/hexanes). Bromide 140b was retrieved as an off-white foam (7.622 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): 12.23/12.04/11.97 (m, 1H), 7.73-6.96 (m, 10H), 5.11-4.85 (m, 3H), 3.61 (m, 1H), 3.45 (m, 1H), 2.33-184 (m, 4H).

LC (Cond. 1): RT=1.42 min; >95% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₂₁H₂₁BrN₃O₂: 426.08; found 426.31

HRMS: Anal. Calcd. for [M+H]⁺ C₂₁H₂₁BrN₃O₂: 426.0817; found: 426.0829

The optical purity of 140b was assessed using the following chiral HPLC methods, and an cc of 99% was observed.

Column: Chiralpak AD, 10 um, 4.6×50 mm

Solvent: 20% ethanol/heptane (isocratic)

Flow rate: 1 ml/min

Wavelength: 254 nm

Relative retention time: 1.82 min (R), 5.23 min (S)

Example 140 Step c

Pd(Ph₃P)₄ (208 mg, 0.180 mmol) was added to a pressure tube containing a mixture of bromide 140b (1.80 g, 4.22 mmol), bis(pinacolato)diboron (2.146 g, 8.45 mmol), KOAc (1.8 g, 11.0 mmol) and 1,4-dioxane (34 mL). The reaction flask was purged with nitrogen, capped and heated with an oil bath at 80° C. for 23 hr. The volatile component was removed in vacuo, and the residue was partitioned carefully between CH₂Cl₂ (70 mL) and an aqueous medium (22 mL water+5 mL saturated NaHCO₃ solution). The aqueous layer was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The oily residue was crystallized from EtOAc/hexanes to afford two crops of boronate 140c as a yellow solid (1.52 g). The mother liquor was evaporated in vacuo and the resulting material was purified by flash chromatography (silica gel; 20-35% EtOAc/CH₂Cl₂) to afford additional 140c as an off-white solid, containing residual pinacol (772 mg).

LC (Cond. 1): RT=1.95 min

LC/MS: Anal. Calcd. for [M+H]⁺ C₂₇H₃₃BN₃O₄: 474.26; found 474.31

Example 140 Steps d-e

Arylbromide 132c was coupled with boronate 140c to afford 140d by using the same procedure described for the synthesis of biaryl 132d. The sample contains the desbromo version of 132c as an impurity. Proceeded to the next step without further purification.

LC (Cond. 1): RT=1.72 min; ˜85% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺C₃₈H₄₂N₇O₄: 660.33; found 660.30

A mixture of 10% Pd/C (226 mg), biaryl 140d (1.25 g) and MeOH (15 mL) was stirred under a balloon of hydrogen for ˜160 hr, where the hydrogen supply was replenished periodically as needed. The reaction mixture was filtered through a pad of diatomaceous earth (Celite®), and the filtrate was evaporated in vacuo to afford crude 140e as a yellowish-brown foam (911 mg). Proceeded to the next step without further purification.

LC (Cond. 1): RT=1.53 min

LC/MS: Anal. Calcd. for [M+H]⁺ C₃₀H₃₆N₇O₂: 526.29; found 526.23

Example 140 Steps f-g

Pyrrolidine 140g was prepared from 140e and Cap-4, via the intermediacy of carbamate 140f, by sequentially employing the amide forming and Boc-deprotection protocols used in the synthesis of Example 132.

LC (Cond. 1): RT=1.09 min; ˜94% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₃₅H₃₇N₈O₃: 617.30; found 617.38

Example 140 methyl((1R)-2-((2S)-2-(5-(4-(5-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-2-pyridinyl)phenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-2-oxo-1-phenylethyl)carbamate

The TFA salt of Example 140 was synthesized from pyrrolidine 140 g and Cap-1 by using the procedure described for the preparation of Example 132 from intermediate 132e.

1.15 min (Cond. 1); >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₅H₄₀N₇O₄: 778.38; found 778.48

HRMS: Anal. Calcd. for [M+H]⁺ C₄₅H₄₀N₇O₄: 778.3829; found 778.3849

The TFA salt of Example 141-143 were synthesized from intermediate 140 g and appropriate reagents in a similar manner.

Examples 141-143

Example Compound Name

RT (LC-Cond.); % homogeneity index; MS data 141 methyl ((1R)-2-oxo-1- phenyl-2-((2S)-2-(5-(4-(5- (2-((2S)-1-((2R)-tetrahydro- 2-furanylcarbonyl)-2- pyrrolidinyl)-1H-imidazol- 5-yl)-2-pyridinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)ethyl)carbamate

1.15 min (Cond. 1); >98% LC/MS: Anal. Calcd. for [M + H]⁺ C₄₀H₄₃N₈O₅: 715.34; found 715.44 HRMS: Anal. Calcd. for [M + H]⁺ C₄₀H₄₃N₈O₅: 715.3356; found 715.3381 142 methyl ((1R)-2-((2S)-2-(5- (4-(5-(2-((2S)-1-((1-methyl- 4-piperidinyl)carbonyl)-2- pyrrolidinyl)-1H-imidazol- 5-yl)-2-pyridinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)-2-oxo-1- phenylethyl)carbamate

1.07 min (Cond. 1); >98% LC/MS: Anal. Calcd. for [M + H]⁺ C₄₂H₄₈N₉O₄: 742.38; found 742.48 HRMS: Anal. Calcd. for [M + H]⁺ C₄₂H₄₈N₉O₄: 742.3829; found 742.3859 143 methyl ((1R)-2-oxo-1- phenyl-2-((2S)-2-(5-(4-(5- (2-((2S)-1-(3- pyridinylacetyl)-2- pyrrolidinyl)-1H-imidazol- 5-yl)-2-pyridinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)ethyl)carbamate

1.09 min (Cond. 1); >98% LC/MS: Anal. Calcd. for [M + H]⁺ C₄₂H₄₂N₉O₄: 736.34; found 736.44 HRMS: Anal. Calcd. for [M + H]⁺ C₄₂H₄₂N₉O₄: 736.3360; 736.3344

Example 144 methyl((1R)-2-((2S)-2-(5-(4-(5-(2-((2S)-1-(4-morpholinylcarbonyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-2-pyridinyl)phenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-2-oxo-1-phenylethyl)carbamate

A DMF (1.5 mL) solution of morpholine-4-carbonyl chloride (8.5 mg, 0.057 mmol) was added to a mixture of i-Pr₂EtN (20 μL, 0.115 mmol) and 140 g (27.3 mg, 0.044 mmol), and stirred for 100 min. The volatile component was removed in vacuo and the residue was purified by a reverse phase HPLC (H₂O/MeOH/TFA) to afford the TFA salt of Example 144 as a yellow foam (34.6 mg).

1.17 min (Cond. 1); >98%

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₀H₄₄N₉O₅: 730.35; found 730.42

HRMS: Anal. Calcd. for [M+H]⁺ C₄₀H₄₄N₉O₅: 730.3465; found 730.3477

Example 145 dimethyl(2,2′-bipyridine-5,5′-diylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))biscarbamate

Example 145 Step a-b

Pd(Ph₃P)₄ (9.6 mg, 0.008 mmol) and LiCl (28 mg, 0.67 mmol) were added to a mixture of arylbromide 132c (98.7 mg, 0.251 mmol) and hexamethylditin (51.6 mg, 0.158 mmol), and heated at 80° C. for ˜3 days. The volatile component was removed in vacuo and the resultant crude material was purified by flash chromatography (silica gel; 0-10% MeOH/EtOAc) followed by a reverse phase HPLC (H₂O/MeOH/TFA). The HPLC elute was neutralized with excess 2.0 N NH₃/MeOH, and the volatile component was removed in vacuo. The residue was partitioned between CH₂Cl₂ and water, and the aqueous phase was washed with CH₂Cl₂ (2×). The combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo to afford carbamate 145a as a film of oil (8.7 mg).

LC (Cond. 1): RT=1.68 min; >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₃₄H₄₃N₈O₄: 627.34; found 627.47

Carbamate 145a was elaborated to pyrrolidine 145b according to the preparation of 132e from 132d. ¹H NMR (DMSO, δ=2.5 ppm; 400 MHz): 12.02 (br signal, 2H), 9.04 (d, J=1.6, 2H), 8.34 (d, J=8.3, 2H), 8.20 (dd, J=8.3, 2.3, 2H), 7.67 (br s, 1H), 4.21 (m, 2H), 3.00-2.85 (m, 4H), 2.12-2.04 (m, 2H), 1.95-1.68 (m, 6H). [Note: the pyrrolidine-NH signal was not observed].

LC (Cond. 1): RT=1.17 min; >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₂₄H₂₇N₈: 427.24; found 427.13

Example 145 dimethyl (2,2′-bipyridine-5,5′-diylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))biscarbamate

Example 145 (TFA salt) was synthesized from 145b according to the preparation of Example 132 from 132e.

LC (Cond. 1): RT=1.63 min; 98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₄H₄₅N₁₀O₆: 809.35; found 809.40

Example 146 (1R)-2-((2S)-2-(5-(5-(4-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)phenyl)-2-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-N,N-dimethyl-2-oxo-1-phenylethanamine

Example 146 Step a

n-BuLi (12.0 mL of 2.5M/hexanes, 30 mmol) was added drop-wise over 15 min to a cooled (−78° C.) toluene (300 mL) semi-solution of 2,5-dibromopyridine (6.040 g, 25.5 mmol), and stirred for 2.5 hr. t-Butyl 2-(methoxy(methyl)amino)-2-oxoethylcarbamate (2.809 g, 12.87 mmol) was added in batches over 7 min, and stirring continued for 1.5 hr at −78° C. The −78° C. bath was replaced with −60° C. bath, which was allowed to warm up to −15° C. over 2.5 hr. The reaction was quenched with saturated NH₄Cl solution (20 mL), and the mixture was allowed to thaw to ambient temperature and the organic layer was separated and evaporated in vacuo. The resulting crude material was purified by flash chromatography (silica gel; 15% EtOAc/hexanes) to afford a reddish brown semisolid, which was washed with hexanes to removed the colored residue. Pyridine 146a was retrieved as an ash colored solid (842 mg). ¹H NMR (DMSO, δ=2.5 ppm; 400 MHz): 8.89 (d, J=2.3, 1H), 8.30 (dd, J=8.4, 2.4, 1H), 7.90 (d, J=8.3, 1H), 7.03 (br t, J=5.7; 0.88H), 6.63 (app br s, 0.12H), 4.55 (d, J=5.8, 2H), 1.40/1.28 (two app s, 7.83H+1.17H).

LC (Cond. 1): RT=2.00 min; >95% homogeneity index

LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₂H₁₅BrNaN₂O₃: 337.02; found 337.13

Example 146 Step b

48% HBr (1.0 mL) was added drop-wise to a dioxane (5.0 mL) solution of carbamate 146a (840 mg, 2.66 mmol) over 3 min, and the reaction mixture was stirred at ambient temperature for 17.5 hr. The precipitate was filtered and washed with dioxane, and dried in vacuo to afford amine the HBr salt of 146b as an off-white solid (672.4 mg; the exact mole equivalent of the HBr salt was not determined). ¹H NMR (DMSO, δ=2.5 ppm; 400 MHz): 8.95 (d, J=2.3, 1 H), 8.37 (dd, J=8.4, 2.3, 1H), 8.2 (br s, 3H), 8.00 (d, J=8.3, 1H), 4.61 (s, 2H).

LC (Cond. 1): RT=0.53 min

LC/MS: Anal. Calcd. for [M+H]⁺ C₇H₈BrN₂O: 214.98; found 215.00

Example 146 Step c

i-Pr₂EtN (2.3 mL, 13.2 mmol) was added drop-wise over 15 min to a heterogeneous mixture of amine 146b (1.365 g), (S)-Boc-proline (0.957 g, 4.44 mmol) and HATU (1.70 g, 4.47 mmol) in DMF (13.5 mL), and stirred at ambient temperature for 1 hr. The volatile component was removed in vacuo and the residue was partitioned between EtOAc (40 mL) and an aqueous medium (20 mL water+1 ml saturated NaHCO₃ solution). The aqueous layer was washed with EtOAc (20 mL), and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resultant crude material was purified by flash chromatography (silica gel; 40-50% EtOAc/hexanes) to afford ketoamide 146c as a faint-yellow foam (1.465 g). ¹H NMR (DMSO, δ=2.5 ppm; 400 MHz): 8.90 (d, J=2.3, 1H), 8.30 (dd, J=8.5, 2.4, 1H), 8.01-8.07 (m, 1H), 7.90 (d, J=8.3, 1H), 4.6 (m, 1H), 4.64 (dd, J=19.1, 5.5, 1H); 4.19 (m, 1H), 3.39 (m, 1H), 3.32-3.26 (m, 1H), 2.20-2.01 (m, 1H), 1.95-1.70 (m, 3H), 1.40/1.35 (two app s, 9H).

LC (Cond. 1): RT=1.91 min

LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₇H₂₂BrN₃NaO₄: 434.07; found 433.96.

Example 146 Step d

A mixture of ketoamide 146c (782.2 mg, 1.897 mmol) and NH₄OAc (800 mg, 10.4 mmol) in xylenes was heated with a microwave (140° C.) for 90 min. The volatile component was removed in vacuo and the residue was carefully partitioned between CH₂Cl₂ and water, where enough saturated NaHCO₃ solution was added to neutralize it. The aqueous phase was extracted with CH₂Cl₂ (2×), and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resultant crude material was purified by flash chromatography (silica gel; 50% CH₂Cl₂/EtOAc) to afford imidazole 146d as an off-white solid (552.8 mg). ¹H NMR (DMSO, δ=2.5 ppm; 400 MHz): 12.49/12.39/12.15/12.06 (br s, 1H), 8.62 (app br s, 0.2H), 8.56 (d, J=2, 0.8H), 8.02 (br d, J=8.5, 0.2H), 7.97 (br d, J=7.8, 0.8H), 7.77 (d, J=8.6, 0.8H), 7.72 (d, J=8.6, 0.2H), 7.61-7.49 (m, 1H), 4.93-4.72 (m, 1H), 3.53 (m, 1H), 3.41-3.32 (m, 1H), 2.33-1.77 (m, 4H), 1.39/1.14 (app br s, 3.7H+5.3H).

LC (Cond. 1): RT=1.67 min; >95% homogeneity index

LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₇H₂₁BrN₄NaO₂: 415.08; found 415.12

Example 146 Step e

NaH (60%; 11.6 mg, 0.29 mmol) was added in one batch to a heterogeneous mixture of imidazole 146d (80 mg, 0.203 mmol) and DMF (1.5 mL), and stirred at ambient condition for 30 min. SEM-Cl (40 μL, 0.226 mmol) was added drop-wise over 2 min to the above reaction mixture, and stirring was continued for 14 hr. The volatile component was removed in vacuo and the residue was partitioned between water and CH₂Cl₂. The aqueous layer was extracted with CH₂Cl₂, and the combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The crude material was purified by a flash chromatography (silica gel; 20% EtOAc/hexanes) to afford 146e as a colorless viscous oil (87.5 mg). The exact regiochemistry of 146e was not determined. ¹H NMR (CDCl₃, δ=7.4 ppm; 400 MHz): 8.53 (d, J=2.2, 1H), 7.90-7.72 (m, 2H), 7.52 (s, 1H), 5.87 (m, 0.46H), 5.41 (m, 0.54H), 5.16 (d, J=10.8, 1H), 5.03-4.85 (m, 1H), 3.76-3.42 (m, 4H), 2.54-1.84 (m, 4H), 1.38/1.19 (br s, 4.3H+4.7H), 0.97-0.81 (m, 2H), −0.03 (s, 9H).

LC (Cond. 1): RT=2.1 min

LC/MS: Anal. Calcd. for [M+H]⁺ C₂₃H₃₆BrN₄O₃Si: 523.17; found 523.24

Example 146 Step f

Pd(Ph₃P)₄ (24.4 mg, 0.021 mmol) was added to a mixture of imidazole 146e (280 mg, 0.535 mmol), 1c (241.5 mg, 0.55 mmol) and NaHCO₃ (148.6 mg, 1.769 mmol) in 1,2-dimethoxyethane (4.8 mL) and water (1.6 mL). The reaction mixture was flushed with nitrogen, heated with an oil bath at 80° C. for ˜24 hr and then the volatile component was removed in vacuo. The residue was partitioned between CH₂Cl₂ and water, and the organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The crude material was purified by a Biotage system (silica gel; 75-100% EtOAc/hexanes) followed by a reverse phase HPLC (H₂O/MeOH/TFA). The HPLC elute was neutralized with 2M NH₃/MeOH and evaporated in vacuo, and the residue was partitioned between water and CH₂Cl₂. The organic layer was dried (MgSO₄), filtered, and concentrated in vacuo to afford 146f as a white foam (162 mg).

LC (Cond. 1): RT=2.1 min

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₁H₅₈N₇O₅Si: 756.43; found 756.55

Example 146 Step g

Carbamate 146f (208 mg, 0.275 mmol) was treated with 25% TFA/CH₂Cl₂ (4.0 mL) and stirred at ambient temperature for 10 hr. The volatile component was removed in vacuo and the residue was first free-based by MCX (MeOH wash; 2.0 M NH₃/MeOH elution) and then purified by a reverse phase HPLC (H₂O/MeOH/TFA), and the resultant material was free-based again (MCX) to afford pyrrolidine 146 g as a film of oil (53.7 mg). ¹H NMR (DMSO, δ=2.5 ppm; 400 MHz): 1.88 (app br s, 2H), 8.83 (d, J=2.1, 1H), 8.07 (dd, J=8.3/2.3, 1H0, 7.87 (d, J=8.5, 1H), 7.84 (d, J=8.3, 2H), 7.71 (d, J=8.3, 2H), 7.55 (s, 1H), 7.50 (br s, 1H), 4.18 (m, 2H), 3.00-2.94 (m, 2H), 2.89-2.83 (m, 2H), 2.11-2.02 (m, 2H), 1.95-1.86 (m, 2H), 1.83-1.67 (m, 4H).

LC (Cond. 1): RT=0.95 min; >98% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₂₅H₂₈N₇: 426.24; found 426.27

Example 146 (1R)-2-((2S)-2-(5-(5-(4-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)phenyl)-2-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-N,N-dimethyl-2-oxo-1-phenylethanamine

Example 146 (TFA salt) was synthesized from pyrrolidine 146 g according to the preparation of Example 132 from intermediate 132e.

LC (Cond. 1): RT=1.42 min; 96.5% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₅H₅₀N₉O₂: 748.41; found 748.57

HRMS: Anal. Calcd. for [M+H]⁺ C₄₅H₅₀N₉O₂: 748.4087; found 748.4100

Example 147 methyl((1R)-2-((2S)-2-(5-(5-(4-(2-((2S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)phenyl)-2-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-2-oxo-1-phenylethyl)carbamate

The TFA salt of Example 147 was prepared similarly from intermediate 146 g by using Cap-4.

LC (Cond. 1): RT=1.66 min; 95% homogeneity index

LC/MS: Anal. Calcd. for [M+H]⁺ C₄₅H₄₆N₉O₆: 808.36; found 808.55

Example 148 (1R,1′R)-2,2′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(4R)-1,3-thiazolidine-4,3-diyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

Example 148 Step a

A solution of bromine (1.3 mL, 25.0 mmol) in 15 mL glacial acetic acid was added drop-wise to a solution of 4-4′-diacetylbiphenyl (3.0 g, 12.5 mmol) in 40 mL acetic acid at 50° C. Upon completion of addition the mixture was stirred at room temperature overnight. The precipitated product was filtered off and re-crystallized from chloroform to give 1,1′-(biphenyl-4,4′-diyl)bis(2-bromoethanone) (3.84 g, 77.5%) as a white solid.

¹H NMR (500 MHz, CHLOROFORM-D) δ ppm 8.09 (4H, d, J=7.93 Hz) 7.75 (4H, d, J=8.24 Hz) 4.47 (4H, s)

Nominal/LRMS—Anal. Calcd. for 369.07 found; (M+H)⁺ −397.33, (M−H)⁻ −395.14

Example 148 Step b

Sodium diformylamide (3.66 g, 38.5 mmol) was added to a suspension of 1,1′-(biphenyl-4,4′-diyl)bis(2-bromoethanone) (6.1 g, 15.4 mmol) in 85 mL acetonitrile. The mixture was heated at reflux for 4 hours and concentrated under reduced pressure. The residue was suspended in 300 mL 5% HCl in ethanol and heated at reflux for 3.5 hours. Reaction was cooled to room temperature and placed in the freezer for 1 hour. Precipitated solid was collected, washed with 200 mL 1:1 ethanol/ether followed by 200 mL pentane, and dried under vacuum to give 1,1′-(biphenyl-4,4′-diyl)bis(2-aminoethanone)dihydrochloride (4.85 g, 92%). Carried on without further purification.

¹H NMR (300 MHz, DMSO-d₆) δ ppm 8.47-8.55 (4H, m) 8.11-8.17 (4H, m) 8.00 (4H, d, J=8.42 Hz) 4.59-4.67 (4H, m).

LCMS—Phenomenex C-18 3.0×50 mm, 0 to 100% B over 4.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.1% TFA, B=90% methanol 10% water 0.1% TFA, t_(R)=0.44 minutes, Anal. Calcd. for C₁₆H₁₆N₂O₂ 268.31 found; 269.09 (M+H)⁺.

Example 148 Step c

To a stirred solution of 1,1′-(biphenyl-4,4′-diyl)bis(2-aminoethanone)dihydrochloride (0.7 g, 2.1 mmol), N-(tert-butoxy carbonyl)-L-thioproline (0.96 g, 4.2 mmol), and HATU (1.68 g, 4.4 mmol) in 14 mL DMF was added diisopropylethyl amine (1.5 mL, 8.4 mmol) drop-wise over 5 minutes. The resulting clear yellow solution was stirred at room temperature overnight (14 hours) and concentrated under reduced pressure. The residue was partitioned between 20% methanol/chloroform and water. The aqueous phase was washed once with 20% methanol/chloroform. The combined organics were washed with brine, dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude product was chromatographed on silica gel by gradient elution with 10-50% ethyl acetate/CH₂Cl₂ to give (4S,4′S)-tert-butyl 4,4′-(2,2′-(biphenyl-4,4′-diyl)bis(2-oxoethane-2,1-diyl))bis(azanediyl)bis(oxomethylene)dithiazolidine-3-carboxylate (0.39 g, 27%) as an orange foam.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.38 (2H, s) 8.12 (4H, d, J=8.56 Hz) 7.94 (4 H, d, J=8.56 Hz) 4.60-4.68 (4H, m) 4.33-4.38 (2H, m) 3.58-3.68 (2H, m) 3.38 (2H, s) 3.08-3.18 (2H, m) 1.40 (18H, s)

LCMS—Water-Sunfire C-18 4.6×50 mm, 0 to 100% B over 4.0 minute gradient, 1 minute hold time, A=10% methanol 90% water 0.1% TFA, B=90% methanol 10% water 0.1% TFA, t_(R)=3.69 min., Anal. Calcd. for C₃₄H₄₂N₄O₈S₂ 698.85 found; 699.12 (M+H)⁺.

Example 148 Step d

(4S,4′S)-tert-butyl 4,4′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))dithiazolidine-3-carboxylate (0.39 g, 0.56 mmol) and ammonium acetate (0.43 g, 5.6 mmol) were suspended in 8 mL o-xylene in a microwave reaction vessel. The mixture was heated under standard microwave conditions at 140° C. for 70 minutes and concentrated under reduced pressure. The residue was dissolved in 30 mL 20% methanol/chloroform and washed with 10% NaHCO₃(aq). The organic layer was washed with brine, dried (MgSO₄), filtered, and concentrated under reduced pressure. The crude product was chromatographed on silica gel by gradient elution with 1-6% methanol/CH₂Cl₂ to give (4S,4′S)-tert-butyl 4,4′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))dithiazolidine-3-carboxylate (0.15 g, 41%) as a yellow solid.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 12.02 (2H, s) 7.70-7.88 (10H, m) 5.28-5.37 (2H, m) 4.68 (2H, d, J=9.16 Hz) 4.47-4.55 (2H, m) 3.46 (2H, s) 3.23 (2H, s) 1.26-1.43 (18H, m)

LCMS—Luna C-18 3.0×50 mm, 0 to 100% B over 3.0 minute gradient, 1 minute hold time, A=5% acetonitrile, 95% water, 10 mm ammonium acetate, B=95% acetonitrile, 5% water, 10 mm ammonium acetate, t_(R)=1.96 min., Anal. Calcd. for C₃₄H₄₀N₆O₄S₂ 660.85 found; 661.30 (M+H)⁺, 659.34 (M−H)⁻

Example 148 Step e

To a solution of (4S,4′S)-tert-butyl 4,4′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))dithiazolidine-3-carboxylate in 1 mL dioxane was added 0.3 mL of a 4.0M solution of HCl in dioxane. The reaction was stirred for 3 hours at room temperature and concentrated under reduced pressure. The resulting tan solid was dried under vacuum to give 4,4′-bis(2-((S)-thiazolidin-4-yl)-1H-imidazol-5-yl)biphenyl tetrahydrochloride (0.12 g, 100%) as a yellow solid.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.09 (2H, s) 8.01 (4H, d, J=8.55 Hz) 7.90 (4 H, d, J=8.55 Hz) 5.08 (2H, t, J=6.10 Hz) 4.38 (2H, d, J=9.16 Hz) 4.23 (2H, d, J=9.46 Hz) 3.48-3.54 (2H, m) 3.35-3.41 (2H, m)

LCMS—Luna C-18 3.0×50 mm, 0 to 100% B over 4.0 minute gradient, 1 minute hold time, A=5% acetonitrile, 95% water, 10 mm ammonium acetate, B=95% acetonitrile, 5% water, 10 mm ammonium acetate, t_(R)=1.70 min., Anal. Calcd. for C₂₄H₂₄N₆S₂ 460.62 found; 461.16 (M+H)⁺, 459.31 (M−H)⁻

Example 148 (1R,1′R)-2,2′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(4R)-1,3-thiazolidine-4,3-diyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

To a stirred solution of (4,4′-bis(2-((S)-thiazolidin-4-yl)-1H-imidazol-5-yl)biphenyl tetrahydrochloride (0.028 g, 0.046 mmol), (R)-2-(dimethylamino)-2-phenylacetic acid (Cap-1, 0.017 g, 0.0.10 mmol), and HATU (0.039 g, 0.10 mmol) in 2 mL DMF was added diisopropylethyl amine (0.05 mL, 0.28 mmol). The reaction was stirred at room temperature overnight (16 hours) and concentrated under reduced pressure. The crude product was purified by reverse-phase preparative HPLC to provide (2R,2′R)-1,1′-((4S,4′S)-4,4′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(thiazolidine-4,3-diyl))bis(2-(dimethylamino)-2-phenylethanone), TFA salt (0.012 g, 21%)

¹H NMR (500 MHz, DMSO-d₆) δ ppm 7.59-7.91 (20H, m) 5.62 (2H, dd, J=6.56, 2.59 Hz) 4.99 (2H, d, J=8.85 Hz) 4.82/4.35 (2H, s) 4.22 (2H, s) 3.42 (2H, s) 3.25 (2H, s) 2.35-2.61 (12H, m)

LCMS—Luna C-18 3.0×50 mm, 0 to 100% B over 7.0 minute gradient, 1 minute hold time, A=5% acetonitrile, 95% water, 10 mm ammonium acetate, B=95% acetonitrile, 5% water, 10 mm ammonium acetate mobile phase t_(R)=3.128 min.

Nominal/LRMS—Calcd. for C₄₄H₄₆N₈O₂S₂ 783.03; found 783.28 (M+H)⁺

Accurate/HRMS—Calcd. for C₄₄H₄₇N₈O₂S₂ 783.3263; 783.3246 (M+H)⁺

Example 151 (1R,1′R)-2,2′-(4,4′-biphenyldiylbis((1-methyl-1H-imidazole-4,2-diyl)(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

Example 151 Step a

To a stirred solution of 1d, (2S,2′S)-tert-butyl 2,2′-(4,4′-(biphenyl-4,4′-diyl)bis(1H-imidazole-4,2-diyl))dipyrrolidine-1-carboxylate (100 mg, 0.16 mmole) and iodomethane (40 μL, 0.16 mmole) in CH₂Cl₂ (2 mL) was added sodium hydride (40%) (21.2 mg, 0.352 mmole). After five hours at ambient temperature, it was concentrated under reduced pressure. The crude reaction product 151a, (2S,2′S)-tert-butyl 2,2′-(4,4′-(biphenyl-4,4′-diyl)bis(1-methyl-1H-imidazole-4,2-diyl))dipyrrolidine-1-carboxylate (˜90 mg) was moved onto next step without further purification (purity ˜85%) LCMS: Anal. Calcd. for: C₃₈H₄₈N₆O₄ 652.83;

Found: 653.51 (M+H)⁺. It should be recognized that multiple methylation isomers are possible in this reaction and no attempt to assign these was made.

Example 151 Step b

151a, (2S,2′S)-tert-butyl 2,2′-(4,4′-(biphenyl-4,4′-diyl)bis(1-methyl-1H-imidazole-4,2-diyl))dipyrrolidine-1-carboxylate (100 mg, 0.153 mmole) treated with 4 M HCl/dioxane (20 mL). After three hours at ambient temperature, it was concentrated under reduced pressure. The crude reaction product, 4,4′-bis(1-methyl-2-((S)-pyrrolidin-2-yl)-1H-imidazol-4-yl)biphenyl(˜110 mg, HCl salt) was moved onto the next step without further purification (purity ˜85%) LCMS: Anal. Calcd. for: C₂₈H₃₂N₆ 452.59; Found: 453.38 (M+H)⁺. Multiple imidazole isomers were present and carried forward.

Example 151

HATU (58.9 mg, 0.150 mmol) was added to a mixture of 151b, 4,4′-bis(1-methyl-2-((S)-pyrrolidin-2-yl)-1H-imidazol-4-yl)biphenyl (45.0 mg, 0.075 mmol), (i-Pr)₂EtN (78 μL, 0.451 mmol) and Cap-1, (R)-2-(dimethylamino)-2-phenylacetic acid (0.026 mg 0.150 mmol) in DMF (1.0 mL). The resultant mixture was stirred at ambient temperature until the coupling was complete as determined by LC/MS analysis. Purification was accomplished by reverse-phase preparative HPLC (Waters-Sunfire 30×100 mm S5, detection at 220 nm, flow rate 30 mL/min, 0 to 90% B over 14 min; A=90% water, 10% ACN, 0.1% TFA, B=10% water, 90% ACN, 0.1% TFA) to provide two isomer of 151, (2R,2′R)-1,1′-((2S,2′S)-2,2′-(4,4′-(biphenyl-4,4′-diyl)bis(1-methyl-1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(2-(dimethylamino)-2-phenylethanone), TFA salts.

Isomer 1: (1R,1′R)-2,2′-(4,4′-biphenyldiylbis((1-methyl-1H-imidazole-4,2-diyl)(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

(8 mg, 8.6%) as a colorless wax.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.84-2.25 (m, 8H) 2.32-2.90 (m, 12H) 3.67-3.92 (m, 8H) 4.07 (s, 2H) 5.23 (s, 2H) 5.51 (s, 2H) 7.51-7.91 (m, 20H)

HPLC Xterra 4.6×50 mm, 0 to 100% B over 10 minutes, one minutes hold time, A=90% water, 10% methanol, 0.2% phosphoric acid, B=10% water, 90% methanol, 0.2% phosphoric acid, RT=2.74 min, 98%.

LCMS: Anal. Calcd. for: C₄₈H₅₄N₈O₂ 775.02; Found: 775.50 (M+H)⁺.

Isomer 2: (1R,1′R)-2,2′-(4,4′-biphenyldiylbis((1-methyl-1H-imidazole-4,2-diyl)(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phenylethanamine)

(10.2 mg, 11%) as a colorless wax.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.83-2.26 (m, 8H) 2.30-2.92 (m, 12H) 3.68-3.94 (m, 8H) 4.06 (s, 2H) 5.25 (d, J=2.14 Hz, 2H) 5.50 (s, 2H) 7.52-7.91 (m, 20H).

HPLC Xterra 4.6×50 mm, 0 to 100% B over 10 minutes, one minutes hold time, A=90% water, 10% methanol, 0.2% phosphoric acid, B=10% water, 90% methanol, 0.2% phosphoric acid, RT=2.75 min, 90%.

LCMS: Anal. Calcd. for: C₄₈H₅₄N₈O₂ 775.02; Found: 775.52 (M+H)⁺.

Example 152

Example 152a-1 Step a 2-Chloro-5-(1-ethoxyvinyl)pyrimidine

To a solution of 5-bromo-2-chloropyrimidine (12.5 g, 64.62 mmol) in dry DMF (175 mL) under N₂ was added tributyl(1-ethoxyvinyl)tin (21.8 mL, 64.62 mmol) and dichlorobis(triphenylphosphine)palladium (II) (2.27 g, 3.23 mmol). The mixture was heated at 100° C. for 3 h before being allowed to stir at room temperature for 16 hr. The mixture was then diluted with ether (200 mL) and treated with aqueous KF soln (55 g of potassium fluoride in 33 mL of water). The two phase mixture was stirred vigorously for 1 h at room temperature before being filtered through diatomaceous earth (Celite®). The filtrate was washed with sat'd NaHCO₃ soln and brine prior to drying (Na₂SO₄). The original aqueous phase was extracted with ether (2×) and the organic phase was treated as above. Repetition on 13.5 g of 5-bromo-2-chloropyrimidine and combined purification by Biotage™ flash chromatography on silica gel (gradient elution on a 65M column using 3% ethyl acetate in hexanes to 25% ethyl acetate in hexanes with 3.0 L) afforded the title compound as a white, crystalline solid (18.2 g, 73%).

¹H NMR (500 MHz, DMSO-d₆) δ 8.97 (s, 2H), 5.08 (d, J=3.7 Hz, 1H), 4.56 (d, J=3.4 Hz, 1H), 3.94 (q, J=7.0 Hz, 2H), 1.35 (t, J=7.0 Hz, 3H).

LCMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=2.53 min, 98.8% homogeneity index.

LCMS: Anal. Calcd. for C₈H₁₀ClN₂O 185.05; found: 185.04 (M+H)⁺.

HRMS: Anal. Calcd. for C₈H₁₀ClN₂O 185.0482; found: 185.0490 (M+H)⁺.

The same method was used for the preparation of Examples 152a-2 & 152a-3:

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Ex- ample 152a-2

t_(R) = 2.24 min 96.4%, condition 1 LRMS: Anal. Calcd. for C₉H₁₀ClN₂O 185.05; found: 185.06 (M + H)⁺. HRMS: Anal. Calcd. for C₈H₁₀ClN₂O 185.0482; found: 185.0476 (M + H)⁺. Ex- ample 152a-3

t_(R) = 2.82 min (52.7%, inseparable with 2,5- dibrompyrazine (t_(R) = 1.99 min, 43.2%)); condition 1 LRMS: Anal. Calcd. for C₈H₁₀BrN₂O 229.00; found: 228.93 (M + H)⁺.

Example 152b-1 Step b (S)-tert-Butyl 2-(5-(2-chloropyrimidin-5-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate or (S)-2-[5-(2-Chloro-pyrimidin-5-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester

NBS (16.1 g, 90.7 mmol) was added in one portion to a stirred solution of 2-chloro-5-(1-ethoxyvinyl)pyrimidine (152a-1, 18.2 g, 98.6 mmol) in THF (267 mL) and H₂O (88 mL) at 0° C. under N₂. The mixture was stirred for 1 h at 0° C. before it was diluted with more H₂O and extracted with ethyl acetate (2×). The combined extracts were washed with sat'd NaHCO₃ soln and brine prior to drying (Na₂SO₄), filtration, and solvent evaporation. LCMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=1.52 min (unsymmetrical peak).

LCMS: Anal. Calcd. for C₆H₁₄BrClN₂O 235.92; found: 236.85 (M+H)⁺.

Example 152c-1 Step c

Half of the crude residue (2-bromo-1-(2-chloropyrimidin-5-yl)ethanone, ˜14.5 g) was dissolved into anhydrous acetonitrile (150 mL) and treated directly with N-Boc-L-proline (9.76 g, 45.35 mmol) and diisopropylethylamine (7.9 mL, 45.35 mmol). After being stirred for 3 h, the solvent was removed in vacuo and the residue was partitioned into ethyl acetate and water. The organic phase was washed with 0.1N hydrochloric acid, sat'd NaHCO₃ soln and brine prior to drying (Na₂SO₄), filtration, and concentration. LCMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=2.66 min.

The same method was used to prepare Examples 152c-2 through 152c-6.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example 152c-2

t_(R) = 1.81 min (condition 2, ~95%) LRMS: Anal. Calcd. for C₁₅H₁₉BrN₄O₂ 386.05 found: 387.07 (M + H)⁺. Example 152c-3

t_(R) = 1.84 min (condition 2, 94%) LRMS: Anal. Calcd. for C₁₅H₁₉BrN₂O₅ 386.05; found: 387.07 (M + H)⁺. Example 152c-3a

t_(R) = 2.65 min; condition 1 LCMS: Anal. Calcd. for C₁₆H₂₀ClN₃O₅ 369.11 found: 391.89 (M + Na)⁺. Example 152c-4

t_(R) = 1.94 min, (condition 2) LCMS: Anal. Calcd. for C₁₆H₂₁BrN₃O₅ 414.07 found: 414.11 (M + H)⁺. Example 152c-5

t_(R) = 2.22 min; condition 1 LCMS: Anal. Calcd. for C₁₄H₁₈ClN₃O₅ 343.09 found: undetermined. Example 152c-6

t_(R) = 2.41 min, condition 1 LCMS: Anal. Calcd. for C₁₄H₁₈ ³⁷BrN₃O₅ 389.04 found: 412.03 (M + Na)⁺.

Example 152d-1 Step d

This residue ((S)-1-tert-butyl 2-(2-(2-chloropyrimidin-5-yl)-2-oxoethyl)pyrrolidine-1,2-dicarboxylate) was taken up in xylenes (200 mL) and treated to NH₄OAc (17.5 g, 0.23 mol). The mixture was heated at 140° C. for 2 hr in a thick-walled, screw-top flask before it was cooled to ambient temperature and suction-filtered. The filtrate was then concentrated, partitioned into ethyl acetate and sat'd NaHCO₃ soln and washed with brine prior to drying (Na₂SO₄), filtration, and concentration The original precipitate was partitioned into aqueous NaHCO₃ soln and ethyl acetate and sonicated for 2 min before being suction-filtered. The filtrate was washed with brine, dried over (Na₂SO₄), filtered, and concentrated to dryness. Purification of the combined residues by Biotage™ flash chromatography on silica gel (65M column, preequilibration with 2% B for 900 mL followed by gradient elution with 2% B to 2% B for 450 ml followed by 2% B to 40% B for 300 mL where B=methanol and A=dichloromethane) afforded the title compound (7.0 g, 44% yield, 2 steps, pure fraction) as an yellowish orange foam. The mixed fractions were subjected to a second Biotage™ chromatography on silica gel (40M column, preequilibration with 1% B for 600 mL followed by gradient elution with 1% B to 1% B for 150 ml followed by 1% B to 10% B for 1500 mL where B=MeOH and A=CH₂Cl₂) afforded additional title compound (2.8 g, 18%) as a brownish-orange foam. ¹H NMR (500 MHz, DMSO-d₆) δ 12.24-12.16 (m, 1H), 9.05 (s, 2H), 7.84-7.73 (m, 1H), 4.90-4.73 (m, 1H), 3.59-3.46 (m, 1H), 3.41-3.31 (m, 1H), 2.32-2.12 (m, 1H), 2.03-1.77 (m, 3H), 1.39 and 1.15 (2s, 9H).

LCMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=1.92 min, 94.7% homogeneity index.

LRMS: Anal. Calcd. for C₁₆H₂₁ClN₅O₂ 350.14; found: 350.23 (M+H)⁺.

HRMS: Anal. Calcd. for C₁₆H₂₁ClN₅O₂ 350.1384; found: 350.1398 (M+H)⁺.

The same method was used to prepare Examples 152d-2 through 152d-6.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example 152d-2

t_(R) = 1.92 min (86.5%); condition 1 LRMS: Anal. Calcd. for C₁₆H₂₁ClN₅O₂ 350.14; found: 350.23 (M + H)⁺. HRMS: Anal. Calcd. for C₁₆H₂₁ClN₅O₂ 350.1384; found: 350.1393 (M + H)⁺. Example 152d-3

t_(R) = 1.90 min (>95%); condition 1 LRMS: Anal. Calcd. for C₁₆H₂₁BrN₅O₂ 394.09; found: 393.82 (M + H)⁺. HRMS: Anal. Calcd. for C₁₆H₂₁BrN₅O₂ 394.0879; found: 394.0884 (M + H)⁺. Example 152d-4

t_(R) = 1.45 min (condition 2, 100%) LRMS: Anal. Calcd. for C₁₅H₁₉BrN₄O₂ 366.07 found: 367.07 (M + H)⁺. Example 152d-5

t_(R) = 1.88 min (>95%); condition 1 LRMS: Anal. Calcd. for C₁₄H₁₈BrN₅O₂ 367.06; found: 368.10 (M + H)⁺. Example 152d-6

t_(R) = 1.66 min (85%); condition 1 LRMS: Anal. Calcd. for C₁₄H₁₈ClN₅O₂ 323.11; found: 324.15 (M + H)⁺.

Example 152e-1 Step e Example 152e-1 (S)-tert-Butyl 2-(5-(2-chloropyrimidin-5-yl)-1-((2-(trimethyl-silyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate

Sodium hydride (60% dispersion in mineral oil, 0.23 g, 5.72 mmol) was added in one portion to a stirred solution of (S)-tert-butyl 2-(5-(2-chloropyrimidin-5-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (152d-1, 2.0 g, 5.72 mmol) in dry DMF (45 mL) at ambient temperature under N₂. The mixture was stirred for 5 min. before SEM chloride (1.01 mL, 5.72 mmol) was added in approx. 0.1 mL increments. The mixture was stirred for 3 h before being quenched with sat'd NH₄Cl soln and diluted with ethyl acetate. The organic phase was washed with sat'd NaHCO₃ soln and brine, dried over (Na₂SO₄), filtered, and concentrated. The original aqueous phase was extracted twice more and the combined residue was purified by Biotage™ flash chromatography (40M column, 50 mL/min, preequilibration with 5% B for 750 mL, followed by step gradient elution with 5% B to 5% B for 150 mL, 5% B to 75% B for 1500 mL, then 75% B to 100% B for 750 mL where solvent B is ethyl acetate and solvent A is hexanes). Concentration of the eluant furnished the title compound as a pale yellow foam (2.35 g, 85%).

¹H NMR (500 MHz, DMSO-d₆) δ 9.04 (s, 2H), 7.98-7.95 (m, 1H), 5.70-5.31 (3 m, 2H), 5.02-4.91 (m, 1H), 3.59-3.49 (m, 3H), 3.45-3.35 (m, 1H), 2.30-2.08 (m, 2H), 1.99-1.83 (m, 2H), 1.36 and 1.12 (2s, 9H), 0.93-0.82 (m, 2H), −0.02 (s, 9H).

LCMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 2 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=2.38 min, 95% homogeneity index.

LRMS: Anal. Calcd. for C₂₂H₃₅ClN₅O₃Si 480.22; found: 480.23 (M+H)⁺.

HRMS: Anal. Calcd. for C₂₂H₃₅ClN₅O₃Si 480.2198; found: 480.2194 (M+H)⁺.

The same method was used to prepare 152e-2 through 152e-4

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example 152e-2

t_(R) = 2.34 min (85.7%); condition 1 LCMS: Anal. Calcd. for C₂₂H₃₅ClN₅O₃Si 480.22; found: 480.22 (M + H)⁺. HRMS: Anal. Calcd. for C₂₂H₃₅ClN₅O₃Si 480.2198 found: 480.2198 (M + H)⁺. Example 152e-3

t_(R) = 3.18 min (>95%); condition 1 LCMS: Anal. Calcd. for C₂₂H₃₅ ³⁷BrN₅O₃Si 526.17; found: 525.99 (M + H)⁺. HRMS: Anal. Calcd. for C₂₂H₃₅ ³⁷BrN₅O₃Si 526.1692; found: 526.1674 (M + H)⁺. Example 152e-4

t_(R) = 2.14 min (condition 2, 96%) LRMS: Anal. Calcd. For C₂₁H₃₃BrN₄O₃Si 495.15 found: 497.13 (M + H)⁺.

Examples 152f-1 to 152f-2 Example 152f-1 (S)-1-(2-(5-(2-chloropyrimidin-5-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-2-(pyridin-3-yl)ethanone

Cold (0° C.) 4 NHCl in dioxanes (5 mL) was added via syringe to (S)-tert-butyl 2-(5-(2-chloropyrimidin-5-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (152d-1, 0.50 g, 1.43 mmol) in a 100 mL pear-shaped flask followed by MeOH (1.0 mL). The suspension was stirred at room temperature for 4 h before it was concentrated down to dryness and placed under high vacuum for 1 h. There was isolated intermediate (S)-2-chloro-5-(2-(pyrrolidin-2-yl)-1H-imidazol-5-yl)pyrimidine trihydrochloride as a pale yellow solid (with an orange tint) which was used without further purification.

HATU (0.60 g, 1.57 mmol) was added in one portion to a stirred solution of intermediate (S)-2-chloro-5-(2-(pyrrolidin-2-yl)-1H-imidazol-5-yl)pyrimidine trihydrochloride (0.46 g, 1.43 mmol, theoretical amount), 2-(pyridin-3-yl)acetic acid (0.25 g, 1.43 mmol) and DIEA (1.0 mL, 5.72 mmol) in anhydrous DMF (10 mL) at ambient temperature. The mixture was stirred at room temperature for 2 h before the DMF was removed in vacuo. The residue was taken up in CH₂Cl₂ and subjected to Biotage™ flash chromatography on silica gel (40M column, preequilibration with 0% B for 600 mL followed by step gradient elution with 0% B to 0% B for 150 mL followed by 0% B to 15% B for 1500 mL followed by 15% B to 25% B for 999 mL where B=MeOH and A=CH₂Cl₂). There was isolated the title compound (0.131 g, 25%, 2 steps) as a yellow solid.

¹H NMR (500 MHz, DMSO-d₆) δ 9.10-9.08 (2s, 2H), 8.72-8.55 (series of m, 2H), 8.21-8.20 and 8.11-8.10 (2m, 1H), 8.00 and 7.93 (2s, 1H), 7.84-7.77 (series of m, 1H), 5.43-5.41 and 5.17-5.15 (2m, 1H), 4.02-3.94 (3 m, 2H), 3.90-3.58 (3 m, 2H), 2.37-2.26 (m, 1H), 2.16-1.85 (2m, 3H).

LCRMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=0.92 min, 95.1% homogeneity index.

LRMS: Anal. Calcd. for C₁₈H₁₈ClN₆O 369.12; found: 369.11 (M+H)⁺.

HRMS: Anal. Calcd. for C₁₈H₁₈ClN₆O 369.1231; found: 369.1246 (M+H)⁺.

Examples 152g-1 to 152g-17 Example 152g-1 From 1c and 152e-1 (S)-2-[5-(2-{4-[2-((S)-1-tert-Butoxycarbonyl-pyrrolidin-2-yl)-3H-imidazol-4-yl]-phenyl}-pyrimidin-5-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester

Pd (Ph₃)₄ (0.12 g, 0.103 mmol) was added in one portion to a stirred suspension of (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (1c, 1.00 g, 2.27 mmol), (S)-tert-butyl 2-(5-(2-chloropyrimidin-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (152c-1, 0.99 g, 2.06 mmol) and NaHCO₃ (0.87 g, 10.3 mmol) in a solution of DME (20 mL) and H₂O (6 mL) at room temperature under N₂. The vessel was sealed and the mixture was placed into a preheated (80° C.) oil bath and stirred at 80° C. for 16 h before additional catalyst (0.12 g) was added. After heating the mixture for an additional 12 h at 80° C., the mixture was cooled to ambient temperature, diluted with ethyl acetate and washed with sat'd NaHCO₃ soln and brine prior to drying over anhydrous sodium sulfate and solvent concentration. Purification of the residue by Biotage™ flash chromatography on silica gel using a 40M column (preequilibrated with 40% B followed by step gradient elution with 40% B to 40% B for 150 mL, 40% B to 100% B for 1500 mL, 100% B to 100% B for 1000 mL where B=ethyl acetate and A=hexanes) furnished the title compound as a yellow foam (1.533 g, 98%). A small amount of the yellow foam was further purified for characterization purposes by pHPLC (Phenomenex GEMINI, 30×100 mm, S10, 10 to 100% B over 13 minutes, 3 minute hold time, 40 mL/min, A=95% water, 5% acetonitrile, 10 mM NH₄OAc, B=10% water, 90% acetonitrile, 10 mM NH₄OAc) to yield 95% pure title compound as a white solid.

¹HNMR (500 MHz, DMSO-d₆) δ 12.30-11.88 (3 m, 1H), 9.17-9.16 (m, 2H), 8.43-8.31 (m, 2H), 7.99-7.35 (series of m, 4H), 5.72-5.30 (3 m, 2H), 5.03-4.76 (2m, 2H), 3.64-3.50 (m, 4H), 3.48-3.31 (m, 2H), 2.36-2.07 (m, 2H), 2.05-1.80 (m, 4H), 1.46-1.08 (2m, 18H), 0.95-0.84 (m, 2H), −0.01 (s, 9H).

HPLC Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=2.91 min, 95% homogeneity index.

LRMS: Anal. Calcd. for C₄₀H₅₇N₈O₅Si 757.42; found: 757.42 (M+H)⁺.

HRMS: Anal. Calcd. for C₄₀H₅₇N₈O₅Si 757.4221; found: 757.4191 (M+H)⁺.

The same procedure was used to prepare Examples 152g-2 through 152g-17:

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example 152g-2

t_(R) = 2.81 min (79%); Condition 1 LRMS: Anal. Calcd. for C₄₀H₅₇N₈O₅Si 757.42; found: 758.05 (M + H)⁺. HRMS: Anal. Calcd. for C₄₀H₅₇N₈O₅Si 757.4221; found: 757.4196 (M + H)⁺. Example 152g-3

t_(R) = 2.89 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₀H₅₇N₈O₅Si 757.42; found: 757.35 (M + H)⁺. HRMS: Anal. Calcd. for C₄₀H₅₇N₈O₅Si 757.4221; found: 757.4191 (M + H)⁺. Example 152g-4

t_(R) = 2.87 min (97%); Condition 1 LRMS: Anal. Calcd. for C₃₈H₅₅N₈O₅S_(i) 731.41; found: 731.26 (M + H)⁺. HRMS: Anal. Calcd. for C₃₈H₅₅N₈O₅S_(i) 731.4065; found: 731.4070 (M + H)⁺. Example 152g-5

t_(R) = 2.94 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₃₈H₅₅N₈O₅Si 731.41; found: 731.26 (M + H)⁺. HRMS: Anal. Calcd. for C₃₈H₅₅N₈O₅Si 731.4065; found: 731.4046 (M + H)⁺. Example 152g-6

t_(R) = 1.99 min (condition 2, 96%) LRMS: Anal. Calcd. for C₃₇H₅₃N₇O₂Si 703.39; found: 704.34 (M + H)⁺. Example 152g-7

t_(R) = 1.99 min (condition 2, 96%) LRMS: Anal. Calcd. for C₃₉H₅₅N₇O₅Si 729.40 found: 730.42 (M + H)⁺. Example 152g-8

t_(R) = 2.15 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₃₇H₄₁N₈O₄ 661.33; found: 661.39 (M + H)⁺. HRMS: Anal. Calcd. for C₃₇H₄₁N₈O₄ 661.3251; found: 661.3268 (M + H)⁺. Example 152g-9

t_(R) = 1.71 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₃₆H₄₀N₉O₃ 646.76; found: 646.47 (M + H)⁺. HRMS: Anal. Calcd. for C₃₆H₄₀N₉O₃ not done found: not done (M + H)⁺. Example 152g- 10

t_(R) = 1.71 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₃₆H₄₀N₉O₃ 646.33; found: 646.37 (M + H)⁺. HRMS: Anal. Calcd. for C₃₆H₄₀N₉O₃ 646.3254; found: 646.3240 (M + H)⁺. Example 152g- 11

t_(R) = 2.12 min (>93.9%); Condition 1 LRMS: Anal. Calcd. for C₃₃H₄₂N₇O₄ 600.33; found: 600.11 (M + H)⁺. HRMS: Anal. Calcd. for C₃₃H₄₂N₇O₄ 600.3298; found: 600.3312 (M + H)⁺. Example 152g- 12

t_(R) = 2.13 min (97.3%); Condition 1 LRMS: Anal. Calcd. for C₃₂H₄₁N₈O₄ 601.33; found: 601.36 (M + H)⁺. HRMS: Anal. Calcd. for C₃₂H₄₁N₈o₄ 601.3251; found: 601.3253 (M + H)⁺. Example 152g- 13

t_(R) = 2.11 min (98.5%); Condition 1 LRMS: Anal. Calcd. for C₃₂H₄₁N₈O₄ 601.33; found: 601.36 (M + H)⁺. HRMS: Anal. Calcd. for C₃₂H₄₁N₈O₄ 601.3251; found: 601.3253 (M + H)⁺. Example 152g- 14

t_(R) = 2.18 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₃₃H₄₃N₈O₄ 615.34; found: 615.38 (M + H)⁺. HRMS: Anal. Calcd. for C₃₃H₄₃N₈O₄ 615.3407; found: 615.3433 (M + H)⁺. Example 152g- 15

t_(R) = 2.20 min (97.7%); Condition 1 LRMS: Anal. Calcd. for C₃₅H₃₉N₈O₄ 635.31; found: 635.36 (M + H)⁺. HRMS: Anal. Calcd. for C₃₅H₃₉N₈O₄ 635.3094; found: 635.3119 (M + H)⁺. Example 152g- 16

t_(R) = 2.26 min (>95%); Condition 1 LRMS: Anal. Calcd C₃₆H₄₁N₈O₄ 649.33; found: 649.39 (M + H)⁺. HRMS: Anal. Calcd. for C₃₆H₄₁N₈o₄ 649.3251; found: 649.3276 (M + H)⁺. Example 152g- 17

t_(R) = 2.98 min (98.5%); Condition 1 LRMS: Anal. Calcd. for C₃₈H₅₄N₈O₅Si 730.39; found: 731.40 (M + H)⁺. HRMS: Anal. Calcd. for C₃₈H₅₄N₈O₅Si 731.4065; found: 731.4045 (M + H)⁺.

Example 152h-1-152h-7 Example 152h-1 from 152g-1 5-((S)-2-Pyrrolidin-2-yl-3H-imidazol-4-yl)-2-[4-((S)-2-pyrrolidin-2-yl-3H-imidazol-4-yl)-phenyl]-pyrimidine

TFA (8 mL) was added in one portion to a stirred solution of (S)-2-[5-(2-{4-[2-((S)-1-tert-butoxycarbonyl-pyrrolidin-2-yl)-3H-imidazol-4-yl]-phenyl}-pyrimidin-5-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester (1.50 g, 1.98 mmol) in dry CH₂Cl₂ (30 mL) at room temperature. The flask was sealed and the mixture was stirred at room temperature for 16 h before the solvent(s) were removed in vacuo. The residue was taken up in methanol, filtered through a PVDF syringe filter (13 mm×0.45 μm), distributed to 8 pHPLC vials and chromatographed by HPLC (gradient elution from 10% B to 100% B over 13 min on a Phenomenex C18 column, 30×100 mm, 10 μm, where A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA). After concentration of the selected test tubes by speed vacuum evaporation, the product was dissolved in methanol and neutralized by passing the solution through an UCT CHQAX 110M75 anion exchange cartridge. There was isolated the title compound as a yellow mustard-colored solid (306.7 mg, 36% yield) upon concentration of the eluant.

¹H NMR (500 MHz, DMSO-d₆) μ 12.50-11.80 (br m, 2H), 9.18 (s, 2H), 8.36 (d, J=8.5 Hz, 2H), 7.89 (d, J=8.2 Hz, 2H), 7.77 (s, 1H), 7.61 (s, 1H), 4.34-4.24 (m, 2H), 3.09-2.89 (m, 4H), 2.18-2.07 (m, 2H), 2.02-1.89 (m, 2H), 1.88-1.72 (m, 4H).

LCMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=1.33 min, >95% homogeneity index.

LRMS: Anal. Calcd. for C₂₄H₂₇N₈ 427.24; found: 427.01 (M+H)⁺.

HRMS: Anal. Calcd. for C₂₄H₂₇N₈ 427.2359; found: 427.2363 (M+H)⁺.

The same conditions were used to prepare Examples 152h-2 through 152h-14.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example 152h-2

t_(R) = 1.36 min (98%); Condition 1 LRMS: Anal. Calcd. for C₂₄H₂₇N₈ 427.24; found: 427.48 (M + H)⁺. HRMS: Anal. Calcd. for C₂₄H₂₇N₈ 427.2359; found: 427.2339 (M + H)⁺. Example 152h-3

t_(R) = 1.17 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₂₂H₂₅N₈ 401.22; found: 401.16 (M + H)⁺. HRMS: Anal. Calcd. for C₂₂H₂₅N₈ 401.2202; found: 401.2193 (M + H)⁺. Example 152h-4

t_(R) = 1.28 min (89.3%); Condition 1 LRMS: Anal. Calcd. for C₂₂H₂₅N₈ 401.22; found: 401.16 (M + H)⁺. HRMS: Anal. Calcd. for C₂₂H₂₅N₈ 401.2202; found: 401.2201 (M + H)⁺. Example 152h-5

t_(R) = 0.93 min; Condition 2 LRMS: Anal. Calcd. for C₂₃H₂₅N₇ 399; found: 400 (M + H)⁺. Example 152h-6

t_(R) = 0.81 min; Condition 2 LRMS: Anal. Calcd. for C₂₁H₂₃N₇ 373; found: 374 (M + H)⁺. Example 152h-7

t_(R) = 1.14 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₂₃H₂₆N₇ 400.23; found: 400.14 (M + H)⁺. HRMS: Anal. Calcd. for C₂₃H₂₆N₇ 400.2250; found: 400.2234 (M + H)⁺. Example 152h-8

t_(R) = 1.29 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₂₂H₂₅N₈ 401.22; found: 401.21 (M + H)⁺. HRMS: Anal. Calcd. for C₂₂H₂₅N₈ 401.2202; found: 401.2204 (M + H)⁺. Example 152h-9

t_(R) = 1.29 min (97.6%); Condition 1 LRMS: Anal. Calcd. for C₂₂H₂₅N₈ 401.22; found: 401.21 (M + H)⁺. HRMS: Anal. Calcd. for C₂₂H₂₅N₈ 401.2202; found: 401.2220 (M + H)⁺. Example 152h- 10

t_(R) = 1.26 min (86.4%); Condition 1 LRMS: Anal. Calcd. for C₂₄H₂₇N₈ 427.24; found: 427.48 (M + H)⁺. HRMS: Anal. Calcd. for C₂₄H₂₇N₈ 427.2359; found: 427.2339 (M + H)⁺. Example 152h- 11

t_(R) = 1.26 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₃₁H₃₂N₉O 546.27; found: 546.28 (M + H)⁺. HRMS: Anal. Calcd. for C₃₁H₃₂N₉O 546.2730 found: 546.2739 (M + H)⁺. Example 152h- 12

t_(R) = 1.39 min (95%); Condition 1 LRMS: Anal. Calcd. for C₃₁H₃₂N₉O 546.27; found: 546.32 (M + H)⁺. HRMS: Anal. Calcd. for C₃₁H₃₂N₉O 546.2730; found: 546.2719 (M + H)⁺. Example 152h- 13

t_(R) = 1.42 min; Condition 1 LRMS: Anal. Calcd. for C₂₃H₂₆N₈ 414.24; found: 415.27 (M + H)⁺. HRMS: Anal. Calcd. for C₂₃H₂₆N₈ 415.2359; found: 415.2371 (M + H)⁺. Example 152h- 14

t_(R) = 1.30 min; Condition 1 LRMS: Anal. Calcd. for C₂₂H₂₄N₈ 400.21; found: 401.24 (M + H)⁺. HRMS: Anal. Calcd. for C₂₂H₂₄N₈ 401.2202; found: 401.2198 (M + H)⁺.

Example 152i-1 to 152i-3 Example 152i-1 from 152g-8 (S)-2-(5-{2-[4-((S)-2-Pyrrolidin-2-yl-3H-imidazol-4-yl)-phenyl]-pyrimidin-5-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester

A solution of (S)-2-[5-(2-{4-[2-((S)-1-Benzyloxycarbonyl-pyrrolidin-2-yl)-3H-imidazol-4-yl]-phenyl}-pyrimidin-5-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester (317.1 mg, 0.48 mmol) in MeOH (1 mL) was added to a stirred suspension of 10% palladium on carbon (60 mg) and K₂CO₃ (70 mg) in a solution of MeOH (5 mL) and H₂O (0.1 mL) at room temperature under N₂. The flask was charged and evacuated three times with H₂ and stirred for 3 h at atmosphere pressure. Additional catalyst (20 mg) was then added and the reaction mixture was stirred further for 3 h before it was suction-filtered through diatomaceous earth (Celite®) and concentrated. The residue was diluted with MeOH, filtered through a PVDF syringe filter (13 mm×0.45 μm), distributed into 4 pHPLC vials and chromatographed (gradient elution from 20% B to 100% B over 10 min on a Phenomenex-Gemini C18 column (30×100 mm, 10 μm) where A=95% water, 5% acetonitrile, 10 mM NH₄OAc, B=10% water, 90% acetonitrile, 10 mM NH₄OAc). After concentration of the selected test tubes by speed vacuum evaporation, there was isolated the title compound as a yellow solid (142.5 mg, 56% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 12.35-12.09 (br m, 1H), 9.17 (s, 2H), 8.35 (d, J=8.3 Hz, 2H), 7.87 (d, J=8.3 Hz, 2H), 7.80-7.72 (m, 1H), 7.56 (s, 1H), 4.92-4.77 (m, 1H), 4.21-4.13 (m, 1H), 3.61-3.05 (2m, 4H), 3.02-2.80 (2m, 2H), 2.37-1.67 (series of m, 6H), 1.41 and 1.17 (2s, 9H).

LCMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=1.77 min, >95% homogeneity index.

LRMS: Anal. Calcd. for C₂₉H₃₅N₈O₂ 527.29; found: 527.34 (M+H)⁺.

HRMS: Anal. Calcd. for C₂₉H₃₅N₈O₂ 527.2883; found: 527.2874 (M+H)⁺.

The same procedure was used to prepare Examples 152i-2 through 152i-3.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example 152i-2

t_(R) = 1.70 min (95.7%); Condition 1 LRMS: Anal. Calcd. for C₂₇H₃₃N₈O₂ 501.27; found: 501.35 (M + H)⁺. HRMS: Anal. Calcd. for C₂₇H₃₃N₈O₂ 501.2726 found: 501.2709 (M + H)⁺. Example 152i-3

t_(R) = 1.77 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₂₈H₃₅N₈O₂ 515.29; found: 515.37 (M + H)⁺. HRMS: Anal. Calcd. for C₂₈H₃₅N₈O₂ 515.2883 found: 515.2869 (M + H)⁺.

Examples 152j-1 to 152j-28

Examples 152j were isolated as TFA or AcOH salts prepared using the procedure to convert Example 148e to 148.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Ex- ample Compound Name Structure Data Ex- ample 152j-1 (1R)-2-((2S)-2-(5-(2- (4-(2-((2S)-1-((2R)- 2-(dimethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-N,N- dimethyl-2-oxo-1- phenylethanamine

t_(R) = 1.61 min; (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₄H₄₉N₁₀O₂ 749.40 found: 749.32 (M + H)⁺ HRMS: Anal. Calcd. for C₄₄H₄₉N₁₀O₂ 749.4040 found: 749.4042 (M + H)⁺ Ex- ample 152j-2 methyl ((1R)-2-((2S)- 2-(5-(2-(4-(2-((2S)-1- ((2R)-2- ((methoxycarbonyl)a mino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 1.99 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₄H₄₅N₁₀O₆ 809.35 found: 809.17 (M + H)⁺ HRMS: Anal. Calcd. for C₄₄H₄₅N₁₀O₆ 809.3524 found: 809.3505 (M + H)⁺ Ex- ample 152j-3 methyl ((1R)-2-oxo- 1-phenyl-2-((2S)-2- (5-(4-(5-(2-((2S)-1- (3-pyridinylacetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)ethyl)car bamate

t_(R) = 1.65 min (92.3%); Condition 1 LRMS: Anal. Calcd. for C₄₁H₄₁N₁₀O₂ 737.33 found: 737.49 (M + H)⁺ HRMS: Anal. Calcd. for C₄₁H₄₁N₁₀O₄ 737.3312 found: 737.3342 (M + H)⁺ Ex- ample 152j-4 methyl ((1R)-2-oxo- 1-phenyl-2-((2S)-2- (5-(2-(4-(2-((2S)-1- (3-pyridinylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)ethyl)car bamate

t_(R) = 1.64 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₁H₄₁N₁₀O₄ 737.33 found: 737.75 (M + H)⁺ HRMS: Anal. Calcd. for C₄₁H₄₁N₁₀O₄ 737.3312 found: 737.3284 (M + H)⁺ Ex- ample 152j-5 5-(2-((2S)-1-((2R)-2- phenyl-2-(1- piperidinyl)acetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2-(4- (2-((2S)-1-((2R)-2- phenyl-2-(1- piperidinyl)acetyl)-2- pyrrolidinyl)-1H- imidazol-4- yl)phenyl)pyrimidine

t_(R) = 1.70 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₅₀H₅₇N₁₀O₂ 829.47 found: 829.39 (M + H)⁺ HRMS: Anal. Calcd. for C₅₀H₅₇N₁₀O₂ 829.4666 found: 829.4658 (M + H)⁺ Ex- ample 152j-6 (2R)-N-methyl-2- phenyl-N-((1S)-1-(4- (4-(5-(2-((2S)-1- ((2R)-2-phenyl-2-(1- piperidinyl)acetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 1H-imidazol-2- yl)ethyl)-2-(1- piperidinyl)acetamide

t_(R) = 1.66 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₉H₅₇N₁₀O₂ 817.47 found: 817.44 (M + H)⁺ HRMS: Anal. Calcd. for C₄₉H₅₇N₁₀O₂ 817.4666 found: 817.4673 (M + H)⁺ Ex- ample 152j-7 (1R)-2-((2S)-2-(5-(5- (4-(2-((2S)-1-((2R)- 2-(dimethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-2- pyrazinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-N,N- dimethyl-2-oxo-1- phenylethanamine

t_(R) = 1.60 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₁H₄₉N₁₀O₂ 749.40 found: 749.31 (M + H)⁺ HRMS: Anal. Calcd. for C₄₄H₄₉N₁₀O₂ 749.4040 found: 749.4031 (M + H)⁺ Ex- ample 152j-8 methyl ((1R)-2-((2S)- 2-(5-(5-(4-(2-((2S)-1- ((2R)-2- ((methoxycarbonyl)a mino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-2- pyrazinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 2.01 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₄H₄₅N₁₀O₆ 809.35 found: 809.24 (M + H)⁺ HRMS: Anal. Calcd. for C₄₄H₄₅N₁₀O₆ 809.3523 found: 809.3493 (M + H)⁺ Ex- ample 152j-9 (1R)-2-((2S)-2-(5-(6- (4-(2-((2S)-1-((2R)- 2-(dimethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-3- pyridazinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-N,N- dimethyl-2-oxo-1- phenylethanamine

t_(R) = 1.76 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₄H₄₉N₁₀O₂ 749.40 found: not obsd (M + H)⁺ HRMS: Anal. Calcd. for C₄₄H₄₉N₁₀O₂ 749.4040 found: 749.4056 (M + H)⁺ Ex- ample 152j-10 methyl ((1R)-2-((2S)- 2-(5-(6-(4-(2-((2S)-1- ((2R)-2- ((methoxycarbonyl)a mino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-3- pyridazinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 2.17 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₄H₄₅N₁₀O₆ 809.35 found: 809.59 (M + H)⁺ HRMS: Anal. Calcd. for C₄₄H₄₅N₁₀O₆ 809.3524 found: 809.3499 (M + H)⁺ Ex- ample 152j-11 (2R)-2- (dimethylamino)-N- ((1S)-1-(5-(4-(5-(2- ((2S)-1-((2R)-2- (dimethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyridinyl)phenyl)- 1H-imidazol-2- yl)ethyl)-2- phenylacetamide

t_(R) = 1.56 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₃H₄₈N₉O₂ 722.39 found: 722.89 (M + H)⁺ HRMS: Anal. Calcd. for C₄₃H₄₈N₉O₂ 722.3931 found: 722.3930 (M + H)⁺ Ex- ample 152j-12 methyl ((1R)-2-((2S)- 2-(5-(6-(4-(2-((1S)-1- (((2R)-2- ((methoxycarobnyl)a mino)-2- phenylace- tyl)amino)eth- yl)-1H-imidazol-5- yl)phenyl)-3- pyridinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 1.95 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₃H₄₄N₉O₆ 782.34 found: 782.93 (M + H)⁺ HRMS: Anal. Calcd. for C₄₃H₄₄N₉O₆ 782.3415 found: 782.3398 (M + H)⁺ Ex- ample 152j-13 (2R)-2- (dimethylamino)-N- ((1S)-1-(5-(4-(6-(2- ((2S)-1-((2R)-2- (dimethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-3- pyridazinyl)phenyl)- 1H-imidazol-2- yl)ethyl)-2- phenylacetamide

t_(R) = 1.55 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₇N₁₀O₂ 723.39 found: 723.88 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₇N₁₀O₂ 723.3883 found: 723.3903 (M + H)⁺ Ex- ample 152j-14 methyl ((1R)-2-((2S)- 2-(5-(6-(4-(2-((1S)-1- (((2R)-2- ((methoxycarobnyl)a mino)-2- phenylace- tyl)amino)eth- yl)-1H-imidazol-5- yl)phenyl)-3- pyridazinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 1.95 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.34 found: 783.95 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.3367 found: 783.3337 (M + H)⁺ Ex- ample 152j-15 methyl ((1R)-2-((2S)- 2-(5-(2-(4-(2-((1S)-1- (((2R)-2- ((methoxycarbonyl)a mino)-2- phenylace- tyl)amino)eth- yl)-1H-imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 1.97 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.34 found: 783.97 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.3367 found: 783.3357 (M + H)⁺ Ex- ample 152j-16 (2R)-2- (dimethylamino)-N- ((1S)-1-(5-(2-(4-(2- ((2S)-1-((2R)-2- (dimethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)ethyl)- 2-phenylacetamide

t_(R) = 1.61 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₇N₁₀O₂ 723.39 found: 723.52 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₇N₁₀O₂ 723.3883 found: 723.3893 (M + H)⁺ Ex- ample 152j-17 methyl ((1R)-2-((2S)- 2-(5-(4-(5-(2-((1S)-1- (((2R)-2- ((methoxycarbonyl)a mino)-2- phenylace- tyl)amino)eth- yl)-1H-imidazol-5- yl)-2- pyrimidinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 1.99 min (95.6%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.34 found: 783.44 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.3367 found: 783.3328 (M + H)⁺ Ex- ample 152j-18 (2R)-2- (dimethylamino)-N- ((1S)-1-(5-(5-(4-(2- ((2S)-1-((2R)-2- (dimethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-2- pyrazinyl)-1H- imidazol-2-yl)ethyl)- 2-phenylacetamide

t_(R) = 1.60 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₇N₁₀O₂ 723.39 found: 723.47 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₇N₁₀O₂ 723.3883 found: 723.3861 (M + H)⁺ Ex- ample 152j-19 methyl ((1R)-2-((2S)- 2-(5-(4-(5-(2-((1S)-1- (((2R)-2- ((methoxycarbonyl)a mino)-2- phenylace- tyl)amino)eth- yl)-1H-imidazol-5- yl)-2- pyrazinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 1.97 min (94.7%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.34 found: 783.69 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.3367 found: 783.3345 (M + H)⁺ Ex- ample 152j-20 (2R)-2- (dimethylamino)-N- ((1S)-1-(5-(4-(5-(2- ((2S)-1-((2R)-2- (dimethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 1H-imidaozl-2- yl)ethyl)-N-methyl-2- phenylacetamide

t_(R) = 1.54 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₃H₄₉N₁₀O₂ 737.40 found: 737.54 (M + H)⁺ HRMS: Anal. Calcd. for C₄₃H₄₉N₁₀O₂ 737.4040 found: 7374066 (M + H)⁺ Ex- ample 152j-21 methyl ((1R)-2-((2S)- 2-(5-(2-(4-(2-((1S)-1- (((2R)-2- ((methoxycarbonyl)a mino)-2- phenylacetyl)(methyl) amino)ethyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 2.00 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₃H₄₅N₁₀O₆ 797.35 found: 797.38 (M + H)⁺ HRMS: Anal. Calcd. for C₄₃H₄₅N₁₀O₆ 797.3524 found: 797.3528 (M + H)⁺ Ex- ample 152j-22 methyl ((1R)-2-((2S)- 2-(5-(4-(5-(2-((1S)-1- (((2R)-2- ((methoxycarbonyl)a mino)-2- phenylace- tyl)amino)eth- yl)-1H-imidazol-5- yl)-2- pyridinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 1.46 min (condition 2, 98%) LRMS: Anal. Calcd. for C₄₃H₄₃N₉O₆ 781.33; found: 782.34 (M + H)⁺. HRMS: Anal. Calcd. for C₄₃H₄₄N₉O₆ 782.3415 found: 782.3417 (M + H)⁺ Ex- ample 152j-23 methyl ((1R)-2- (((1S)-1-(5-(6-(4-(2- ((1S)-1-(((2R)-2- ((methoxycarbonyl)a mino)-2- phenylace- tyl)amino)eth- yl)-1H-imidazol-5- yl)phenyl)-3- pyridinyl)-1H- imidazol-2- yl)ethyl)amino)-2- oxo-1- phenylethyl)carbamate

t_(R) = 1.44 min condition 2, 90%) LRMS: Anal. Calcd. for C₄₁H₄₁N₉O₆ 755.32; found: 756.35 (M + H)⁺. HRMS: Anal. Calcd. for C₄₁H₄₂N₉O₆ 756.3258 found: 756.3239 (M + H)⁺. Ex- ample 152j-24 (2R)-2- (dimethylamino)-N- ((1S)-1-(5-(6-(4-(2- ((1S)-1-(((2R)-2- (dimethylamino)-2- phenylace- tyl)amino)eth- yl)-1H-imidazol-5- yl)phenyl)-3- pyridinyl)-1H- imidazol-2-yl)ethyl)- 2-phenylacetamide

t_(R) = 1.18 min (condition 2, 91%) LRMS: Anal. Calcd. for C₄₁H₄₅N₉O₂ 695.37; found: 696.37 (M + H)⁺. HRMS: Anal. Calcd. for C₄₁H₄₆N₉O₂ 696.3774 found: 696.3806 (M + H)⁺. Ex- ample 152j-25

t_(R) = 2.08 min (95.8%); Condition 1 LRMS: Anal. Calcd. for C₃₈H₄₄N₉O₅ 706.35; found: 706.53 (M + H)⁺. HRMS: Anal. Calcd. for C₃₈H₄₄N₉O₅ 706.3465; found: 706.3492 (M + H)⁺. Ex- ample 152j-26

t_(R) = 2.04 min (96.4%); Condition 1 LRMS: Anal. Calcd. for C₃₇H₄₂N₉O₅ 692.33; found: 692.49 (M + H)⁺. HRMS: Anal. Calcd. for C₃₇H₄₂N₉O₅ 692.3309; found: 692.3322 (M + H)⁺. Ex- ample 152j-27

t_(R) = 2.04 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₃₉H₄₄N₉O₅ 718.35; found: 718.49 (M + H)⁺. HRMS: Anal. Calcd. for C₃₉H₄₄N₉O₅ 718.3465; found: 718.3483 (M + H)⁺. Ex- ample 152j-28 methyl ((1R)-2-((2S)- 2-(5-(5-(4-(2-((1S)-1- (((2R)-2- ((methoxycarbonyl)a mino)-2- phenylace- tyl)amino)eth- yl)-1H-imidazol-5- yl)phenyl)-2- pyrazinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1- phenylethyl)carbamate

t_(R) = 2.00 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.34 found: 783.96 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₃N₁₀O₆ 783.3367 found: 783.3375 (M + H)⁺

Examples 152k-1 to 152k- Example 152k-1 from 152j-27 {(R)-2-Oxo-1-phenyl-2-[(S)-2-(5-{4-[5-((S)-2-pyrrolidin-2-yl-3H-imidazol-4-yl)-pyrimidin-2-yl]-phenyl}-1H-imidazol-2-yl)-pyrrolidin-1-yl]-ethyl}-carbamic acid methyl ester

Cold (0° C.) 4 NHCl in dioxanes (4 mL) was added via syringe to (S)-2-{5-[2-(4-{2-[(S)-1-((R)-2-methoxycarbonylamino-2-phenyl-acetyl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-phenyl)-pyrimidin-5-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carboxylic acid tert-butyl ester (104.6 mg, 0.146 mmol) in a 100 mL pear-shaped flask followed by MeOH (0.5 mL). The homogeneous mixture was stirred at room temperature for 15 min before a precipitate was observed. After stirring further for 1.75 h, the suspension was diluted with ether and hexanes. Suction-filtration of a small portion of the suspension yielded the title compound as a yellow solid which was used for characterization purposes. The balance of the suspension was concentrated down to dryness and placed under high vacuum for 16 h. There was isolated the rest of the title compound also as a yellow solid (137.7 mg, 123%) which was used without further purification.

¹H NMR (500 MHz, DMSO-d₆) δ 15.20 and 14.66 (2m, 1H), 10.29 (br s, 0.7H), 9.38-9.36 (m, 2H), 8.55-8.00 (series of m, 4H), 7.42-7.28 (2m, 3H), 5.53-4.00 (series of m, 7H), 3.99-3.13 (series of m, 4H), 3.57 and 3.52 (2s, 3H), 2.50-1.84 (series of m, 8H).

LCMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=1.79 min, >95% homogeneity index.

LRMS: Anal. Calcd. for C₃₄H₃₆N₉O₃ 618.29; found: 618.42 (M+H)⁺.

HRMS: Anal. Calcd. for C₃₄H₃₆N₉O₃ 618.2921; found: 618.2958 (M+H)⁺.

The same procedure was used to prepare Examples 152k-2 through 152k-3.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example Compound Name Structure Data Example 152k-2

t_(R) = 1.74 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₃₂H₃₄N₉O₃ 592.28; found: 592.41 (M + H)⁺. HRMS: Anal. Calcd. for C₃₂H₃₄N₉O₃ 592.2785; found: 592.2775 (M + H)⁺. Example 152k-3

t_(R) = 1.79 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₃₃H₃₆N₉O₃ 606.29; found: 606.43 (M + H)⁺. HRMS: Anal. Calcd. for C₃₃H₃₆N₉O₃ 606.2941; found: 606.2925 (M + H)⁺.

Examples 152l-1 to 152l-3

Examples 152l-1 through 152l-3 were isolated as TFA or AcOH salts prepared using the same procedure to convert Example 148e to 148.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Ex- am- ple Compound Name Structure Data Ex- am- ple 152l- 1 methyl ((1R)-2- (methyl((1S)-1-(4-(4-(5- (2-((2S)-1-((2R)-2- phenyl-2-(1- piperidinyl)acetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)-1H- imidazol-2- yl)ethyl)amino)-2-oxo- 1-phenylethyl)carbamate

t_(R) = 1.87 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₆H₅₁N₁₀O₄ 807.41 found: 807.57 (M + H)⁺ HRMS: Anal. Calcd. for C₄₆H₅₁N₁₀O₄ 807.4095 found: 807.4128 (M + H)⁺ Ex- am- ple 152l- 2 methyl ((1R)-2-oxo-1- phenyl-2-(((1S)-1-(4-(4- (5-(2-((2S)-1-((2R)-2- phenyl-2-(1- piperidinyl)acetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)-1H- imidazol-2- yl)ethyl)amino)ethyl) carbamate

t_(R) = 1.83 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₅H₄₉N₁₀O₄ 793.39 found: 793.52 (M + H)⁺ HRMS: Anal. Calcd. for C₄₅H₄₉N₁₀O₄ 793.3938 found: 793.3934 (M + H)⁺ Ex- am- ple 152l- 3 methyl ((1R)-2-oxo-1- phenyl-2-((2S)-2-(4-(4- (5-(2-((2S)-1-((2R)-2- phenyl-2-(1- piperidinyl)acetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)ethyl) carbamate

t_(R) = 1.87 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₇H₅₁N₁₀O₄ 819.41 found: 819.50 (M + H)⁺ HRMS: Anal. Calcd. for C₄₇H₅₁N₁₀O₄ 819.4095 found: 819.4127 (M + H)⁺

Examples 153a-1 Through 153a-4 Example 153a-1 Prepared From 152e-1 (S)-2-[5-{5′-[2-((S)-1-tert-Butoxycarbonyl-pyrrolidin-2-yl)-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazol-4-yl]-[2,2′]bipyrimidinyl-5-yl}-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester

To a stirred solution of (S)-tert-butyl 2-(5-(2-chloropyrimidin-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (1.0 g, 2.08 mmol) and dichlorobis(benzonitrile) palladium (40 mg, 0.104 mmol) in dry DMF (10 mL) at room temperature under argon was added neat tetrakis(dimethylamino)ethylene (1.0 mL, 4.16 mmol). The mixture was heated to 60° C. for 15 h before it was diluted with ethyl acetate and suction-filtered through diatomaceous earth (Celite®). The filtrate was washed with sat'd NaHCO₃ soln and brine prior to drying over Na₂SO₄ and solvent evaporation. Purification of the residue by Biotage™ flash chromatography on silica gel (step gradient elution with 15% B to 15% B for 150 mL, 15% B to 75% B for 1500 mL, 75% B to 100% B for 1000 mL, 100% B to 100% B for 1000 mL where B=ethyl acetate and A=hexane followed by a second gradient elution with 10% B to 100% B for 700 mL where B=methanol and A=ethyl acetate) furnished the title compound as a caramel-colored, viscous oil (487.8 mg, 26% yield).

¹H NMR (500 MHz, DMSO-d₆) δ 9.27 (s, 4H), 8.09-8.06 (m, 2H), 5.73-5.66 and 5.50-5.44 (2m, 2H), 5.06-4.93 (m, 2H), 3.60-3.39 (2m, 8H), 2.32-2.08 (3 m, 4H), 2.00-1.85 (m, 4H), 1.37 and 1.14 (2s, 18H), 0.95-0.84 (m, 4H), −0.01 (s, 18H).

LCMS Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=3.37 min, >95% homogeneity index.

LRMS: Anal. Calcd. for C₄₄H₆₉N₁₀O₆S_(i2) 889.49; found: 889.57 (M+H)⁺.

HRMS: Anal. Calcd. for C₄₄H₆₉N₁₀O₆S_(i2) 889.4940; found: 889.4920 (M+H)⁺.

The same procedure was used to prepare Examples 153a-2 through 153a-4.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Ex- ample Compound Name Structure Data Ex- ample 153a-2

t_(R) = 3.37 min (89.6%); Condition 1 LRMS: Anal. Calcd. for C₄₄H₆₉N₁₀O₆Si₂ 889.49; found: 889.56 (M + H)⁺. HRMS: Anal. Calcd. for C₄₄H₆₉N₁₀O₆Si₂ 889.494; found: 889.4951 (M + H)⁺. Ex- ample 153a-3

t_(R) = 3.37 min (95%); Condition 1 LRMS: Anal. Calcd. for C₄₄H₆₉N₁₀O₆S_(i2) 889.49; found: 889.51 (M + H)⁺. HRMS: Anal. Calcd. for C₄₄H₆₉N₁₀O₆S_(i2) 889.4940; found: 889.4915 (M + H)⁺. Ex- ample 153a-4

t_(R) = 2.3 min (condition 2) LRMS: Anal. Calcd. for C₄₂H₆₆N₈Si₂ 834; found: 835 (M + H)⁻.

Example 153b-1-153b-3

The hydrolysis reactions was performed as above for Example 152h.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Example Compound Name Structure Data Example 153b-1

t_(R) = 1.18 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₂₂H₂₅N₁₀ 429.23; found: 429.01 (M + H)⁺. HRMS: Anal. Calcd. for C₂₂H₂₅N₁₀ 429.2264; found: 429.2259 (M + H)⁺. Example 153b-2

t_(R) = 1.26 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₁H₄₁N₁₀O₂ 737.33 found: 737.49 (M + H)⁺ HRMS: Anal. Calcd. for C₄₁H₄₁N₁₀O₄ 737.3312 found: 737.3342 (M + H)⁺ Example 153b-3

t_(R) = 1.40 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₂₂H₂₅N₁₀ 429.23; found: 429.20 (M + H)⁺. HRMS: Anal. Calcd. for C₂₂H₂₅N₁₀: 429.2264; Found: 429.2254 (M + H)⁺ Example 153b-4

t_(R) = 0.85 min (condition 1) LCMS: Anal. Calcd. for C₂₀H₂₂N₈ 374; found: 375 (M + H)⁺.

Examples 153c-1 to 153c-7

Examples 153c-1 through 153c-7 were isolated as TFA or AcOH salts using the procedure used to convert Example 148e to 148.

LC conditions: Condition 1: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Condition 2: Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, 220 nm, 5 μL injection volume.

Ex- ample Compound Name Structure Data Ex- ample 153c-1 (1R,1′R)-2,2′-(3,3′- bipyridazine-6,6′- diylbis(1H-imidazole- 5,2-diyl(2S)-2,1- pyrrolidinediyl))bis(N, N-dimethyl-2-oxo-1- phenylethanamine)

t_(R) = 1.55 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₇N₁₂O₂ 751.39 found: 751.64 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₇N₁₂O₂ 751.3945 found: 751.3936 (M + H)⁺ Ex- ample 153c-2 dimethyl (3,3′- bipyridazine-6,6′- diylbis(1H-imidazole- 5,2-diyl(2S)-2,1- pyrrolidinediyl((1R)- 2-oxo-1-phenyl-2,1- ethanediyl))) biscarbamate

t_(R) = 1.95 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₃N₁₂O₆ 811.34 found: 811.22 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₃N₁₂O₆ 811.3429 found: 811.3406 (M + H)⁺ Ex- ample 153c-3 (1R,1′R)-2,2′-(2,2′- bipyrimidine-5,5′- diylbis(1H-imidazole- 5,2-diyl(2S)-2,1- pyrrolidinediyl))bis(N, N-dimethyl-2-oxo-1- phenylethanamine)

t_(R) = 1.51 min (>90%*); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₇N₁₂O₂ 751.39 found: 751.21 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₇N₁₂O₂ 751.3945 found: 751.3921 (M + H)⁺ Ex- ample 153c-4 dimethyl (2,2′- bipyrimidine-5,5′- diylbis(1H-imidazole- 5,2-diyl(2S)-2,1- pyrrolidinediyl((1R)- 2-oxo-1-phenyl-2,1- ethanediyl))) biscarbamate

t_(R) = 1.88 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₃N₁₂O₆ 811.34 found: 811.10 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₃N₁₂O₆ 811.3429 found: 811.3401 (M + H)⁺ Ex- ample 153c-5 (1R,1′R)-2,2′-(2,2′- bipyrazine-5,5′- diylbis(1H-imidazole- 5,2-diyl(2S)-2,1- pyrrolidinediyl))bis(N, N-dimethyl-2-oxo-1- phenylethanamine)

t_(R) = 1.61 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₇N₁₂O₂ 751.39 found: 751.30 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₇N₁₂O₂ 751.3945 found: 751.3943 (M + H)⁺ Ex- ample 153c-6 dimethyl (2,2′- bipyrazine-5,5′- diylbis(1H-imidazole- 5,2-diyl(2S)-2,1- pyrrolidinediyl((1R)- 2-oxo-1-phenyl-2,1- ethanediyl))) biscarbamate

t_(R) = 2.00 min (>95%); Condition 1 LRMS: Anal. Calcd. for C₄₂H₄₃N₁₂O₆ 811.34 found: 811.23 (M + H)⁺ HRMS: Anal. Calcd. for C₄₂H₄₃N₁₂O₆ 811.3429 found: 811.3407 (M + H)⁺ Ex- ample 153c-7 dimethyl (2,2′- bipyridine-5,5′- diylbis(1H-imidazole- 5,2-diyl(1S)-1,1- ethanediylimino((1R)- 2-oxo-1-phenyl-2,1- ethanediyl))) biscarbamate

t_(R) = 1.42 min (condition 2, 94%) LRMS: Anal. Calcd. for C₄₀H₄₀N₁₀O₆ 756.31; found: 757.34 (M + H)⁺. HRMS: Anal. Calcd. for C₄₀H₄₁N₁₀O₆ 757.3211 found: 747.3180 (M + H)⁺. Section F LC Conditions for Determining Retention Time Condition 7 Column: Phenomenex C18 10u 4.6×30 mm Start % B=0 Final % B=100 Gradient Time=3 min Flow Rate=4 mL/Min Wavelength=220 Solvent A=10% methanol-90% H₂O-0.1% TFA Solvent B=90% methanol-10% H₂O-0.1% TFA

Compound F70 was prepared following the procedure described in Anna Helms et al., J. Am. Chem. Soc. 1992 114(15) pp 6227-6238.

Compound F71 was prepared in analogous fashion to the procedure used to synthesize Example 1.

¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.69-0.95 (m, 12H) 1.92 (s, 12H) 1.97-2.27 (m, 8H) 2.40 (s, 2H) 3.55 (s, 6H) 3.73-3.97 (m, 4H) 4.12 (t, J=7.78 Hz, 2H) 5.14 (t, J=7.02 Hz, 2H) 7.34 (d, J=8.24 Hz, 2H) 7.49-7.70 (m, 4H) 8.04 (s, 2H) 14.59 (s, 2H) RT=2.523 minutes (condition 7, 96%); LRMS: Anal. Calcd. for C44H58N8O6 794.45; found: 795.48 (M+H)⁺.

Section cj Synthesis of Carbamate Replacements Example cj-2 and cj-3

Preparation of (S)-tert-Butyl 2-(5-(4′-(2-((S)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-2)

To a solution of (S)-tert-butyl 2-(5-(4′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-1) (1.00 g, 1.91 mmol), iPr₂NEt (1.60 mL, 9.19 mmol) and N-Z-valine (0.62 g, 2.47 mmol) in DMF (10 mL) was added HATU (0.92 g, 2.42 mmol). The solution was allowed to stir at rt for 1 h and then it was poured into ice water (ca. 250 mL) and allowed to stand for 20 min. The mixture was filtered and the solid washed with water and then dried in vacuo overnight to afford a colorless solid (1.78 g) which was used as such in the next step. LCMS: Anal. Calcd. for C₄₄H₅₁N₇O₅: 757; found: 758 (M+H)⁺.

A mixture of this material (1.70 g) and 10% Pd—C (0.37 g) in MeOH (100 mL) was hydrogenated (balloon pressure) for 12 h. The mixture was then filtered and the solvent removed in vacuo. The residue was purified by silica gel chromatography (Biotage system/0-10% MeOH—CH₂Cl₂) to afford the title compound as a light yellow foam (0.90 g, 76%).

¹HNMR (400 MHz, DMSO-d₆) δ 12.18 (s, 0.35H), 11.73 (s, 0.65H), 11.89 (s, 0.65H), 11.82 (s, 0.35H), 7.77-7.81 (m, 3H), 7.57-7.71 (m, 5H), 7.50-7.52 (m, 2H), 5.17 (dd, J=3.6, 6.5 Hz, 0.3H), 5.08 (dd, J=3.6, 6.5 Hz, 0.7H), 4.84 (m, 0.3H), 4.76 (m, 0.7H), 3.67-3.69 (m, 1H), 3.50-3.62 (m, 1H), 3.34-3.47 (m, 2H), 2.22-2.28 (m, 2H), 2.10-2.17 (m, 2H), 1.74-2.05 (m, 6H), 1.40 (s, 4H), 1.15 (s, 5H), 0.85-0.91 (m, 4H), 0.79 (d, J=6.5 Hz, 2H).

LCMS: Anal. Calcd. for C₃₆H₄₅N₇O₃: 623; found: 624 (M+H)⁺.

Preparation of (S)-tert-Butyl 2-(5-(4′-(2-((S)-1-((R)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-3)

(S)-tert-Butyl 2-(5-(4′-(2-((S)-1-((R)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-3) was prepared using the same method used to prepare cj-2 to give a colorless foam (1.15 g, 76%). ¹HNMR (400 MHz, DMSO-d₆) δ 12.17 (s, 0.35H), 12.04 (s, 0.65H), 11.89 (s, 0.65H), 11.81 (s, 0.35H), 7.78-7.83 (m, 3H), 7.60-7.71 (m, 5H), 7.43-7.52 (m, 2H), 5.22-5.25 (m, 0.4H), 5.05-5.07 (m, 0.6H), 4.83-4.86 (m, 0.5H), 4.72-4.78 (m, 0.5H), 3.78-3.84 (m, 1H), 3.49-3.64 (m, 2H), 3.35-3.43 (m, 2H), 2.19-2.32 (m, 1H), 2.04-2.17 (m, 3H), 1.95-2.04 (m, 2H), 1.76-1.90 (m, 3H), 1.40 (s, 4H), 1.15 (s, 5H), 0.85-0.91 (m, 4H), 0.67 (d, J=6.5 Hz, 1H), 0.35 (d, J=6.5 Hz, 1H). LCMS: Anal. Calcd. for C₃₆H₄₅N₇O₃: 623; found: 624 (M+H)⁺.

Example cj-4 and cj-5

Preparation of (S)-tert-Butyl 2-(5-(4′-(2-((S)-1-((S)-3-methyl-2-(pyrimidin-2-ylamino)butanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-4)

A mixture of (S)-tert-butyl 2-(5-(4′-(2-((S)-1-((s)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-2) (0.45 g, 0.72 mmol), 2-bromopyrimidine (0.37 g, 2.34 mmol) and iPr₂NEt (0.20 mL, 1.18 mmol) in toluene-DMSO (4:1, 5 mL) was heated at 90° C. overnight. The volatiles were removed in vacuo and the residue was purified by preparative HPLC (YMC Pack C-18, 30×100 mm/MeCN—H₂O-TFA). The title compound (0.56 g, 74%), as its TFA salt, was obtained as a yellow-orange glass.

¹HNMR (400 MHz, DMSO-d₆) δ 14.56 (br s, 2H), 8.28 (d, J=5.0 Hz, 1H), 8.12-8.20 (m, 2H), 7.94-7.97 (m, 3H), 7.83-7.91 (m, 5H), 7.06 (d, J=8.1 Hz, 1H), 6.62 (app t, J=5.0 Hz, 1H), 4.99-5.10 (m, 2H), 4.50 (app t, J=7.7 Hz, 1H), 4.07-4.12 (m, 2H), 3.83-3.87 (m, 1H), 3.56-3.62 (m, 1H), 3.40-3.47 (m, 2H), 2.36-2.41 (m, 1H), 1.94-2.22 (m, 6H), 1.40 (s, 4H), 1.17 (s, 5H), 0.88 (app t, J=6.5 Hz, 6H).

LCMS: Anal. Calcd. for C₄₀H₄₇N₉O₃: 701; found: 702 (M+H)⁺.

Preparation of (S)-tert-Butyl-2-(5-(4′-(2-((S)-1-((R)-3-methyl-2-(pyrimidin-2-ylamino)butanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-5)

The TFA salt of the title compound was prepared following the same method used to prepare cj-4 to give a light yellow solid (0.375 g, 59%).

¹HNMR (400 MHz, DMSO-d₆) δ 14.67 (br s, 2H), 8.30 (d, J=4.3 Hz, 1H), 8.04-8.19 (m, 2H), 7.84-7.96 (m, 8H), 6.88 (d, J=8.6 Hz, 1H), 6.61 (app t, J=4.5 Hz, 1H), 5.17 (dd, J=4.4, 8.0 Hz, 1H), 5.00-5.07 (m, 1H), 4.67 (dd, J=7.3, 8.1 Hz, 1H), 3.91-3.96 (m, 1H), 3.70-3.75 (m, 1H), 3.56-3.62 (m, 1H), 3.42-3.45 (m, 1H), 2.39-2.43 (m, 2H), 2.04-2.16 (m, 5H), 1.94-1.97 (m, 2H), 1.40 (s, 4H), 1.17 (s, 5H), 0.95 (d, J=6.6 Hz, 2.5H), 0.91 (d, J=6.6 Hz, 2.5H), 0.86 (d, J=6.6 Hz, 0.5H), 0.81 (d, J=6.6 Hz, 0.5H).

LCMS: Anal. Calcd. for C₄₀H₄₇N₉O₃: 701; found: 702 (M+H)⁺.

Example cj-6 and cj-7

Preparation of 1-Methyl-2-(methylthio)-4,5-dihydro-1H-imidazole hydroiodide

The title compound was prepared according to: Kister, J.; Assef, G.; Dou, H. J.-M.; Metzger, J. Tetrahedron 1976, 32, 1395. Thus, a solution of N-methylethylenediamine (10.8 g, 146 mmol) in EtOH-H₂O (1:1, 90 mL) was preheated to 60° C. and CS₂ (9.0 mL, 150 mmol) was added dropwise. The resulting mixture was heated at 60° C. for 3 h and then conc. HCl (4.7 mL) was slowly added. The temperature was raised to 90° C. and stirring was continued for 6 h. After the cooled mixture had been stored at −20° C., it was filtered and the resulting solid dried in vacuo to afford 1-methylimidazolidine-2-thione (8.43 g, 50%) as a beige solid.

¹HNMR (400 MHz, CDCl₃) δ 5.15 (s, br, 1H), 3.67-3.70 (m, 2H), 3.53-3.58 (m, 2H), 3.11 (s, 3H).

To a suspension of 1-methylimidazolidine-2-thione (5.17 g, 44.5 mmol) in acetone (50 mL) was added MeI (2.9 mL, 46.6 mmol). The solution was allowed to stir at room temperature for 4 h and the resulting solid was quickly filtered and then dried in vacuo to give 1-methyl-2-(methylthio)-4,5-dihydro-1H-imidazole hydroiodide (8.79 g, 77%) as beige solid.

¹HNMR (400 MHz, CDCl₃) δ 9.83 (s, br, 1H), 3.99-4.12 (m, 4H), 3.10 (s, 3H), 2.99 (s, 3H).

Preparation of (S)-tert-Butyl 2-(5-(4′-(2-((S)-1-((S)-3-methyl-2-(1-methyl-4-5-dihydroimidazol-2-ylamino)butanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-6)

A mixture of (s)-tert-butyl 2-(5-(4′-(2-((S)-1-((s)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)-pyrrolidine-1-carboxylate (cj-2) (0.280 g, 0.448 mmol) and 1-methyl-2-(methylthio)-4,5-dihydro-1H-imidazole hydroiodide (cj-3a) (0.121 g, 0.468 mmol) in CH₃CN (5 mL) was heated at 90° C. for 12 h. Another 0.030 g of 1-methyl-2-(methylthio)-4,5-dihydro-1H-imidazole hydroiodide (cj-3a) was added and heating continued for a further 12 h. The crude reaction mixture was directly purified by prep HPLC (Luna C-18/MeCN—H₂O-TFA) to give the TFA salt of the title compound (0.089 g) as a light yellow solid which was used as such in the subsequent steps.

LCMS: Anal. Calcd. for C₄₀H₅₁N₉O₃: 705; found: 706 (M+H)⁺.

Preparation of (S)-tert-Butyl 2-(5-(4′-(2-((S)-1-((R)-3-methyl-2-(1-methyl-4-5-dihydroimidazol-2-ylamino)butanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-7)

The title compound was prepared from cj-3 according to the method described for the synthesis of cj-6, except that the reaction mixture was initially purified by prep HPLC (YMC-Pack 25×250 mm/MeCN—H₂O—NH₄OAc) and then repurified by prep HPLC (Luna Phenyl-hexyl//MeCN—H₂O—NH₄OAc). This gave the desired product (0.005 g) as a foam which was used as such in the subsequent steps.

LCMS: Anal. Calcd. for C₄₀H₅₁N₉O₃: 705; found: 706 (M+H)⁺.

Example cj-8 and cj-9

Preparation of (S)-tert-Butyl 2-(5-(4′-(2-((S)-1-((S)-3-methyl-2-(3,4-dihydroimidazol-2-ylamino)butanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-8)

A mixture of (S)-tert-butyl 2-(5-(4′-(2-((S)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-2) (0.298 g, 0.480 mmol), 4,5-dihydro-1H-imidazole-2-sulfonic acid (AstaTech) (0.090 g, 0.60 mmol) and iPr₂NEt (0.083 mL, 0.48 mmol) in EtOH (4 mL) was heated at 100° C. for 12 h. The cooled mixture was evaporated to dryness and the residue was purified by prep HPLC (Luna 5u C18/MeCN—H₂O-TFA, ×2) to afford the TFA salt of the title compound (0.390 g, 73%) as a light yellow solid.

¹HNMR (400 MHz, DMSO-d₆) δ 14.66 (br s, 2H), 8.51 (br s, 1H), 8.20 (d, J=10.1 Hz, 2H), 8.10 (br s, 1H), 7.82-7.91 (m, 7H), 7.30 (br s, 1H), 5.12 (t, J=7.1 Hz, 1H), 4.97-5.05 (m, 2H), 4.37 (dd, J=4.3, 10.1 Hz, 2H), 3.82-3.86 (m, 2H), 3.73-3.77 (m, 2H), 3.59 (s, 4H), 3.39-3.48 (m, 2H), 2.15-2.25 (m, 2H), 1.93-2.07 (m, 5H), 1.40 (s, 4H), 1.17 (s, 5H), 0.93 (d, J=6.6 Hz, 3H), 0.69 (br s, 3H).

LCMS: Anal. Calcd. for C₃₉H₄₉N₉O₃: 691; found: 692 (M+H)⁺.

Preparation of (S)-tert-Butyl 2-(5-(4′-(2-((S)-1-((R)-3-methyl-2-(3,4-dihydroimidazol-2-ylamino)butanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-9)

The title compound was prepared from cj-3 according to the same method used to prepare cj-8 to afford the TFA salt (0.199 g, 57%) as a yellow glass.

¹HNMR (400 MHz, DMSO-d₆) δ 14.58 (br s, 4H), 8.23 (d, J=9.6 Hz, 1H), 8.11 (s, 1H), 7.87-7.89 (m, 6H), 7.25 (br s, 1H), 5.17-5.20 (m, 1H), 4.96-5.04 (m, 1H), 4.37 (dd, J=5.5, 9.6 Hz, 1H), 3.91-3.95 (m, 2H), 3.37-3.46 (m, partially obscured by H₂O, 4H), 2.39-2.42 (m, partially obscured by solvent, 2H), 2.01-2.09 (m, 4H), 1.94-1.98 (m, 2H), 1.40 (s, 3H), 1.17 (s, 6H), 0.95 (d, J=6.5 Hz, 2.5H), 0.85 (d, J=6.5 Hz, 2.5H), 0.66 (d, J=7.0 Hz, 0.5H), 0.54 (d, J=6.5 Hz, 0.5H).

LCMS: Anal. Calcd. for C₃₉H₄₉N₉O₃: 691; found: 692 (M+H)⁺.

Example cj-1

Preparation of (S)-3-Methyl-2-(pyrimidin-2-ylamino)-1-((S)-2-(5-(4′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)butan-1-one (cj-10a).

Step 1: A solution of the TFA salt of (S)-tert-butyl 2-(5-(4′-(2-((S)-1-((S)-3-methyl-2-(pyrimidin-2-ylamino)butanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (cj-4) (0.208 g, 0.199 mmol) in a mixture CH₂Cl₂ (4 mL) and TFA (3 mL) was stirred at room temperature for 1.5 h. The solvents were then removed in vacuo and the residue was purified by prep HPLC (Luna 5u C18/MeCN—H₂O-TFA) to give the TFA salt of the title compound (0.391 g) as an orange gum.

¹HNMR (400 MHz, DMSO-d₆) δ 14.53 (br s, 3H), 9.52-9.57 (m, 2H), 8.98-9.04 (m, 2H), 8.28 (d, J=4.6 Hz, 2H), 8.13 (br s, 1H), 7.79-7.91 (m, 7H), 7.07 (d, J=8.1 Hz, 1H), 6.62 (app t, J=4.8 Hz, 1H), 5.07 (t, J=7.1 Hz, 1H), 4.72-4.78 (m, 2H), 4.48-4.51 (m, 1H), 4.08-4.12 (m, 2H), 3.28-3.36 (m, 2H), 2.37-2.42 (m, 2H), 1.97-2.22 (m, 6H), 0.88 (app t, J=4.5 Hz, 6H).

LCMS: Anal. Calcd. for C₃₅H₃₉N₉O: 601; found: 602 (M+H)⁺.

Similarly, the following example was prepared according to the representative method above;

Example Structure LCMS cj-10a (from cj-3)

LCMS: Anal. Calcd. for C₃₅H₃₉N₉O: 601; found: 602 (M + H)⁺.

Preparation of methyl ((1S)-2-methyl-1-(((2S)-2-(5-(4′-(2-((2S)-1-(N-2-pyrimidinyl-L-valyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate (cj-11)

methyl((1S)-2-methyl-1-(((2S)-2-(5-(4′-(2-((2S)-1-(N-2-pyrimidinyl-L-valyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate

Step 2: To a solution of the TFA salt of (S)-3-methyl-2-(pyrimidin-2-ylamino)-1-((S)-2-(5-(4′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)butan-1-one (cj-10) (0.208 g, 0.197 mmol) in DMF (4 mL) was added iPr₂NEt (0.20 mL, 1.15 mmol), (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (0.049 g, 0.28 mmol) and HATU (0.105 g, 0.276 mmol). The solution was stirred for 1.5 h at room temperature, diluted with MeOH (2 mL) and purified directly by prep HPLC (Luna 5u C18/MeCN—H₂O—NH₄OAc). This material was repurified by flash chromatography (SiO₂/2-10% MeOH—CH₂Cl₂) to give a solid which was lyophilized from CH₃CN—H₂O to give the title compound (48.6 mg, 32%) as a colourless solid.

¹HNMR (400 MHz, DMSO-d₆) δ 11.78 (br s, 1H), 8.28 (d, J=4.5 Hz, 1H), 7.76-7.79 (m, 4H), 7.66-7.69 (m, 4H), 7.48-7.51 (m, 2H), 7.29 (d, J=8.6 Hz, 1H), 6.93 (d, J=8.1 Hz, 1H), 6.60 (app t, J=4.5 Hz, 1H), 5.03-5.09 (m, 2H), 4.48 (t. J=8.1 Hz, 1H), 3.99-4.08 (m, 2H), 3.78-3.85 (m, 2H) 3.53 (s, 3H), 2.12-2.21 (m, 4H), 1.87-2.05 (m, 7H), 0.83-0.97 (m, 12H).

LCMS: Anal. Calcd. for C₄₂H₅₀N₁₀O₄:758; found: 759 (M+H)⁺.

Example-cj-13

Preparation of Methyl (S)-1-((S)-2-(5-(4′-(2-((S)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate (cj-13)

To a solution of methyl (S)-3-methyl-1-oxo-1-((S)-2-(5-(4′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate (cj-12) (1.16 g, 1.99 mmol), Z-Val-OH (0.712 g, 2.83 mmol) and iPr₂NEt (0.70 mL, 5.42 mmol) in DMF (40 mL) was added HATU (1.10 g, 2.89 mmol) portionwise. The mixture was allowed to stir at room temperature for 1 h and was then poured into ice-water (400 mL) and allowed to stand for 20 min. The mixture was filtered and the solid washed with cold water and allowed to air dry overnight to give the Z-protected intermediate. LCMS: Anal. Calcd. for C₄₆H₅₄N₈O₆: 814; found: 815 (M+H)⁺.

The obtained solid was dissolved in MeOH (80 mL), 10% Pd—C (1.0 g) was added and the mixture was hydrogenated at room temperature and atmospheric pressure for 3 h. The mixture was then filtered and the filtrate concentrated in vacuo. The resulting residue was purified by flash chromatography (SiO₂/5-20% MeOH—CH₂Cl₂) to afford the title compound (1.05 g, 77%) as a colorless foam. ¹HNMR (400 MHz, DMSO-d₆) δ 11.75 (s, 1H), 7.75-7.79 (m, 3H), 7.61-7.67 (m, 5H), 7.49 (s, 1H), 7.26-7.28 (m, 1H), 5.05-5.09 (m, 2H), 4.03-4.09 (m, 2H), 3.77-3.80 (m, 1H), 3.66-3.70 (m, 1H), 3.52 (s, 3H), 3.40-3.47 (m, 2H), 2.21-2.26 (m, 1H), 2.10-2.17 (m, 3H), 1.81-2.02 (m, 6H), 0.77-0.92 (m, 12H).

LCMS: Anal. Calcd. for C₃₈H₄₈N₈O₄: 680; found: 681 (M+H)⁺.

Example cj-15

Preparation of Methyl (S)-1-((S)-2-(5-(4′-(2-((S)-1-((S)-2-((Z/E)-(cyanoimino)(phenoxy)methylamino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate (cj-14)

A mixture of methyl (S)-1-((S)-2-(5-(4′-(2-((S)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate (cj-13) (0.329 g, 0.527 mmol) and diphenyl cyanocarbonimidate (0.128 g, 0.537 mmol) in iPrOH (10 mL) was stirred at room temperature for 12 h. The resulting solid was filtered and air-dried to give the title compound (0.187 g, 43%) as a cream-colored solid. This material was used as such in the next step without further purification.

LCMS: Anal. Calcd. for C₄₆H₅₂N₁₀O₅: 824; found: 825 (M+H)⁺.

Preparation of methyl((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-(N-(5-amino-1-methyl-1H-1,2,4-triazol-3-yl)-L-valyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate (cj-15a, R═H)

A solution of methyl (S)-1-((S)-2-(5-(4′-(2-((S)-1-((S)-2-((Z/E)-(cyanoimino)(phenoxy)methylamino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate (cj-14) (0.074 g, 0.090 mmol) and hydrazine hydrate (0.05 mL, 0.88 mmol) in iPrOH (2 mL) was heated at 75° C. for 7 h. The solvent was then removed in vacuo and the residue was purified by prep HPLC (Luna 5u C18/MeCN—H₂O—NH₄OAc) to give foam which was lyophilized from CH₃CN—H₂O to give the title compound (0.032 g, 46%) as a colorless solid.

¹HNMR (400 MHz, DMSO-d₆) δ 12.17 (s, 1H), 11.75 (m, 2H), 10.66-10.84 (m, 2H), 7.76-7.79 (m, 3H), 7.62-7.74 (m, 4H), 7.49-7.51 (m, 1H), 7.24-7.29 (m, 2H), 5.28-5.32 (m, 1H), 5.05-5.08 (m, 2H), 4.04-4.09 (m, 3H), 3.87-3.94 (m, 2H), 3.72-3.81 (m, 2H), 3.53 (s, 3H), 2.09-2.17 (m, 2H), 1.90-2.02 (m, 6H), 0.81-0.99 (m, 12H).

LCMS: Anal. Calcd. for C₄₀H₅₀N₁₂O₄: 762; found: 763 (M+H)⁺.

Preparation of Methyl (S)-1-((S)-2-(5-(4′-(2-((S)-1-((S)-2-(5-amino-1-methyl-1H-1,2,4-triazol-3-ylamino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate (cj-15b, R=Me)

A solution of methyl (S)-1-((S)-2-(5-(4′-(2-((S)-1-((S)-2-((Z/E)-(cyanoimino)(phenoxy)methylamino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate (cj-14) (0.105 g, 0.128 mmol) and N-methylhydrazine (0.010 mL, 0.188 mmol) in iPrOH (2 mL) was heated at 75° C. for 3 h. A second portion of N-methylhydrazine (0.010 mL, 0.188 mmol) was added and heating was continued for 7 h. The volatiles were then removed in vacuo and the residue was purified by prep HPLC (Luna 5u C18/MeCN—H₂O—NH₄OAc) to give a foam which was further purified by flash chromatography (SiO₂/0-20% MeOH—CH₂Cl₂). The resulting material was lyophilized from CH₃CN—H₂O to give the title compound (0.029 g, 29%) as a colorless solid.

¹HNMR (400 MHz, DMSO-d₆) δ 13.79 (s, 0.4H), 12.19 (s, 1H), 11.76 (m, 1.6H), 7.77-7.85 (m, 4H), 7.62-7.71 (m, 4H), 7.49-7.51 (m, 1H), 7.24-7.29 (m, 1H), 6.31 (d, J=9.1 Hz, 0.5H), 6.09 (d, J=9.1 Hz, 1.5H), 5.87 (s, 1H), 5.34-5.36 (m, 1H), 5.04-5.08 (m, 2H), 4.89 (s, 1H), 4.75 (s, 2H), 3.53 (s, 3H), 2.10-2.17 (s, 3H), 1.94-2.02 (m, 6H), 0.81-0.98 (m, 12H).

LCMS: Anal. Calcd. for C₄₁H₅₂N₁₂O₄: 776; found: 777 (M+H)⁺.

HRMS: Anal. Calcd. for C₄₁H₅₂N₁₂O₄: 776.4234; found: 777.4305 (M+H)⁺.

Example cj-16 and cj-17

Preparation of methyl((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-(N-(5-amino-1,2,4-oxadiazol-3-yl)-L-valyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate (cj-16)

A solution of methyl (S)-1-((S)-2-(5-(4′-(2-((S)-1-((S)-2-((Z/E)-(cyanoimino)(phenoxy)methylamino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate (cj-14) (0.120 g, 0.205 mmol) and hydroxylamine hydrochloride (0.0213 g, 0.307 mmol) in iPrOH (5 mL) was heated at 75° C. for 3 h. A second portion of hydroxylamine hydrochloride (0.0213 g, 0.307 mmol) was added and heating continued for 7 h. The volatiles were then removed in vacuo and the residue was purified by prep HPLC (Luna 5u C18/MeCN—H₂O—NH₄OAc) to give a foam which was further purified by flash chromatography (SiO₂/5% MeOH—CH₂Cl₂). The resulting colorless wax was lyophilized from CH₃CN—H₂O to give the title compound (0.0344 g, 22%) as a colorless solid.

¹HNMR (400 MHz, DMSO-d₆) δ 12.18-12.22 (m, 1H), 11.80 (s, 1H), 11.75 (s, 1 h), 8.03-8.06 (m, 1H), 7.77 (app d, J=8.1 Hz, 2H), 7.62-7.73 (m, 4H), 7.50 (dd, J=2.0, 5.5 Hz, 1H), 7.24-7.29 (m, 2H), 5.69 (s, 1H), 5.06-5.11 (m, 2H), 4.14 (t, J=8.6 Hz, 1H), 4.06 (unresolved dd, J=8.0, 8.6 Hz, 1H), 3.78-3.90 (m, 3H), 3.53 (s, 3H), 3.01 (br s, 2H), 2.10-2.19 (m, 3H), 1.90-2.04 (m, 5H), 0.81-0.96 (m, 12H).

LCMS: Anal. Calcd. for C₄₀H₄₉N₁₁O₅: 763; found: 764 (M+H)⁺.

Preparation of methyl ((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-(N-(cyano(dimethyl)carbamimidoyl)-L-valyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate (cj-17)

A solution of methyl (S)-1-((S)-2-(5-(4′-(2-((S)-1-((S)-2-((Z/E)-(cyanoimino)(phenoxy)methylamino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate (cj-14) (0.115 g, 0.198 mmol) and dimethylamine hydrochloride (0.0257 g, 0.315 mmol) in iPrOH (5 mL) was heated at 90° C. for 12 h. A second portion of dimethylamine hydrochloride (0.0257 g, 0.315 mmol) was added and heating was continued for 48 h. The volatiles were then removed in vacuo and the residue was purified by prep HPLC (Luna 5u C18/MeCN—H₂O—NH₄OAc) and then repurified by flash chromatography (SiO₂/5% MeOH—CH₂Cl₂). The resulting colorless wax was lyophilized from CH₃CN—H₂O to give the title compound (0.0318 g, 21%) as a colorless solid.

¹HNMR (400 MHz, DMSO-d₆) δ 12.22 (m, 0.6H), 11.81 (s, 1H), 11.75 (s, 1H), 12.17-12.22 (m, 0.5H), 11.99-12.04 (m, 0.5H), 11.75-11.81 (m, 1H), 7.76-7.79 (m, 3H), 7.62-7.73 (m, 5H), 7.50 (t, J=2.0 Hz, 1H), 7.23-7.29 (m, 1H), 6.64 (d, J=8.1 Hz, 1H), 5.06-5.08 (m, 2H), 4.47 (t, J=8.1 Hz, 2H), 4.06 (unresolved dd, J=8.0, 8.6 Hz, 1H), 3.84-3.90 (m, 2H), 3.76-3.82 (m, 3H), 3.53 (s, 3H), 3.00 (s, 6H), 2.11-2.20 (m, 3H), 1.90-2.04 (m, 5H), 0.97 (d, J=6.5 Hz, 3H), 0.89-0.91 (m, 6H), 0.84 (d, J=6.5 Hz, 3H).

LCMS: Anal. Calcd. for C₄₂H₅₃N₁₁O₄: 775; found: 776 (M+H)⁺

Preparation of Methyl (S)-3-methyl-1-oxo-1-((S)-2-(5-(4′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate (cj-12)

Synthesized from Intermediate-28d and Cap-51 as in Example 28e, followed by Boc removal with TFA/CH₂Cl₂ and free base formation with MCX resin.

¹HNMR (400 MHz, MeOH-d₄) δ 7.79-7.82 (m, 3H), 7.65-7.75 (m, 5H), 7.48 (s, 1H), 7.32 (s, 1H), 5.19 (dd, J=5.5, 5.7 Hz, 1H), 4.75 (t, J=7.8 Hz, 1H), 4.25 (d, J=7.3 Hz, 1H), 3.88-4.04 (m, 2H), 3.67 (s, 3H), 3.35-3.51 (m, 3H), 2.43-2.51 (m, 1H), 2.02-2.38 (m, 7H), 0.97 (d, J=6.5 Hz, 3H), 0.92 (d, J=6.9 Hz, 3H).

LCMS: Anal. Calcd. for C₃₃H₃₉N₇O₃: 581; found: 582 (M+H)⁺.

Section OL LC Conditions:

Condition 1: Solvent A: 5% acetonitrile/95% water/10 mmol ammonium acetate; Solvent B: 95% acetonitrile/5% water/10 mmol ammonium acetate; Column: Phenomenex GEMINI 5u C18 4.6×5.0 mm; Wavelength: 220 nM; Flow rate: 4 ml/min; 0% B to 100% B over 3 min with a 1 min hold time.

Condition 2: Solvent A: 5% acetonitrile/95% water/10 mmol ammonium acetate; Solvent B: 95% acetonitrile/5% water/10 mmol ammonium acetate; Column: Phenomenex GEMINI 5u C18 4.6×5.0 mm; Wavelength: 220 nM; Flow rate: 4 ml/min; 0% B to 100% B over 2 min with a 1 min hold time

Condition 3: Solvent A: 5% acetonitrile/95% water/10 mmol ammonium acetate; Solvent B: 95% acetonitrile/5% water/10 mmol ammonium acetate; Column: Phenomenex GEMINI 5u C18 4.6×5.0 mm; Wavelength: 220 nM; Flow rate: 4 ml/min; 0% B to 100% B over 4 min with a 1 min hold time

Condition 4: Solvent A: 10% MeOH/90% water/0.1% TFA; Solvent B: 90% MeOH/10% water/0.1% TFA; Column: Phenomenex 10u C18 3.0×5.0 mm; Wavelength: 220 nM; Flow rate: 4 ml/min; 0% B to 100% B over 4 min with a 1 min hold time

Condition 5: Solvent A: 5% acetonitrile/95% water/10 mmol ammonium acetate; Solvent B: 95% acetonitrile/5% water/10 mmol ammonium acetate; Column: Phenomenex GEMINI 5u C18 4.6×5.0 mm; Wavelength: 220 nM; Flow rate: 4 ml/min; 0% B to 100% B over 9 min with a 1 min hold time

Condition 6: Solvent A: 10% MeOH/90% water/0.2% H₃PO₄; Solvent B: 90% MeOH/10% water/0.2% H₃PO₄; Column: Phenomenex 5u C-18 4.6×50 mm; Wavelength: 220 nM; Flow rate: 1.5 ml/min; 0% B to 100% B over 14 min with a 3 min hold time

Condition 7: Solvent A: 10% MeOH/90% water/0.1% TFA; Solvent B: 90% MeOH/10% water/0.1% TFA; Column: Phenomenex 10u C18 3.0×5.0 mm; Wavelength: 220 nM; Flow rate: 4 ml/min; 0% B to 100% B over 3 min with a 1 min hold time

Condition 8: Solvent A: 10% MeOH/90% water/0.1% TFA; Solvent B: 90% MeOH/10% water/0.1% TFA; Column: Phenomenex 10u C18 3.0×5.0 mm; Wavelength: 220 nM; Flow rate: 4 ml/min; 0% B to 100% B over 2 min with a 1 min hold time

Experimentals Caps:

Step a: Dimethylcarbamoyl chloride (0.92 mL, 10 mmol) was added slowly to a solution of (S)-benzyl 2-amino-3-methylbutanoate hydrochloride (2.44 g; 10 mmol) and Hunig's base (3.67 mL, 21 mmol) in THF (50 mL). The resulting white suspension was stirred at room temperature overnight (16 hours) and concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (MgSO₄), filtered, and concentrated under reduced pressure. The resulting yellow oil was purified by flash chromatography, eluting with ethyl acetate:hexanes (1:1). Collected fractions were concentrated under vacuum providing 2.35 g (85%) of Intermediate Cap OL-1 as a clear oil. ¹H NMR (300 MHz, DMSO-d₆) δ ppm 0.84 (d, J=6.95 Hz, 3H) 0.89 (d, J=6.59 Hz, 3H) 1.98-2.15 (m, 1H) 2.80 (s, 6H) 5.01-5.09 (m, J=12.44 Hz, 1H) 5.13 (d, J=12.44 Hz, 1H) 6.22 (d, J=8.05 Hz, 1H) 7.26-7.42 (m, 5H). LC (Cond. 1): RT=1.76 min; MS: Anal. Calcd. for [M+H]⁺ C₁₆H₂₂N₂O₃: 279.17; found 279.03.

Step b: To Intermediate Cap OL-1 (2.35 g; 8.45 mmol) in 50 ml MeOH was added Pd/C (10%; 200 mg) and the resulting black suspension was flushed with N₂ (3×) and placed under 1 atm of H₂. The mixture was stirred at room temperature overnight and filtered though a microfiber filter to remove the catalyst. The resulting clear solution was then concentrated under reduced pressure to obtain 1.43 g (89%) of Cap OL-2 as a white foam, which was used without further purification. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.87 (d, J=4.27 Hz, 3H) 0.88 (d, J=3.97 Hz, 3H) 1.93-2.11 (m, 1H) 2.80 (s, 6H) 3.90 (dd, J=8.39, 6.87 Hz, 1H) 5.93 (d, J=8.54 Hz, 1H) 12.36 (s, 1H).). LC (Cond. 1): RT=0.33 min; MS: Anal. Calcd. for [M+H]⁺ C₈H₁₇N₂O₃: 1898.12; found 189.04.

Cap OL-3 was prepared from (S)-benzyl 2-aminopropanoate hydrochloride according to the method described for Cap OL-2. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.27 (d, J=7.32 Hz, 3H) 2.80 (s, 6H) 4.06 (qt, 1H) 6.36 (d, J=7.32 Hz, 1H) 12.27 (s, 1H). LC (Cond. 1): RT=0.15 min; MS: Anal. Calcd. for [M+H]⁺ C₆H₁₃N₂O₃: 161.09; found 161.00.

Cap OL-4 was prepared from (S)-tert-butyl 2-amino-3-methylbutanoate hydrochloride and 2-fluoroethyl chloroformate according to the method described for Cap-47. ¹HNMR (500 MHz, DMSO-d₆) δ ppm 0.87 (t, J=6.71 Hz, 6H) 1.97-2.10 (m, 1H) 3.83 (dd, J=8.39, 5.95 Hz, 1H) 4.14-4.18 (m, 1H) 4.20-4.25 (m, 1H) 4.50-4.54 (m, 1H) 4.59-4.65 (m, 1H) 7.51 (d, J=8.54 Hz, 1H) 12.54 (s, 1H)

Cap OL-5 was prepared from (S)-diethyl alanine and methyl chloroformate according to the method described for Cap-51. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.72-0.89 (m, 6H) 1.15-1.38 (m, 4H) 1.54-1.66 (m, 1H) 3.46-3.63 (m, 3H) 4.09 (dd, J=8.85, 5.19 Hz, 1H) 7.24 (d, J=8.85 Hz, 1H) 12.55 (s, 1H). LC (Cond. 2): RT=0.66 min; MS: Anal. Calcd. for [M+H]⁺ C₉H₁₈NO₄:204.12; found 204.02.

Analytical Data Ex- (Cond 1: 3 min ample gradient, 4 min run; Num- Cond 2: 2 min ber Compound Name Heterocycles with New Caps gradient, 3 min run) D71 tert-butyl (2S)-2- (5-(2-(4-(2-((2S)-1- ((2R)-2- (diethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidine- carboxylate

t_(R) = 1.82 min, (97.7%), (Cond 1) LRMS: Anal. Calcd. for C₄₁H₅₀N₉O₃ 716.40; found: 716.44 (M + H)⁺. HRMS: Anal. Calcd. for C₄₁H₅₀N₉O₃ 716.4037; found: 716.4056 (M + H)⁺. D72 (1R)-N,N-diethyl- 2-oxo-1-phenyl-2- ((2S)-2-(5-(4-(5-(2- ((2S)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimi- dinyl)phenyl)- 1H-imidazol-2- yl)-1- pyrrolidinyl) ethanamine

t_(R) = 1.56 min, (~95.3%, has shoulder), (Cond 1) LRMS: Anal. Calcd. for C₃₆H₄₂N₉O 616.35; found: 616.37 (M + H)⁺. HRMS: Anal. Calcd. for C₃₆H₄₂N₉O 616.3512; found: 616.3540 (M + H)⁺. D73 methyl ((1S)-2- ((2S)-2-(5-(4-(5-(2- ((2S)-1-(N- (methoxycarbonyl)- L-alanyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimi- dinyl)phenyl)- 1H-imidazol-2- yl)-1-pyrrolidinyl)- 1-methyl-2- oxoethyl)carbamate

t_(R) = 1.52 min, (96.2%), (Cond 1) LRMS: Anal. Calcd. for C₃₄H₄₁N₁₀O₆ 685.32; found: 685.21 (M + H)⁺. HRMS: Anal. Calcd. for C₃₄H₄₁N₁₀O₆ 685.3211; found: 685.3196 (M + H)⁺. D74 methyl ((1S)-1- (((2S)-2-(5-(2-(4- (2-((2S)-1-((2S)-2- ((methoxycarbonyl) amino)-3- methylbutanoyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl) carbonyl)-2- methylpropyl) carbamate

t_(R) = 2.09 min, (95%), (Cond 1) LRMS: Anal. Calcd. for C₃₈H₄₉N₁₀O₆ 741.38; found: 741.26 (M + H)⁺. HRMS: Anal. Calcd. for C₃₈H₄₉N₁₀O₆ 741.3837; found: 741.3824 (M + H)⁺. D75 methyl ((1S)-1- cyclopropyl-2- ((2S)-2-(5-(2-(4-(2- ((2S)-1-((2S)-2- cyclopropyl-2- ((methoxycarbonyl) amino)acetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2- oxoethyl)carbamate

t_(R) = 1.98 min, (95%), (Cond 1) LRMS: Anal. Calcd. for C₃₈H₄₅N₁₀O₆ 737.35; found: 737.22 (M + H)⁺. HRMS: Anal. Calcd. for C₃₈H₄₅N₁₀O₆ 737.3524; found: 737.3555 (M + H)⁺. D76 methyl ((1S)-1- (((2S)-2-(5-(2-(4- (2-((2S)-1-((2R)-2- (diethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)carbon yl)-2- methylpropyl) carbamate

t_(R) = 1.69 min, (95%), (Cond 1) LRMS: Anal. Calcd. for C₄₃H₅₃N₁₀O₄ 773.43; found: 773.30 (M + H)⁺. HRMS: Anal. Calcd. for C₄₃H₅₃N₁₀O₄ 773.4251; found: 773.4280 (M + H)⁺. D77 methyl ((1S)-2- ((2S)-2-(5-(2-(4-(2- ((2S)-1-((2R)-2- (diethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-1- methyl-2- oxoethyl)carbamate

t_(R) = 1.81 min, (97.5%), (Cond 1) LRMS: Anal. Calcd. for C₄₁H₄₉N₁₀O₄ 745.39; found: 745.27 (M + H)⁺. HRMS: Anal. Calcd. for C₄₁H₄₉N₁₀O₄ 745.3938; found: 745.3939 (M + H)⁺. Section J Ex- am- Num- ber Compound Name Structure Analytical Data J.1a

t_(R) = 1.7 min, (Cond 2); LCMS: C₁₀H₉BrO₃ found: 257 (M + H)⁺. J.1b

t_(R) = 1.9 min, (Cond 2); LCMS: C₁₁H₁₁BrO₃ found: 271 (M + H)⁺. J.1c

t_(R) = 2.1 min, (Cond 2); LCMS: C₁₆H₁₃BrO₃ found: 332 (M + H)⁺. J1

t_(R) = 2.2 min, (Cond 2); LCMS: C₂₀H₂₄BrNO₇ found: 470 (M + H)⁺. J2

t_(R) = 2.2 min, (Cond 2); LCMS: C₂₁H₂₆BrNO₇ found: 484 (M + H)⁺. J3

t_(R) = 2.3 min, (Cond 2); LCMS: C₂₆H₂₈BrNO₇ found: 546 (M + H)⁺. J4

t_(R) = 1.84 min, (100%)(Cond 2); LRMS: Anal. Calcd. for C₂₀H₂₄BrN₃O₄; 450.10; found: 450.13 and 452.13 (M + H)⁺. J5

t_(R) = 1.93 min, (99%) (Cond 2); Reported in J5. J6

t_(R) = 2.1 min, (93%) (Cond 2); LRMS: Anal. Calcd. for C₂₆H₂₉BrN₃O₄ 526.13; found: 526.16 and 528.16 (M + H)⁺. J7

t_(R) = 1.7 min, (100%) (Cond 2); Reported in J7. J32

t_(R) = 1.96 min, (96%) (Cond 2); LRMS: Anal. Calcd. for C₁₁H₁₁BrF₃N₂O 323.00; found: 323.05 and 325.05 (M + H)⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 7.58(d, J = 8.4 Hz, 2 H), 7.21 (d, J = 8.4 Hz, 2 H), 3.06 (s, 6 H). J32.a

t_(R) = 2.19 min, (96%) (Cond 2); Reported in J32.a J32.b

t_(R) = 2.3 min, (73%) (Cond 2); LCMS: C₂₅H₃₄BF₃N₃O₄ found: 508 (M + H)⁺. J33.a tert-butyl (2S)-2- (5-(4′-(2-((1S)-1- ((tert- butoxycarbonyl)(meth- yl)amino)ethyl)- 1H-imidazol-5-yl)- 4-biphenylyl)-4- (trifluoromethyl)- 1H-imidazol-2-yl)- 1- pyrrolidine- carboxylate

t_(R) = 1.97 min, (97%) (Cond 2); LRMS: Anal. Calcd. for C₃₆H₄₄F₃N₆O₄ 681.34; found: 681.31 (M + H)⁺. HRMS: Anal. Calcd. for C₃₆H₄₄F₃N₆O₄ 681.3376; found: 681.3383 (M + H)⁺. J34.a tert-butyl (2S)-2- (5-(4-(5-(2-((2S)-1- (tert- butoxycarbonyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 4- (trifluoromethyl)- 1H-imidazol-2-yl)- 1- pyrrolidine- carboxylate

t_(R) = 1.97 min, (93%) (Cond 2); LRMS: Anal. Calcd. for C₃₅H₄₂F₃N₈O₄ 695.33; found: 695.28 (M + H)⁺. J35.a

LCMS: C₂₆H₂₈F₃N₆ found: 481 (M + H)⁺. J36.a

t_(R) = 1.45 min, (Cond 2); LCMS: C₂₅H₂₆F₃N₈ found: 495 (M + H)⁺. J42.a methyl ((1S)-2- ((2S)-2-(5-(4′-(2- ((1S)-1-((N- (methoxycarbonyl)- L- alanyl)(methyl)ami no)ethyl)-1H- imidazol-5-yl)-4- biphenylyl)-4- (trifluoromethyl)- 1H-imidazol-2-yl)- 1-pyrrolidinyl)-1- methyl-2- oxoethyl)carbamate

t_(R) = 1.69 min, (100%)(Cond 2); LRMS: Anal. Calcd. for C₃₆H₄₂F₃N₈O₆ 739.32; found: 739.31 (M + H)⁺. HRMS: Anal. Calcd. for C₃₆H₄₂F₃N₈O₆ 739.3179; found: 739.3195 (M + H)⁺. J46 methyl ((1R)-2- ((2S)-2-(5-(4-(5-(2- ((2S)-1-((2R)-2- ((methoxycarbonyl) amino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 4- (trifluoromethyl)- 1H-imidazol-2-yl)- 1-pyrrolidinyl)-2- oxo-1- phenylethyl) carbamate

t_(R) = 1.82 min, (98%) (Cond 2); LRMS: Anal. Calcd. for C₄₅H₄₄F₃N₁₀O₆ 877.34; found: 877.29 (M + H)⁺. HRMS: Anal. Calcd. for C₄₅H₄₄F₃N₁₀O₆ 877.3397; found: 877.3403 (M + H)⁺. J47 (1R)-2-((2S)-2-(5- (4-(5-(2-((2S)-1- ((2R)-2- (diethylamino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 4- (trifluoromethyl)- 1H-imidazol-2-yl)- 1-pyrrolidinyl)- N,N-diethyl-2-oxo- 1- phenylethanamine

t_(R) = 1.58 min, (97%) (Cond 2); LRMS: Anal. Calcd. for C₄₉H₅₆F₃N₁₀O₂ 873.44; found: 873.40 (M + H)⁺. HRMS: Anal. Calcd. for C₄₉H₅₆F₃N₁₀O₂ 873.4540; found: 873.4536 (M + H)⁺. J48 methyl ((1S)-1- (((2S)-2-(5-(2-(4- (2-((2S)-1-((2S)-2- ((methoxycarbonyl) amino)-3- methylbutanoyl)-2- pyrrolidinyl)-4- (trifluoromethyl)- 1H-imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)carbon yl)-2- methylpropyl) carbamate

t_(R) = 1.85 min, (99%) (Cond 2); LRMS: Anal. Calcd. for C₃₉H₄₈F₃N₁₀O₆ 809.37; found: 809.37 (M + H)⁺. HRMS: Anal. Calcd. for C₃₉H₄₈F₃N₁₀O₆ 809.3710; found: 809.3683 (M + H)⁺. J49 methyl ((1S)-1- cyclopropyl-2- ((2S)-2-(5-(4-(5-(2- ((2S)-1-((2S)-2- cyclopropyl-2- ((methoxycarbonyl) amino)acetyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 4- (trifluoromethyl)- 1H-imidazol-2-yl)- 1-pyrrolidinyl)-2- oxoethyl)carbamate

t_(R) = 1.75 min, (100%)(Cond 2); LRMS: Anal. Calcd. for C₃₉H₄₄F₃N₁₀O₆ 805.34; found: 805.34 (M + H)⁺. HRMS: Anal. Calcd. for C₃₉H₄₄F₃N₁₀O₆ 805.3397; found: 805.3384 (M + H)⁺. J50 methyl ((1S)-2- ((2S)-2-(5-(4-(5-(2- ((2S)-1-(N- (methoxycarbonyl)- L-alanyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 4- (trifluoromethyl)- 1H-imidazol-2-yl)- 1-pyrrolidinyl)-1- methyl-2- oxoethyl)carbamate

t_(R) = 1.61 min, (94%) (Cond 2); LRMS: Anal. Calcd. for C₃₅H₄₀F₃N₁₀O₆ 753.31; found: 753.31 (M + H)⁺. HRMS: Anal. Calcd. for C₃₅H₄₀F₃N₁₀O₆ 753.3084; found: 753.3099 (M + H)⁺. J51 (2R)-1-((2S)-2-(5- (4-(5-(2-((2S)-1- ((2R)-2- (diethylamino)prop anoyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 4- (trifluoromethyl)- 1H-imidazol-2-yl)- 1-pyrrolidinyl)- N,N-diethyl-1-oxo- 2-propanamine

t_(R) = 1.41 min, (92%) (Cond 2); LRMS: Anal. Calcd. for C₃₉H₅₂F₃N₁₀O₂ 749.42; found: 749.37 (M + H)⁺. HRMS: Anal. Calcd. for C₃₉H₅₂F₃N₁₀O₂ 749.4227; found: 749.4223 (M + H)⁺.

Cond 1: LCMS conditions: Phenomenex-Luna 4.6×50 mm S10, 0 to 100% B over 3 min, 4 min stop time, 4 mL/min, 220 nm, A: 10% MeOH-90% H2O-0.1% TFA; B: 90% MeOH-10% H2O-0.1% TFA

Cond 2: LCMS conditions: Phenomenex-Luna 4.6×50 mm S10, 0 to 100% B over 2 min, 3 min stop time, 4 mL/min, 220 nm, A: 10% MeOH-90% H2O-0.1% TFA; B: 90% MeOH-10% H2O-0.1% TFA

Example J2 (2S)-2-(1-(4-bromophenyl)-3-ethoxy-1,3-dioxopropan-2-yl) 1-tert-butyl pyrrolidine-1,2-dicarboxylate

The ethyl 3-(4-bromophenyl)-3-oxopropanoate (15 g, 55 mmol) was dissolved in CH₂Cl₂ (600 mL) and freshly recrystallized NBS (9.8 g, 55 mmol) was added and the solution stirred 18 hr. The reaction mixture was washed with NaHCO₃ solution, brine, and dried (MgSO₄), filtered, and concentrated to give a residue which was not purified. Ethyl 2-bromo-3-(4-bromophenyl)-3-oxopropanoate (16.5 g, 48 mmol) and N-Boc-L-proline (10 g, 48 mmol) were taken up in acetonitrile (450 mL) and Hunig's base (16 mL, 95 mmol) was added and the solution stirred 18 hr. The solvent was removed by rotary evaporation and the residue taken up in ethyl acetate, washed with 0.1 N HCl, and brine. ¹H NMR (300 MHz, DMSO-d₆) δ 7.95 (d, J=8.4 Hz, 2H), 7.79 (d, J=8.4 Hz, 2H), 6.68-6.65 (m, 1H), 4.39-4.30 (m, 1H), 4.21-4.12 (m, 2H), 2.27-2.21 (m, 1H), 2.0-1.95 (m, 1H), 1.90-1.76 (m, 2H), 1.39 (s, 2H), 1.31 (s, 9H), 1.11 (t, J=7.3 Hz, 3H).

LRMS: Anal. Calcd. for C₂₁H₂₆BrNO₇ 484.09; found: 410.08 (M+H)⁺.

Example J5 (S)-ethyl 5-(4-bromophenyl)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazole-4-carboxylate

A 1 L pressure bottle was charged with (2S)-2-(1-(4-bromophenyl)-3-ethoxy-1,3-dioxopropan-2-yl) 1-tert-butyl pyrrolidine-1,2-dicarboxylate J2 (7 g, 35 mmol) and 11 g of NH₄OAc in 125 mL of Xylene, and the reaction was heated at 140° C. for 3.5 hr. After being cooled, the solution was partition between ethyl acetate and water. The organic layer was concentrated and the resultant residue applied to a Biotage 40 m silica gel cartridge and eluted by 20-100% gradient, ethyl acetate/Hex to give 3 g (45%). ¹H NMR (300 MHz, CDCl₃) δ 12.75 (br. s, 7.82), (br. s, 2H), 7.50 (d, J=8.4 Hz, 2H), 4.96-4.92 (m, 1H), 4.23 (q, J=6.6 Hz, 2H), 3.68-3.50 (m, 1H), 3.40-3.32 (m, 1H), 2.19-2.15 (m, 1H), 1.99-1.89 (m, 3H), 1.48/1.13 (s, 9H), 1.23 (t, J=7.3 Hz, 3H). LRMS: Anal. Calcd. for C₂₁H₂₆BrN₃O₄ 464.12; found: 464.15 and 466.15 (M+H)⁺.

Example J7 (S)-tert-butyl 2-(5-(4-bromophenyl)-4-(methylcarbamoyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate

(S)-ethyl 5-(4-bromophenyl)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazole-4-carboxylate (1 g, 2.1 mmol) was dissolved in 2M methylamine in MeOH (35 mL) and heated in a pressure vessel at 70° C. for 48 h. The reaction mixture was concentrated and the residue applied to a Biotage 25 m silica gel cartridge and eluted by 10-100% gradient, ethyl acetate/Hex to give 556 mg (57%). ¹H NMR (300 MHz, DMSO-d₆) δ 12.5 (br.s, 1H), 7.86-7.82 (m, 1H), 7.77 (d, J=8.4 Hz, 2H), 7.61 (d, J=8.7 Hz, 2H), 4.83-4.70 (m, 1H), 3.69-3.52 (br.s, 1H), 3.42-3.32 (m, 1H), 2.71 (d, 4.8 Hz, 3H), 2.30-1.78 (m, 4H), 1.19-1.14 (m, 9H).

LRMS: Anal. Calcd. for C₂₀H₂₆BrN₄O₃ 449.12; found: 449.15 and 451.14 (M+H)⁺.

Example J32.a (S)-tert-butyl 2-(5-(4-bromophenyl)-4-(trifluoromethyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate

3-(4-bromophenyl)-3-(2,2-dimethylhydrazono)-1,1,1-trifluoropropan-2-one (2.0 g, 6.2 mmol) was suspended in 5N sulfuric acid (60 mL) and heated at 45° C. for 6 h. The temperature was raised to 85° C. for 2 h, and upon cooling a precipitate formed. This material which was isolated by filtration to give 1-(4-bromophenyl)-3,3,3-trifluoropropane-1,2-dione 1.6 g (92%) as a yellow solid. The dione (1.6 g, 5.7 mmol) was taken up in methanol (30 mL), N-(tert-butoxycarbonyl)-L-prolinal (1 g, 5.0 mmol) was added, followed by addition of 28% ammonium hydroxide solution (10 mL). The reaction was stirred at room temperature for 18 h, poured onto dichloromethane (200 mL), washed with water and dried with MgSO₄. Filtration, concentration and application to a 40 M Biotage cartridge, gradient elution with 5%-30% ethyl acetate/Hexanes, gave J32.a 1.3 g (50%). ¹H NMR (300 MHz, DMSO-d₆) δ 12.88 (br.s, 1H), 7.72 (d, J=8.4 Hz, 2H), 7.39 (d, J=8.0 Hz, 2H), 4.84-4.70 (m, 1H), 3.57-3.49 (m, 1H), 3.39-3.29 (m, 1H), 2.31-2.20 (m, 1H), 1.98-1.78 (m, 3H), 1.39/1.13 (m, 9H). LRMS: Anal. Calcd. for C₁₉H₂₀BrF₃N₃O₂ 458.07; found: 458.06 and 460.06 (M−H)⁻. HRMS: Anal. Calcd. for Cl₉H₂₂BrF₃N₃O₂ 460.0847; found: 460.0866 and 462.0840 (M+H)⁺.

Section D

Entry Compound Name Structure **Data D1

t_(R) = 2.65 min, (86.7%) LCMS: Anal. Calcd. for C₈H₁₅BrFO 296.88; found: 296.91 (M + H)⁺. D2

t_(R) = 2.66 min, (80%) LCMS: Anal. Calcd. for C₈H₄BrClFO 270.92; found: ND (M + H)⁺. D3

t_(R) = 2.57 min, (95%) LCMS: Anal. Calcd. for C₉H₉BrO₂ 228.99; found: 229.00 (M + H)⁺. D4

t_(R) = 2.38 min, (95.0%) LRMS: Anal. Calcd. for C₁₉H₂₀ ⁷⁹BrFN₃O₂ 444.07; found: 444.04 (M + H)⁺. HRMS: Anal. Calcd. for C₁₉H₂₀ ⁷⁹BrFN₃O₂ 444.0721; found: 444.0736 (M + H)⁺ D5

t_(R) = 2.27 min, (95%) LRMS: Anal. Calcd. for C₁₈H₂₂BrFN₃O₂ 410.09 and 412.08; found: 410.08 and 412.08 (M + H)⁺. HRMS: Anal. Calcd. for C₁₈H₂₂ ⁷⁹BrFN₃O₂ 410.0879; found: 410.0893 (M + H)⁺. D6

t_(R) = 2.26 min, (95%) LRMS: Anal. Calcd. for C₁₉H₂₅BrN₃O₃ 422.11 and 424.11; found: 422.10 and 424.10 (M + H)⁺. HRMS: Anal. Calcd. for C₁₉H₂₅ ⁷⁹BrN₃O₃ 422.1079; found: 422.1089 (M + H)⁺. D7

t_(R) = 2.28 min, (95%) LRMS: Anal. Calcd. for C₁₈H₂₁ClF₂N₃O₂ 384.13; found: 384.13 (M + H)⁺. HRMS: Anal. Calcd. for C₁₈H₂₁ClF₂N₃O₂ 384.1290; found: 384.1301 (M + H)⁺. D8

t_(R) = 2.62 min, (~50%) and 1.95 min (~50%, boronic acid) LRMS: Anal. Calcd. for C₂₄H₃₄BFN₃O₄ 458.26; found: 458.23 (M + H)⁺. HRMS: Anal. Calcd. for C₂₄H₃₄BFN₃O₄ 458.2626; found: 458.2610 (M + H)⁺. D13 tert-butyl (2S)-2-(5- (2-(4-(2-((2S)-1-(tert- butoxycarbonyl)-2- pyrrolidinyl)-1H- imidazol-4-yl)-3- fluorophenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinecarboxylate

t_(R) = 2.27 min, (95%) LRMS: Anal. Calcd. for C₃₄H₄₂FN₈O₄ 645.33; found: 645.34 (M + H)⁺. HRMS: Anal. Calcd. for C₃₄H₄₂FN₈O₄ 645.3313; found: 645.3323 (M + H)⁺. D32 2-(3-fluoro-4-(2- ((2S)-2-pyrrolidinyl)- 1H-imidazol-5- yl)phenyl)-5-(2-((2S)- 2-pyrrolidinyl)-1H- imidazol-5- yl)pyrimidine

t_(R) = 1.63 min, (95%) LRMS: Anal. Calcd. for C₂₄H₂₆FN₈ 445.23; found: 445.23 (M + H)⁺. HRMS: Anal. Calcd. for C₂₄H₂₆FN₈ 445.2264; found: 445.2268 (M + H)⁺. D67 methyl ((1S)-2-((2S)- 2-(5-(2-fluoro-4-(5- (2-((2S)-1-(N- (methoxycarbonyl)- L-alanyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)-1- methyl-2- oxoethyl)carbamate

t_(R) = 1.58 min, (91.1%) LRMS: Anal. Calcd. for C₃₄H₄₀FN₁₀O₆ 703.31; found: 703.27 (M + H)⁺. HRMS: Anal. Calcd. for C₃₄H₄₀FN₁₀O₆ 703.3116; found: 703.3101 (M + H)⁺. D68 methyl ((1S)-1- (((2S)-2-(5-(2-fluoro- 4-(5-(2-((2S)-1-((2S)- 2-((methoxycarbonyl) amino)-3- methylbutanoyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)carbonyl)- 2-methylpropyl) carbamate

t_(R) = 1.95 min, (99.3%) LRMS: Anal. Calcd. for C₃₈H₄₈FN₁₀O₆ 759.37; found: 759.30 (M + H)⁺. HRMS: Anal. Calcd. for C₃₈H₄₈FN₁₀O₆ 759.3742; found: 759.3715 (M + H)⁺. D69 methyl ((1R)-2-((2S)- 2-(5-(2-(3-fluoro-4- (2-((2S)-1-((2R)-2- ((methoxycarbonyl) amino)-2- phenylacetyl)-2- pyrrolidinyl)-1H- imidazol-5- yl)phenyl)-5- pyrimidinyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-2-oxo- 1-phenylethyl) carbamate

t_(R) = 2.05 min, (99.3%) LRMS: Anal. Calcd. for C₄₄H₄₄FN₁₀O₆ 827.34; found: 827.27 (M + H)⁺. HRMS: Anal. Calcd. for C₄₄H₄₄FN₁₀O₆ 827.3429; found: 827.3407 (M + H)⁺. D70 methyl ((1S,2R)-1- (((2S)-2-(5-(2-fluoro- 4-(5-(2-((2S)-1-(N- (methoxycarbonyl)- O-methyl-L- threonyl)-2- pyrrolidinyl)-1H- imidazol-5-yl)-2- pyrimidinyl)phenyl)- 1H-imidazol-2-yl)-1- pyrrolidinyl)carbonyl)- 2-methoxypropyl) carbamate

t_(R) = 1.79 min, (93.0%) LRMS: Anal. Calcd. for C₃₈H₄₈FN₁₀O₈ 791.36; found: 791.31 (M + H)⁺. HRMS: Anal. Calcd. for C₃₈H₄₈FN₁₀O₈ 791.3641; found: 791.3636 (M + H)⁺. **LCMS conditions: Phenomenex-Luna 4.6 × 50 mm S10, 0 to 100% B over 3 min, 4 min stop time, 4 mL/min, 220 nm, A: 10% MeOH-90% H2O-0.1% TFA; B: 90% MeOH-10% H2O-0.1% TFA

Example D5 (S)-tert-butyl 2-(5-(4-bromo-2-fluorophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate

Bromine (0.54 mL, 10.6 mmol) was added dropwise to a cold (0° C.) solution of 4-bromo-2-fluoroacetophenone (2.30 g, 10.6 mmol) in dioxane (80 mL) and tetrahydrofuran (80 mL). The mixture was stirred for 1 h at 0° C. and warmed to RT for 15 h. The mixture was diluted with ethyl acetate, washed with saturated NaHCO₃ solution, 5% sodium thiosulfate solution and brine prior to drying (Na₂SO₄). 2-Bromo-1-(4-bromo-2-fluorophenyl)ethanone (D1) was isolated as a colorless film which solidified upon further concentration under high vacuum. This solid was dissolved into anhydrous acetonitrile (50 mL) and treated with N-Boc-L-proline (2.28 g, 10.6 mmol) and diisopropylethylamine (1.85 mL, 10.6 mmol). After being stirred for 3 h at RT, the solvent was removed in vacuo and the residue was partitioned into ethyl acetate and water. The organic phase was washed with 0.1N hydrochloric acid, saturated NaHCO₃ solution and brine prior to drying (Na₂SO₄), filtration, and concentration. This residue was taken up in xylenes (50 mL) and treated to solid NH₄OAc (4.1 g, 53.0 mmol). The mixture was heated at 140° C. for 2 hr in a thick-walled, screw-top flask before it was cooled to ambient temperature, diluted with ethyl acetate and washed with saturated NaHCO₃ solution and brine prior to drying (Na₂SO₄) and concentration. Purification of the residue by Biotage™ flash chromatography on silica gel (65M column, preequilibration with 16% B for 1800 mL followed by gradient elution with 16% B to 16% B for 450 mL, 16% B to 50% B for 2199 ml and finally 50% B to 100% B for 2199 mL) afforded title compound (D5) (3.61 g, 83%) as a brownish/caramel-colored oil. A small portion (40 mg) of the title compound was further purified by preparative HPLC (20% B to 100% B over 14 min where B is 10 mM NH₄OAc in 10:90 H₂O/ACN and A is 10 mM NH₄OAc in 95:5 H₂O/CAN using a Phenomenex-Gemini 30×100 mm S10 column flowing at 40 mL/min) to afford pure title compound (31.8 mg) as a white solid.

¹H NMR (500 MHz, DMSO-d₆) δ 12.13-11.95 (m, 1H), 7.94 (br s, 1H), 7.54 (d, J=10.7 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 7.36-7.34 (m, 1H), 4.86-4.77 (2m, 1H), 3.54 (m, 1H), 3.38-3.32 (m, 1H), 2.28-2.14 (2m, 1H), 2.05-1.78 (2m, 3H), 1.39 and 1.14 (2s, 9H).

HPLC Phenomenex LUNA C-18 4.6×50 mm, 0 to 100% B over 3 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=2.27 min, 95% homogeneity index.

LRMS: Anal. Calcd. for C₁₈H₂₂BrFN₃O₂ 410.09 and 412.09; found: 410.08 and 412.08 (M+H)⁺.

HRMS: Anal. Calcd. for C₁₈H₂₂BrFN₃O₂ 410.0879; found: 410.0893 (M+H)⁺.

Section M: LC Conditions were as follows:

Condition 1 Column = Phenomenex-Luna 3.0 × 50 mm S10 Start % B = 0 Final % B = 100 Gradient time = 2 min Stop time = 3 min Flow Rate = 4 mL/min Wavelength = 220 nm Slovent A = 0.1% TFA in 10% methanol/90% H₂O Solvent B = 0.1% TFA in 90% methanol/10% H₂O Condition 2 Column = Phenomenex-Luna 4.6 × 50 mm S10 Start % B = 0 Final % B = 100 Gradient time = 2 min Stop time = 3 min Flow Rate = 5 mL/min Wavelength = 220 nm Slovent A = 0.1% TFA in 10% methanol/90% H₂O Solvent B = 0.1% TFA in 90% methanol/10% H₂O Condition 3 Column = HPLC XTERRA C18 3.0 × 50 mm S7 Start % B = 0 Final % B = 100 Gradient time = 3 min Stop time = 4 min Flow Rate = 4 mL/min Wavelength = 220 nm Slovent A = 0.1% TFA in 10% methanol/90% H₂O Solvent B = 0.1% TFA in 90% methanol/10% H₂O Condition M1 Column: Luna 4.6 × 50 mm S10 Start % B = 0 Final % B = 100 Gradient time = 3 min Stop time = 4 min Flow rate = 4 mL/min Solvent A: = 95% H₂0: 5% CH₃CN, 10 mm Ammonium acetate Solvent B: = 5% H₂O: 95% CH₃CN; 10 mm Ammonium acetate

Example M114 4,4′-bis(2-((2S)-1-(N-(methoxycarbonyl)-L-valyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-2-biphenylcarboxylic acid

Example M114 Step a

DMF (20 mL) was added to mixture of KHCO₃ (1.84 g, 18.4 mmol) and 2-bromo-5-iodobenzoic acid (4.99 g, 15.3 mmol) and the resulting mixture was stirred for 15 min. Benzyl bromide (2.4 mL, 20.2 mmol) was added drop-wise over 5 min and stirring was continued at ambient condition for ˜20 hr. Most of the volatile component was removed in vacuo and the residue was partitioned between CH₂Cl₂ (50 mL) and water (50 mL), and the organic layer was washed with water (50 mL), dried (MgSO₄), filtered, and concentrated. The resulting crude material was purified with flash chromatography (7% EtOAc/hexanes) to afford ester M114a as a colorless viscous oil (6.01 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 8.07 (d, J=2.0, 1H), 7.81 (dd, J=8.4, 2.1, 1H), 7.53 (d, J=8.4, 1H), 7.48 (m, 2H), 7.43-7.34 (m, 3H), 5.34 (s, 2H). LC (Cond. 1): RT=2.1 min; LC/MS: Anal. Calcd. for [M+Na]⁺ C₁₄H₁₀BrINaO₂: 438.88; found 438.83.

Example M114 Step b-d

Ester M114a was elaborated to ester M114d by employing a three step protocol employed in the synthesis of bromide 121c from 1-bromo-4-iodo-2-methylbenzene. M114d: ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.04/11.97 (br s, 1H), 8.12 (d, J=2.0, 0.92H), 7.99 (app br s, 0.08H), 7.81 (dd, J=8.3, 2.0, 0.92H), 7.74-7.62 (m, 2.08H), 7.50 (app br d, J=7.0, 2H), 7.44-7.35 (m, 3H), 5.38 (s, 2H), 4.79 (m, 1H), 3.52 (app br s, 1H), 3.36 (m, 1H), 2.24-1.79 (m, 4H), 1.39/5.11 (two s, 9H). LC (Cond. 1): RT=1.66 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₆H₂₉BrN₃O₄: 526.13; found 526.16.

Example M114 Step e

Ester M114e was prepared from bromide M114d and boronate 1c according to the preparation of dimer 1d. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.18/12.00/11.91/11.83 (four br s, 2H), 8.11-7.03 (m, 14H), 5.10 (s, 2H), 4.85-4.78 (m, 2H), 3.55 (app br s, 2H), 3.37 (m, 2H), 2.29-1.80 (m, 8H), 1.41/1.16 (two s, 18H). LC (Cond. 1): RT=1.54 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₄₄H₅₁N₆O₆: 759.39; found 759.63.

Example M114 Step f

A mixture of benzyl ester M114e (1.005 g, 1.325 mmol) and 10% Pd/C (236 mg) in MeOH (20 mL) was stirred under a balloon of H₂ for 5 hr. The reaction mixture was then treated with a 1:1 mixture of MeOH and CH₂Cl₂, filtered through a pad of diatomaceous earth (Celite®-521), and the filtrate was rotervaped to afford acid M114f (840 mg), contaminated with Ph₃PO which was a carryover from the Suzuki coupling step. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.17/11.98/11.89/11.81 (four app br s, 2H), 8.04-7.31 (m, 9H), 4.85-4.78 (m, 2H), 3.55 (app br s, 2H), ˜3.37 (m, 2H, overlapped with water signal) 2.27-1.84 (m, 8H), 1.41/1.16 (two s, 18H). LC (Cond. 1): RT=1.37 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₇H₄₅N₆O₆: 669.34; found 669.53.

Example M114 Step g

4N HCl/dioxane (8.0 mL) and CH₂Cl₂ (2.0 mL) were sequentially added to carbamate M114f (417 mg, 0.623 mmol), the mixture was vigorously stirred 5.5 hr, and then the volatile component was removed in vacuo to afford the HCl (0.4×) salt of pyrrolidine M114g (487 mg), contaminated with Ph₃PO impurity. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz) after D₂O exchange: δ 8.23 (d, J=1.7, 1H), 8.09-8.04 (m, 3H), 7.92 (d, J=8.3, 2H), 7.53 (d, J=8.1, 1H), 7.48 (d, J=8.3, 2H), 5.00 (app br t, J=8.3, 1H), 4.90 (app br t, J=8.4, 1H), 3.6-3.3 (m, 4H), 2.5-1.99 (m, 8H). LC (Cond. 1): RT=0.92 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₇H₂₉N₆O₂: 469.24; found 469.31.

Example M114

HATU (79.9 mg, 0.21 mmol) was added to a DMF (3.0 mL) solution of pyrrolidine M114g.4HCl (80 mg, 0.13 mmol), Cap-51 (92.4 mg, 0.527 mmol) and i-Pr₂EtN (160 μL, 0.919 mmol), and the reaction mixture was stirred at ambient condition for 2 hr. The volatile component was removed in vacuo and the residue was purified with a combination of MCX (MeOH wash; 2.0 M NH₃/MeOH elution) and a reverse phase HPLC (CH₃CN/H₂O/NH₄OAc) to afford the acetic acid salt of Example M 14. LC (Cond. 1): RT=1.20 min; >98 homogeneity index. LC/MS: Anal. Calcd. for [M+H]⁺ C₄₁H₅₁N₈O₈: 783.38; found 783.34. HRMS Calcd. for [M+H]⁺ C₄₁H₅₁N₈O₈: 783.3830; found 783.3793.

Example M118 methyl((1S)-1-(((2S)-2-(5-(2′-carbamoyl-4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate

Example M118 Step a

Et₃N (300 μL, 2.15 mmol) was added to a mixture of acid M114f (198.3 mg, 0.297 mmol), HOBt (94.2 mg, 0.697 mmol), EDCI (0.66 mmol), NH₄Cl (101 mg, 1.89 mmol) in DMF (8.0 mL) and stirred for 17 hr at ambient condition. The reaction mixture was filtered through 0.45 μm filter, the volatile component was removed in vacuo and the residue was partitioned between CH₂Cl₂ and water. The organic layer was concentrated and the resulting crude material was purified with a reverse phase HPLC (MeOH/H₂O/TFA).

The above product was treated with 25% TFA/CH₂Cl₂ (4.0 mL) and the reaction mixture was stirred for 2.5 hr at ambient condition. The volatile component was removed in vacuo and the residue was free-based (MCX; MeOH wash; 2.0 M NH₃/MeOH elution) to afford amide M118a (67.2 mg). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 11.83 (br s, 2H), 7.81-7.80 (m, 2H), 7.73 (d, J=8.3, 2H), 7.65 (br s, 1H), 7.52 (br S, 1H), 7.44 (br s, 1H), 7.41 (d, J=8.3, 2H), 7.36 (d, J=8.3, 1H), 7.31 (br s, 1H), 4.16 (app t, J=7.2, 2H), 3.00-2.94 (m, 2H), 2.88-2.82 (m, 2H), 2.10-2.01 (m, 2H), 1.94-1.85 (m, 2H), 1.83-1.66 (m, 4H). LC (Cond. 1): RT=0.89 min; >95 homogeneity index. LC/MS: Anal. Calcd. for [M+H]⁺ C₂₇H₃₀N₇O: 468.25; found 468.24.

Example M118

The TFA salt of Example M118 was prepared from intermediate M118a and Cap-51 according to the procedure described for Example 1. LC (Cond. 1): RT=1.16 min; 97% homogeneity index. LC/MS: Anal. Calcd. for [M+H]⁺ C₄₁H₅₂N₉O₇: 782.40; found 782.40. HRMS: Anal. Calcd. for [M+H]⁺ C₄₁H₅₂N₉O₇: 782.3990; found 782.3979.

Example M119 methyl((1S)-1-(((2S)-2-(5-(2-(hydroxymethyl)-4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate

Example M119 Step a

DIBAL-H (8.0 mL of 1.0 M/CH₂Cl₂, 8.0 mmol) was added drop-wise to an ice-water cooled CH₂Cl₂ (20 mL) solution of benzyl ester M114e (1.216 g, 1.60 mmol), and the reaction mixture was stirred for 1 hr and an additional DIBAL-H (0.5 mL of 1.0 M/CH₂Cl₂, 0.5 mmol) was added and stirring was continued for ˜2.5 hr. The reaction was quenched with excess saturated NH₄Cl solution and the mixture was diluted with water and extracted with CH₂Cl₂ (3×). The combined organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The resulting crude material was purified with a Biotage (100 g silica gel; 2-6% MeOH/EtOAc) to afford alcohol M119a as an off-white foam (610 mg). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 12.23 (brs, 0.19H), 12.17 (brs, 0.19H), 11.89 (brs, 0.81H), 11.82 (brs, 0.81H), 7.97 (s, 0.81H), 7.84 (s, 0.19H), 7.78 (d, J=8.1, 1.62H), 7.69-7.20 (m, 6.38H), 5.21-5.15 (m, 1H), 4.86-4.78 (m, 2H), 4.49-4.45 (m, 2H), ˜3.54 (m, 2H), 3.40-3.34 (m, 2H), 2.30-1.80 (m, 8H), 1.41/1.17 (two s, 18H). LC (Cond. 1): RT=1.36 min. LC/MS: Anal. Calcd. for [M+H]⁺ C₃₇H₄₇N₆O₅: 655.36; found 655.34.

Example M119 Step b

25% TFA/CH₂Cl₂ (3.0 mL) was added to carbamate M119a (105 mg, 0.160 mmol) and the mixture was stirred at ambient condition for 4.5 hr. The volatile component was removed in vacuo and the residue was free-based (MCX; MeOH wash; 2.0 M NH3/MeOH elution) to afford pyrrolidine M119b, contaminated with its trifluoroacetylated derivative of unknown regiochemistry. The sample was dissolved in MeOH (1.5 mL) and treated with 1.0 M NaOH/H₂O (300 μL, 0.3 mmol) and the mixture was stirred for 2.75 hr. It was then directly submitted to MCX purification (MeOH wash; 2.0 M NH₃/MeOH elution) to afford M119b as a film of white solid (63.8 mg). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 11.82 (br s, 2H), 7.96 (s, 1H), 7.77 (d, J=8.0, 2H), 7.66 (d, J=8.0, 1H), 7.46 (br s, 1H), 7.42 (br s, 1H), 7.36 (d, J=8.0, 2H), 7.21 (d, J=8.0, 1H), 5.16 (app br s, 1H), 4.46 (s, 2H), 4.16 (app t, J=7.1, 2H), 3.00-2.82 (two m, 4H; there is a broad base line signal in this region from the pyrrolidine NH that was not included in the integration), 2.10-2.01 (m, 2H), 1.94-1.85 (m, 2H), 1.83-1.67 (m, 4H). LC (Cond. 1): RT=0.78 min. LC/MS: Anal. Calcd. for [M+H]⁺ C₂₇H₃₁N₆O: 455.26; found 455.27.

Example M119

Example M119 was prepared from M119b and Cap-51 according to the procedure described for Example 1, with the exception that a reverse phase HPLC with ACN/H₂O/NH₄OAC solvent system was employed for the purification step. LC (Cond. 1): RT=1.15 min; 98% homogeneity index. LC/MS: Anal. Calcd. for [M+H]⁺ C₄₁H₅₃N₈O₇: 769.40; found 769.40. HRMS: Anal. Calcd. for [M+H]⁺ C₄₁H₅₃N₈O₇: 769.4037; found 769.4023.

Example M120 methyl((1S)-1-(((2S)-2-(5-(2-((dimethylamino)methyl)-4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate

Example M120 Step a

CH₂Cl₂ (6.0 mL) was added to a mixture alcohol M119a (501 mg, 0.765 mmol), TPAP (29.1, 0.083 mmol) and 4-methylmorpholine N-oxide (135.8 mg, 1.159 mmol), and the resultant heterogeneous mixture was vigorously stirred at ambient condition for 14.5 hr. Additional TPAP (11.0 mg, 0.031 mmol) and 4-methylmorpholine N-oxide (39 mg, 0.33 mmol) were added and stirring was continued for an additional 24 hr. The mixture was filtered through diatomaceous earth (Celite®), the filtrate was rotervaped and the resulting crude material was purified with a Biotage (2% MeOH/EtOAc) to afford aldehyde M120a as a yellow viscous oil (195.6 mg). LC (Cond. 1): RT=1.37 min. LC/MS: Anal. Calcd. for [M+H]⁺ C₃₇H₄₅N₆O₅: 653.35; found 653.40.

Example M120 Step b

NaCNBH₃ (33 mg, 0.50 mmol) was added in one batch to a MeOH (3.0 mL) solution of aldehyde M120a (195.6 mg, 0.30 mmol) and Me₂NH (200 μL of 40% solution in H₂O), and the reaction mixture was stirred for 4 hr. The volatile component was removed in vacuo and the residue was purified with a flash chromatography (sample was loaded as a silica gel mesh; 3-15% MeOH/CH₂Cl₂) to afford amine M120b as an off-white foam (120 mg). LC (Cond. 1): RT=1.32 min. LC/MS: Anal. Calcd. for [M+H]⁺ C₃₉H₅₂N₇O₄: 682.41; found 682.42.

Example M120 Step c

Carbamate M120b was converted to M120c by employing the protocol described for the preparation of 1e from 1d. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 11.82 (br s, 2H), 7.87 (s, 1H), 7.77 (d, J=8.0, 2H), 7.65 (d, J=7.8, 1H), 7.45/7.43 (overlapping two br s, 2H), 7.37 (d, J=7.8, 2H), 7.21 (d, J=7.8, 1H), 4.87 (m, 0.1H), 4.17 (m, 1.90H), ˜3.3 (signal of Me₂NCH₂ overlapped with that of water), 3.01-2.94 (m, 2H), 2.89-2.83 (m, 2H), 2.10 (s, 6H), 2.10-2.01 (m, 2H), 1.94-1.85 (m, 2H), 1.81-1.67 (m, 4H). LC (Cond. 1): RT=0.79 min. LC/MS: Anal. Calcd. for [M+H]⁺ C₂₉H₃₆N₇: 482.30; found 482.35.

Example M120

The TFA salt of Example M120 was prepared from pyrrolidine M120c and Cap-51 according to the procedure described for Example 1. LC (Cond. 1): RT=1.06 min; 96% homogeneity index. LC/MS: Anal. Calcd. for [M+H]⁺ C₄₃H₅₈N₉O₆: 796.45; found 796.48. HRMS: Anal. Calcd. for [M+H]⁺ C₄₃H₅₈N₉O₆: 796.4510; found 796.4515.

Example M121 dimethyl((2-((dimethylamino)methyl)-4,4′-biphenyldiyl)bis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))biscarbamate

The TFA salt of Example M121 was prepared from M120c and Cap-4 according to the procedure described for Example 1. LC (Cond. 1): RT=1.15 min; >98% homogeneity index. LC/MS: Anal. Calcd. for [M+H]⁺ C₄₉H₅₄N₉O₆: 796.45; found 864.46. HRMS: Anal. Calcd. for [M+H]⁺ C₄₉H₅₄N₉O₆: 864.4197; found 864.4222.

Example M122 methyl((1S)-1-(((1S,3S,5S)-3-(5-(4′-(2-((1S,3S,5S)-2-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-azabicyclo[3.1.0]hex-3-yl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-2-azabicyclo[3.1.0]hex-2-yl)carbonyl)-2-methylpropyl)carbamate

Example M122 Step a

Diisopropyl ethylamine (1.81 mL, 10.4 mmol) was slowly added to acetonitrile (20 mL) solution of (1S,3S,5S)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.10]hexane-3-carboxylic acid (2.36 g, 10.4 mmol) and (2-(4′-(2-bromoacetyl)biphenyl-4-yl)-2-oxoethyl)bromonium (2.0 g, 5.05 mmol), and the reaction mixture was stirred at ambient conditions for 16 hr. The solvent was evaporated and the residue was partitioned between ethyl acetate and water (1:1, 40 mL each). The organic layer was washed with Sat. NaHCO₃ (2×10 mL), brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to afford ketoester M122a (3.58 g) as a viscous amber oil, which solidified upon storage in a refrigerator. ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 8.20 (m, 4H), 7.97 (d, J=8.5, 4H), 5.71-5.48 (m, 4H), 4.69 (m, 2H), 3.44 (m, 2H), 3.3 (m, 2H), 2.76-2.67 (m, 2H), 2.27 (m, 2H), 1.60 (m, 2H), 1.44/1.38 (two s, 18H), 0.78 (m, 2H), 0.70 (m, 2H). LC (Cond. 1): RT=1.70 min; LC/MS: the molecular ion was not picked up.

Example M122 Step b

Ammonium acetate (2.89 g, 37.5 mmol) was added to a toluene (20 mL) solution of ketoester M122a (2.58 g, 3.75 mmol), and the resulting mixture was heated at 120° C. for 4.5 hr, while azaetroping the water that is formed with a Dean-Stark set-up. The reaction mixture was cooled to room temperature and the volatile component was removed in vacuo. Sat. NaHCO₃ solution (10 mL) was added to the solid and the mixture was stirred for 30 min, and the solid was filtered, dried in vacuo and submitted to a Biotage purification (28-100% EtOAc/hexanes) to afford imidazole M122b as light yellow solid (0.6 g). LC (Cond. 1): RT=1.52 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₃₈H₄₅N₆O₄: 649.35; found 649.78.

Example M1122 Step c

4 N HCl in dioxane (5 mL) was added to a ice-water cooled dioxane (16 mL) solution of carbamate M122b (0.8 g, 1.2 mmol), the ice-water bath was removed and the mixture was stirred at ambient condition for 4 hr. Big chunks of solid that formed during the reaction were broken up with a spatula. Removal of the volatile component in vacuo afforded pyrrolidine M122c (0.4 HCl) as yellow solid (0.73 g). ¹H NMR (DMSO-d₆, δ=2.5 ppm, 400 MHz): δ 7.90 (d, J=8.3, 4H), 7.84 (br s, 2H), 7.79 (d, J=8.3, 4H), 5.24 (m, 2H), 3.38 (m, 2H), 2.71 (m, 2H), ˜2.50 (2H, overlapped with solvent signal), 1.93 (m, 2H), 1.38 (m, 2H), 0.96 (m, 2H). LC (Cond. 1): RT=1.03 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₂₈H₂₉N₆: 449.25; found 449.59.

Example M122

The TFA salt of Example M122 was prepared from M122c and Cap-51 according to the procedure described for Example 1. LC (Cond. 1): RT=1.34 min; LC/MS: Anal. Calcd. for [M+H]⁺ C₄₂H₅₁N₈O₆: 763.39; found 763.73.

Section R

Example R1 tert-butyl(1S,1′S)-1,1′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpropane-1,1-diyl)dicarbamate (3)

A solution of 1,1′-(biphenyl-4,4′-diyl)bis(2-bromoethanone) (1) (5.14 g, 18.4 mmol) and N-Boc-L-Valine (8.00 g, 36.8 mmol) in dry CH₃CN (40 mL) was treated with iPr₂NEt (7.05 mL, 40.5 mmol) and the solution was allowed to stir at rt overnight. The solvent was removed in vacuo and the resulting slurry was partitioned between EtOAc and H₂O. The layers were separated and the aq phase was extracted with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo. The residue was suspended in toluene (100 mL) and NH₄OAc (14.2 g, 184.2 mmol) was added. The mixture was heated reflux for 16 h with azeotropic removal of H₂O (Dean-Stark). The mixture was cooled to rt and concentrated to dryness in vacuo. The residue was purified column chromatography (biotage) eluting with 0 to 40% CH₃CN in CH₂Cl₂ and then 10% MeOH in CH₂Cl₂ to afford the title compound (5.77 g, 50%) as a yellow foam. ¹HNMR (500 MHz, DMSO-d₆) δ 11.77-11.93 (m, 2H), 7.80 (s, br, 4H), 7.66-7.68 (m, 4H), 7.53 (s, br, 2H), 6.89 (d, J=7.7 Hz, 2H), 4.43 (app t, J=8.2 Hz, 2H), 2.05-2.11 (m, 2H), 1.38 (s, 18H), 0.90 (d, J=6.6 Hz, 6H), 0.78 (d, J=6.6 Hz, 6H). LCMS: Anal. Calcd. for C₃₆H₄₈N₆O₄: 628; found: 629 (M+H)⁺.

Example R2 tert-butyl (1R,1′R)-1,1′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpropane-1,1-diyl)dicarbamate

The title compound was prepared according to the method in Example R1 starting with 1,1′-(biphenyl-4,4′-diyl)bis(2-bromoethanone) (1) and N-Boc-D-Valine. LCMS: Anal. Calcd. for C₃₆H₄₈N₆O₄: 628; found: 629 (M+H)⁺.

Example R3 (1S,1′S)-1,1′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpropan-1-amine)

A solution of tert-butyl(1R,1′R)-1,1′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpropane-1,1-diyl)dicarbamate (1.00 g, 1.59 mmol) in CH₂Cl₂ (30 mL) was added TFA (20 mL) and the solution was allowed to stir at rt for 5 h. The solvents were removed in vacuo, the residue was dissolved in CH₂Cl₂: MeOH (1:1) (ca. 10 mL) and absorbed onto an MCX cation exchange cartridge (Oasis). The resin was washed with MeOH and the desired material was released by elution with NH₃ in MeOH (2M). The solvents were removed in vacuo to afford the title compound (0.622 g, 91%) as a yellow foam which was sufficiently pure for use in subsequent steps. ¹HNMR (300 MHz, CD₃OD) δ 7.76 (app d, J=8.4 Hz, 4H), 7.68 (app d, J=8.4 Hz, 4H), 7.38 (s, 2H), 3.77 (d, J=7.3 Hz, 2H), 2.07 (sept, J=7.0 Hz, 2H), 1.03 (d, J=7.0 Hz, 6H), 0.88 (d, J=7.0 Hz, 6H). LCMS: Anal. Calcd. for C₂₆H₃₂N₆: 428; found: 429 (M+H)⁺.

Example R4 (1R,1′R)-1,1′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpropan-1-amine)

The title compound was prepared according to the method given in Example R3 starting with tert-butyl (1R,1′R)-1,1′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpropane-1,1-diyl)dicarbamate. LCMS: Anal. Calcd. for C₂₆H₃₂N₆: 428; found: 429 (M+H)⁺.

Example R5 dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2S)-1-oxo-1,2-propanediyl)))biscarbamate

A solution of (1S,1′S)-1,1′-(5,5′-(biphenyl-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpropan-1-amine) (120 mg, 0.280 mmol), (S)-2-(methoxycarbonylamino)propanoic acid (124 mg, 0.840 mmol) and iPr₂NEt (0.489 mL, 2.80 mmol) in DMF (5 mL) was treated with HATU (426 mg, 1.12 mmol) and the reaction mixture was stirred at rt for 2 h. The reaction mixture was partitioned between H₂O and EtOAc, the layers separated and the aq phase was extracted with EtOAc. The combined organic layers were concentrated in vacuo and purified by column chromatography (Biotage, 25S eluting with 0 to 40% CH₃CN in CH₂Cl₂ and then 10% MeOH in CH₂Cl₂. The appropriate fractions were concentrated in vacuo and the residue was purified by prep HPLC (CH₃CN—H₂O-TFA). Two subsequent purifications by prep HPLC (CH₃CN—H₂O—NH₄OAc) followed by a final prep HPLC (CH₃CN—H₂O-TFA) afforded the TFA salt of the title compound (4.9 mg, 2%) as a colorless solid. ¹HNMR (300 MHz, CD₃OD) δ 7.89 (s, 2H), 7.86 (s, 8H), 4.87 (d, J=8.5 Hz, 2H), 4.19 (q, J=7.0 Hz, 2H), 3.65 (s, 6H), 1.33 (d, J=7.0 Hz, 6H), 1.14 (d, J=7.0 Hz, 6H), 0.96 (d, J=7.0 Hz, 6H). LCMS: Anal. Calcd. for C₃₆H₄₆N₈O₆: 686; found: 687 (M+H)⁺.

TABLE 1A The following were prepared similary starting with the appropriate amine and substitute amino acid. Example Compound Name Structure Analytical Data Example R6 dimethyl (4,4′- biphenyldiylbis(1H- imidazole-4,2- diyl((1S)-2-methyl- 1,1- propanediyl)imino ((2S,3R)- 3-methoxy- 1-oxo-1,2- butanediyl))) biscarbamate

LCMS: Anal. Calcd. for C₄₀H₅₄N₈O₈: 774; found: 775 (M + H)⁺. Example R7 dimethyl (4,4′- biphenyldiylbis(1H- imidazole-4,2- diyl((1S)-2-methyl- 1,1- propanediyl)imino ((2S)-3-methyl- 1-oxo-1,2- butanediyl))) biscarbamate

LCMS: Anal. Calcd. for C₄₀H₅₄N₈O₆: 742; found: 743 (M + H)⁺. Example R8 dimethyl (4,4′- biphenyldiylbis(1H- imidazole-4,2- diyl((1S)-2-methyl- 1,1- propanediyl)imino ((2S)-4- methoxy- 1-oxo-1,2- butanediyl))) biscarbamate

LCMS: Anal. Calcd. for C₄₀H₅₄N₈O₈: 774; found: 775 (M + H)⁺. Example R9 dimethyl (4,4′- biphenyldiylbis(1H- imidazole-4,2- diyl((1R)-2-methyl- 1,1- propanediyl)imino ((2S)-3- methyl- 1-oxo-1,2- butanediyl))) biscarbamate

LCMS: Anal. Calcd. for C₄₀H₅₄N₈O₆: 742; found: 743 (M + H)⁺. Example R10 dimethyl (4,4′- biphenyldiylbis(1H- imidazole-4,2- diyl((1R)-2-methyl- 1,1- propanediyl)imino ((2S)- 1-oxo-1,2- propanediyl))) biscarbamate

LCMS: Anal. Calcd. for C₃₆H₄₆N₈O₆: 686; found: 687 (M + H)⁺. Example R11 dimethyl (4,4′- biphenyldiylbis(1H- imidazole-4,2- diyl((1R)-2-methyl- 1,1- propanediyl)imino ((2S)-4- methoxy- 1-oxo-1,2- butanediyl))) biscarbamate

LCMS: Anal. Calcd. for C₄₀H₅₄N₈O₈: 774; found: 775 (M + H)⁺. Example R12 dimethyl (4,4′- biphenyldiylbis(1H- imidazole-4,2- diyl((1R)-2-methyl- 1,1- propanediyl)imino ((2S,3R)-3- methoxy- 1-oxo-1,2- butanediyl))) biscarbamate

LCMS: Anal. Calcd. for C₄₀H₅₄N₈O₈: 774; found: 775 (M + H)⁺. Example R13 dimethyl (4,4′- biphenyldiylbis(1H- imidazole-4,2- diyl((1R)-2-methyl- 1,1- propanediyl)imino ((2R)-3- methyl- 1-oxo-1,2- butanediyl))) biscarbamate

Anal. Calcd. for C₄₀H₅₄N₈O₆: 742; found: 743 (M + H)⁺. Example R14 dimethyl (4,4′- biphenyldiylbis(1H- imidazole-4,2- diyl((1S)-2-methyl- 1,1- propanediyl)imino ((2R)-3- methyl- 1-oxo-1,2- butanediyl))) biscarbamate

Anal. Calcd. for C₄₀H₅₄N₈O₆: 742; found: 743 (M + H)⁺.

Example R15 (S)-tert-butyl 1-(5-(4-bromophenyl)-1H-imidazol-2-yl)-2-methylpropylcarbamate

A solution of 2-bromo-1-(4-bromophenyl)ethanone (6.23 g, 22.3 mmol) and N-Boc-L-Valine (5.00 g, 23.0 mmol) in dry CH₃CN (30 mL) was treated with iPr₂NEt (4.40 mL, 25.3 mmol) and the solution was allowed to stir at rt overnight. The solvent was removed in vacuo and the resulting slurry was partitioned between EtOAc and H₂O. The layers were separated and the aq phase was extracted with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to give a yellow oil. LCMS: Anal. Calcd. for C₁₈H₂₄BrNO₅: 413, 415; found: 412, 414 (M−H)⁻. The residue was suspended in toluene (60 mL) and NH₄OAc (8.61 g, 111.7 mmol) was added. The mixture was heated reflux for 16 h with azeotropic removal of H₂O (Dean-Stark). The mixture was cooled to rt and concentrated to dryness in vacuo. The residue was purified column chromatography (biotage) eluting with 10% MeOH in CH₂Cl₂ to afford the title compound (8.55 g, 94%) as a yellow foam. ¹HNMR (500 MHz, CD₃OD) δ 7.84 (s, 1H), 7.66 (app d, J=8.9 Hz, 2H), 7.64 (app d, J=8.9 Hz, 2H), 4.65 (d, J=7.7 Hz, 1H), 2.23-2.27 (m, 1H), 1.42 (s, 9H), 1.07 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz, 3H). LCMS: Anal. Calcd. for C₁₈H₂₄BrN₃O₂: 393, 395; found: 394, 396 (M+H)⁺.

Example R16 (R)-tert-butyl 1-(5-(4-bromophenyl)-1H-imidazol-2-yl)-2-methylpropylcarbamate

The title compound was prepared starting from 2-bromo-1-(4-bromophenyl)ethanone and N-Boc-D-Valine using the method given in Example 15. ¹HNMR (500 MHz, CD₃OD) δ 7.83 (s, 1H), 7.68 (app d, J=8.7 Hz, 2H), 7.64 (app d, J=8.7 Hz, 2H), 4.65 (d, J=7.3 Hz, 1H), 2.22-2.26 (m, 1H), 1.42 (s, 9H), 1.08 (d, J=6.7 Hz, 3H), 0.93 (d, J=6.7 Hz, 3H). LCMS: Anal. Calcd. for C₁₈H₂₄BrN₃O₂: 393, 395; found: 394, 396 (M+H)⁺.

Example R17 (S)-tert-butyl 2-(5-(4′-(2-((S)-1-(tert-butoxycarbonylamino)-2-methylpropyl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate

A solution of (S)-tert-butyl 1-(5-(4-bromophenyl)-1H-imidazol-2-yl)-2-methylpropylcarbamate (2.00 g, 5.07 mmol), (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (2.23 g, 5.07 mmol) and NaHCO₃ (1.49 g, 17.8 mmol) in DME (50 mL) and Water (15 mL) was degassed by evacuating and backfilling with N₂.

Tetrakis(triphenylphosphine)palladium(0) (0.293 g, 0.254 mmol) was added and the reaction mixture was heated overnight at 100° C. The mixture was cooled to rt and the DME was removed in vacuo. The residue was partitioned between H₂O and EtOAc and the layers separated. The aq phase was extracted with EtOAc and the combined organic layers were concentrated to dryness in vacuo and purified by column chromatography (Biotage) eluting with a gradient of 0 to 40% CH₃CN in CH₂Cl₂ and then 0 to 10% MeOH in CH₂Cl₂. The title compound (2.05 g, 65% yield) was obtained as a brown foam. This material was used as is in subsequent steps. LCMS: Anal. Calcd. for C₃₆H₄₆N₆O₄: 626; found: 627 (M+H)⁺.

Example R17A (S)-2-methyl-1-(5-(4′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)propan-1-amine

To a solution of (S)-tert-butyl 2-(5-(4′-(2-((S)-1-(tert-butoxycarbonylamino)-2-methylpropyl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (2.05 g, 3.27 mmol) in CH₂Cl₂ (20 mL) was added TFA (5 mL, 64.9 mmol) and the solution was allowed to stir for 2 h. The solvents were removed in vacuo, the residue was dissolved in CH₂Cl₂: MeOH (1:1) (ca. 10 mL) and absorbed onto an MCX cation exchange cartridge (Oasis). The resin was washed with MeOH and the desired material was released by elution with NH₃ in MeOH (2M). The solvents were removed in vacuo to afford the title compound (0.622 g, 91%) as a yellow foam which was sufficiently pure for use in subsequent steps. ¹HNMR (500 MHz, CD₃OD) δ 7.85-7.88 (m, 4H), 7.75 (m, app d, J=8.2 Hz, 4H), 7.70 (app d, J=5.8 Hz, 2H), 4.96 (t, J=8.2 Hz, 1H), 4.30 (d, J=8.5 Hz, 1H), 3.54-3.57 (m, 1H), 3.47-3.52 (m, 1H), 2.55-2.62 (m, 1H), 2.38-2.46 (m, 1H), 2.28-2.36 (m, 1H), 2.15-2.24 (m, 1H), 1.17 (d, J=6.7 Hz, 3H), 0.94 (d, J=6.7 Hz, 3H). LCMS: Anal. Calcd. for C₂₆H₃₀N₆: 426; found: 427 (M+H)⁺.

Example R18 N²-(methoxycarbonyl)-N-((1S)-1-(4-(4′-(2-((2S)-1-(N-(methoxycarbonyl)-L-valyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-2-methylpropyl)-L-valinamide

A single neck 50 mL flask equipped with a magnetic stirrer was charged with (S)-2-methyl-1-(5-(4′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)propan-1-amine (80 mg, 0.188 mmol) and (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (99 mg, 0.563 mmol) in DMF (5 mL) and DIEA (0.328 mL, 1.875 mmol) was added. To this solution was added HATU (285 mg, 0.750 mmol) added and the reaction was allowed to stir for 4 h rt. The reaction mixture was partitioned between H₂O and EtOAc, the layers separated and the aq phase was extracted with EtOAc. The combined organic layers were concentrated in vacuo and purified by column chromatography (Biotage, 25S) eluting with 0 to 40% CH₃CN in CH₂Cl₂ and then 10% MeOH in CH₂Cl₂. The appropriate fractions were concentrated in vacuo and the residue was purified by prep HPLC (CH₃CN—H₂O-TFA) and then a subsequent purification by prep HPLC (CH₃CN—H₂O—NH₄OAc) gave the title compound (31.8 mg, 23%) as a colorless solid. ¹HNMR (500 MHz, CD₃OD) δ 7.71 (m, 4H), 7.64-7.67 (m, 4H), 7.35 (s, 1H), 7.32 (s, 1H), 5.33-5.34 (m, 0.2H), 5.17 (dd, J=7.6, 5.5 Hz, 0.8H), 4.77 (d, J=9.2 Hz, 1H), 4.22 and 4.10 (d, J=7.6 Hz, 1H, rotamers 4:1 ratio), 3.97-4.01 (m, 1H), 3.94 (d, J=7.0 Hz, 1H), 3.84-3.89 (m, 1H), 3.64 (s, 6H), 2.28-2.35 (m, 1H), 2.18-2.27 (m, 3H), 1.98-2.08 (m, 3H), 1.05 (d, J=6.7 Hz, 3H), 0.98 and 0.94 (d, J=6.7 Hz, 3H), 0.90 (d, J=6.7 Hz, 6H), 0.88 (d, J=6.7 Hz, 3H), 0.86 (d, J=6.7 Hz, 3H). LCMS: Anal. Calcd. for C₄₀H₅₂N₈O₆: 740; found: 741 (M+H)⁺.

TABLE 2A The following were prepared similary starting with the appropriate amine and substitute amino acid. Example Compound Name Structure Analytical Data Example R19 methyl ((1S,2R)-2- methoxy-1-(((2S)-2- (4-(4′-(2-((1S)-1-((N- (methoxycarbonyl)- O-methyl-L- threonyl)amino)-2- methylpropyl)-1H- imidazol-4-yl)-4- biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)carbonyl) propyl)carbamate

LCMS: Anal. Calcd. for C₄₀H₅₂N₈O8: 772 found: 773 (M + H)⁺. Example R20 methyl ((1S)-3- methoxy-1-(((2S)-2- (4-(4′-(2-((1S)-1-((N- (methoxycarbonyl)- O-methyl-L- homoseryl)amino)-2- methylpropyl)-1H- imidazol-4-yl)-4- biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)carbonyl) propyl)carbamate

LCMS: Anal. Calcd. for C₄₀H₅₂N₈O8: 772 found: 773 (M + H)⁺. Example R21 methyl ((1S)-2-((2S)- 2-(4-(4′-(2-((1S)-1- ((N- (methoxycarbonyl)-L- alanyl)amino)-2- methylpropyl)-1H- imidazol-4-yl)-4- biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-1- methyl-2- oxoethyl)carbamate

LCMS: Anal. Calcd. for C₃₆H₄₄N₈O₆: 684; found: 685 (M + H)⁺. Example R22 N²-(methoxy- carbonyl)- N-((1R)-1-(4-(4′-(2- ((2S)-1-(N- (methoxycarbonyl)-L- valyl)-2-pyrrolidinyl)- 1H-imidazol-4-yl)-4- biphenylyl)-1H- imidazol-2-yl)-2- methylpropyl)-L- valinamide

LCMS: Anal. Calcd. for C₄₀H₅₂N₈O₆: 740; found: 741 (M + H)⁺. Example R23 methyl ((1S,2R)-2- methoxy-1-(((2S)-2- (4-(4′-(2-((1R)-1-((N- (methoxycarbonyl)- O-methyl-L- threonyl)amino)-2- methylpropyl)-1H- imidazol-4-yl)-4- biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)carbonyl) propyl)carbamate

LCMS: Anal. Calcd. for C₄₀H₅₂N₈O₈: 772 found: 773 (M + H)⁺. Example R24 methyl ((1S)-3- methoxy-1-(((2S)-2- (4-(4′-(2-((1R)-1-((N- (methoxycarbonyl)- O-methyl-L- homoseryl)amino)-2- methylpropyl)-1H- imidazol-4-yl)-4- biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)carbonyl) propyl)carbamate

LCMS: Anal. Calcd. for C₄₀H₅₂N₈O₈: 772; found: 773 (M + H)⁺. Example R25 methyl ((1S)-2-((2S)- 2-(4-(4′-(2-((1R)-1- ((N-(methoxy- carbonyl)-L- alanyl)amino)-2- methylpropyl)-1H- imidazol-4-yl)-4- biphenylyl)-1H- imidazol-2-yl)-1- pyrrolidinyl)-1- methyl-2- oxoethyl)carbamate

LCMS: Anal. Calcd. for C₃₆H₄₄N₈O₆: 684; found: 685 (M + H)⁺.

Example Structure Analytical Data Example A

LCMS: Anal. Calcd. for C₁₆H₂₁BrN₂O₄: 385 found: 386 (M + H)⁺. Example B

LCMS: Anal. Calcd. for C₁₆H₂₁BrN₃O₂: 366 found: 367 (M + H)⁺. Example C

LCMS: Anal. Calcd. for C₂₂H₃₂BN₃O₄: 413; found: 414 (M + H)⁺. Example D

LCMS: Anal. Calcd. for C₃₇H₄₀N₆O₄: 632; found: 633 (M + H)⁺. Example E

LCMS: Anal. Calcd. for C₂₉H₃₄N₆O₂: 498 found: 499 (M + H)⁺. Example F

LCMS: Anal. Calcd. for C₂₄H₂₆N₆: 398; found: 399 (M + H)⁺. Example R26

LCMS: Anal. Calcd. for C₃₈H₄₈N₈O₆: 712; found: 713 (M + H)⁺. Example R27

LCMS: Anal. Calcd. for C₃₈H₄₈N₈O₈: 744; found: 745 (M + H)⁺. Example R28

LCMS: Anal. Calcd. for C₃₄H₄₀N₈O₆: 756; found: 757 (M + H)⁺.

Example R29

A single neck 50 mL flask equipped with a magnetic stirrer was charged with a compound from, Example E (150 mg, 180 mmol) in Methanol (5 mL). To this solution was added a slurry of Palladium on carbon 10% (100 mg) in Methanol (2 mL). The mixture was purged with 60 psi of Hydrogen. The mixture was shaked on a Parr overnight at room temperature. The contain of the reactor was analyzed by LC-MS and showed a 20% completion. A slurry of Palladium Hydroxide on carbon 20% (100 mg) in Acetic acid (2 mL) was added. The mixture was purged with hydrogen and shake on a Parr shaker with 60 psi of Hydrogen over the weekend. The reaction was filtered through a pad of Celite and the filtrate was evaporated in vacuo. The residue was purified by prep HPLC (CH₃CN—H₂O-TFA) to give the compound (Example 29) 32 mg 23% yield as a white solid. LCMS: Anal. Calcd. for C₃₉H₅₀N₈O₇: 742; found: 743 (M+H)⁺

Example Structure Analytical Data Example G

LCMS: Anal. Calcd. for C₂₄H₂₈BrNO₆: 506 found: No ionization (M + H)⁺. Example H

LCMS: Anal. Calcd. for C₂₄H₂₈BrN₃O₃: 486 found: 487 (M + H)⁺. Example I

LCMS: Anal. Calcd. for C₄₂H₅₀BN₆O₅: 718 found: 719 (M + H)⁺. Example J

LCMS: Anal. Calcd. for C₄₆H₅₆N₈O₇: 832; found: 833 (M + H)⁺. Example R29

LCMS: Anal. Calcd. for C₄₆H₅₆N₈O₇: 742 found: 743 (M + H)⁺.

Scheme 3

Example R30 N-(5-(4-bromophenyl)-1H-imidazol-2-yl)acetamide

A mixture of 2-bromo-1-(4-bromophenyl)ethanone (2.00 g, 7.20 mmol) and acetylguanidine (2.18 g, 21.6 mmol) in DMF (40 mL) was stirred at rt for 48 h. The solution was concentrated to dryness in vacuo and the resulting brown solid was of sufficient purity for use in the next step. LCMS: Anal. Calcd. for C₁₁H₁₀BrN₃O: 279, 281; found: 280, 282 (M+H)⁺.

Example R31 (S)-tert-butyl 2-(5-(4′-(2-acetamido-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate

A mixture of N-(5-(4-bromophenyl)-1H-imidazol-2-yl)acetamide (0.604 g, 2.16 mmol), (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (0.950 g, 2.16 mmol), NaHCO₃ (0.636 g, 7.57 mmol) in DME (20 mL) and H₂O (5 mL) was degassed by evacuating and back-filling with N₂ (×3). To this solution Pd(PPh₃)₄ (0.125 g, 0.11 mmol) was added and the suspension heated at 125° C. for 24 h. The mixture was evaporated to dryness in vacuo and the residue was purified by column chromatography (Biotage) eluting with a gradient of 0 to 10% MeOH in CH₂C₂. The material was then purified by prep HPLC (CH₃CN—H₂O—NH₄OAc) to afford the title compound as a colorless solid. 7.76 (app dd, J=8.4, 2.2 Hz, 4H), 7.69 (app d, J=8.4 Hz, 2H), 7.66 (app d, J=8.4 Hz, 2H), 7.45 (s, 1H), 7.23 (s, 1H), 3.66-3.72 (m, 1H), 3.48-3.53 (s, 1H), 2.34-2.46 (m, 1H), 2.18 (s, 3H), 1.96-2.10 (m, 3H), 1.46, 1.25 (s, 9H, rotamers, 1:2 ratio). LCMS: Anal. Calcd. for C₂₉H₃₂N₆O₃: 512; found: 513, 282 (M+H)⁺.

Example R32 (S)-5-(4′-(2-(pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-amine

Step 1. A solution of (S)-tert-butyl 2-(5-(4′-(2-acetamido-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (55.0 mg, 0.11 mmol) in CH₂Cl₂ (5 mL) and TFA (1 mL) was allowed to stir at rt for 3 h. The reaction mixture was concentrated in vacuo to give the TFA salt of the title compound (55.0 mg) which was carried directly to the next step. LCMS: Anal. Calcd. for C₂₄H₂₄N₆O: 412; found: 413 (M+H)⁺.

Step 2. The brown oil from Step 1 was suspended in 25% conc. HCl in MeOH (10 mL) and heated at reflux for 3 h. The volatiles were removed under reduced pressure and the residue was purified by prep HPLC (CH₃CN—H₂O-TFA) to give the TFA salt of the title compound (20 mg, 42%). LCMS: Anal. Calcd. for C₂₂H₂₂N₆: 370; found: 371 (M+H)⁺.

Example R33 (S)-2-methoxycarbonylamino-N-(5-(4′-(2-((S)-1-((S)-2-methoxycarbonylamino-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)-3-methylbutanamide

To a solution of (S)-5-(4′-(2-(pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-amine trifluoroacetic acid salt (20 mg, 0.04 mmol), (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (25 mg, 0.14 mmol) and iPr₂NEt (0.09 mL, 0.53 mmol) in DMF (5 mL) was added HATU (54 mg, 0.14 mmol). The solution was allowed to stir for 3 h and then poured into H₂O. The mixture was concentrated to dryness in vacuo and the residue was purified by prep HPLC (CH₃CN—H₂O-TFA) affording the title compound and recovered starting material. The recovered starting material was resubjected to the reaction conditions and purified as above. The two lots of product were then purified by prep HPLC (CH₃CN—H₂O—NH₄OAc) to give the title compound as a tan solid (18 mg, 76%). ¹HNMR (400 MHz, CD₃OD) δ 7.80-7.88 (m, 9H), 7.56 (s, 1H), 5.24 (app t, J=7.6 Hz, 1H), 4.23 (d, J=7.1 Hz, 1H), 4.18 (d, J=6.6 Hz, 1H), 4.08-4.13 (m, 1H), 3.83-3.90 (m, 1H), 3.68 (s, 3H), 3.65 (s, 3H), 2.54-2.63 (m, 1H), 2.17-2.30 (m, 4H), 2.01-2.09 (m, 1H). LCMS: Anal. Calcd. for C₃₆H₄₄N₈O₆: 684; found: 685 (M+H)⁺.

The following Examples were prepared as described in the above examples using the appropriate starting materials:

Example R34

Example R35

Example R36

Example R37 Biological Activity

An HCV Replicon assay was utilized in the present disclosure, and was prepared, conducted and validated as described in commonly owned PCT/US2006/022197 and in O'Boyle et. al. Antimicrob Agents Chemother. 2005 April; 49(4):1346-53.

HCV 1b-377-neo replicon cells were used to test the currently described compound series as well as cells resistant to compound A due to a Y2065H mutation in NS5A (described in application PCT/US2006/022197). The compounds tested were determined to have more than 10-fold less inhibitory activity on cells resistant to compound A than wild-type cells indicating a related mechanism of action between the two compound series. Thus, the compounds of the present disclosure can be effective to inhibit the function of the HCV NS5A protein and are understood to be as effective in combinations as previously described in application PCT/US2006/022197 and commonly owned WO/O4014852. Further, the compounds of the present disclosure can be effective against the HCV 1b genotype. It should also be understood that the compounds of the present disclosure can inhibit multiple genotypes of HCV. Table 2 shows the EC50 values of representative compounds of the present disclosure against the HCV 1b genotype. In one embodiment compounds of the present disclosure are active against the 1a, 1b, 2a, 2b, 3a, 4a, and 5a genotypes. EC50 ranges against HCV 1b are as follows: A=1-10 μM; B=100-999 nM; C=1-99 nM; and D=1-999 μM.

The compounds of the present disclosure may inhibit HCV by mechanisms in addition to or other than NS5A inhibition. In one embodiment the compounds of the present disclosure inhibit HCV replicon and in another embodiment the compounds of the present disclosure inhibit NS5A.

TABLE 2 Example Range 1 D 24-4e C 24-4f B 24-4g A 25-1 D 25-2 D 25-3 D 25-4 D 25-5 D 25-6 C 25-7 C 25-8 D 24-4h D 120-9 D 120 D 120-5 C 120-6 C 120-7 D 120-8 C 103-3 D 103-4 D 103-1 D 103-2 D 103-5 D 103-6 C 103-8 D 103-7 D 151 isomer 1 C 151 isomer 2 B 152j-9 C 152j-10 C 152j-1 C 152j-2 D 153c-5 C 153c-6 C 153c-2 C 153c-1 C 152j-7 C 152j-8 D 153c-3 A 153c-4 A 152j-11 D 152j-12 D 152j-15 D 152j-28 D 152j-13 C 152j-14 C 152j-19 D 152j-16 D 152j-3 D 152j-20 C 152j-17 D 152j-18 D 152j-3 D 152j-5 D 152j-6 D 152l-2 D 152l-1 D 152j-24 D 152j-23 D 153c-7 C 152j-22 D 24-18-2 D 24-18-1 D 24-18-4 D 24-18-5 D 24-18-6 D 24-18-3 D 152j-21 D 152l-3 D 131.1-2 D 131.1-1 D 24-4a D 120-1 D 120-2 D 120-3 D 120-4 D 24-10 D 24-9 D 24-8 D 24-11 C 24-12 C 11 C 24-16 D 24-18 D 24-17 D 24-15 C 24-13 B 24-14 C 24-4b C 24-4c D 24-4d D 148 C 149 D 150 C 24-5 D 24-6 D 24-7 D 24-1 D 24-2 D 24-3 D 28-1 D 28-2 D 28-3 D 28-4 D 28-5 D 84-1 D 84-2 D 84-3 D 84-4 D 84-7 C 84-10 C 84-12 D 84-14 C 84-15 C 84-17 D 84-18 C 84-19 C 84-20 C 84-24 D 84-26 D 84-27 D 84-28 D 84-32 D 84-33 D 84-34 C 84-35 D 84-36 D 84-38 D 84-39 D 84-40 D 84-44 D 84-46 D 84-47 D 84-48 D 84-49 D 84-50 D 84-51 D 84-52 D 84-53 D 84-54 D 84-55 D 84-56 D 84-57 D 84-58 D 84-59 D 84-60 D 84-61 D 84-62 D 84-63 D 84-64 D 84-65 C-D 84-66 C-D 84-67 D 84-68 C 84-69 D 84-70 C 84-71 C 84-72 C 84-73 C 84-74 D 84-75 C 84-76 D 84-77 D 84-78 D 84-79 D 84-80 D 84-81 D 84-82 D 84-83 D 84-84 D 84-85 D 84-86 D 84-87 D 94-1 D 94-2 C 94-3 D 94-6 C-D 94-9 D 94-10 D 94-12 C 94-13 D 94-17 D 94-19 D 94-20 C 94-24 D 94-25 D 94-26 D 94-27 C 94-30 D 94-32 C 94-33 C 94-34 C 94-36 D 94-37 C 94-38 D 94-42 D 94-44 D 94-45 D 94-46 D 94-47 D 94-48 D 94-49 D 94-50 D 94-51 D 94-52 D 94-53 D 94-54 D 94-55 D 94-56 D 107-1 D 107-2 D 107-3 D 107-4 D 107-5 D 107-6 D 107-7 D 107-8 D 107-9 D 107-10 D 107-11 D 107-12 D 107-13 D 107-14 D 107-15 D 107-16 D 107-17 D 107-18 D 107-19 D 107-20 D 107-21 D 107-22 D 107-23 D 107-24 D 107-25 D 107-26 D 107-27 D 107-28 D 107-29 D 107-30 D 107-31 D 107-32 D 107-33 D 107-34 D 107-35 D 107-36 D 107-37 D 107-38 D 107-39 D 107-40 D 107-41 D 107-42 D 107-43 D 107-44 D 2 D 3 D 4 D 5 C 6 C 7 D 8 D 24-23 D 9 C 10 C 11 C 12 C 13 C 14 B 15 C 16 C 17 D 18 D 19 D 20 C 21 D 22 D 23 D 24 C 25 D 26 C 27 C 28 C 29 D 30 C 31 D 32 C 33 D 34 D 35 D 36 D 37 D 38 D 39 D 40 D 41 D 42 D 43 D 44 D 45 D 46 D 47 D 48 D 49 D 50 B 51 D 52 D 53 D 54 D 55 D 56 D 57 D 58 D 59 D 60 D 61 D 62 D 63 D 64 D 65 C 67 D 68 D 69 D 70 C 71 D 72 C 73 D 74 D 75 D 76 D 77 D 78 D 79 D 80 D 81 D 82 D 83 D 84 D 85 D 86 D 87 D 88 D 89 D 90 D 91 D 92 D 93 D 94 D 95 D 96 D 97 D 98 D 99 D 100 D 101 D 102 D 103 D 104 D 105 D 106 D 107 D 108 D 109 C 110 D 111 D 112 D 113 D 114 D 115 D 116 D 117 D 118 D 119 D 120 D 121 D 122 D 123 D 124 D 125 D 126 D 127 D 128 D 129 D 130 D 131 D 132 D 133 C 134 D 135 D 136 D 138 D 139 D 140 D 141 D 142 C 143 D 144 D 145 D 146 D 147 D LS2 C LS3 C LS4 C LS16 C LS6 B LS11 A LS14 D LS20 D LS21 D LS22 D LS23 D LS24 D LS25 D LS26 D LS27 D′mer 1 D LS27 D′mer 2 D LS36 D LS37 D F5 D F6 D F7 D F8 D F14 D F15 D F16 D F17 D F20 B F21 B F22 B F25 D F26 C F27 C F28 C F29 C F30 C F32 B F33 B F34 C F35 B F37 B F38 D F39 D Diastereomers F41 D F43 D F48 D F49 C F51 D F52 D F53 D F54 D F55 D F56 D F57 D F58 D F60 D F61 C F62 C F63 D F64 C F65 B F66 C F67 C F69 B F70 B F71 D cj-48 B cj-49 C cj-50 D cj-51 D cj-52 D cj-53 D cj-54 D cj-55 D cj-56 D cj-57 D cj-58 D cj-59 D cj-60 D cj-61 D cj-62 D cj-63 D cj-64 D cj-65 D cj-66 D cj-67 D cj-68 D cj-69 D cj-70 D cj-71 D cj-72 D cj-73 D cj-74 C cj-75 D cj-76 D cj-77 D cj-78 D cj-79 D cj-80 D cj-81 D cj-82 D cj-83 D cj-84 D cj-85 D cj-86 D cj-87 D cj-88 D cj-89 D cj-90 D cj-91 D cj-92 C cj-93 D cj-94 D cj-95 D cj-96 D cj-97 D cj-98 D cj-99 D cj-100 D cj-101 D cj-102 D cj-103 D cj-104 D cj-105 D cj-106 D cj-107 D cj-108 D cj-109 D cj-110 D cj-111 D cj-112 D cj-113 D cj-114 D cj-115 D cj-116 D cj-117 D cj-118 D cj-119 D cj-120 D cj-121 D cj-122 D cj-45 D cj-41 D cj-47 C cj-43 D cj-44 D cj-40 D cj-46 D cj-42 D cj-36 D cj-37 D cj-38 D cj-39 D cj-32 D cj-33 D cj-34 D cj-35 C cj-136 D cj-137 C cj-138 A cj-139 C cj-140 B cj-141 A cj-142 A cj-143 A cj-144 D cj-145 C cj-146 B cj-147 C cj-148 C cj-149 C cj-150 C cj-151 C cj-152 C cj-153 D cj-154 D cj-155 C cj-156 D cj-126 D cj-127 C cj-128 D cj-129 D cj-130 D cj-131 C cj-132 B cj-133 C cj-134 C cj-135 C cj-125 C cj-15c D cj-20c D cj-20b D cj-20a D cj-17 D cj-16 D cj-20d D cj-20 D cj-15a D cj-15 D cj-15d D cj-11n C cj-11o C cj-11p D cj-11m C cj-11h D cj-11i D cj-11j D cj-11k D cj-11e A cj-11f C cj-11g C cj-11d D cj-11b D cj-11 D cj-11a D cj-11c D JG-3 D JG-4 C JG-5 D JG-6 C JG-7 D JG-8 D JG-9 D JG-10 C JG-12 D JG-13 C JG-14 D JG-15 D JG-16 D JG-17 D OL-1 D OL-2 D OL-3 C OL-4 D OL-5 D OL-6 D OL-7 D OL-8 D OL-9 D OL-10 D OL-11 D OL-12 D OL-13 D OL-19 D OL-20 C OL-21 D D73 D D74 D D75 D D76 D D77 D J16 D J17 D J18 D J19 D J20 D J21 D J22 D J23 D J24 D J25 D J26 D J27 D J28 C J29 D J30 C J31 D J37 D J38 D J39 D J40 D J41 D J42 D J42.a D J45 D J46 D J47 D J48 D J49 D J50 D J51 C D33 D D34 D D35 D D36 D D37 D D38 D D39 D D40 D D41 D D42 D D43 D D44 D D45 D D46 D D47 D D48 D D49 D D50 D D51 D D52 D D53 D D54 D D55 D D56 D D57 D D58 D D59 D D60 D D61 D D62 D D63 D D64 D D65 D D66 D D67 D D68 D D69 D D70 D M1 >A M2 C M3 C M4 B M5 A M6 A M7 >A M8 A M9 B M10 >A M11 C M12 C M13 B M14 B M15 B M16 A M17 B M18 A M19 >A M21 C M22 A M23 C M24 C M25 C M26 B M27 C M28 A M28-2 B M29 >A M30 C M31 C M32 B M33 C M34 C M35 C M36 C M37 C M38 C M39 C M40 C M41 C M42 C M43 C M44 B M45 C M46 C M47 C M48 C M49 C M50 C M51 C M52 C M53 C M54 C M55 C M56 C M57 C M58 C M59 C M60 C M61 C M62 C M63 C M64 C M65 C M66a B M66b B M66x C M67a B M67b B M68 B M69 B M70 C M71 C M72 C M73 B M74 C M75 C M76 C M77 C M78 C M79 C M80 C M81 B M82 C M83 C M84 C M85 C M86 C M87 C M88 C M89 C M90 A M91 C M91x C M91y B M92 A M93 C M94 C M95 C M96 B M97 C M98 C M99 C M100 C M101 B M102 C M103 B M104 B M105 C M106 C M107 C M108 C M109 C M110 C M111 A M112 C M113 C M114 >A M115 >A M116 >A M117 >A M118 >A M119 B M120 B M121 B M122 C M123 A M124 C M125 C M126 C M127 C M128 C M129 A M130 C R26 D R27 D R28 D R34 D R35 B R29 D R36 D R20 D R37 D R33 C

It will be evident to one skilled in the art that the present disclosure is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

The compounds of the present disclosure may inhibit HCV by mechanisms in addition to or other than NS5A inhibition. In one embodiment the compounds of the present disclosure inhibit HCV replicon and in another embodiment the compounds of the present disclosure inhibit NS5A. Compounds of the present disclosure may inhibit multiple genotypes of HCV. 

1. A compound selected from dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2S)-1-oxo-1,2-propanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2S,3R)-3-methoxy-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2S)-3-methyl-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2S)-4-methoxy-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2S)-3-methyl-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2S)-1-oxo-1,2-propanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2S)-4-methoxy-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2S,3R)-3-methoxy-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2R)-3-methyl-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2R)-3-methyl-1-oxo-1,2-butanediyl)))biscarbamate; N²-(methoxycarbonyl)-N-((1S)-1-(4-(4′-(2-((2S)-1-(N-(methoxycarbonyl)-L-valyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-2-methylpropyl)-L-valinamide; methyl((1S,2R)-2-methoxy-1-(((2S)-2-(4-(4′-(2-((1S)-1-((N-(methoxycarbonyl)-O-methyl-L-threonyl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate; methyl((1S)-3-methoxy-1-(((2S)-2-(4-(4′-(2-((1S)-1-((N-(methoxycarbonyl)-O-methyl-L-homoseryl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate; methyl((1S)-2-((2S)-2-(4-(4′-(2-((1S)-1-((N-(methoxycarbonyl)-L-alanyl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-1-methyl-2-oxoethyl)carbamate; N²-(methoxycarbonyl)-N-((1R)-1-(4-(4′-(2-((2S)-1-(N-(methoxycarbonyl)-L-valyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-2-methylpropyl)-L-valinamide; methyl((1S,2R)-2-methoxy-1-(((2S)-2-(4-(4′-(2-((1R)-1-((N-(methoxycarbonyl)-O-methyl-L-threonyl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate; methyl((1S)-3-methoxy-1-(((2S)-2-(4-(4′-(2-((1R)-1-((N-(methoxycarbonyl)-O-methyl-L-homoseryl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate; methyl((1S)-2-((2S)-2-(4-(4′-(2-((1R)-1-((N-(methoxycarbonyl)-L-alanyl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-1-methyl-2-oxoethyl)carbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2S)-1-oxo-1,2-propanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2S,3R)-3-methoxy-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2S)-3-methyl-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2S)-4-methoxy-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2S)-3-methyl-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2S)-1-oxo-1,2-propanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2S)-4-methoxy-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2S,3R)-3-methoxy-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1R)-2-methyl-1,1-propanediyl)imino((2R)-3-methyl-1-oxo-1,2-butanediyl)))biscarbamate; dimethyl(4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((1S)-2-methyl-1,1-propanediyl)imino((2R)-3-methyl-1-oxo-1,2-butanediyl)))biscarbamate; N²-(methoxycarbonyl)-N-((1S)-1-(4-(4′-(2-((2S)-1-(N-(methoxycarbonyl)-L-valyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-2-methylpropyl)-L-valinamide; methyl((1S,2R)-2-methoxy-1-(((2S)-2-(4-(4′-(2-((1S)-1-((N-(methoxycarbonyl)-O-methyl-L-threonyl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate; methyl((1S)-3-methoxy-1-(((2S)-2-(4-(4′-(2-((1S)-1-((N-(methoxycarbonyl)-O-methyl-L-homoseryl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate; methyl((1S)-2-((2S)-2-(4-(4′-(2-((1S)-1-((N-(methoxycarbonyl)-L-alanyl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-1-methyl-2-oxoethyl)carbamate; N²-(methoxycarbonyl)-N-((1R)-1-(4-(4′-(2-((2S)-1-(N-(methoxycarbonyl)-L-valyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-2-methylpropyl)-L-valinamide; methyl((1S,2R)-2-methoxy-1-(((2S)-2-(4-(4′-(2-((1R)-1-((N-(methoxycarbonyl)-O-methyl-L-threonyl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate; methyl((1S)-3-methoxy-1-(((2S)-2-(4-(4′-(2-((1R)-1-((N-(methoxycarbonyl)-O-methyl-L-homoseryl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)propyl)carbamate; and methyl((1S)-2-((2S)-2-(4-(4′-(2-((1R)-1-((N-(methoxycarbonyl)-L-alanyl)amino)-2-methylpropyl)-1H-imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-1-methyl-2-oxoethyl)carbamate; or a pharmaceutically acceptable salt thereof.
 2. A compound selected from

or a pharmaceutically acceptable salt thereof.
 3. A composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
 4. The composition of claim 3 further comprising one or two additional compounds having anti-HCV activity.
 5. The composition of claim 4 wherein at least one of the additional compounds is an interferon or a ribavirin.
 6. The composition of claim 5 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.
 7. The composition of claim 4 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.
 8. The composition of claim 4 wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.
 9. A composition comprising a compound of claim 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
 10. The composition of claim 9 further comprising one or two additional compounds having anti-HCV activity.
 11. The composition of claim 10 wherein at least one of the additional compounds is an interferon or a ribavirin.
 12. The composition of claim 11 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.
 13. The composition of claim 10 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.
 14. The composition of claim 10 wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.
 15. A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
 16. The method of claim 15 further comprising administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of claim 1, or a pharmaceutically acceptable salt thereof.
 17. The method of claim 16 wherein at least one of the additional compounds is an interferon or a ribavirin.
 18. The method of claim 17 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.
 19. The method of claim 16 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.
 20. The method of claim 16 wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.
 21. A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of claim 2, or a pharmaceutically acceptable salt thereof.
 22. The method of claim 21 further comprising administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of claim 2, or a pharmaceutically acceptable salt thereof.
 23. The method of claim 22 wherein at least one of the additional compounds is an interferon or a ribavirin.
 24. The method of claim 23 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.
 25. The method of claim 22 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.
 26. The method of claim 22 wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection. 